Heterocyclic compound and use thereof

ABSTRACT

Provided is a compound represented by the formula (I): 
                         
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer&#39;s disease or attention deficit hyperactivity disorder (ADHD) and the like.

TECHNICAL FIELD

The present invention relates to a heterocyclic compound, particularly aheterocyclic compound having an AMPA(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptorpotentiating action.

BACKGROUND OF THE INVENTION

Glutamate is the most abundant excitatory neurotransmitter in themammalian central nervous system. Glutamate plays a pivotal role incognition, mood, and motor function, and its neurotransmission becomesunstable in psychiatric diseases and neurological disorder. Glutamatereceptors are divided into ligand gated ion channels and Gprotein-coupled receptors, and the ligand gated ion channels are furtherdivided into α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)receptors, N-methyl-D-aspartic acid (NMDA) receptors, and kainic acid(KA) receptors. (non-patent document 1)

AMPA receptor is one kind of receptor for excitatory neurotransmitterglutamate, and was named for the selective activation of the receptor byAMPA. AMPA receptors are composed of 4 subunits (GluR1, GluR2, GluR3,GluR4). Each subunit exists in flip and flop alternatively splicedvariants. AMPA receptors form homo- or hetero-tetramers composed ofthese subunits in vivo. The physiological property of AMPA receptor hasbeen reported to change depending on the subunit composition.(non-patent documents 1, 2, 3)

The importance of AMPA receptor in cerebrophysiology is well known, anda compound having an AMPA receptor potentiating action is expected to beuseful as a prophylactic or therapeutic drug for psychiatric diseases,neurodegenerative diseases, cognitive disorders, sleep disorders and thelike. (non-patent documents 4, 5)

As a heterocyclic compound, patent document 1 discloses disodium{4-(acetylamino)-8-[(3-{2-[4-(acetylamino)-2,2-dioxido-7-(sulfonatomethyl)-6H-pyrazolo[5,1-c][1,2,4]thiadiazin-8-yl]ethenyl}-5,5-dimethylcyclohex-2-en-1-yl)methylidene]-2,2-dioxido-8H-pyrazolo[5,1-c][1,2,4]thiadiazin-7-yl}methanesulfonate.

In addition, non-patent document 6 discloses2,2,2-trichloro-N-(7,7-diphenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]thiadiazol-3-ylidene)acetamide.

DOCUMENT LIST Patent Document

-   [patent document 1] JP-A-H4-37742

Non-patent Documents

[Non-patent Document 1]

-   Pharmacological Reviews, Vol. 51, 7-61, 1999    [Non-patent Document 2]-   Neuropharmacology, Vol. 34, 123-139, 1995    [Non-patent Document 3]-   Ann. Rev. Neurosci., Vol. 25, 103-126, 2002    [Non-patent Document 4]-   CNS & Neurological Disorders-Drug Targets, Vol. 7, 129-143, 2008    [Non-patent Document 5]-   Current Opinion in Drug Discovery and Development, Vol. 9, 571-579,    2006    [Non-patent Document 6]-   Journal of the Chemical Society, Perkin Transactions 1: Organic and    Bio-Organic Chemistry (1993), (1), 27-9

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

The present invention aims to provide a heterocyclic compound having anAMPA receptor potentiating action (AMPA receptor potentiator; sometimesto be also referred to as AMPA receptor positive modulator, AMPAkine,AMPA receptor allosteric modulator, AMPA receptor positive allostericmodulator, or positive allosteric activator of AMPA receptor).

Means of Solving the Problems

The present inventors have found that a compound represented by thefollowing formula (I′) or a salt thereof (compound (I′) in the presentspecification, or sometimes to be referred to as the compound of thepresent invention) has an AMPA receptor potentiating action, andconducted further studies and completed the present invention. In thepresent specification, compound (I′) and a prodrug thereof are sometimesto be collectively referred to as the compound of the present invention.

A compound represented by the following formula (I) and a salt thereof,which are encompassed in the scope of compound (I′), are novelcompounds.

Accordingly, the present invention provides the following and the like.

-   [1] A compound represented by the formula (I):

wherein

ring A is an optionally substituted 5-7-membered heterocycle,

ring B is an optionally substituted 5-8-membered heterocycle having, asa ring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 to 3 hetero atoms selected from a nitrogenatom, an oxygen atom and a sulfur atom,

ring D is an optionally substituted non-aromatic hydrocarbon ring, anoptionally substituted non-aromatic heterocycle, an optionallysubstituted aromatic hydrocarbon ring, or an optionally substitutedaromatic heterocycle,

W is optionally substituted C₁₋₃ alkylene, or optionally substitutedC₂₋₃ alkenylene,

L is a bond, or a spacer having the main chain having an to atom numberof 1-8, and

n is 0, 1 or 2,

provided when

a partial structural formula represented by the formula (I):

wherein L^(x) is a bond or a spacer having the main chain having an atomnumber of 1-7, one or both of ring A and ring B has(have)substituent(s),

-   excluding the following compounds;-   2,2,2-trichloro-N-(7,7-diphenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]thiadiazol-3-ylidene)acetamide,-   {4-(acetylamino)-8-[(3-{(2-[4-(acetylamino)-2,2-dioxido-7-(sulfonatomethyl)-6H-pyrazolo[5,1-c][1,2,4]thiadiazin-8-yl]ethenyl}-5,5-dimethylcyclohex-2-en-1-yl)methylidene]-2,2-dioxido-8H-pyrazolo[5,1-c][1,2,4]thiadiazin-7-yl}methanesulfonic    acid,-   3-tert-butyl-5-[(7-tert-butyl-2,2-dioxido-3,4-dihydro-6H-pyrazolo[5,1-c][1,2,4]thiadiazin-8-yl)diazenyl]-1H-pyrazole-4-carbonitrile,-   ethyl    2-[(4-{[(2-butoxy-4-octylphenyl)sulfonyl]amino}-3-ethyl-7-methyl-2,2-dioxido-6H-pyrazolo[5,1-c][1,2,4]thiadiazin-8-yl)diazenyl]benzoate,-   7-methyl-4,8-diphenyl-6H-pyrazolo[5,1-c][1,2,4]thiadiazine    2,2-dioxide,    or a salt thereof (hereinafter sometimes to be referred to as    compound (I));-   [2] the compound of [1], wherein ring A and ring B are each an    optionally substituted 6-membered ring,

ring B has, as a ring-constituting atom besides carbon atom, onenitrogen atom, and optionally further has 1 to 3 nitrogen atoms,

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)-, —S—,—SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene,

or a salt thereof;

-   [3] the compound of [2], wherein W is optionally substituted    —CH₂—CH₂—, and

n is 2,

or a salt thereof;

-   [4] the compound of [2] or [3], wherein the partial structural    formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from

-   a halogen atom;-   hydroxy;-   C₁₋₆ alkyl optionally substituted by a halogen atom;-   C₁₋₆ alkoxy; and-   C₁₋₆ alkyl-carbonyl,    or a salt thereof;-   [5] the compound of any one of [2]-[4], wherein L is a bond, or a    salt thereof;-   [6] the compound of any one of [2]-[5], wherein ring D is an    optionally substituted 3-8-membered monocyclic non-aromatic    hydrocarbon ring, an optionally substituted 6-14-membered aromatic    hydrocarbon ring, an optionally substituted 6-14-membered    non-aromatic hydrocarbon ring, an optionally substituted    5-6-membered monocyclic aromatic heterocycle, an optionally    substituted 3-8-membered monocyclic non-aromatic heterocycle, an    optionally substituted 8-14-membered condensed aromatic heterocycle    or an optionally substituted 6-14-membered condensed non-aromatic    heterocycle, or a salt thereof;-   [7] the compound of any one of [2]-[6], wherein ring D is optionally    substituted C₃₋₇ cycloalkane,-   optionally substituted C₆₋₁₄ arene,-   optionally substituted dihydronaphthalene,-   optionally substituted tetrahydronaphthalene,-   optionally substituted dihydroinden,-   optionally substituted thiophene,-   optionally substituted azetidine,-   optionally substituted piperidine,-   optionally substituted furan,-   optionally substituted pyridine,-   optionally substituted pyrazole,-   optionally substituted 1,2,4-oxadiazole,-   optionally substituted dihydrobenzodioxin,-   optionally substituted dihydrobenzofuran,-   optionally substituted benzodioxole,-   optionally substituted benzofuran,-   optionally substituted indole,-   optionally substituted quinoline,-   optionally substituted benzimidazole,-   optionally substituted benzothiazole,-   optionally substituted indazole, or-   optionally substituted dibenzothiophene,    or a salt thereof;-   [8] the compound of any one of [2]-[7], wherein ring D is C₃₋₇    cycloalkane, C₆₋₁₄ arene, dihydronaphthalene, tetrahydronaphthalene,    dihydroinden, thiophene, azetidine, piperidine, furan, pyridine,    pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxin, dihydrobenzofuran,    benzodioxole, benzofuran, indole, quinoline, benzimidazole,    benzothiazole, indazole or dibenzothiophene, optionally substituted    by 1-4 substituents selected from-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom, 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl and 3)    C₁₋₆ alkoxycarbonyl;-   (6) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or    phenyl;-   (7) C₁₋₆ alkyl-carbonyl;-   (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy;-   (9) C₂₋₆ alkenyl substituted by phenyl;-   (10) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom, C₁₋₆ alkyl, C₃₋₇ cycloalkyl and C₁₋₆ alkoxy;-   (11) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇    cycloalkyl;-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) oxetane substituted by a halogen atom;-   (16) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl;-   (17) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (18) di-C₁₋₆ alkylcarbamoyl;-   (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (20) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted    by a halogen atom, tetrahydrofuran and tetrahydropyran;-   (21) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or    C₂₋₆ alkylenedioxy;-   (22) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (23) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy optionally    substituted by a halogen atom;-   (24) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆    alkyl optionally substituted by a halogen atom;-   (25) silyloxy substituted by C₁₋₆ alkyl;-   (26) tetrahydrofuranyloxy;-   (27) tetrahydropyranyloxy; and-   (28) dihydrobenzofuranyloxy,    or a salt thereof;-   [9] the compound of any one of [2]-[8], wherein ring D is benzene    optionally substituted by 1-3 substituents selected from-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom, 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl and 3)    C₁₋₆ alkoxycarbonyl;-   (5) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or    phenyl;-   (6) C₁₋₆ alkyl-carbonyl;-   (7) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy;-   (8) C₂₋₆ alkenyl substituted by phenyl;-   (9) phenyl optionally substituted by a halogen atom or C₁₋₆ alkyl;-   (10) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇    cycloalkyl;-   (11) pyrrolidine;-   (12) dihydrobenzofuran;-   (13) morpholine;-   (14) oxetane substituted by a halogen atom;-   (15) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl;-   (16) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (17) di-C₁₋₆ alkylcarbamoyl;-   (18) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (19) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted    by a halogen atom, tetrahydrofuran and tetrahydropyran;-   (20) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or    C₂₋₆ alkylenedioxy;-   (21) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (22) phenyloxy optionally substituted by substituent(s) selected    from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy optionally    substituted by a halogen atom;-   (23) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆    alkyl optionally substituted by a halogen atom;-   (24) silyloxy substituted by C₁₋₆ alkyl;-   (25) tetrahydrofuranyloxy;-   (26) tetrahydropyranyloxy; and-   (27) dihydrobenzofuranyloxy,    or a salt thereof;-   [10] the compound of any one of [2]-[4] and [6]-[7], wherein the    partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s)

-   selected from-   a halogen atom;-   hydroxy;-   C₁₋₆ alkyl optionally substituted by a halogen atom;-   C₁₋₆ alkoxy; and-   C₁₋₆ alkyl-carbonyl,

ring D is C₃₋₇ cycloalkane, C₆₋₁₄ arene, dihydronaphthalene,tetrahydronaphthalene, dihydroinden, thiophene, azetidine, piperidine,furan, pyridine, pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxin,dihydrobenzofuran, benzodioxole, benzofuran, indole, quinoline,benzimidazole, benzothiazole, indazole or dibenzothiophene, eachoptionally substituted by 1-4 substituents selected from

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) optionally substituted C₁₋₆ alkyl;-   (6) optionally substituted C₃₋₇ cycloalkyl;-   (7) substituted carbonyl;-   (8) substituted C₂₋₆ alkenyl;-   (9) optionally substituted C₆₋₁₄ aryl;-   (10) optionally substituted C₇₋₁₆ aralkyl;-   (11) optionally substituted pyrazole-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) substituted oxetane;-   (16) substituted sulfanyl;-   (17) substituted C₁₋₆ alkylsulfonyloxy;-   (18) di-C₁₋₆ alkyl-carbamoyl;-   (19) substituted dioxaborolane;-   (20) optionally substituted C₁₋₆ alkoxy;-   (21) C₃₋₇ cycloalkyloxy;-   (22) optionally substituted C₃₋₇ cycloalkenyloxy;-   (23) optionally substituted C₆₋₁₄ aryloxy;-   (24) optionally substituted C₇₋₁₆ aralkyloxy;-   (25) optionally substituted pyridyloxy;-   (26) substituted silyloxy;-   (27) tetrahydrofuranyloxy;-   (28) tetrahydropyranyloxy; and-   (29) dihydrobenzofuranyloxy, and

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)-, —S—,—SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene,

or a salt thereof;

-   [11] the compound of any one of [2]-[4], [6]-[8] and [10],    wherein the partial structural formula represented by the formula    (I):

ring B is optionally substituted by substituent(s) (preferably 1-2)selected from

-   a halogen atom;-   hydroxy;-   C₁₋₆ alkyl optionally substituted by halogen atom(s) (preferably    1-3);-   C₁₋₆ alkoxy; and-   C₁₋₆ alkyl-carbonyl,

ring D is C₃₋₇ cycloalkane, C₆₋₁₄ arene, dihydronaphthalene,tetrahydronaphthalene, dihydroinden, thiophene, azetidine, piperidine,furan, pyridine, pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxin,dihydrobenzofuran, benzodioxole, benzofuran, indole, quinoline,benzimidazole, benzothiazole, indazole or dibenzothiophene, eachoptionally substituted by 1-4 substituents selected from

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) C₁₋₆ alkyl optionally substituted by substituent(s) (preferably    1-3) selected from 1) a halogen atom, 2) phenyl optionally    substituted by substituent(s) (preferably 1-3) selected from halogen    atom(s) (preferably 1-3) and C₁₋₆ alkyl (preferably 1-3) and 3) C₁₋₆    alkoxycarbonyl;-   (6) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl    (preferably 1-2) or phenyl (preferably 1-2);-   (7) C₁₋₆ alkyl-carbonyl;-   (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy    (preferably 1-2);-   (9) C₂₋₆ alkenyl substituted by phenyl (preferably 1-2);-   (10) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom, C₁₋₆ alkyl, C₃₋₇ cycloalkyl and C₁₋₆ alkoxy;-   (11) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by halogen atom(s)    (preferably 1-3), and C₃₋₇ cycloalkyl;-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) oxetane substituted by halogen atom(s) (preferably 1-3);-   (16) sulfanyl substituted by halogen atom(s) (preferably 1-6) or    C₁₋₆ alkyl (preferably 1-3);-   (17) C₁₋₆ alkylsulfonyloxy substituted by halogen atom(s)    (preferably 1-3);-   (18) di-C₁₋₆ alkylcarbamoyl;-   (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (20) C₁₋₆ alkoxy optionally substituted by substituent(s)    (preferably 1-3) selected from a halogen atom, C₃₋₇ cycloalkyl,    phenyl optionally substituted by halogen atom(s) (preferably 1-3),    tetrahydrofuran and tetrahydropyran;-   (21) C₃₋₇ cycloalkyloxy optionally substituted (preferably 1-3) by    C₁₋₆ alkyl, oxo or C₂₋₆ alkylenedioxy;-   (22) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (23) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by halogen atom(s) (preferably 1-3), and C₁₋₆ alkoxy    optionally substituted by halogen atom(s) (preferably 1-3);-   (24) pyridyloxy optionally substituted (preferably 1-3) by a halogen    atom, or C₁₋₆ alkyl optionally substituted by halogen atom(s)    (preferably 1-3);-   (25) silyloxy substituted by C₁₋₆ alkyl (preferably 1-3);-   (26) tetrahydrofuranyloxy;-   (27) tetrahydropyranyloxy; and-   (28) dihydrobenzofuranyloxy,

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)-, —S—,—SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene,

or a salt thereof;

-   [12] the compound of any one of [2]-[4], [6]-[8] and [10]-[11],    wherein the partial structural formula represented by the formula    (I):

ring B is optionally substituted by substituent(s) (preferably 1-2)selected from a halogen atom, hydroxy, C₁₋₆ alkyl and C₁₋₆ alkoxy,

ring D is C₃₋₇ cycloalkane, benzene, naphthalene, pyridine or thiopheneoptionally substituted by 1 to 3 substituents selected from

-   (1) a halogen atom;-   (2) hydroxy;-   (3) C₁₋₆ alkyl optionally substituted by substituent(s) (preferably    1-3) selected from 1) a halogen atom, and 2) phenyl optionally    substituted by substituent(s) (preferably 1-3) selected from a    halogen atom and C₁₋₆ alkyl;-   (4) C₃₋₇ cycloalkyl;-   (5) phenyl-carbonyl;-   (6) C₂₋₆ alkenyl substituted by phenyl (preferably 1-2);-   (7) phenyl optionally substituted by halogen atom(s) (preferably    1-3) or C₁₋₆ alkyl (preferably 1-3);-   (8) pyrrolidine;-   (9) dihydrobenzofuran;-   (10) C₁₋₆ alkylsulfonyloxy substituted by halogen atom(s)    (preferably 1-3);-   (11) C₁₋₆ alkoxy optionally substituted by substituent(s)    (preferably 1-3) selected from a halogen atom, C₃₋₇ cycloalkyl,    phenyl substituted by halogen atom(s) (preferably 1-3),    tetrahydrofuran and tetrahydropyran;-   (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (14) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by halogen atom(s) (preferably 1-3), and C₁₋₆ alkoxy;-   (15) pyridyloxy substituted by halogen atom(s) (preferably 1-3), or    C₁₋₆ alkyl (preferably 1-3) substituted by halogen atom(s)    (preferably 1-3);-   (16) tetrahydrofuranyloxy;-   (17) tetrahydropyranyloxy; and-   (18) dihydrobenzofuranyloxy, and

L is a bond, —O—, —O—CH₂—, —CO—NH—, C₁₋₆ alkylene, or C₂₋₆ alkynylene,

or a salt thereof;

-   [13] the compound of any one of [2]-[12], wherein the partial    structural formula represented by the formula (I):

ring B is optionally substituted by C₁₋₆ alkyl (preferably 1-2),

ring D is benzene optionally substituted by 1 to 3 substituents selectedfrom

-   (1) a halogen atom;-   (2) hydroxy;-   (3) C₁₋₆ alkyl optionally substituted by substituent(s) (preferably    1-3) selected from 1) a halogen atom, and 2) phenyl optionally    substituted by substituent(s) (preferably 1-3) selected from halogen    atom(s) (preferably 1-3) and C₁₋₆ alkyl (preferably 1-3);-   (4) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl    (preferably 1-2) or phenyl (preferably 1-2);-   (5) phenyl-carbonyl;-   (6) C₂₋₆ alkenyl substituted by phenyl (preferably 1-2);-   (7) phenyl optionally substituted by halogen atom(s) (preferably    1-3) or C₁₋₆ alkyl (preferably 1-3);-   (8) pyrrolidine;-   (9) dihydrobenzofuran;-   (10) C₁₋₆ alkylsulfonyloxy substituted by halogen atom(s)    (preferably 1-3);-   (11) C₁₋₆ alkoxy optionally substituted by substituent(s)    (preferably 1-3) selected from a halogen atom, C₃₋₇ cycloalkyl,    phenyl substituted by halogen atom(s) (preferably 1-3),    tetrahydrofuran and tetrahydropyran;-   (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (14) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by halogen atom(s) (preferably 1-3), and C₁₋₆ alkoxy;-   (15) pyridyloxy substituted (preferably 1-3) by a halogen atom, or    C₁₋₆ alkyl substituted by halogen atom(s) (preferably 1-3);-   (16) tetrahydrofuranyloxy;-   (17) tetrahydropyranyloxy; and-   (18) dihydrobenzofuranyloxy, and

L is a bond,

or a salt thereof;

-   [14] 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   [15]    9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   [16]    9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   [17]    9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   [18] a medicament containing a compound represented by the formula    (I′):

wherein

ring A′ is an optionally substituted 5-7-membered heterocycle,

ring B′ is an optionally substituted 5-8-membered heterocycle having, asa ring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 to 3 hetero atoms selected from a nitrogenatom, an oxygen atom and a sulfur atom,

ring D′ is an optionally substituted non-aromatic hydrocarbon ring, anoptionally substituted non-aromatic heterocycle, an optionallysubstituted aromatic hydrocarbon ring, or an optionally substitutedaromatic heterocycle,

W′ is optionally substituted C₁₋₃ alkylene, or optionally substitutedC₂₋₃ alkenyl,

L′ is a bond, or a spacer having the main chain having an atom number of1-8, and

n is 0, 1 or 2

or a salt thereof;

-   [19] the medicament of [18], which is an AMPA receptor potentiator;-   [20] the medicament of [18], which is a prophylactic or therapeutic    agent for depression, schizophrenia, Alzheimer's disease or    attention deficit hyperactivity disorder;-   [21] a method for the prophylaxis or treatment of depression,    schizophrenia, Alzheimer's disease or attention deficit    hyperactivity disorder, comprising administering an effective amount    of a compound represented by the formula (I′) or a salt thereof of    [18] to a mammal;-   [22] use of a compound represented by the formula (I′) or a salt    thereof of [18] for the production of a prophylactic or therapeutic    drug for depression, schizophrenia, Alzheimer's disease or attention    deficit hyperactivity disorder;-   [23] use of a compound represented by the formula (I′) or a salt    thereof of [18] for the prophylaxis or treatment of depression,    schizophrenia, Alzheimer's disease or attention deficit    hyperactivity disorder.

The present invention also provides the following embodiments and thelike.

-   [1A]

A compound represented by the formula (I):

wherein

ring A is an optionally substituted 5-7-membered heterocycle,

ring B is an optionally substituted 5-8-membered heterocycle having, asa ring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 to 3 hetero atoms selected from a nitrogenatom, an oxygen atom and a sulfur atom,

ring D is an optionally substituted non-aromatic hydrocarbon ring, anoptionally substituted non-aromatic heterocycle, an optionallysubstituted aromatic hydrocarbon ring, or an optionally substitutedaromatic heterocycle,

W is optionally substituted C₁₋₃ alkylene, or optionally substitutedC₂₋₃ alkenylene,

L is a bond, or a spacer having the main chain having an atom number of1-8, and

n is 0, 1 or 2,

provided when

a partial structural formula represented by the formula (I):

wherein L^(x) is a bond or a spacer having the main chain having an atomnumber of 1-7, one or both of ring A and ring B has(have)substituent(s),excluding the following compounds;

-   2,2,2-trichloro-N-(7,7-diphenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]thiadiazol-3-ylidene)acetamide,    and-   {4-(acetylamino)-8-[(3-{2-[4-(acetylamino)-2,2-dioxido-7-(sulfonatomethyl)-6H-pyrazolo[5,1-c][1,2,4]thiadiazin-8-yl]ethenyl}-5,5-dimethylcyclohex-2-en-1-yl)methylidene]-2,2-dioxido-8H-pyrazolo[5,1-c][1,2,4]thiadiazin-7-yl}methanesulfonic    acid,    or a salt thereof;-   [2A] a prodrug of the compound of [1A] or a salt thereof;-   [3A] a medicament containing the compound of [1A] or a salt thereof    or a prodrug thereof;-   [4A] an AMPA receptor potentiator containing a compound represented    by the formula (I′):

wherein

ring A′ is an optionally substituted 5-7-membered heterocycle,

is ring B′ is an optionally substituted 5-8-membered heterocycle having,as a ring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 to 3 hetero atoms selected from a nitrogenatom, an oxygen atom and a sulfur atom,

ring D′ is an optionally substituted non-aromatic hydrocarbon ring, anoptionally substituted non-aromatic heterocycle, an optionallysubstituted aromatic hydrocarbon ring, or an optionally substitutedaromatic heterocycle,

W′ is optionally substituted C₁₋₃ alkylene, or optionally substitutedC₂₋₃ alkenylene,

L′ is a bond, or a spacer having the main chain having an atom number of1-8, and

n is 0, 1 or 2,

-   or a salt thereof, or a prodrug thereof;-   [5A] the AMPA receptor potentiator of [4A], which is a prophylactic    or therapeutic drug for depression, schizophrenia or attention    deficit hyperactivity disorder;-   [6A] a method for the prophylaxis or treatment of depression,    schizophrenia or attention deficit hyperactivity disorder,    comprising administering an effective amount of the compound    represented by the formula (I′) or a salt thereof of [4A] or a    prodrug thereof to a mammal;-   [7A] use of the compound represented by the formula (I′) or a salt    thereof of [4A] or a prodrug thereof for the production of a    prophylactic or therapeutic drug for depression, schizophrenia or    attention deficit hyperactivity disorder;-   [8A] use of the compound represented by the formula (I′) or a salt    thereof of [4A], or a prodrug thereof for the prophylaxis or    treatment of depression, schizophrenia or attention deficit    hyperactivity disorder;-   [9A] a medicament containing the compound of any one of [1]-[17] or    a salt thereof;-   [10A] the medicament of [9A], which is an AMPA receptor potentiator;-   [11A] the medicament of [9A], which is a prophylactic or therapeutic    agent for depression, schizophrenia, Alzheimer's disease or    attention deficit hyperactivity disorder;-   [12A] a method of potentiating AMPA receptor, comprising    administering an effective amount of the compound of any one of    [1]-[17] or a salt thereof to a mammal;-   [13A] a method for the prophylaxis or treatment of depression,    schizophrenia, Alzheimer's disease or attention deficit    hyperactivity disorder, comprising administering an effective amount    of the compound of any one of [1]-[17] or a salt thereof to a    mammal;-   [13B] a method for the prophylaxis or treatment of depression,    comprising administering an effective amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13C] a method for the prophylaxis or treatment of schizophrenia,    comprising administering an effective amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13C′] a method for the prophylaxis or treatment of a positive    symptom of schizophrenia, comprising administering an effective    amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13C″] a method for the prophylaxis or treatment of a negative    symptom of schizophrenia, comprising administering an effective    amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13C″′] a method for the prophylaxis or treatment of cognitive    impairment in schizophrenia, comprising administering an effective    amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13D] a method for the prophylaxis or treatment of Alzheimer's    disease, comprising administering an effective amount of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [13E] a method for the prophylaxis or treatment of attention deficit    hyperactivity disorder, comprising administering an effective amount    of-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide; or-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide, or a salt thereof, to a mammal;-   [14A] use of the compound of any one of [1]-[17] or a salt thereof    for the production of an AMPA receptor potentiator;-   [15A] use of the compound of any one of [1]-[17] or a salt thereof    for the production of a prophylactic or therapeutic drug for    depression, schizophrenia, Alzheimer's disease or attention deficit    hyperactivity disorder;-   [16A] the compound of any one of [1]-[17] or a salt thereof for use    for potentiating AMPA receptor;-   [17A] use of the compound of any one of [1]-[17] or a salt thereof    for the prophylaxis or treatment of depression, schizophrenia,    Alzheimer's disease or attention deficit hyperactivity disorder.

Effect of the Invention

According to the present invention, a useful compound having an AMPAreceptor potentiating action and useful as a prophylactic or therapeuticdrug for depression, schizophrenia, Alzheimer's disease or attentiondeficit hyperactivity disorder (ADHD) and the like can be provided.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is explained in detail in the following.

In the present specification, the hydrogen atoms in the chemicalstructural formulas are sometimes to be abbreviated according toconventional use in the chemical field.

In the present specification, unless otherwise specified, examples ofthe “halogen atom” include fluorine, chlorine, bromine, and iodine.

In the present specification, unless otherwise specified, “optionallyhalogenated” and “halogeno” mean optionally having one or more (e.g., 1to 3) a halogen atoms as substituents.

In the present specification, unless otherwise specified, examples ofthe “non-aromatic hydrocarbon ring” include a non-aromatic hydrocarbonring having a carbon number of 3 to 8 such as C₃₋₈ cycloalkane, C₅₋₈cycloalkene, C₅₋₈ cycloalkadiene, bridged cyclic hydrocarbon having acarbon number of 5 to 8 and the like.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₈ cycloalkane” include cyclopropane, cyclobutane, cyclopentane,cyclohexane, cycloheptane, and cyclooctane.

In the present specification, unless otherwise specified, examples ofthe “C₅₋₈ cycloalkene” include cyclopentene, cyclohexene, cycloheptene,and cyclooctene.

In the present specification, unless otherwise specified, examples ofthe “C₅₋₈ cycloalkadiene” include cyclopentadiene, cyclohexadiene,cycloheptadiene, and cyclooctadiene.

In the present specification, unless otherwise specified, examples ofthe “bridged cyclic hydrocarbon having a carbon number of 5 to 8”include bicyclo[2.1.0]pentane, bicyclo[2.2.1]heptane,bicyclo[3.2.1]octane, bicyclo[2.2.1]hept-2-en, andtricyclo[2.2.1.0]heptane.

In the present specification, unless otherwise specified, examples ofthe “aromatic hydrocarbon ring” include an aromatic hydrocarbon ringhaving a carbon number of 6 to 14. Specific examples thereof include abenzene ring, a naphthalene ring, an anthracene ring and a phenanthrenering.

In the present specification, unless otherwise specified, the “aromatichydrocarbon ring” may be monocyclic, bicyclic or tricyclic.

In the present specification, unless otherwise specified, examples ofthe “heterocycle” include a 3- to 14-membered heterocycle containing 1to 4 hetero atoms selected from a nitrogen atom (N), a sulfur atom (S)and an oxygen atom (O).

In the present specification, unless otherwise specified, examples ofthe “heterocycle” include non-aromatic heterocycle, and aromaticheterocycle.

In the present specification, unless otherwise specified, examples ofthe “non-aromatic heterocycle” include monocyclic non-aromaticheterocycle, and condensed non-aromatic heterocycle.

In the present specification, unless otherwise specified, examples ofthe “monocyclic non-aromatic heterocycle” include a 3- to 8-memberednon-aromatic heterocycle such as an oxirane ring, an azetidine ring, anoxetane ring, a thietane ring, a pyrrolidine ring, a dihydrofuran ring,a tetrahydrofuran ring, a tetrahydrothiophene ring, an imidazolidinering, an oxazolidine ring, an isooxazoline ring, a piperidine ring, adihydropyran ring, a tetrahydropyran ring, a tetrahydrothiopyran ring, amorpholine ring, a thiomorpholine ring, a piperazine ring, adihydrooxazin ring, a tetrahydrooxazin ring, a dihydropyrimidine ring, atetrahydropyrimidine ring, an azepane ring, an oxepane ring, a thiepanering, an oxazepane ring, a thiazepane ring, an azocane ring, an oxocanering, a thiocane ring, an oxazocane ring, a thiazocane ring and thelike.

In the present specification, unless otherwise specified, examples ofthe “condensed non-aromatic heterocycle” include a monocyclicnon-aromatic heterocycle condensed with 1 or 2 rings selected from anon-aromatic hydrocarbon ring having a carbon number of 3 to 8, abenzene ring, a monocyclic non-aromatic heterocycle, and a 5- or6-membered aromatic heterocycle. Specific examples thereof include abicyclic condensed non-aromatic heterocycle such as dihydroindole,dihydroisoindole, dihydrobenzofuran, dihydrobenzodioxine,dihydrobenzodioxepine, tetrahydrobenzofuran, chromene, dihydroquinoline,tetrahydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline,dihydrophthalazine, tetrahydrobenzoazepine and the like.

In the present specification, unless otherwise specified, examples ofthe “aromatic heterocycle” include monocyclic aromatic heterocycle, andcondensed aromatic heterocycle.

In the present specification, unless otherwise specified, examples ofthe “monocyclic aromatic heterocycle” include a 5- or 6-memberedaromatic heterocycle such as a furan ring, a thiophene ring, a pyrrolering, an oxazole ring, an isoxazole ring, a thiazole ring, anisothiazole ring, an imidazole ring, a pyrazole ring, a 1,2,3-oxadiazolering, a 1,2,4-oxadiazole ring, a 1,3,4-oxadiazole ring, a furazan ring,a 1,2,3-thiadiazole ring, a 1,2,4-thiadiazole ring, a 1,3,4-thiadiazolering, a 1,2,3-triazole ring, a 1,2,4-triazole ring, a tetrazole ring, apyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, atriazine ring and the like.

In the present specification, unless otherwise specified, examples ofthe “condensed aromatic heterocycle” include a monocyclic aromaticheterocycle condensed with 1 or 2 rings selected from a benzene ring,and a 5- or 6-membered aromatic heterocycle. Specific examples thereofinclude a bicyclic condensed aromatic heterocycle such as quinoline,isoquinoline, quinazoline, quinoxaline, benzofuran, benzothiophene,benzoxazole, benzisoxazole, benzothiazole, benzimidazole, benzotriazole,indole, indolizine, indazole, pyrrolopyrazine (e.g.,1H-pyrrolo[2,3-b]pyrazine, 1H-pyrrolo[2,3-b]pyrazine,pyrrolo[1,2-a]pyrazine), pyrazolopyridine (e.g.,pyrazolo[1,5-a]pyridine), imidazopyridine (e.g.,1H-imidazo[4,5-b]pyridine, 1H-imidazo[4,5-c]pyridine,2H-imidazo[1,2-a]pyridine, imidazo[1,2-a]pyridine,imidazo[1,5-a]pyridine), triazolopyridine (e.g.,1H-[1,2,3]triazolo[4,5-b]pyridine, 1H-[1,2,3]triazolo[4,5-c]pyridine,[1,2,4]triazolo[4,3-a]pyridine, [1,2,4]triazolo[1,5-a]pyridine),imidazopyrazine (e.g., 1H-imidazo[4,5-b]pyrazine,imidazo[1,2-a]pyrazine, imidazo[1,5-a]pyrazine), triazolopyrazine (e.g.,[1,2,4]triazolo[1,5-a]pyrazine), pyrazolopyridine (e.g.,1H-pyrazolo[4,3-c]pyridine), pyrazolothiophene (e.g.,2H-pyrazolo[3,4-b]thiophene), pyrazolotriazine (e.g.,pyrazolo[5,1-c][1,2,4]triazine) and the like.

In the present specification, unless otherwise specified, examples ofthe “alkyl (group)” include a C₁₋₆ alkyl (group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkyl (group)” include methyl, ethyl, n-propyl, isopropyl,n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl,and hexyl.

In the present specification, unless otherwise specified, the“optionally halogenated C₁₋₆ alkyl (group)” means a C₁₋₆ alkyl (group)optionally substituted by a halogen atom, and specific examples thereofinclude trifluoromethyl.

In the present specification, unless otherwise specified, examples ofthe “alkenyl (group)” include a C₂₋₆ alkenyl (group).

In the present specification, unless otherwise specified, examples ofthe “C₂₋₆ alkenyl (group)” include vinyl, 1-propen-1-yl, 2-propen-1-yl,isopropenyl, 2-buten-1-yl, 4-penten-1-yl, and 5-hexen-1-yl.

In the present specification, unless otherwise specified, examples ofthe “alkynyl (group)” include a C₂₋₆ alkynyl group. Examples of the“C₂₋₆ alkynyl (group)” include ethynyl, 1-propyn-1-yl, 2-propyn-1-yl,4-pentyn-1-yl, and 5-hexyn-1-yl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyl-C₂₋₆ alkynyl (group)” include cyclopropylethynyl.

In the present specification, unless otherwise specified, examples ofthe “non-aromatic cyclic hydrocarbon group” include a C₃₋₇ cycloalkyl(group), a C₃₋₇ cycloalkenyl (group) and a C₄₋₁₀ cycloalkadienyl(group), each of which may be condensed with one or more (preferably 1or 2) hydrocarbon rings.

Examples of the “hydrocarbon ring” include the aforementioned“non-aromatic hydrocarbon ring” and the aforementioned “aromatichydrocarbon ring”.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyl (group)” include cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, and cycloheptyl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkenyl (group)” include cyclopropenyl, cyclobutenyl,cyclopentenyl, cyclohexenyl, and cycloheptenyl.

In the present specification, unless otherwise specified, examples ofthe “C₄₋₁₀ cycloalkadienyl (group)” include cyclobutadienyl,cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl,cyclononadienyl, and cyclodecadienyl.

In the present specification, unless otherwise specified, the “aromaticcyclic hydrocarbon group” may be monocyclic, bicyclic or tricyclic.

In the present specification, unless otherwise specified, examples ofthe “aromatic cyclic hydrocarbon group” include C₆₋₁₄ aryl (group) andthe like. Specific examples thereof include phenyl, 1-naphthyl,2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, and 2-anthryl.

In the present specification, unless otherwise specified, examples ofthe “C₇₋₁₆ aralkyl (group)” include benzyl, phenethyl, diphenylmethyl,1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl,4-phenylbutyl, 5-phenylpentyl, 2-biphenylylmethyl, 3-biphenylylmethyl,and 4-biphenylylmethyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ aryl-C₂₋₆ alkenyl (group)” include styryl.

In the present specification, unless otherwise specified, examples ofthe “C₁₋₇ alkylene (group)” (i.e., C₁₋₆ alkanediyl group) includemethylene, ethylene, trimethylene, tetramethylene, 2-butenylene,2-methyltetramethylene, pentamethylene, and hexamethylene.

In the present specification, unless otherwise specified, examples ofthe “C₂₋₇ alkylene(group)” include an alkylene (group) having a carbonnumber of 2 to 7 from the aforementioned “C₁₋₇ alkylene (group)”.Examples of the “C₁₋₃ alkylene (group)” include an alkylene (group)having a carbon number of 1 to 3 from the aforementioned “C₁₋₇ alkylene(group)”.

In the present specification, unless otherwise specified, examples ofthe “C₂₋₆ alkenylene (group)” include —CH═CH—, —CH═C(CH₃)—C(CH₃)═CH—,—CH═CH—CH₂—, —CH₂—CH═CH—, —C(CH₃)₂—CH═CH—, —CH₂—CH═CH—CH₂—,—CH₂—CH₂—CH═CH—, —CH═CH—CH═CH—, —CH═CH—CH₂—CH₂—CH₂—, and —CH═C(C₂H₅)—.

In the present specification, unless otherwise specified, examples ofthe “C₂₋₃ alkenylene (group)” include an alkenylene (group) having acarbon number of 2 to 3 from the aforementioned “C₂₋₆alkenylene(group)”.

In the present specification, unless otherwise specified, examples ofthe “C₂₋₆ alkynylene (group)” include —CH₂—C ≡C—, —CH₂—C≡C—CH(CH₃)—, and—CH₂—C≡C—CH₂—CH₂—.

In the present specification, unless otherwise specified, the“heterocyclic group” (and heterocycle moiety in substituents) is anon-aromatic heterocyclic group, or an aromatic heterocyclic group(i.e., heteroaryl group).

In the present specification, unless otherwise specified, the“heterocyclic group” may be monocyclic, bicyclic or tricyclic.

In the present specification, unless otherwise specified, the“heterocyclic group” is, for example, a 3- to 14-membered heterocyclicgroup containing 1 to 4 hetero atoms selected from an oxygen atom, asulfur atom and a nitrogen atom and the like.

In the present specification, unless otherwise specified, the“non-aromatic heterocyclic group” may be saturated or unsaturated.

In the present specification, unless otherwise specified, examples ofthe “non-aromatic heterocyclic group” include a 3- to 14-memberednon-aromatic heterocyclic group.

In the present specification, unless otherwise specified, examples ofthe “3- to 14-membered non-aromatic heterocyclic group” include a 3- to6-membered non-aromatic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom,which may be condensed with a 5- or 6-membered ring.

In the present specification, unless otherwise specified, examples ofthe “3- to 6-membered non-aromatic heterocyclic group containing 1 to 4hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogenatom” include tetrahydrofuryl, oxazolidinyl, imidazolinyl (e.g.,1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl), aziridinyl (e.g.,1-aziridinyl, 2-aziridinyl), azetidinyl (e.g., 1-azetidinyl,2-azetidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl,3-pyrrolidinyl), piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl,3-piperidinyl), azepanyl (e.g., 1-azepanyl, 2-azepanyl, 3-azepanyl,4-azepanyl), azocanyl (e.g., 1-azocanyl, 2-azocanyl, 3-azocanyl,4-azocanyl), piperazinyl (e.g., 1,4-piperazin-1-yl, 1,4-piperazin-2-yl),diazepinyl (e.g., 1,4-diazepin-1-yl, 1,4-diazepin-2-yl,1,4-diazepin-5-yl, 1,4-diazepin-6-yl), diazocanyl (e.g.,1,4-diazocan-1-yl, 1,4-diazocan-2-yl, 1,4-diazocan-5-yl,1,4-diazocan-6-yl, 1,5-diazocan-1-yl, 1,5-diazocan-2-yl,1,5-diazocan-3-yl), tetrahydropyranyl (e.g., tetrahydropyran-4-yl),morpholinyl (e.g., 4-morpholinyl), thiomorpholinyl (e.g.,4-thiomorpholinyl), 2-oxazolidinyl, dihydrofuryl, dihydropyranyl,dihydroquinolyl, and 2,3-dihydro-1H-imidazo[1,2-a]imidazol-1-yl.

In the present specification, unless otherwise specified, examples ofthe “5- or 6-membered ring” include a hydrocarbon ring having a carbonnumber of 5 or 6 (e.g., cyclopentane, cyclohexane, cyclopentene,cyclohexene, cyclopentadiene, cyclohexadiene, benzene) and a 5- or6-membered heterocycle.

In the present specification, unless otherwise specified, examples ofthe “5- or 6-membered heterocycle” include the aforementioned“heterocycle” which is a 5- or 6-membered ring. In the presentspecification, unless otherwise specified, examples of the “3- to6-membered non-aromatic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atomwhich is condensed with a 5- or 6-membered ring” include2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl.

In the present specification, unless otherwise specified, examples ofthe “aromatic heterocyclic group” include 5- or 6-membered monocyclicaromatic heterocyclic group, and 5- to 10-membered aromatic condensedheterocyclic group.

In the present specification, unless otherwise specified, examples ofthe “5- or 6-membered monocyclic aromatic heterocyclic group” include a5- or 6-membered monocyclic aromatic heterocyclic group containing 1 to4 hetero atoms selected from an oxygen atom, a sulfur atom and anitrogen atom, such as pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl,3-pyrrolyl), furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl,3-thienyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl),imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), isoxazolyl(e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxazolyl (e.g.,2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isothiazolyl (e.g., 3-isothiazolyl,4-isothiazolyl, 5-isothiazolyl), thiazolyl (e.g., 2-thiazolyl,4-thiazolyl, 5-thiazolyl), triazolyl (e.g., 1,2,3-triazol-4-yl,1,2,4-triazol-3-yl), oxadiazolyl (e.g., 1,2,4-oxadiazol-3-yl,1,2,4-oxadiazol-5-yl), thiadiazolyl (e.g., 1,2,4-thiadiazol-3-yl,1,2,4-thiadiazol-5-yl), tetrazolyl, pyridyl (e.g., 2-pyridyl, 3-pyridyl,4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl),pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), andpyrazinyl and the like.

In the present specification, unless otherwise specified, examples ofthe “5- to 10-membered aromatic condensed heterocyclic group” include a5- to 10-membered aromatic condensed heterocyclic group containing 1 to4 hetero atoms selected from an oxygen atom, a sulfur atom and anitrogen atom such as isoindolyl (e.g., 1-isoindolyl, 2-isoindolyl,3-isoindolyl, 4-isoindolyl, 5-isoindolyl, 6-isoindolyl, 7-isoindolyl),indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl,6-indolyl, 7-indolyl), benzo[b]furanyl (e.g., 2-benzo[b]furanyl,3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl,6-benzo[b]furanyl, 7-benzo[b]furanyl), benzo[c]furanyl (e.g.,1-benzo[c]furanyl, 4-benzo[c]furanyl, 5-benzo[c]furanyl),benzo[b]thienyl, (e.g., 2-benzo[b]thienyl, 3-benzo[b]thienyl,4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl,7-benzo[b]thienyl), benzo[c]thienyl (e.g., 1-benzo[c]thienyl,4-benzo[c]thienyl, 5-benzo[c]thienyl), indazolyl (e.g., 1-indazolyl,2-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl,7-indazolyl), benzimidazolyl (e.g., 1-benzimidazolyl, 2-benzimidazolyl,4-benzimidazolyl, 5-benzimidazolyl), 1,2-benzoisoxazolyl (e.g.,1,2-benzoisoxazol-3-yl, 1,2-benzoisoxazol-4-yl, 1,2-benzoisoxazol-5-yl,1,2-benzoisoxazol-6-yl, 1,2-benzoisoxazol-7-yl), benzoxazolyl (e.g.,2-benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl,7-benzoxazolyl), 1,2-benzoisothiazolyl (e.g., 1,2-benzoisothiazol-3-yl,1,2-benzoisothiazol-4-yl, 1,2-benzoisothiazol-5-yl,1,2-benzoisothiazol-6-yl, 1,2-benzoisothiazol-7-yl), benzothiazolyl(e.g., 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl,6-benzothiazolyl, 7-benzothiazolyl), isoquinolyl (e.g., 1-isoquinolyl,3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl), quinolyl (e.g.,2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl), cinnolinyl(e.g., 3-cinnolinyl, 4-cinnolinyl, 5-cinnolinyl, 6-cinnolinyl,7-cinnolinyl, 8-cinnolinyl), phthalazinyl (e.g., 1-phthalazinyl,4-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl, 7-phthalazinyl,8-phthalazinyl), quinazolinyl (e.g., 2-quinazolinyl, 4-quinazolinyl,5-quinazolinyl, 6-quinazolinyl, 7-quinazolinyl, 8-quinazolinyl),quinoxalinyl (e.g., 2-quinoxalinyl, 3-quinoxalinyl, 5-quinoxalinyl,6-quinoxalinyl, 7-quinoxalinyl, 8-quinoxalinyl), pyrazolo[1,5-a]pyridyl(e.g., pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-3-yl,pyrazolo[1,5-a]pyridin-4-yl, pyrazolo[1,5-a]pyridin-5-yl,pyrazolo[1,5-a]pyridin-6-yl, pyrazolo[1,5-a]pyridin-7-yl),imidazo[1,2-a]pyridyl (e.g., imidazo[1,2-a]pyridin-2-yl,imidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-5-yl,imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyridin-7-yl,imidazo[1,2-a]pyridin-8-yl) and the like.

In the present specification, unless otherwise specified, examples ofthe “alkoxy (group)” include C₁₋₆ alkoxy (group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkoxy (group)” include methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, andhexyloxy.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyloxy (group)” include cyclopropyloxy, cyclobutyloxy,cyclopentyloxy, and cyclohexyloxy.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ aryloxy (group)” include phenyloxy, 1-naphthyloxy, and2-naphthyloxy.

In the present specification, unless otherwise specified, examples ofthe “C₇₋₁₆ aralkyloxy (group)” include benzyloxy, and phenethyloxy.

In the present specification, unless otherwise specified, examples ofthe “alkyl-carbonyloxy (group)” include a C₁₋₆ alkyl-carbonyloxy(group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkyl-carbonyloxy (group)” include acetoxy, and propionyloxy.

In the present specification, unless otherwise specified, examples ofthe “alkoxy-carbonyloxy (group)” include a C₁₋₆ alkoxy-carbonyloxy(group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkoxy-carbonyloxy (group)” include methoxycarbonyloxy,ethoxycarbonyloxy, propoxycarbonyloxy, and butoxycarbonyloxy.

In the present specification, unless otherwise specified, examples ofthe “mono-alkyl-carbamoyloxy (group)” include a mono-C₁₋₆alkyl-carbamoyloxy (group).

In the present specification, unless otherwise specified, examples ofthe “mono-C₁₋₆ alkyl-carbamoyloxy (group)” include methylcarbamoyloxy,and ethylcarbamoyloxy.

In the present specification, unless otherwise specified, examples ofthe “di-alkyl-carbamoyloxy (group)” include a di-C₁₋₆ alkyl-carbamoyloxy(group).

In the present specification, unless otherwise specified, examples ofthe “di-C₁₋₆ alkyl-carbamoyloxy (group)” include dimethylcarbamoyloxy,and diethylcarbamoyloxy.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ aryl-carbonyloxy (group)” include benzoyloxy andnaphthylcarbonyloxy.

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₆₋₁₄ aryl-carbamoyloxy (group)” includephenylcarbamoyloxy and naphthylcarbamoyloxy.

In the present specification, unless otherwise specified, examples ofthe heterocycle moiety of the “heterocyclyl-oxy (group)” include thosesimilar to the aforementioned “heterocyclic group”. Specific examples ofthe “heterocyclyl-oxy (group)” include a 3- to 14-memberedheterocyclyl-oxy (group) containing 1 to 5 hetero atoms selected from anitrogen atom, a sulfur atom, and an oxygen atom.

In the present specification, unless otherwise specified, examples ofthe aromatic heterocycle moiety of the “aromatic heterocyclyl-oxy(group)” include those similar to the “aromatic heterocyclic group” asan example of the aforementioned “heterocyclic group”. Specifically asthe “aromatic heterocyclyl-oxy (group)”, for example, a 5- to14-membered aromatic heterocyclyl-oxy containing 1 to 5 hetero atomsselected from a nitrogen atom, a sulfur atom, and an oxygen atom can bementioned.

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkylsulfonyloxy group” include methylsulfonyloxy, andethylsulfonyloxy.

In the present specification, unless otherwise specified, examples ofthe “halogeno C₁₋₆ alkylsulfonyloxy group” includehalogenomethylsulfonyloxy, and halogenoethylsulfonyloxy.

In the present specification, unless otherwise specified, examples ofthe “alkylsulfanyl (group)” include a C₁₋₆ alkylsulfanyl (group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkylsulfanyl (group)” include methylsulfanyl, ethylsulfanyl,n-propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl, sec-butylsulfanyl,and tert-butylsulfanyl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkylsulfanyl (group)” include cyclopropylsulfanyl,cyclobutylsulfanyl, cyclopentylsulfanyl, and cyclohexylsulfanyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ arylsulfanyl (group)” include phenylsulfanyl,1-naphthylsulfanyl, and 2-naphthylsulfanyl.

In the present specification, unless otherwise specified, examples ofthe “C₇₋₁₆ aralkylsulfanyl (group)” include benzylsulfanyl, andphenethylsulfanyl.

In the present specification, unless otherwise specified, examples ofthe heterocycle moiety of the “heterocyclyl-sulfanyl (group)” includethose similar to the aforementioned “heterocyclic group”. Specificallyas the “heterocyclyl-sulfanyl (group)”, for example, a 3- to 14-memberedheterocyclyl-sulfanyl (group) containing 1 to 5 hetero atoms selectedfrom a nitrogen atom, a sulfur atom, and an oxygen atom can bementioned.

In the present specification, unless otherwise specified, examples ofthe “alkyl-carbonyl (group)” include C₁₋₆ alkyl-carbonyl.

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkyl-carbonyl (group)” include acetyl, propionyl, andpivaloyl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyl-carbonyl (group)” include cyclopropylcarbonyl,cyclopentylcarbonyl, and cyclohexylcarbonyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ aryl-carbonyl (group)” include benzoyl, 1-naphthoyl, and2-naphthoyl.

In the present specification, unless otherwise specified, examples ofthe “C₇₋₁₆ aralkyl-carbonyl (group)” include phenylacetyl, and3-phenylpropionyl.

In the present specification, unless otherwise specified, examples ofthe heterocycle moiety of the “heterocyclyl-carbonyl (group)” includethose similar to the aforementioned “heterocyclic group”. Specifically,a 3- to 14-membered heterocyclyl-carbonyl (group) containing 1 to 5hetero atoms selected from a nitrogen atom, a sulfur atom, and an oxygenatom can be mentioned, and more specifically, for example, picolinoyl,nicotinoyl, isonicotinoyl, 2-thenoyl, 3-thenoyl, 2-furoyl, 3-furoyl,1-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, aziridin-1-ylcarbonyl,aziridin-2-ylcarbonyl, azetidin-1-ylcarbonyl, azetidin-2-ylcarbonyl,pyrrolidin-1-ylcarbonyl, pyrrolidin-2-ylcarbonyl,pyrrolidin-3-ylcarbonyl, piperidin-1-ylcarbonyl, piperidin-2-ylcarbonyl,piperidin-3-ylcarbonyl, azepan-1-ylcarbonyl, azepan-2-ylcarbonyl,azepan-3-ylcarbonyl, azepan-4-ylcarbonyl, azocan-1-ylcarbonyl,azocan-2-ylcarbonyl, azocan-3-ylcarbonyl, azocan-4-ylcarbonyl,1,4-piperazin-1-ylcarbonyl, 1,4-piperazin-2-ylcarbonyl,1,4-diazepan-1-ylcarbonyl, 1,4-diazepan-2-ylcarbonyl,1,4-diazepan-5-ylcarbonyl, 1,4-diazepan-6-ylcarbonyl,1,4-diazocan-1-ylcarbonyl, 1,4-diazocan-2-ylcarbonyl,1,4-diazocan-5-ylcarbonyl, 1,4-diazocan-6-ylcarbonyl,1,5-diazocan-1-ylcarbonyl, 1,5-diazocan-2-ylcarbonyl, and1,5-diazocan-3-ylcarbonyl can be mentioned.

In the present specification, unless otherwise specified, examples ofthe “optionally esterified carboxy (group)” include carboxy, optionallysubstituted alkoxy-carbonyl, optionally substituted C₆₋₁₄aryloxy-carbonyl, optionally substituted C₇₋₁₆ aralkyloxy-carbonyl,optionally substituted silyloxy-carbonyl (e.g., TMS-O—CO—, TES-O—CO—,TBS-O—CO—, TIPS-O—CO—, TBDPS-O—CO—) and the like.

In the present specification, unless otherwise specified, examples ofthe “alkoxy-carbonyl (group)” include a “C₁₋₆ alkoxy-carbonyl (group)”.

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkoxy-carbonyl (group)” include methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, and tert-butoxycarbonyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ aryloxy-carbonyl (group)” include phenoxycarbonyl.

In the present specification, unless otherwise specified, examples ofthe “C₇₋₁₆ aralkyloxy-carbonyl (group)” include benzyloxycarbonyl, andphenethyloxycarbonyl.

In the present specification, unless otherwise specified, examples ofthe “alkylsulfonyl (group)” include a C₁₋₆ alkylsulfonyl (group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkylsulfonyl (group)” include methylsulfonyl, andethylsulfonyl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkylsulfonyl (group)” include cyclopropylsulfonyl,cyclobutylsulfonyl, cyclopentylsulfonyl, and cyclohexylsulfonyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ arylsulfonyl (group)” include phenylsulfonyl,1-naphthylsulfonyl, and 2-naphthylsulfonyl.

In the present specification, unless otherwise specified, examples ofthe heterocycle moiety of the “heterocyclyl-sulfonyl (group)” includethose similar to the aforementioned “heterocyclic group”. Specificallyas the “heterocyclyl-sulfonyl (group)”, for example, a 3- to 14-memberedheterocyclyl-sulfonyl (group) containing 1 to 5 hetero atoms selectedfrom a nitrogen atom, a sulfur atom, and an oxygen atom can bementioned.

In the present specification, unless otherwise specified, examples ofthe “alkylsulfinyl (group)” include a C₁₋₆ alkylsulfinyl (group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkylsulfinyl (group)” include methylsulfinyl, andethylsulfinyl.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkylsulfinyl (group)” include cyclopropylsulfinyl,cyclobutylsulfinyl, cyclopentylsulfinyl, and cyclohexylsulfinyl.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ arylsulfinyl (group)” include phenylsulfinyl,1-naphthylsulfinyl, and 2-naphthylsulfinyl.

In the present specification, unless otherwise specified, to examples ofthe heterocycle moiety of the “heterocyclyl-sulfinyl (group)” includethose similar to the aforementioned “heterocyclic group”. Specificallyas the “heterocyclyl-sulfinyl (group)”, for example, a 3- to 14-memberedheterocyclyl-sulfinyl (group) containing 1 to 5 hetero atoms selectedfrom a nitrogen atom, a sulfur atom, and an oxygen atom can bementioned.

In the present specification, unless otherwise specified, examples ofthe “alkyl-carbamoyl (group)” include mono- or di-C₁₋₆ alkyl-carbamoyl(group).

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₁₋₆ alkyl-carbamoyl (group)” include methylcarbamoyl,dimethylcarbamoyl, ethylcarbamoyl, and propylcarbamoyl.

In the present specification, unless otherwise specified, examples ofthe “mono- or di-alkylamino (group)” include a mono- or di-C₁₋₆alkylamino (group).

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₁₋₆ alkylamino (group)” include methylamino,ethylamino, propylamino, dimethylamino, and diethylamino.

In the present specification, unless otherwise specified, examples ofthe “alkyl-carbonylamino (group)” include C₁₋₆ alkyl-carbonylamino(group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkyl-carbonylamino (group)” include acetylamino,propionylamino, and pivaloylamino.

In the present specification, unless otherwise specified, examples ofthe “heterocycle (group)” of the “heterocyclyl-amino (group)” includethose similar to the aforementioned “heterocyclic group”, and examplesof the “heterocyclyl-amino (group)” include 2-pyridyl-amino.

In the present specification, unless otherwise specified, examples ofthe “heterocyclyl-carbonyl” of the “heterocyclyl-carbonylamino (group)”include those similar to the aforementioned “heterocyclyl-carbonyl”, andexamples of the “heterocyclyl-carbonylamino (group)” includepyridyl-carbonylamino.

In the present specification, unless otherwise specified, examples ofthe “heterocycle (group)” of the “heterocyclyl-oxycarbonylamino (group)”include those similar to the aforementioned “heterocyclic group”, andexamples of the “heterocyclyl-oxycarbonylamino (group)” include2-pyridyl-oxycarbonylamino.

In the present specification, unless otherwise specified, examples ofthe “heterocycle (group)” of the “heterocyclyl-sulfonylamino (group)”include those similar to the aforementioned “heterocyclic group”, andexamples of the “heterocyclyl-sulfonylamino (group)” include2-pyridyl-sulfonylamino.

In the present specification, unless otherwise specified, examples ofthe “alkoxy-carbonylamino (group)” include a C₁₋₆ alkoxy-carbonylamino(group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkoxy-carbonylamino (group)” include methoxycarbonylamino,ethoxycarbonylamino, propoxycarbonylamino, and but oxycarbonylamino.

In the present specification, unless otherwise specified, examples ofthe “alkylsulfonylamino (group)” include a C₁₋₆ alkylsulfonylamino(group).

In the present specification, unless otherwise specified, examples ofthe “C₁₋₆ alkylsulfonylamino (group)” include methylsulfonylamino, andethylsulfonylamino.

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₃₋₇ cycloalkylamino (group)” include cyclopropylamino,cyclopentylamino, and cyclohexylamino.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyl-carbonylamino (group)” includecyclopropylcarbonylamino, cyclopentylcarbonylamino, andcyclohexylcarbonylamino.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkyloxy-carbonylamino (group)” includecyclopropoxycarbonylamino, cyclopentyloxycarbonylamino, andcyclohexyloxycarbonylamino.

In the present specification, unless otherwise specified, examples ofthe “C₃₋₇ cycloalkylsulfonylamino (group)” includecyclopropylsulfonylamino, cyclopentylsulfonylamino, andcyclohexylsulfonylamino.

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₆₋₁₄ arylamino (group)” include phenylamino, anddiphenylamino.

In the present specification, unless otherwise specified, examples ofthe “mono- or di-C₇₋₁₆ aralkylamino (group)” include benzylamino.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₄₄ aryl-carbonylamino (group)” include benzoylamino andnaphthoylamino.

In the present specification, unless otherwise specified, examples ofthe “C₆₋₁₄ arylsulfonylamino (group)” include phenylsulfonylamino,2-naphthylsulfonylamino, and 1-naphthylsulfonylamino.

The substituents of the compound of the present specification areexplained in the following.

[Substituent Group A]

In the present specification, substituent group A consists of thefollowing substituents (1)-(52).

-   (1) a halogen atom,-   (2) a nitro group,-   (3) a cyano group,-   (4) an optionally esterified carboxy group,-   (5) an optionally substituted alkyl group,-   (6) an optionally substituted alkenyl group,-   (7) an optionally substituted alkynyl group (e.g., an optionally    substituted C₃₋₇ cycloalkyl-C₂₋₆ alkynyl group),-   (8) an optionally substituted C₃₋₇ cycloalkyl group,-   (9) an optionally substituted C₆₋₁₄ aryl group,-   (10) an optionally substituted C₇₋₁₆ aralkyl group,-   (11) an optionally substituted C₆₋₁₄ aryl-C₂₋₆ alkenyl group,-   (12) an optionally substituted heterocyclic group,-   (13) a hydroxy group,-   (14) an optionally substituted alkoxy group,-   (15) an optionally substituted C₃₋₇ cycloalkyloxy group,-   (16) an optionally substituted C₆₋₁₄ aryloxy group,-   (17) an optionally substituted C₇₋₁₆ aralkyloxy group,-   (18) an optionally substituted alkyl-carbonyloxy group,-   (19) an optionally substituted alkoxy-carbonyloxy group,-   (20) an optionally substituted mono-alkyl-carbamoyloxy group,-   (21) an optionally substituted di-alkyl-carbamoyloxy group,-   (22) an optionally substituted C₆₋₁₄ aryl-carbonyloxy group,-   (23) an optionally substituted mono- or di-C₆₋₁₄ aryl-carbamoyloxy    group,-   (24) an optionally substituted heterocyclyl-oxy group (e.g.,    optionally substituted aromatic heterocyclyl-oxy group),-   (25) an optionally substituted C₁₋₆ alkylsulfonyloxy group (e.g.,    optionally substituted halogeno C₁₋₆ alkylsulfonyloxy group),-   (26) a sulfanyl (mercapto) group,-   (27) an optionally substituted alkylsulfanyl group,-   (28) an optionally substituted C₃₋₇ cycloalkylsulfanyl group,-   (29) an optionally substituted C₆₋₁₄ arylsulfanyl group,-   (30) an optionally substituted C₇₋₁₆ aralkylsulfanyl group,-   (31) an optionally substituted heterocyclyl-sulfanyl group,-   (32) a formyl group,-   (33) an optionally substituted alkyl-carbonyl group,-   (34) an optionally substituted C₃₋₇ cycloalkyl-carbonyl group,-   (35) an optionally substituted C₆₋₁₄ aryl-carbonyl group,-   (36) an optionally substituted C₇₋₁₆ aralkyl-carbonyl group,-   (37) an optionally substituted heterocyclyl-carbonyl group,-   (38) an optionally substituted alkylsulfonyl group,-   (39) an optionally substituted C₃₋₇ cycloalkylsulfonyl group,-   (40) an optionally substituted C₆₋₁₄ arylsulfonyl group,-   (41) an optionally substituted heterocyclyl-sulfonyl group,-   (42) an optionally substituted alkylsulfinyl group,-   (43) an optionally substituted C₃₋₇ cycloalkylsulfinyl group,-   (44) an optionally substituted C₆₋₁₄ arylsulfinyl group,-   (45) an optionally substituted heterocyclyl-sulfinyl group,-   (46) a sulfo group,-   (47) a sulfamoyl group,-   (48) a sulfinamoyl group,-   (49) a sulfenamoyl group,-   (50) a thiocarbamoyl group,-   (51) an optionally substituted carbamoyl group [e.g., an optionally    substituted alkyl-carbamoyl group and the like],-   (52) an optionally substituted amino group-   [e.g.,-   an amino,-   an optionally substituted mono- or di-alkylamino group,-   an optionally substituted mono- or di-C₃₋₇ cycloalkylamino group,-   an optionally substituted mono- or di-C₆₋₁₄ arylamino group,-   an optionally substituted mono- or di-C₇₋₁₆ aralkylamino group,-   an optionally substituted heterocyclyl-amino group,-   an optionally substituted C₆₋₁₄ aryl-carbonylamino group,-   a formylamino group,-   an optionally substituted alkyl-carbonylamino group (e.g.,    mono-(C₁₋₆ alkyl-carbonyl)-amino group),-   an optionally substituted C₃₋₇ cycloalkyl-carbonylamino group,-   an optionally substituted heterocyclyl-carbonylamino group,-   an optionally substituted alkoxy-carbonylamino group,-   an optionally substituted C₃₋₇ cycloalkyloxy-carbonylamino group,-   an optionally substituted heterocyclyl-oxycarbonylamino group,-   an optionally substituted carbamoylamino group,-   an optionally substituted alkylsulfonylamino group,-   an optionally substituted C₃₋₇ cycloalkylsulfonylamino group,-   an optionally substituted heterocyclyl-sulfonylamino group,-   an optionally substituted C₆₋₁₄ arylsulfonylamino group]

In substituent group A, examples of each substituent of

-   “optionally substituted alkoxy-carbonyl group”,-   “optionally substituted alkyl group”,-   “optionally substituted alkenyl group”,-   “optionally substituted alkynyl group”,-   “optionally substituted alkoxy group”,-   “optionally substituted alkyl-carbonyloxy group”,-   “optionally substituted alkoxy-carbonyloxy group”,-   “optionally substituted mono-alkyl-carbamoyloxy group”,-   “optionally substituted di-alkyl-carbamoyloxy group”,-   “optionally substituted alkylsulfanyl group”,-   “optionally substituted alkyl-carbonyl group”,-   “optionally substituted alkylsulfonyl group”,-   “optionally substituted alkylsulfinyl group”,-   “optionally substituted alkyl-carbamoyl group”,-   “optionally substituted mono- or di-alkylamino group”,-   “optionally substituted alkyl-carbonylamino group”,-   “optionally substituted mono-(C₁₋₆ alkyl-carbonyl)-amino group”,-   “optionally substituted alkoxy-carbonylamino group”, and-   “optionally substituted alkylsulfonylamino group” include    substituents selected from the following substituent group B. The    number of the substituents is 1 to the maximum substitutable number,    more preferably 1 to 3, more preferably 1.

In substituent group A, examples of each substituent of

-   “optionally substituted C₆₋₁₄ aryloxy-carbonyl group”,-   “optionally substituted C₇₋₁₆ aralkyloxy-carbonyl group”,-   “optionally substituted C₃₋₇ cycloalkyl-C₂₋₆ alkynyl group”,-   “optionally substituted C₃₋₇ cycloalkyl group”,-   “optionally substituted C₆₋₁₄ aryl group”,-   “optionally substituted C₇₋₁₆ aralkyl group”,-   “optionally substituted C₆₋₁₄ aryl-C₂₋₆ alkenyl group”,-   “optionally substituted heterocyclic group”,-   “optionally substituted C₃₋₇ cycloalkyloxy group”,-   “optionally substituted C₆₋₁₄ aryloxy group”,-   “optionally substituted C₇₋₁₆ aralkyloxy group”,-   “optionally substituted C₆₋₁₄ aryl-carbonyloxy group”,-   “optionally substituted mono- or di-C₆₋₁₄ aryl-carbamoyloxy group”,-   “optionally substituted heterocyclyl-oxy group”,-   “optionally substituted aromatic heterocyclyl-oxy group”,-   “optionally substituted C₃₋₇ cycloalkylsulfanyl group”,-   “optionally substituted C₆₋₁₄ arylsulfanyl group”,-   “optionally substituted C₇₋₁₆ aralkylsulfanyl group”,-   “optionally substituted heterocyclyl-sulfanyl group”,-   “optionally substituted C₃₋₇ cycloalkyl-carbonyl group”,-   “optionally substituted C₆₋₁₄ aryl-carbonyl group”,-   “optionally substituted C₇₋₁₆ aralkyl-carbonyl group”,-   “optionally substituted heterocyclyl-carbonyl group”,-   “optionally substituted C₃₋₇ cycloalkylsulfonyl group”,-   “optionally substituted C₆₋₁₄ arylsulfonyl group”,-   “optionally substituted heterocyclyl-sulfonyl group”,-   “optionally substituted C₃₋₇ cycloalkylsulfinyl group”,-   “optionally substituted C₆₋₁₄ arylsulfinyl group”,-   “optionally substituted heterocyclyl-sulfinyl group”,-   “optionally substituted carbamoyl group”,-   “optionally substituted amino group”,-   “optionally substituted mono- or di-C₃₋₈ cycloalkylamino group”,-   “optionally substituted mono- or di-C₈₋₁₄ arylamino group”,-   “optionally substituted mono- or di-C₇₋₁₈ aralkylamino group”,-   “optionally substituted heterocyclyl-amino group”,-   “optionally substituted C₆₋₁₄ aryl-carbonylamino group”,-   “optionally substituted C₃₋₈ cycloalkyl-carbonylamino group”,-   “optionally substituted heterocyclyl-carbonylamino group”,-   “optionally substituted C₃₋₈ cycloalkoxy-carbonylamino group”,-   “optionally substituted heterocyclyl-oxycarbonylamino group”,-   “optionally substituted carbamoylamino group”,-   “optionally substituted alkylsulfonylamino group”,-   “optionally substituted C₃₋₈ cycloalkylsulfonylamino group”,-   “optionally substituted heterocyclyl-sulfonylamino group”, and-   “optionally substituted C₆₋₁₄ arylsulfonylamino group” include    substituents selected from the following substituent group B and the    following substituent group B′. The number of the substituents is 1    to the maximum substitutable number, more preferably 1 to 3, more    preferably 1.    [Substituent Group B]

In the present specification, substituent group B consists of thefollowing substituents (a)-(bb).

-   (a) a halogen atom,-   (b) a hydroxy group,-   (c) a nitro group,-   (d) a cyano group,-   (e) an optionally substituted C₆₋₁₄ aryl group [for example, a C₆₋₁₄    aryl group optionally substituted by one or more (e.g., 1 to 5)    substituents selected from the group consisting of a halogen atom,    hydroxy, cyano, amino, optionally halogenated C₁₋₆ alkyl, mono- or    di-C₁₋₆ alkylamino, mono- or di-C₆₋₁₄ arylamino, mono- or di-C₇₋₁₆    aralkylamino, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, formyl, C₁₋₆    alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆    aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryloxy-carbonyl,    C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆ alkylsulfanyl, C₁₋₆ alkylsulfinyl,    C₁₋₆ alkylsulfonyl, carbamoyl, thiocarbamoyl, mono- or di-C₁₋₆    alkyl-carbamoyl, and mono- or di-C₆₋₁₄ aryl-carbamoyl and the like],-   (f) an optionally substituted C₆₋₁₄ aryloxy group [for example, a    C₆₋₁₄ aryloxy group optionally substituted by one or more (e.g., 1    to 5) substituents selected from the group consisting of a halogen    atom, hydroxy, cyano, amino, optionally halogenated C₁₋₆ alkyl,    mono- or di-C₁₋₆ alkylamino, mono- or di-C₆₋₁₄ arylamino, mono- or    di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, formyl, C₁₋₆    alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆    aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryloxy-carbonyl,    C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆ alkylsulfanyl, C₁₋₆ alkylsulfinyl,    C₁₋₆ alkylsulfonyl, carbamoyl, thiocarbamoyl, mono- or di-C₁₋₆    alkyl-carbamoyl, and mono- or di-C₆₋₁₄ aryl-carbamoyl and the like],-   (g) an optionally substituted C₇₋₁₆ aralkyloxy group [for example, a    C₇₋₁₆ aralkyloxy group optionally substituted by one or more (e.g.,    1 to 5) substituents selected from the group consisting of a halogen    atom, hydroxy, cyano, amino, optionally halogenated C₁₋₆ alkyl,    mono- or di-C₁₋₆ alkylamino, mono- or di-C₆₋₁₄ arylamino, mono- or    di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, formyl, C₁₋₆    alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆    aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryloxy-carbonyl,    C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆ alkylsulfanyl, C₁₋₆ alkylsulfinyl,    C₁₋₆ alkylsulfonyl, carbamoyl, thiocarbamoyl, mono- or di-C₁₋₆    alkyl-carbamoyl, and mono- or di-C₆₋₁₄ aryl-carbamoyl and the like],-   (h) an optionally substituted mono- or di-5- to 10-membered    heterocyclic group containing 1 to 4 hetero atoms selected from a    nitrogen atom, a sulfur atom, and an oxygen atom [for example, a    mono- or di-5- to 10-membered heterocyclic group containing 1 to 4    hetero atoms selected from a nitrogen atom, a sulfur atom, and an    oxygen atom (e.g., furyl, pyridyl, thienyl, pyrrolidino,    1-piperidinyl, 4-piperidyl, piperazinyl, 1-morpholinyl,    4-thiomorpholinyl, azepan-1-yl, azocan-1-yl, azonan-1-yl,    3,4-dihydroisoquinolin-2-yl), which is optionally substituted by one    or more (e.g., 1 to 5) substituents selected from the group    consisting of a halogen atom, hydroxy, cyano, amino, optionally    halogenated C₁₋₆ alkyl, mono- or di-C₁₋₆ alkylamino, mono- or    di-C₆₋₁₄ arylamino, mono- or di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl,    C₁₋₆ alkoxy, formyl, C₁₋₆ alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl,    C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl,    C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆    alkylsulfanyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamoyl,    thiocarbamoyl, mono- or di-C₁₋₆ alkyl-carbamoyl, and mono- or    di-C₆₋₁₄ aryl-carbamoyl and the like],-   (i) an optionally substituted amino group [for example, an amino    group optionally substituted by 1 or 2 substituents selected from    the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₆₋₁₄ aryl, C₇₋₁₆    aralkyl, a heterocyclic group, and heterocyclyl-alkyl, each of which    is optionally substituted (examples of the substituent of the “C₁₋₆    alkyl, C₂₋₆ alkenyl, C₆₋₁₄ aryl, C₇₋₁₆ aralkyl, a heterocyclic    group, and heterocyclyl-alkyl, each of which is optionally    substituted” include a halogen atom, hydroxy, cyano, amino,    optionally halogenated C₁₋₆ alkyl (which is not substituent of alkyl    and alkenyl), mono- or di-C₁₋₆ alkylamino, mono- or di-C₆₋₁₄    arylamino, mono- or di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl, C₁₋₆    alkoxy, formyl, C₁₋₆ alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl, C₆₋₁₄    aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₃₋₇    cycloalkyloxy-carbonyl, C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆    aralkyloxy-carbonyl, C₁₋₆ alkylsulfanyl, C₃₋₇ cycloalkylsulfanyl,    C₁₋₆ alkylsulfinyl, C₃₋₇ cycloalkylsulfinyl, C₁₋₆ alkylsulfonyl,    C₃₋₇ cycloalkylsulfonyl, carbamoyl, thiocarbamoyl, mono- or di-C₁₋₆    alkyl-carbamoyl, and mono- or di-C₆₋₁₄ aryl-carbamoyl and the like.    The number of the substituents is one or more (e.g., 1 to 5).    Examples of the “heterocyclyl-” of the “heterocyclic group” and    “heterocyclyl-alkyl” include those similar to the aforementioned    “heterocyclic group”.)],-   (j) a C₃₋₇ cycloalkyl,-   (k) an optionally substituted C₁₋₆ alkoxy group [for example, a C₁₋₆    alkoxy group optionally substituted by one or more (e.g., 1 to 5)    substituents selected from the group consisting of a halogen atom,    hydroxy, amino, mono- or di-C₁₋₆ alkylamino, mono- or di-C₆₋₁₄    arylamino, C₃₋₇ cycloalkyl, C₁₋₆ alkoxy, formyl, C₁₋₆    alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl, C₆₋₁₄ aryl-carbonyl, C₇₋₁₆    aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, C₆₋₁₄ aryloxy-carbonyl,    C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆ alkylsulfanyl, C₁₋₆ alkylsulfinyl,    C₁₋₆ alkylsulfonyl, carbamoyl, thiocarbamoyl, mono- or di-C₁₋₆    alkyl-carbamoyl, and mono- or di-C₆₋₁₄ aryl-carbamoyl,    trimethylsilyl (TMS) and the like],-   (l) a formyl group,-   (m) a C₁₋₆ alkyl-carbonyl group (e.g., acetyl etc.)-   (n) a C₃₋₇ cycloalkyl-carbonyl group,-   (o) a C₆₋₁₄ aryl-carbonyl group,-   (p) a C₇₋₁₆ aralkyl-carbonyl group,-   (q) a C₁₋₆ alkoxy-carbonyl group,-   (r) a C₆₋₁₄ aryloxy-carbonyl group,-   (s) a C₇₋₁₆ aralkyloxy-carbonyl group,-   (t) a C₁₋₆ alkylsulfanyl group,-   (u) a C₁₋₆ alkylsulfinyl group,-   (v) a C₁₋₆ alkylsulfonyl group,-   (w) a carbamoyl group,-   (x) a thiocarbamoyl group,-   (y) a mono-C₁₋₆ alkyl-carbamoyl group (e.g., methylcarbamoyl,    ethylcarbamoyl and the like),-   (z) a di-C₁₋₆ alkyl-carbamoyl group (e.g., dimethylcarbamoyl,    diethylcarbamoyl, ethylmethylcarbamoyl and the like),-   (aa) a mono- or di-C₆₋₁₄ aryl-carbamoyl group (e.g. phenylcarbamoyl,    1-naphthylcarbamoyl, 2-naphthylcarbamoyl and the like), and-   (bb) a mono- or di-5- to 7-membered heterocyclyl containing 1 to 4    hetero atoms selected from a nitrogen atom, a sulfur atom, and an    oxygen atom-carbamoyl group (e.g. 2-pyridylcarbamoyl,    3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-thienylcarbamoyl,    3-thienylcarbamoyl and the like).    [Substituent Group B′]

In the present specification, substituent group B′ consists of thefollowing substituents (a)-(c).

-   (a) an optionally substituted C₁₋₆ alkyl group [for example, a C₁₋₆    alkyl group optionally substituted by one or more (e.g., 1 to 5)    substituents selected from the group consisting of a halogen atom,    hydroxy, cyano, amino, mono- or di-C₁₋₆ alkylamino, mono- or    di-C₆₋₁₄ arylamino, mono- or di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl,    C₁₋₆ alkoxy, formyl, C₁₋₆ alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl,    C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl,    C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆    alkylsulfanyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamoyl,    thiocarbamoyl, mono- or di-C₁₋₆ alkyl-carbamoyl, and mono- or    di-C₆₋₁₄ aryl-carbamoyl and the like],-   (b) an optionally substituted C₂₋₆ alkenyl group [for example, a    C₂₋₆ alkenyl group optionally substituted by one or more (e.g., 1    to 5) substituents selected from the group consisting of a halogen    atom, hydroxy, cyano, amino, mono- or di-C₁₋₆ alkylamino, mono- or    di-C₆₋₁₄ arylamino, mono- or di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl,    C₁₋₆ alkoxy, formyl, C₁₋₆ alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl,    C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl,    C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, C₁₋₆    alkylsulfanyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamoyl,    thiocarbamoyl, mono- or di-C₁₋₆ alkyl-carbamoyl, and mono- or    di-C₆₋₁₄ aryl-carbamoyl and the like], and-   (c) an optionally substituted C₂₋₆ alkynyl group [for example, a    C₂₋₆ alkynyl group optionally substituted by one or more (e.g., 1    to 5) substituents selected from the group consisting of a halogen    atom, hydroxy, cyano, amino, mono- or di-C₁₋₆ alkylamino, mono- or    di-C₆₋₁₄ arylamino, mono- or di-C₇₋₁₆ aralkylamino, C₃₋₇ cycloalkyl,    C₁₋₆ alkoxy, formyl, C₁₋₆ alkyl-carbonyl, C₃₋₇ cycloalkyl-carbonyl,    C₆₋₁₄ aryl-carbonyl, C₇₋₁₆ aralkyl-carbonyl, C₁₋₆ alkoxy-carbonyl,    C₆₋₁₄ aryloxy-carbonyl, C₇₋₁₆ aralkyloxy-carbonyl, C₃₋₆    alkylsulfanyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, carbamoyl,    thiocarbamoyl, mono- or di-C₁₋₆ alkyl-carbamoyl, and mono- or    di-C₆₋₁₄ aryl-carbamoyl and the like].    [Substituent Group C]

In the present specification, substituent group C consists of thefollowing substituents (1)-(6).

-   (1) an oxo group,-   (2) an imino group,-   (3) an imino group optionally substituted by one substituent    selected from an optionally substituted alkyl group, an optionally    substituted C₃₋₇ cycloalkyl group, an optionally substituted C₆₋₁₄    aryl group, an optionally substituted C₇₋₁₆ aralkyl group, an    optionally substituted heterocyclic group, a hydroxy group, an    optionally substituted alkoxy group, an optionally substituted C₃₋₇    cycloalkyloxy group, an optionally substituted C₆₋₁₄ aryloxy group,    an optionally substituted C₇₋₁₆ aralkyloxy group, and an optionally    substituted heterocyclyl-oxy group,-   (4) a methylidene group optionally substituted by 1 or 2    substituents selected from an optionally substituted alkyl group, an    optionally substituted C₃₋₇ cycloalkyl group, an optionally    substituted C₆₋₁₄ aryl group, an optionally substituted C₇₋₁₆    aralkyl group, and an optionally substituted heterocyclic group,-   (5) an optionally substituted C₃₋₇ cycloalkylidene group, and-   (6) a C₂₋₇ alkylene group optionally substituted by one or more    (e.g., 1-3) substituents selected from an optionally substituted    alkyl group, an optionally substituted C₃₋₇ cycloalkyl group, an    optionally substituted C₆₋₁₄ aryl group, an optionally substituted    C₇₋₁₆ aralkyl group, and an optionally substituted heterocyclic    group (when the C₂₋₇ alkylene group is a divalent group on one    carbon atom, in other words, when the C₂₋₇ alkylene group    substitutes two hydrogen atoms on the aforementioned carbon atom,    the C₂₋₇ alkylene group forms C₃₋₈ cycloalkane together with the    aforementioned carbon atom).

Examples of the “optionally substituted alkyl group”, “optionallysubstituted C₃₋₇ cycloalkyl group”, “optionally substituted C₆₋₁₄ arylgroup”, “optionally substituted C₇₋₁₆ aralkyl group”, “optionallysubstituted heterocyclic group”, “optionally substituted alkoxy group”,“optionally substituted C₃₋₇ cycloalkyloxy group”, “optionallysubstituted C₆₋₁₄ aryloxy group”, “optionally substituted C₇₋₁₆aralkyloxy group”, and “optionally substituted heterocyclyl-oxy group”as the substituent of the substituents constituting substituent group Cinclude those similar to the substituents described as the substituentsconstituting substituent group A.

In addition, examples of the substituent of the “optionally substitutedC₃₋₇ cycloalkylidene group” include substituents selected from theabove-mentioned substituent group B and the above-mentioned substituentgroup B′. The number of the substituents is 1 to substitutable maximumnumber, more preferably 1-3, more preferably 1.

The symbols in the formula (I) and the formula (I′) are explained in thefollowing. For simplification of the description, the symbols in theformula (I) are explained, and respective symbols in the formula (I′)are the same as the corresponding ones in the formula (I).

Ring A is an optionally substituted 5-7-membered heterocycle.

Ring A is preferably an optionally substituted 6-membered heterocycle.Ring A is, for example, an optionally substituted 5-7-membered(preferably, 6-membered) heterocycle having, as ring-constituting atombesides carbon atom, two nitrogen atoms and one optionally mono- ordi-oxidized sulfur atom.

W is optionally substituted C₁₋₃ alkylene, or optionally substitutedC₂₋₃ alkenylene.

W is preferably, for example, optionally substituted ethylene(—CH₂—CH₂—), more preferably, ethylene (—CH₂—CH₂—).

As the “5-7-membered heterocycle” of the “optionally substituted5-7-membered heterocycle” for ring A, for example,4,5-dihydro-1,2,4-thiadiazole, 5,6-dihydro-4H-1,2,4-thiadiazine,4H-1,2,4-thiadiazine, 4,5,6,7-tetrahydro-1,2,4-thiadiazepine,4,5-dihydro-1,2,4-thiadiazepine, and 4,7-dihydro-1,2,4-thiadiazepine,and S-mono or dioxides thereof can be specifically mentioned.

As the substituent of the “optionally substituted 5-7-memberedheterocycle” for ring A, substituents selected from the aforementionedsubstituent group A can be mentioned. The number of the substituents ispreferably 0 (i.e., unsubstituted), or 1 to 5.

When two substituents are present on a single atom, the two substituentsmay be taken together to form a divalent substituent. As the divalentsubstituent, substituents selected from the aforementioned substituentgroup C can be mentioned.

Ring A is preferably, for example, 5,6-dihydro-4H-1,2,4-thiadiazine1,1-dioxide.

Ring B is an optionally substituted 5-8-membered heterocycle having, asa ring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 to 3 hetero atoms selected from a nitrogenatom, an oxygen atom and a sulfur atom.

As the “5-8-membered heterocycle having, as a ring-constituting atombesides carbon atom, one nitrogen atom, and optionally further having 1to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and asulfur atom” of the “optionally substituted 5-8-membered heterocyclehaving, as a ring-constituting atom besides carbon atom, one nitrogenatom, and optionally further having 1 to 3 hetero atoms selected from anitrogen atom, an oxygen atom and a sulfur atom” for ring B,non-aromatic heterocycle can be mentioned. The non-aromatic heterocyclemay be saturated or unsaturated.

Examples of the “non-aromatic heterocycle” include pyrrolidine ring,pyrazolidine ring, imidazolidine ring, 1,3-oxazolidine ring,isoxazolidine ring, 1,3-thiazolidine ring, isothiazolidine ring,piperidine ring, piperazine ring, morpholine ring, thiomorpholine ring,hexahydropyrimidine ring, hexahydropyridazine ring,3,4-dihydro-2H-1,4-oxazine ring, 4,5-dihydro-1H-imidazole ring,1,2-dihydropyridine ring, 1,2-dihydropyrazine ring,3,4-dihydro-2H-1,4-thiazine ring, 1,6-dihydropyrimidine ring,1,6-dihydropyridazine ring, 2,3-dihydro-1H-pyrazole ring,2,3-dihydroisoxazole ring, 2,3-dihydroisothiazole ring,2,5-dihydro-1H-1,2,3-triazole ring, 4,5-dihydro-1H-1,2,3-triazole ring,2,3-dihydro-1,2,5-oxadiazole ring, 2,3-dihydro-1,2,5-thiadiazole ring,1,2,3,6-tetrahydropyridine ring, 1,2,3,4-tetrahydropyridine ring,1,2,3,6-tetrahydropyrazine ring, 1,2,3,4-tetrahydropyrazine ring,1,2,3,4-tetrahydropyrimidine ring, 1,4,5,6-tetrahydropyrimidine ring,1,2,5,6-tetrahydropyrimidine ring, 1,2,3,6-tetrahydropyridazine ring,1,4,5,6-tetrahydropyridazine ring, 1,2,3,4-tetrahydropyridazine ring,4,5-dihydro-1,2,4-triazine ring, 1,6-dihydro-1,2,3-triazine ring,1,6-dihydro-1,2,4-triazine ring, azepane ring, 1,4-diazepane ring,1,4-oxazepane ring, 1,4-thiazepane ring, azocane ring, 1,4-diazocanering, 1,5-diazocane ring, 1,4-oxazocane ring, 1,5-oxazocane ring,1,4-thiazocane ring, and 1,5-thiazocane ring and the like. Thestructures of the above-mentioned “non-aromatic heterocycle” are shownbelow.

As the substituent of the “optionally substituted 5-8-memberedheterocycle having, as a ring-constituting atom besides carbon atom, onenitrogen atom, and optionally further having 1 to 3 hetero atomsselected from a nitrogen atom, an oxygen atom and a sulfur atom” forring B, substituents selected from the aforementioned substituent groupA can be mentioned. The number of the substituents is preferably 0(i.e., unsubstituted), or 1 to 5.

When two substituents are present on a single atom, the two substituentsmay be taken together to form a divalent substituent. As the divalentsubstituent, substituents selected from the aforementioned substituentgroup C can be mentioned.

Ring B is preferably, for example, a 6-membered heterocycle having, as aring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having one hetero atom selected from a nitrogen atom,an oxygen atom and a sulfur atom, which is optionally substituted bysubstituent(s) selected from a fluorine atom, a hydroxy group, a C₁₋₆alkyl group optionally substituted by 1 to 3 halogen atoms, a C₁₋₆alkoxy group and a C₁₋₆ alkyl-carbonyl group, more preferably, a6-membered heterocycle having, as a ring-constituting atom besidescarbon atom, one nitrogen atom, and optionally further having 1 to 3nitrogen atoms, which is optionally substituted by substituent(s)selected from a fluorine atom, a hydroxy group, a C₁₋₆ alkyl groupoptionally substituted by 1 to 3 halogen atoms, a C₁₋₆ alkoxy group anda C₁₋₆ alkyl-carbonyl group.

The “optionally substituted 6-membered heterocycle” is preferably, forexample, a 1,2-dihydropyridine ring, a 1,2-dihydropyrazine ring, apiperazine ring or a piperidine ring.

The substituent of the “optionally substituted 6-membered heterocycle”is preferably, for example, a fluorine atom, a hydroxy group, a C₁₋₆alkyl group optionally substituted by 1 to 3 halogen atoms, a C₁₋₆alkoxy group or a C₁₋₆ alkyl-carbonyl group.

Ring D is an optionally substituted non-aromatic hydrocarbon ring, anoptionally substituted non-aromatic heterocycle, an optionallysubstituted aromatic hydrocarbon ring, or an optionally substitutedaromatic heterocycle.

As the “non-aromatic hydrocarbon ring” of the “optionally substitutednon-aromatic hydrocarbon ring” for ring D, those mentioned above can bementioned.

As the “non-aromatic heterocycle” of the “optionally substitutednon-aromatic heterocycle” for ring D, those mentioned above can bementioned.

As the “aromatic hydrocarbon ring” of the “optionally substitutedaromatic hydrocarbon ring” for ring D, those mentioned above can bementioned.

As the “aromatic heterocycle” of the “optionally substituted aromaticheterocycle” for ring D, those mentioned above can be mentioned.

As the substituent of each of the “optionally substituted non-aromatichydrocarbon ring”, “optionally substituted non-aromatic heterocycle”,“optionally substituted aromatic hydrocarbon ring” and “optionallysubstituted aromatic heterocycle” for ring D, substituents selected fromthe aforementioned substituent group A can be mentioned. The number ofthe substituents is preferably 0 (i.e., unsubstituted), or 1 to 5.

When two substituents are present on a single atom, the two substituentsmay be taken together to form a divalent substituent. As the divalentsubstituent, substituents selected from the aforementioned substituentgroup C can be mentioned.

Ring D is preferably an aromatic hydrocarbon ring having a carbon numberof 6 to 14, a 5- or 6-membered aromatic heterocycle or a bicycliccondensed heterocycle, each of which is optionally substituted.

As each of the “aromatic hydrocarbon ring having a carbon number of 6 to14”, “5- or 6-membered aromatic heterocycle” and “bicyclic condensedheterocycle”, those mentioned above can be mentioned.

Ring D is preferably a 3-8-membered monocyclic non-aromatic hydrocarbonring, a 6-14-membered aromatic hydrocarbon ring, a 6-14-memberednon-aromatic hydrocarbon ring, a 5-6-membered monocyclic aromaticheterocycle, a 3-8-membered monocyclic non-aromatic heterocycle, a8-14-membered condensed aromatic heterocycle or a 6-14-memberedcondensed non-aromatic heterocycle, each of which is optionallysubstituted.

Ring D is particularly preferably, for example, C₃₋₇ cycloalkane, C₆₋₁₄arene (e.g., benzene ring, naphthalene ring), dihydronaphthalene ring,tetrahydronaphthalene ring, dihydroindene ring, azetidine ring,piperidine ring, furan ring, pyridine ring, pyrazole ring,1,2,4-oxadiazole ring, dihydrobenzodioxine ring, dihydrobenzofuran ring,benzodioxole ring, benzofuran ring, indole ring, quinoline ring,benzimidazole ring, benzothiazole ring, indazole ring, dibenzothiophenering or thiophene ring), each of which is optionally substituted.

The substituent of ring D is preferably, for example, 1 to 3substituents selected from the group consisting of

a halogen atom,

a cyano group,

a C₁₋₆ alkyl group optionally substituted by 1 to 3 halogen atoms,

a C₃₋₇ cycloalkyl group,

a C₆₋₁₄ aryl group,

a C₁₋₆ alkoxy group optionally substituted by 1 to 3 halogen atoms,

a C₆₋₁₄ aryloxy group,

a C₁₋₆ alkyl-carbonyl group, and

a mono- or di-C₁₋₆ alkyl-carbamoyl group,

or, for example, 1 to 3 substituents selected from the group consistingof

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom, 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl and 3)    C₁₋₆ alkoxycarbonyl;-   (6) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or    phenyl;-   (7) C₁₋₆ alkyl-carbonyl;-   (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy;-   (9) C₂₋₆ alkenyl substituted by phenyl;-   (10) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom, C₁₋₆ alkyl, C₃₋₇ cycloalkyl and C₁₋₆ alkoxy;-   (11) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇    cycloalkyl;-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) oxetane substituted by a halogen atom;-   (16) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl;-   (17) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (18) di-C₁₋₆ alkylcarbamoyl;-   (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (20) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted    by a halogen atom, tetrahydrofuran and tetrahydropyran;-   (21) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or    C₂₋₆ alkylenedioxy;-   (22) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (23) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy optionally    substituted by a halogen atom;-   (24) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆    alkyl optionally substituted by a halogen atom;-   (25) silyloxy substituted by C₁₋₆ alkyl;-   (26) tetrahydrofuranyloxy;-   (27) tetrahydropyranyloxy; and-   (28) dihydrobenzofuranyloxy.

L is a bond, or a spacer having the main chain having an atom number of1-8.

The “main chain” of the “spacer having the main chain having an atomnumber of 1-8” for L mean a divalent straight chain connecting thering-constituting atom of ring D and the ring-constituting atom of ringB. The “main chain” consists of 1-8 atoms selected from a carbon atomand a hetero atom (e.g., nitrogen atom, oxygen atom, sulfur atom etc.),and may be saturated or unsaturated. The nitrogen atom constituting themain chain is optionally substituted by a substituent (e.g., C₁₋₆ alkylgroup). S may be oxidized.

The “spacer having the main chain having an atom number of 1-8” for L ispreferably, for example, —Y^(a)—X^(a)—, —X^(a)—Y^(a)—, or—Y^(a)—X^(a)—Y^(b)—

-   (X^(a) is a bond, —O—, —NR^(a)—, —S(O)n-, —CO—NR^(a)—, —NR^(a)—CO—,    —SO₂—NR^(a)—, —NR^(a)—SO₂—, —NR^(a)—CO—NR^(b)—, —NR^(a)—OCO—, or    —OCO—NR^(a)—;-   n is 0, 1 or 2;-   Y^(a) and Y^(b) are the same or different and each is a bond, an    optionally substituted C₁₋₆ alkylene group, a C₂₋₆ alkenylene group,    or a C₂₋₆ alkynylene group;-   R^(a) is a hydrogen atom, an optionally substituted C₁₋₆ alkyl    group, or an optionally substituted C₃₋₆ cycloalkyl group.

L is preferably, for example, a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—,—NH—CO—, —S—, —SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene, or C₂₋₆alkynylene, particularly preferably a bond.

n is 0, 1 or 2.

n is preferably, for example, 2.

Preferable examples of the substituent, moiety, ring and the likeexplained in the present specification are more preferably used incombination.

As compound (I′), preferred is a compound wherein, for example, L is abond and ring D is an optionally substituted benzene ring.

As compound (I′), preferred is, for example, compound (I-A) below.

[Compound (I-A)]

A compound represented by the formula (I-A)

wherein

ring B is an optionally substituted 6-membered heterocycle having, as aring-constituting atom besides carbon atom, one nitrogen atom, andoptionally further having 1 hetero atom selected from a nitrogen atom,an oxygen atom and a sulfur atom,

ring D is an aromatic hydrocarbon ring having a carbon number of 6 to14, a 5- or 6-membered aromatic heterocycle, or a bicyclic condensedheterocycle, each of which is optionally substituted by 1-3 substituentsselected from

a halogen atom,

a cyano group,

a C₁₋₆ alkyl group optionally substituted by 1 to 3 halogen atoms,

a C₃₋₇ cycloalkyl group,

a C₆₋₁₄ aryl group,

a C₁₋₆ alkoxy group optionally substituted by 1 to 3 halogen atoms,

a C₆₋₁₄ aryloxy group,

a C₁₋₆ alkyl-carbonyl group, and

a mono- or di-C₁₋₆ alkyl-carbamoyl group,

-   L is a bond, —O—, —CO—NH—, —NH—CO—, —S—, —SO—, —SO₂—, C₁₋₆ alkylene,    C₂₋₆ alkenylene, or C₂₋₆ alkynylene, and-   n is 2,    or a salt thereof.

As compound (I-A), particularly preferred is a compound wherein ring Bis a 6-membered heterocycle, having, as a ring-constituting atom besidescarbon atom, one nitrogen atom, and further having one hetero atomselected from a nitrogen atom, an oxygen atom and a sulfur atom, whichis optionally substituted by C₁₋₆ alkyl group optionally substituted by1 to 3 halogen atoms, or a salt thereof.

In another embodiment of the present invention, of compounds (1), acompound wherein

ring A and ring B are each an optionally substituted 6-membered ring,

ring B has, as a ring-constituting atom besides carbon atom, onenitrogen atom, and optionally further has 1 to 3 nitrogen atoms, and

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)-, —S—,—SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene

(hereinafter sometimes to be referred to as compound (I-i)) ispreferable.

Of the above-mentioned compounds (I-i), a compound wherein

W is optionally substituted —CH₂—CH₂—, and

n is 2

(hereinafter sometimes to be referred to as compound (I-ii)) is morepreferable.

Of compounds (I-i)-(I-ii), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from

-   a halogen atom;-   hydroxy;-   C₁₋₆ alkyl optionally substituted by a halogen atom;-   C₁₋₆ alkoxy; and-   C₁₋₆ alkyl-carbonyl    (hereinafter sometimes to be referred to as compound (I-iii)) is    more preferable.

Alternatively, of compounds (I-i)-(I-iii), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from ahalogen atom, hydroxy, C₁₋₆ alkyl and C₁₋₆ alkoxy

(hereinafter sometimes to be referred to as compound (I-iv)) is morepreferable.

Alternatively, of compounds (I-i)-(I-iv), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by C₁₋₆ alkyl

(hereinafter sometimes to be referred to as compound (I-v)) is morepreferable.

Alternatively, of compounds (I-i)-(I-v), a compound wherein

L is a bond, —O—, —O—CH₂—, C₁₋₆ alkylene or C₂₋₆ alkynylene

(hereinafter sometimes to be referred to as compound (I-yl)) is morepreferable.

Alternatively, of compounds (I-i)-(I-yl), a compound wherein

L is a bond

(hereinafter sometimes to be referred to as compound (I-vii)) is morepreferable.

Alternatively, of compounds (I-i)-(I-vii), a compound wherein

ring D is an optionally substituted 3-8-membered monocyclic non-aromatichydrocarbon ring, an optionally substituted 6-14-membered aromatichydrocarbon ring, an optionally substituted 6-14-membered non-aromatichydrocarbon ring, an optionally substituted 5-6-membered monocyclicaromatic heterocycle, an optionally substituted 3-8-membered monocyclicnon-aromatic heterocycle, an optionally substituted 8-14-memberedcondensed aromatic heterocycle or an optionally substituted6-14-membered condensed non-aromatic heterocycle (hereinafter sometimesto be referred to as compound (I-viii)) is more preferable.

Alternatively, of compounds (I-i)-(I-viii), a compound wherein

ring D is

-   optionally substituted C₃₋₇ cycloalkane,-   optionally substituted C₆₋₁₄ arene,-   optionally substituted dihydronaphthalene,-   optionally substituted tetrahydronaphthalene,-   optionally substituted dihydroindene,-   optionally substituted thiophene,-   optionally substituted azetidine,-   optionally substituted piperidine,-   optionally substituted furan,-   optionally substituted pyridine,-   optionally substituted pyrazole,-   optionally substituted 1,2,4-oxadiazole,-   optionally substituted dihydrobenzodioxine,-   optionally substituted dihydrobenzofuran,-   optionally substituted benzodioxole,-   optionally substituted benzofuran,-   optionally substituted indole,-   optionally substituted quinoline,-   optionally substituted benzimidazole,-   optionally substituted benzothiazole,-   optionally substituted indazole, or-   optionally substituted dibenzothiophene    (hereinafter sometimes to be referred to as compound (I-ix)) is more    preferable.

Alternatively, of compounds (I-i)-(I-ix), a compound wherein

ring D is C₃₋₇ cycloalkane, C₆₋₁₄ arene, dihydronaphthalene,tetrahydronaphthalene, dihydroindene, thiophene, azetidine, piperidine,furan, pyridine, pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxine,dihydrobenzofuran, benzodioxole, benzofuran, indole, quinoline,benzimidazole, benzothiazole, indazole or dibenzothiophene, each ofwhich is optionally substituted by 1-4 substituents selected from

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom, 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl and 3)    C₁₋₆ alkoxycarbonyl;-   (6) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or    phenyl;-   (7) C₁₋₆ alkyl-carbonyl;-   (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy;-   (9) C₂₋₆ alkenyl substituted by phenyl;-   (10) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom, C₁₋₆ alkyl, C₃₋₇ cycloalkyl and C₁₋₆ alkoxy;-   (11) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇    cycloalkyl;-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) oxetane substituted by a halogen atom;-   (16) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl;-   (17) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (18) di-C₁₋₆ alkylcarbamoyl;-   (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (20) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted    by a halogen atom, tetrahydrofuran and tetrahydropyran;-   (21) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or    C₂₋₆ alkylenedioxy;-   (22) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (23) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy optionally    substituted by a halogen atom;-   (24) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆    alkyl optionally substituted by a halogen atom;-   (25) silyloxy substituted by C₁₋₆ alkyl;-   (26) tetrahydrofuranyloxy;-   (27) tetrahydropyranyloxy; and-   (28) dihydrobenzofuranyloxy    (hereinafter sometimes to be referred to as compound (I-x)) is more    preferable.

Alternatively, of compounds (I-i)-(I-ix), a compound wherein

ring D is C₃₋₇ cycloalkane, benzene, naphthalene, pyridine or thiophene,each of which is optionally substituted (hereinafter sometimes to bereferred to as compound (I-xi)) is more preferable.

Alternatively, of compounds (I-i)-(I-xi), a compound wherein

ring D is benzene optionally substituted by 1-3 substituents selectedfrom

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom, 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl, and 3)    C₁₋₆ alkoxycarbonyl;-   (5) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or    phenyl;-   (6) C₁₋₆ alkyl-carbonyl;-   (7) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy;-   (8) C₂₋₆ alkenyl substituted by phenyl;-   (9) phenyl optionally substituted by a halogen atom or C₁₋₆ alkyl;-   (10) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇    cycloalkyl;-   (11) pyrrolidine;-   (12) dihydrobenzofuran;-   (13) morpholine;-   (14) oxetane substituted by a halogen atom;-   (15) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl;-   (16) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (17) di-C₁₋₆ alkylcarbamoyl;-   (18) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (19) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted    by a halogen atom, tetrahydrofuran and tetrahydropyran;-   (20) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or    C₂₋₆ alkylenedioxy;-   (21) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (22) phenyloxy optionally substituted by substituent(s) selected    from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy optionally    substituted by a halogen atom;-   (23) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆    alkyl optionally substituted by a halogen atom;-   (24) silyloxy substituted by C₁₋₆ alkyl;-   (25) tetrahydrofuranyloxy;-   (26) tetrahydropyranyloxy; and-   (27) dihydrobenzofuranyloxy    (hereinafter sometimes to be referred to as compound (I-xii)) is    more preferable.

Alternatively, of compounds (I-i)-(I-xii), a compound wherein

ring D is benzene optionally substituted by 1-3 substituents selectedfrom

-   (1) a halogen atom;-   (2) hydroxy;-   (3) C₁₋₆ alkyl optionally substituted by substituent(s) selected    from 1) a halogen atom and 2) phenyl optionally substituted by    substituent(s) selected from a halogen atom and C₁₋₆ alkyl;-   (4) C₃₋₇ cycloalkyl;-   (5) phenyl-carbonyl;-   (6) C₂₋₆ alkenyl substituted by phenyl;-   (7) phenyl optionally substituted by a halogen atom or C₁₋₆ alkyl;-   (8) pyrrolidine;-   (9) dihydrobenzofuran;-   (10) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom;-   (11) C₁₋₆ alkoxy optionally substituted by substituent(s) selected    from a halogen atom, C₃₋₇ cycloalkyl, phenyl substituted by a    halogen atom, tetrahydrofuran and tetrahydropyran;-   (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl;-   (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl;-   (14) phenyloxy optionally substituted by 1-3 substituent(s) selected    from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by a halogen atom, and C₁₋₆ alkoxy;-   (15) pyridyloxy substituted by a halogen atom, or C₁₋₆ alkyl    substituted by a halogen atom;-   (16) tetrahydrofuranyloxy;-   (17) tetrahydropyranyloxy; and-   (18) dihydrobenzofuranyloxy    (hereinafter sometimes to be referred to as compound (I-xiii)) is    more preferable.

Alternatively, of compounds (I-i)-(I-iii) and (I-viii)-(I-ix), acompound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from

-   a halogen atom;-   hydroxy;-   C₁₋₆ alkyl optionally substituted by a halogen atom;-   C₁₋₆ alkoxy; and-   C₁₋₆ alkyl-carbonyl,

ring D is C₃₋₇ cycloalkane, C₆₋₁₄ arene, dihydronaphthalene,tetrahydronaphthalene, dihydroindene, thiophene, azetidine, piperidine,furan, pyridine, pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxine,dihydrobenzofuran, benzodioxole, benzofuran, indole, quinoline,benzimidazole, benzothiazole, indazole or dibenzothiophene, each ofwhich is optionally substituted by 1-4 substituents selected from

-   (1) a halogen atom;-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) optionally substituted C₁₋₆ alkyl;-   (6) optionally substituted C₃₋₇ cycloalkyl;-   (7) substituted carbonyl;-   (8) substituted C₂₋₆ alkenyl;-   (9) optionally substituted C₆₋₁₄ aryl;-   (10) optionally substituted C₇₋₁₆ aralkyl;-   (11) optionally substituted pyrazole;-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) substituted oxetane;-   (16) substituted sulfanyl;-   (17) substituted C₁₋₆ alkylsulfonyloxy;-   (18) di-C₁₋₆ alkyl-carbamoyl;-   (19) substituted dioxaborolane;-   (20) optionally substituted C₁₋₆ alkoxy;-   (21) C₃₋₇ cycloalkyloxy;-   (22) optionally substituted C₃₋₇ cycloalkenyloxy;-   (23) optionally substituted C₆₋₁₄ aryloxy;-   (24) optionally substituted C₇₋₁₆ aralkyloxy;-   (25) optionally substituted pyridyloxy;-   (26) substituted silyloxy;-   (27) tetrahydrofuranyloxy;-   (28) tetrahydropyranyloxy; and-   (29) dihydrobenzofuranyloxy,

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)-, —S—,—SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene

(hereinafter sometimes to be referred to as compound (I-xiv)) is morepreferable.

Alternatively, of compounds (I-i)-(I-iii) and (I-viii)-(I-x), a compoundwherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from

-   a halogen atom (e.g., a fluorine atom, chlorine atom);-   hydroxy;-   C₁₋₆ alkyl (e.g., methyl) optionally substituted by a halogen atom    (e.g., a fluorine atom);-   C₁₋₆ alkoxy (e.g., methoxy); and-   C₁₋₆ alkyl-carbonyl (e.g., methylcarbonyl),

ring D is C₃₋₇ cycloalkane (e.g., cyclohexane), C₆₋₁₄ arene (e.g.,benzene, naphthalene), dihydronaphthalene, tetrahydronaphthalene,dihydroindene, thiophene, azetidine, piperidine, furan, pyridine,pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxine, dihydrobenzofuran,benzodioxole, benzofuran, indole, quinoline, benzimidazole,benzothiazole, indazole or dibenzothiophene, each of which is optionallysubstituted by 1-4 substituents selected from

-   (1) a halogen atom (e.g., a fluorine atom, chlorine atom);-   (2) cyano;-   (3) hydroxy;-   (4) oxo;-   (5) C₁₋₆ alkyl (e.g., methyl, ethyl, isopropyl, butyl, isobutyl,    sec-butyl, tert-butyl) optionally substituted by substituent(s)    selected from 1) a halogen atom (e.g., a fluorine atom), 2) phenyl    optionally substituted by substituent(s) selected from a halogen    atom (e.g., a fluorine atom) and C₁₋₆ alkyl (e.g., methyl) and 3)    C₁₋₆ alkoxycarbonyl (e.g., methoxycarbonyl);-   (6) C₃₋₇ cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl,    cyclohexyl) optionally substituted by C₁₋₆ alkoxycarbonyl (e.g.,    methoxycarbonyl) or phenyl;-   (7) C₁₋₆ alkyl-carbonyl (e.g., methylcarbonyl);-   (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy (e.g.,    methoxy);-   (9) C₂₋₆ alkenyl (e.g., vinyl) substituted by phenyl;-   (10) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom (e.g., a fluorine atom, chlorine atom), C₁₋₆    alkyl (e.g., methyl), C₃₋₇ cycloalkyl and C₁₋₆ alkoxy (e.g.,    methoxy);-   (11) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl (e.g., methyl) optionally substituted by a halogen    atom (e.g., a fluorine atom), and C₃₋₇ cycloalkyl (e.g.,    cyclopropyl);-   (12) pyrrolidine;-   (13) dihydrobenzofuran;-   (14) morpholine;-   (15) oxetane substituted by a halogen atom (e.g., a fluorine atom);-   (16) sulfanyl substituted by a halogen atom (e.g., a fluorine atom)    or C₁₋₆ alkyl (e.g., methyl);-   (17) C₁₋₆ alkylsulfonyloxy (e.g., methylsulfonyloxy) substituted by    a halogen atom (e.g., a fluorine atom);-   (18) di-C₁₋₆ alkylcarbamoyl (e.g., dimethylcarbamoyl,    diethylcarbamoyl);-   (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane;-   (20) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,    butoxy, isobutoxy, sec-butoxy, tert-butoxy, neopentoxy,    1-ethylpropoxy) optionally substituted by substituent(s) selected    from a halogen atom (e.g., a fluorine atom), C₃₋₇ cycloalkyl (e.g.,    cyclopropyl, cyclopentyl, cyclohexyl), phenyl optionally substituted    by a halogen atom (e.g., a fluorine atom), tetrahydrofuran and    tetrahydropyran;-   (21) C₃₋₇ cycloalkyloxy (e.g., cyclopropyloxy, cyclobutyloxy,    cyclopentyloxy, cyclohexyloxy, cycloheptyloxy) optionally    substituted by C₁₋₆ alkyl (e.g., methyl), oxo or C₂₋₆ alkylenedioxy    (e.g., 1,2-ethylenedioxy);-   (22) C₃₋₇ cycloalkenyloxy (e.g., cyclohexenyloxy) optionally    substituted by C₁₋₆ alkyl (e.g., methyl);-   (23) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom (e.g., a fluorine atom, chlorine atom,    bromine atom), cyano, hydroxy, C₁₋₆ alkyl (e.g., methyl, ethyl,    isopropyl, tert-butyl) optionally substituted by a halogen atom    (e.g., a fluorine atom), and C₁₋₆ alkoxy (e.g., methoxy, isopropoxy,    butoxy) optionally substituted by a halogen atom (e.g., a fluorine    atom);-   (24) pyridyloxy optionally substituted by a halogen atom (e.g.,    chlorine atom), or C₁₋₆ alkyl (e.g., methyl) optionally substituted    by a halogen atom (e.g., a fluorine atom);-   (25) silyloxy substituted by C₁₋₆ alkyl (e.g., methyl, tert-butyl);-   (26) tetrahydrofuranyloxy;-   (27) tetrahydropyranyloxy; and-   (28) dihydrobenzofuranyloxy,

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —NH—CO—, —CO—NH—NH—CO—,—CO—N(C₁₋₆ alkyl)-, —N(C₁₋₆ alkyl)-CO—, —S—, —SO—, —SO₂—, —CH₂—S—,—CH₂—SO—, —CH₂—SO₂—, C₁₋₆ alkylene (e.g., ethylene), C₂₋₆ alkenylene(e.g., ethenylene) or C₂₋₆ alkynylene (e.g., ethynylene)

(hereinafter sometimes to be referred to as compound (I-xv)) is morepreferable.

Alternatively, of compounds (I-i)-(I-iv), (I-viii)-(I-xi) and(I-xiv)-(I-xv), a compound wherein the partial structural formularepresented by the formula (I):

ring B is optionally substituted by substituent(s) (preferably 1-2)selected from a halogen atom, hydroxy, C₁₋₆ alkyl and C₁₋₆ alkoxy,

ring D is C₃₋₇ cycloalkane, benzene, naphthalene, pyridine or thiophene,each of which is optionally substituted by 1 to 3 substituents selectedfrom

-   (1) a halogen atom;-   (2) hydroxy;-   (3) C₁₋₆ alkyl optionally substituted by substituent(s) (preferably    1-3) selected from 1) a halogen atom, and 2) phenyl optionally    substituted by substituent(s) (preferably 1-3) selected from a    halogen atom and C₁₋₆ alkyl;-   (4) C₃₋₇ cycloalkyl;-   (5) phenyl-carbonyl;-   (6) C₂₋₆ alkenyl substituted by phenyl (preferably 1-2);-   (7) phenyl optionally substituted by halogen atom(s) (preferably    1-3) or C₁₋₆ alkyl (preferably 1-3);-   (8) pyrrolidine;-   (9) dihydrobenzofuran;-   (10) C₁₋₆ alkylsulfonyloxy substituted by halogen atom(s)    (preferably 1-3);-   (11) C₁₋₆ alkoxy optionally substituted by substituent(s)    (preferably 1-3) selected from a halogen atom, C₃₋₇ cycloalkyl,    phenyl substituted by halogen atom(s) (preferably 1-3),    tetrahydrofuran and tetrahydropyran;-   (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (14) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by halogen atom(s) (preferably 1-3), and C₁₋₆ alkoxy;-   (15) pyridyloxy substituted by halogen atom(s) (preferably 1-3), or    C₁₋₆ alkyl (preferably 1-3) substituted by halogen atom(s)    (preferably 1-3);-   (16) tetrahydrofuranyloxy;-   (17) tetrahydropyranyloxy; and-   (18) dihydrobenzofuranyloxy, and

L is a bond, —O—, —O—CH₂—, —CO—NH—, C₁₋₆ alkylene, or C₂₋₆ alkynylene

(hereinafter sometimes to be referred to as compound (I-xvi)) is morepreferable.

Alternatively, of compounds (I-i)-(I-xvi), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by one C₁₋₆ alkyl,

ring D is benzene optionally mono-substituted by

-   (1) C₃₋₇ cycloalkyloxy, or-   (2) phenyloxy optionally mono-substituted by C₁₋₆ alkyl, and

L is a bond

(hereinafter sometimes to be referred to as compound (I-xvii)) is morepreferable.

Alternatively, of compounds (I-i)-(I-xvi), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by C₁₋₆ alkyl (preferably 1-2),

ring D is benzene optionally substituted by 1 to 3 substituents selectedfrom

-   (1) a halogen atom;-   (2) hydroxy;-   (3) C₁₋₆ alkyl optionally substituted by substituent(s) (preferably    1-3) selected from 1) a halogen atom, and 2) phenyl optionally    substituted by substituent(s) (preferably 1-3) selected from halogen    atom(s) (preferably 1-3) and C₁₋₆ alkyl (preferably 1-3);-   (4) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl    (preferably 1-2) or phenyl (preferably 1-2);-   (5) phenyl-carbonyl;-   (6) C₂₋₆ alkenyl substituted by phenyl (preferably 1-2);-   (7) phenyl optionally substituted by halogen atom(s) (preferably    1-3) or C₁₋₆ alkyl (preferably 1-3);-   (8) pyrrolidine;-   (9) dihydrobenzofuran;-   (10) C₁₋₆ alkylsulfonyloxy substituted by halogen atom(s)    (preferably 1-3);-   (11) C₁₋₆ alkoxy optionally substituted by substituent(s)    (preferably 1-3) selected from a halogen atom, C₃₋₇ cycloalkyl,    phenyl substituted by halogen atom(s) (preferably 1-3),    tetrahydrofuran and tetrahydropyran;-   (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl    (preferably 1-3);-   (14) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally    substituted by halogen atom(s) (preferably 1-3), and C₁₋₆ alkoxy;-   (15) pyridyloxy substituted (preferably 1-3) by a halogen atom, or    C₁₋₆ alkyl substituted by halogen atom(s) (preferably 1-3);-   (16) tetrahydrofuranyloxy;-   (17) tetrahydropyranyloxy; and-   (18) dihydrobenzofuranyloxy, and

L is a bond

(hereinafter sometimes to be referred to as compound (I-xviii)) is morepreferable.

Alternatively, of compounds (I-i)-(I-iii), (I-viii)-(I-x) and(I-xiv)-(I-xv), a compound wherein

the partial structural formula represented by the formula (I):

ring B is optionally substituted by substituent(s) selected from

a halogen atom (e.g., a fluorine atom, chlorine atom); C₁₋₆ alkyl (e.g.,methyl) optionally substituted by a halogen atom (e.g., a fluorineatom); and C₁₋₆ alkoxy (e.g., methoxy),

ring D is C₃₋₇ cycloalkane (e.g., cyclohexane), C₆₋₁₄ arene (e.g.,benzene, naphthalene), tetrahydronaphthalene, dihydroindene, thiophene,pyridine, indole or benzothiazole, each of which is optionallysubstituted by 1 to 3 substituents selected from

-   (1) a halogen atom (e.g., a fluorine atom, chlorine atom);-   (2) hydroxy;-   (3) oxo;-   (4) C₁₋₆ alkyl (e.g., methyl, ethyl, isopropyl, butyl, isobutyl)    optionally substituted by substituent(s) selected from 1) a halogen    atom (e.g., a fluorine atom), and 2) phenyl optionally substituted    by substituent(s) selected from a halogen atom (e.g., a fluorine    atom) and C₁₋₆ alkyl (e.g., methyl);-   (5) C₃₋₇ cycloalkyl (e.g., cyclobutyl) optionally substituted by    phenyl;-   (6) C₁₋₆ alkyl-carbonyl (e.g., methylcarbonyl);-   (7) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy (e.g.,    methoxy);-   (8) phenyl optionally substituted by 1 to 3 substituents selected    from a halogen atom (e.g., a fluorine atom, chlorine atom), C₁₋₆    alkyl (e.g., methyl), and C₁₋₆ alkoxy (e.g., methoxy);-   (9) pyrazole optionally substituted by 1 to 3 substituents selected    from C₁₋₆ alkyl (e.g., methyl) optionally substituted by a halogen    atom (e.g., a fluorine atom), and C₃₋₇ cycloalkyl (e.g.,    cyclopropyl);-   (10) pyrrolidine;-   (11) morpholine;-   (12) oxetane substituted by a halogen atom (e.g., a fluorine atom);-   (13) sulfanyl substituted by C₁₋₆ alkyl (e.g., methyl);-   (14) C₁₋₆ alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy,    butoxy, tert-butoxy, neopentoxy, 1-ethylpropoxy) optionally    substituted by substituent(s) selected from a halogen atom (e.g., a    fluorine atom), phenyl substituted by a halogen atom (e.g., a    fluorine atom), tetrahydrofuran and tetrahydropyran;-   (15) C₃₋₇ cycloalkyloxy (e.g., cyclopropyloxy, cyclobutyloxy,    cyclohexyloxy, cycloheptyloxy) optionally substituted by oxo;-   (16) phenyloxy optionally substituted by 1 to 3 substituents    selected from a halogen atom (e.g., a fluorine atom, chlorine atom,    bromine atom), cyano, hydroxy, C₁₋₆ alkyl (e.g., methyl, ethyl)    optionally substituted by a halogen atom (e.g., a fluorine atom),    and C₁₋₆ alkoxy (e.g., methoxy);-   (17) pyridyloxy substituted by C₁₋₆ alkyl (e.g., methyl) optionally    substituted by a halogen atom (e.g., a fluorine atom); and-   (18) dihydrobenzofuranyloxy,

L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, C₁₋₆ alkylene (e.g.,ethylene), C₂₋₆ alkenylene (e.g., ethenylene) or C₂₋₆ alkynylene (e.g.,ethynylene)

(hereinafter sometimes to be referred to as compound (I-xix)) is morepreferable.

Moreover, in another embodiment of the present invention, of compounds(1), a compound wherein

ring D is benzene optionally mono-substituted by

-   (1) C₃₋₇ cycloalkyloxy, or-   (2) phenyloxy optionally substituted by one C₁₋₆ alkyl    (hereinafter sometimes to be referred to as compound (I-xix)) is    preferable.

Specific examples of compound (I) include the Example compounds.Therefrom

-   9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof;-   9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof; and-   9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine    2,2-dioxide or a salt thereof    are preferable.

When compound (I′) is a salt, examples of such salt include metal salt,ammonium salt, salt with organic base, salt with inorganic acid, saltwith organic acid, salt with basic or acidic amino acid and the like.Preferable examples of the metal salt include alkali metal salts such assodium salt, potassium salt and the like; alkaline earth metal saltssuch as calcium salt, magnesium salt, barium salt and the like; aluminumsalt and the like. Preferable examples of the salt with organic baseinclude salts with trimethylamine, triethylamine, pyridine, picoline,2,6-lutidine, ethanolamine, diethanolamine, triethanolamine,cyclohexylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and thelike. Preferable examples of the salt with inorganic acid include saltswith hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid,phosphoric acid and the like. Preferable examples of the salt withorganic acid include salts with formic acid, acetic acid,trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaricacid, maleic acid, citric acid, succinic acid, malic acid,methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid andthe like. Preferable examples of the salt with basic amino acid includesalts with arginine, lysine, ornithine and the like, and preferableexamples of the salt with acidic amino acid include salts with asparticacid, glutamic acid and the like. Of these, pharmaceutically acceptablesalts are preferable. When the compound has an acidic functional group,examples thereof include inorganic salts such as alkali metal salts(e.g., sodium salt, potassium salt, etc.), alkaline earth metal salts(e.g., calcium salt, magnesium salt, barium salt, etc.) and the like,ammonium salts, and the like. When the compound has a basic functionalgroup, examples thereof include salts with inorganic acids such ashydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid,phosphoric acid and the like, and salts with organic acids such asacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid,maleic acid, citric acid, succinic acid, methanesulfonic acid,p-toluenesulfonic acid and the like.

When compound (I′) has isomers such as tautomer, optical isomer,stereoisomer, positional isomer, rotational isomer and the like, anyisomers and mixture of isomers are encompassed in the compound of thepresent invention. Furthermore, when compound (I′) has an opticalisomer, an optical isomer separated from a racemate is also encompassedin compound (I′).

Compound (I′) may be a crystal, and a single crystal form and a mixtureof crystal forms are encompassed in compound (1′).

Compound (I′) may be a pharmaceutically acceptable cocrystal or acocrystal salt. Here, the cocrystal or cocrystal salt means acrystalline substance, which is constituted from two or more kinds ofspecific solids each having different physical properties (e.g.,structure, melting point, heat of fusion, hygroscopicity, solubility,stability and the like) at room temperature. The cocrystal and cocrystalsalt can be produced according to a cocrystallization method known perse.

Compound (I′) may be a solvate (e.g., hydrate etc.) or a non-solvate,both of which are encompassed in the compound (I′).

A compound labeled or substituted with an isotope (e.g., ²H, ³H, ¹¹C,¹⁴C, ¹⁸F, ³⁵S, ¹²⁵I and the like) and the like is also encompassed incompound (I′). The compound labeled with or substituted by an isotopecan be used as a tracer (PET tracer) to be used for, for example,Positron Emission Tomography (PET), and is useful in the field ofmedical diagnosis and the like.

[Production Method]

The production method of compound (I) of the present invention isexplained in the following. Compound (I′) encompassing compound (I) canalso be produced according to the production method of compound (I)explained hereafter.

Compound (I) of the present invention is obtained according to, forexample, the method shown in the following Reaction Scheme or a methodanalogous thereto and the like. Each symbol in the compounds in thereaction schemes is as defined above. Each compound shown in thereaction scheme may form a salt. Examples of the salt include saltssimilar to the salts of compound (I′). In addition, a reaction mixtureof the compound obtained in each step can be used directly or as a crudeproduct for the next reaction. The compound can also be isolated fromthe reaction mixture according to a conventional method, and can beeasily purified by a method known per se, for example, separation meanssuch as extraction, concentration, neutralization, filtration,distillation, recrystallization, distillation, chromatography and thelike. Alternatively, as the compound in the scheme, a commerciallyavailable product can also be used directly.

Schematic showing of the reaction schemes is given below.

In the formulas, X, Xa, Xb are leaving groups. Examples of the “leavinggroup” include halogen atoms; sulfonyloxy groups such asp-toluenesulfonyloxy group, methanesulfonyloxy group,trifluoromethanesulfonyloxy group and the like, and the like. X ispreferably a halogen atom such as chlorine, bromine, iodine and thelike. Xa and Xb are each preferably a halogen atom such as fluorine,chlorine and the like. Xc is a halogen atom such as fluorine, chlorine,bromine, iodine and the like. P is a protecting group. Examples of the“protecting group” include a t-butyldimethylsilyl group, a t-butoxycarbamate group, a 1,8-diaminonaphthyl group and the like. R is afunctional group such as a cyano group, an ester group, a carboxy group,an amido group, an aldehyde group, an acyl group, an imino group, aprotected amino group, an alkoxy group, a nitro group, an azido group,an isocyanato group and the like. R′ is a functional group such as anester group, a carboxy group, an amido group, an aldehyde group, anamino group, an amidine, a hydroxyamidine, an alkylimidate, a hydroxygroup, a hydroxymethyl group and the like, which is obtained byconverting R. Y is an organic metal functional group such as a boricacid, a borate, a vinylboric acid, a vinylborate, a propenylboric acid,a propenylborate, a magnesium halide, lithium and the like; an organicfunctional group such as a carboxy group, an ester group, an aminogroup, an aldehyde group, an amido group, a hydroxy group, ahydroxymethyl group, a sulfanyl(mercapto) group, asulfanylmethyl(mercaptomethyl) group, an aminomethyl group, anisocyanato group, a carbamate group, an ethynyl group, a hydrazido groupand the like; a halogen atom such as fluorine, chlorine, bromine, iodineand the like; hydrogen atom and the like, which is capable of forming alinker (L) by reacting with X or R′. Particularly, when ring D is asaturated ring, Y may be a carbonyl group formed together with thering-constituting carbon atom, or a ring-constituting nitrogen atomitself. R¹ is an optionally substituted alkyl group, an alkylcarbonylgroup or a protecting group, R² is a hydroxy group, an optionallysubstituted alkyl group, or deuterium, and R³ is an optionallysubstituted alkyl group. Ring Ba is an unsaturated ring encompassed inthe definition of ring B, and ring Bb is a saturated ring encompassed inthe definition of ring B. In addition, ring A, ring B, ring D, L and Ware as defined in the claims.

The production method of compound (I) is explained below according tothe aforementioned Reaction Schemes.

[Step 1]

Compound (IIa′) may be a commercially available product, or can also beproduced according to a known method or a method analogous thereto. Forexample, in Step 1, compound (IIa′) can be produced by subjectingcompound (IIa) to a coupling reaction or nucleophilic substitutionreaction with a nucleophilic reagent such as a metal cyanide and thelike, or reacting compound (IIa) with an organic metal and the like, andthen reacting the resulting compound with an electrophilic reagent suchas carbon dioxide and the like.

The coupling reaction with a nucleophilic reagent such as metal cyanideand the like is carried out, for example, using a base and a palladiumreagent or a copper reagent. A phosphine ligand may be used asnecessary.

Examples of the base used for this reaction include alkali metalhydroxide such as sodium hydroxide, potassium hydroxide and the like;alkali metal hydrogencarbonate such as sodium hydrogen carbonate and thelike; alkali metal carbonate such as sodium carbonate, potassiumcarbonate and the like; cesium salts such as cesium carbonate and thelike; alkali metal phosphates such as tripotassium phosphate and thelike; alkali metal hydrides such as sodium hydride, potassium hydrideand the like; sodium amide; alkali metal alkoxides such as sodiummethoxide, sodium ethoxide and the like; amines such as trimethylamine,triethylamine, N-ethyl-N-isopropylpropan-2-amine, diisopropylamine andthe like; cyclic amines such as pyridine, 4-dimethylaminopyridine, DBU(1,8-diazabicyclo[5.4.0]undec-7-ene) and the like, and the like.

Examples of the palladium reagent includetetrakis(triphenylphosphine)palladium(0),bis(triphenylphosphine)palladium(II) dichloride,tris(dibenzylideneacetone)dipalladium(0),trans-dichlorobis(tri-o-tolylphosphine)palladium(II), palladium(II)trifluoroacetate, palladium(II) acetate and the like.

Examples of the copper catalyst include copper iodide, copper bromide,copper chloride, copper acetate and the like.

Examples of the phosphine ligand include triphenylphosphine,2,2′-bis(diphenylphosphino)-1,1′-binaphthyl,2-(di-tert-butylphosphino)biphenyl, 2-(dicyclohexylphosphino)biphenyl,2-(dicyclohexylphosphino)-2′,6′-dimethoxy-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′,4′,6′-triisopropyl-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl,1,1′-bis(diphenylphosphino)ferrocene, tri-tert-butylphosphine,tricyclohexylphosphine,(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) and the like.

In this reaction, for example, cyclohexyl-1,2-diamine,N,N′-dimethylcyclohexyl-1,2-diamine or picoline acid and the like may beused as necessary.

This reaction can be carried out without solvent or in a known solvent,for example, water; alcohols such as methanol, ethanol and the like;ethers such as diethyl ether, 1,4-dioxane, 1,2-dimethoxyethane,tetrahydrofuran and the like; aromatic hydrocarbons such as benzene,toluene, xylene and the like; esters such as ethyl acetate and the like;halogenated hydrocarbons such as chloroform, dichloromethane and thelike; nitriles such as acetonitrile and the like; amides such asN,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidinoneand the like; ketones such as acetone, 2-butanone and the like;sulfoxides such as dimethylsulfoxide and the like, and the like. Thesesolvents may be used alone or mixed at a suitable ratio.

This reaction may be carried out under an atmosphere of, for example,nitrogen, argon and the like as necessary.

In this reaction, per 1 mol of the starting compound, the amount of thenucleophilic reagent such as a metal cyanide and the like is generallyabout 0.5-about 10 mol, preferably about 1-about 5 mol, the amount ofthe base is generally about 0.1-about 100 equivalents, preferably about1-about equivalents, the amount of the palladium reagent or copperreagent is generally about 0.01-about 2 equivalents, preferably about0.01-about 0.5 equivalents, the amount of the phosphine ligand isgenerally about 0.01-about 2 equivalents, preferably about 0.01-about0.5 equivalents, and the amount of the cyclohexyl-1,2-diamine isgenerally about 0.01-about 2 equivalents, preferably about 0.01-about 1equivalents. The reaction temperature is generally 0° C.-200° C.,preferably 50° C.-150° C. The reaction time is about 0.1-about 100 hr,preferably about 0.5-about 50 hr.

A base may be used in the substitution reaction with a nucleophilicreagent such as metal cyanide and the like as necessary. Examples of thebase used for the reaction include alkali metal hydroxide such as sodiumhydroxide, potassium hydroxide and the like; alkali metalhydrogencarbonate such as sodium hydrogen carbonate and the like; alkalimetal carbonate such as sodium carbonate, potassium carbonate and thelike; cesium salts such as cesium carbonate and the like; alkali metalhydrides such as sodium hydride, potassium hydride and the like; sodiumamide; alkali metal alkoxides such as sodium methoxide, sodium ethoxideand the like; amine such as trimethylamine, triethylamine,diisopropylamine and the like; cyclic amine such as pyridine,4-dimethylaminopyridine, DBU and the like, and the like.

This reaction can be carried out without solvent or in a known solvent,for example, water; alcohols such as methanol, ethanol and the like;ethers such as diethyl ether, 1,4-dioxane, tetrahydrofuran and the like;aromatic hydrocarbons such as benzene, toluene, xylene and the like;esters such as ethyl acetate and the like; halogenated hydrocarbons suchas chloroform, dichloromethane and the like; nitriles such asacetonitrile and the like; amides such as N,N-dimethylformamide,N,N-dimethylacetamide, 1-methyl-2-pyrrolidinone and the like; ketonessuch as acetone, 2-butanone and the like; sulfoxides such asdimethylsulfoxide and the like, and the like. These solvents may be usedalone or mixed at a suitable ratio.

This reaction may be carried out under atmosphere such as nitrogen,argon and the like, as necessary.

In this reaction, per 1 mol of the starting compound, the amount of thenucleophilic reagent such as a metal cyanide and the like is generallyabout 1-about 10 mol, preferably about 1-about 5 mol, and the amount ofthe base is generally about 0.1-about 100 equivalents, preferably about1-about 5 equivalents. The reaction temperature is generally 0° C.-200°C., preferably 50° C.-150° C. The reaction time is about 0.1-about 100hr, preferably about 0.5-about 50 hr.

The organic metal and the like used in the step of the reaction with anelectrophilic reagent such as carbon dioxide and the like after thereaction with the organic metal and the like include LDA (lithiumdiisopropylamide), butyllithium, methylmagnesium bromide and the like.

This reaction can be carried out in a suitable solvent such as anaprotonic solvent and the like (e.g., polar compound (e.g., DMF(N,N-dimethylformamide), DMSO (dimethyl sulfoxide), HMPA(hexamethylphosphoric triamide)), a nitrile compound (e.g.,acetonitrile, propionitrile), an ether compound (THF (tetrahydrofuran),dioxane, diethyl ether, dibutyl ether, dimethoxyethane), a ketonecompound (acetone, methyl ethyl ketone, methyl isobutyl ketone), anaromatic hydrocarbon (e.g., benzene, toluene, xylene and the like), ahalogenated aromatic hydrocarbon (e.g., monochlorobenzene,dichlorobenzene and the like), an aliphatic hydrocarbon (hexane,heptane, octane), and a mixed solvent thereof, and the like).

The reaction temperature is generally about −78 to about 60° C.,preferably about −20 to about 20° C. A temperature not less than or notmore than these temperatures can be employed as necessary. The reactiontime is generally about 10 min-about 24 hr, preferably about 30 min-12hr. A reaction time not less than or not more than the above can beemployed as necessary.

[Step 2]

Compound (IIa″) may be a commercially available product, or can also beproduced according to a known method or a method analogous thereto. Forexample, in step 2, compound (IIa″) can be produced by converting thefunctional group R of compound (IIa′) into a functional group R′ usinghydrolysis, oxidation, reduction, nucleophilic addition, deprotectionand the like.

The representative examples of some of the functional group R are morespecifically explained in the following.

(1) Hydrolysis of Cyano Group, Amido Group or Ester Group

For example, an amido group or an ester group can be converted to acarboxyl group by hydrolysis. A cyano group can be converted to an estergroup, an amido group and the like by hydrolysis, and converted to acarboxyl group by employing strong conditions such as heating, prolongedreaction time and the like.

For these reactions, hydrolysis method under basic conditions or acidicconditions is generally employed.

The hydrolysis under basic conditions is carried out, for example, bytreatment with an alkali such as lithium hydroxide, sodium hydroxide,potassium hydroxide and the like. The hydrolysis is preferably carriedout by dissolving compound (IIa′) in an alcohol such as methanol,ethanol and the like; a water-soluble solvent such as tetrahydrofuran,dioxane and the like; or a mixed solvent thereof, and treating thesolution with an aqueous alkali solution such as an aqueous sodiumhydroxide solution, an aqueous lithium hydroxide solution and the like.

In this reaction, the amount of the aqueous alkali solution is generallyabout 1-about 10 equivalents, per 1 mol of the starting compound. Thereaction temperature is generally 0° C.-100° C., preferably 20° C.-100°C. The reaction time is about 0.1-about 100 hr, preferably about0.5-about 50 hr.

The hydrolysis under acidic conditions is carried out, for example, bytreatment with an acid such as hydrochloric acid, sulfuric acid, nitricacid and the like. The hydrolysis is preferably carried out bydissolving compound (IIa′) in an alcohol such as methanol, ethanol andthe like; a water-soluble solvent such as tetrahydrofuran, dioxane andthe like; or a mixed solvent thereof, and treating the solution with anaqueous acid solution such as hydrochloric acid, sulfuric acid, nitricacid and the like.

In this reaction, the amount of the aqueous acid solution is generallyabout 1-about 10 equivalents, per 1 mol of the starting compound. Thereaction temperature is generally 0° C.-100° C., preferably 20° C.-100°C. The reaction time is about 0.1-about 100 hr, preferably about0.5-about 50 hr.

(2) Reduction of Cyano Group, Ester Group or Amido Group

Alternatively, for example, a cyano group or an ester group can beconverted to an aldehyde group by reduction, an ester group can beconverted to a hydroxymethyl group by reduction, and a cyano group or anamido group can be converted to an aminomethyl group by reduction.

Examples of the reducing agent include metal hydrides such as sodiumborohydride, lithium aluminum hydride, diisopropyl aluminum hydride andthe like; boranes such as borane-tetrahydrofuran complex and the like,and the like. The amount of the reducing agent to be used is about0.5-about mol, preferably about 1-about 5 mol, per 1 mol of thecompound. In addition, an acid catalyst can be added together with thereducing agent when desired. Examples of the acid catalyst includeproton acids (e.g., acetic acid, trifluoroacetic acid and the like),Lewis acids (e.g., aluminum chloride and the like) and the like.

This reaction can be advantageously carried out without solvent or in asolvent inert to the reaction. Such solvent is not particularly limitedas long as the reaction proceeds, and examples thereof include water;alcohols such as methanol, ethanol, propanol and the like; hydrocarbonssuch as cyclohexane, hexane, benzene, toluene, xylene, mesitylene andthe like; organic acids such as formic acid, acetic acid and the like;ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diethylether, diisopropyl ether and the like; anilines such asN,N-dimethylaniline, N,N-diethylaniline and the like; halogenatedhydrocarbons such as dichloromethane, chloroform, carbon tetrachloride,1,2-dichloroethane and the like; a mixed solvent thereof and the like.

The reaction temperature is generally about 0 to about 120° C.,preferably about 25 to about 60° C. A temperature not less than or notmore than these temperatures can be employed as necessary. The reactiontime is generally about 10 min-about 24 hr, preferably about 30 min-12hr. A reaction time not less than or not more than the above can beemployed as necessary.

(3) Reduction of Azido Group or Nitro Group

Alternatively, an azido group or a nitro group can be converted to anamino group by reduction. This reaction can be specifically carried out,for example, by reduction with a metal reducing reagent such as lithiumborohydride, lithium aluminum hydride and the like as a reducing agent,or catalytic reduction with a transition metal (palladium-carbon,platinum oxide, Raney-nickel, rhodium, ruthenium etc.). Examples of theorganic solvent used for the reduction reaction include methanol,ethanol, tertiary butyl alcohol, tetrahydrofuran, diethyl ether,dioxane, acetone, ethyl acetate, acetic acid, benzene, toluene, xylene,dimethylformamide, dimethylsulfoxide and the like.

The reaction temperature for the reduction reaction is generally −20 to80° C., preferably about 0 to about 40° C. A temperature not less thanor not more than these temperatures can be employed as necessary. Thereaction time for the reduction reaction is generally 5 min-24 hr,preferably about 30 min-12 hr. A reaction time not less than or not morethan the above can be employed as necessary.

(4) Deprotection of Protected Amino Group

Alternatively, a protected amino group can be converted to an aminogroup by deprotection.

Examples of the deprotection of the protecting group such as an acetylgroup, a benzoyl group and the like include deprotection under acidicconditions, deprotection by basic hydrolysis, and the like.

The deprotection under acidic conditions is carried out, for example,without solvent or in an organic solvent (e.g., methylene chloride,chloroform, toluene, fluorobenzene, trifluorobenzene, dioxane, ethylacetate, anisole, methanol, ethanol, isopropyl alcohol etc.), water ormixed solvent thereof, in the presence of an organic acid (acetic acid,trifluoroacetic acid, methanesulfonic acid etc.), an inorganic acid(hydrochloric acid, sulfuric acid etc.) or a mixture thereof (hydrogenbromide/acetic acid etc.), at 0 to 100° C. A temperature not less thanor not more than these temperatures can be employed as necessary.

The deprotection by basic hydrolysis is carried out, for example, in anorganic solvent (e.g., an ether (tetrahydrofuran, dioxane,dimethoxyethane, diethyl ether etc.), an alcohol (methanol, ethanoletc.), a benzene (benzene, toluene etc.), a ketone (acetone, methylethyl ketone etc.), a nitrile (acetonitrile etc.), an amide(dimethylformamide etc.)), water, or a mixture of two or more kindsthereof, in the presence of an inorganic acid (sodium hydroxide,potassium hydroxide etc.), at 0 to 200° C. A temperature not less thanor not more than these temperatures can be employed as necessary.

Examples of the deprotection of a protecting group such as a benzoylgroup, a benzyloxycarbonyl group, a t-butoxycarbonyl group and the likeinclude deprotection under acidic conditions, deprotection byhydrogenolysis, and the like.

The deprotection under acidic conditions is carried out, for example, inan organic solvent (methylene chloride, chloroform, toluene,fluorobenzene, trifluorobenzene, dioxane, ethyl acetate, anisole,methanol, ethanol, isopropyl alcohol etc.) or in the absence of anorganic solvent, or a aqueous solution thereof, in the presence of anorganic acid (acetic acid, trifluoroacetic acid, methanesulfonic acidetc.), an inorganic acid (hydrochloric acid, sulfuric acid etc.) or amixture thereof (hydrogen bromide/acetic acid etc.), at 0 to 100° C. Atemperature not less than or not more than these temperatures can beemployed as necessary.

The deprotection by hydrogenolysis is carried out, for example, in asolvent (an ether (tetrahydrofuran, dioxane, dimethoxyethane, diethylether etc.), an alcohol (methanol, ethanol etc.), a benzene (benzene,toluene etc.), a ketone (acetone, methyl ethyl ketone etc.), a nitrile(acetonitrile etc.), an amide (dimethylformamide etc.), water, ethylacetate, acetic acid or a mixture of two or more kinds thereof), in thepresence of a catalyst (palladium-carbon, palladium black, palladiumhydroxide, platinum oxide, Raney-nickel etc.), under a hydrogenatmosphere, under normal pressure or pressurization, or in the presenceof ammonium formate, at 0 to 100° C. A temperature not less than or notmore than these temperatures can be employed as necessary.

Examples of the deprotection of a protecting group such as a benzylgroup and the like include deprotection by reaction with 1-chloroethylchlorocarbonate, and reacting the resulting quaternary salt with asolvent such as methanol and the like, or deprotection byhydrogenolysis, and the like.

The reaction with 1-chloroethyl chlorocarbonate is advantageouslycarried out without solvent or in a solvent inert to the reaction. Suchsolvent is not particularly limited as long as the reaction proceeds.For example, the reaction is carried out in an organic solvent(methylene chloride, 1,2-dichloroethane, chloroform, toluene,fluorobenzene, trifluorobenzene, dioxane, ethyl acetate etc.), at 0 to100° C. A temperature not less than or not more than these temperaturescan be employed as necessary. And then, the reaction mixture isconcentrated to give a quaternary salt, and then the quaternary salt isdissolved in an alcohol such as methanol, ethanol and the like; or in amixed solvent of the alcohol and a solvent inert to the reaction such astetrahydrofuran, dioxane and the like.

In this reaction, the reaction temperature is generally 0° C.-100° C.,preferably 20° C.-80° C. The reaction time is about 0.1-about 100 hr,preferably about 0.5-about 10 hr.

The deprotection by hydrogenolysis is carried out, for example, in asolvent (a ether (tetrahydrofuran, dioxane, dimethoxyethane, diethylether etc.), an alcohol (methanol, ethanol etc.), a benzene (benzene,toluene etc.), a ketone (acetone, methyl ethyl ketone etc.), a nitrile(acetonitrile etc.), an amide (dimethylformamide etc.), water, ethylacetate, acetic acid or a mixture of two or more kinds thereof), in thepresence of a catalyst (palladium-carbon, palladium black, palladiumhydroxide, platinum oxide, Raney-nickel etc.), under a hydrogenatmosphere, under normal pressure or pressurization, or in the presenceof ammonium formate, at 0 to 100° C. A temperature not less than or notmore than these temperatures can be employed as necessary.

The series of reaction time for the deprotection is generally about 10min-about 72 hr, preferably about 30 min-24 hr. A reaction time not lessthan or not more than the above can be employed as necessary.

The amino-protecting group is not particularly limited as long as it canbe easily and selectively removed, and a group other than theabove-mentioned protecting groups may also be employed. For example,those described in T. W. Greene, Protective groups in Organic Synthesis3rd edition, Wiley, New York, 1999 can be used. These protecting groupscan be removed corroding to a known method or a method analogousthereto, for example, by treatment with an acid, a base, ultravioletrays, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate,tetrabutylammonium fluoride, palladium acetate and the like, reductionreaction, or hydrolysis. The reduction reaction can be carried outaccording to a known method or a method analogous thereto, for example,by reduction with a metal reducing reagent such as lithium borohydride,lithium aluminum hydride and the like as a reducing agent, or catalyticreduction with a transition metal (palladium-carbon, platinum oxide,Raney-nickel, rhodium, ruthenium etc.). Examples of the organic solventused for the reduction reaction include methanol, ethanol, tertiarybutyl alcohol, tetrahydrofuran, diethyl ether, dioxane, acetone, ethylacetate, acetic acid, benzene, toluene, xylene, dimethylformamide,dimethylsulfoxide and the like.

The reaction temperature for the reduction reaction is generally −20 to150° C., preferably about 20 to about 80° C. A temperature not less thanor not more than these temperatures can be employed as necessary. Thereaction time for the reduction reaction is generally 5 min-24 hr,preferably about 30 min-12 hr. A reaction time not less than or not morethan the above can be employed as necessary.

The hydrolysis can be carried out according to a known method or amethod analogous thereto, for example, by treatment with an acid, abase, an enzyme and the like.

[Step 3]

In step 3, compound (IV) is obtained by reacting compound (IIa) or(IIa′) with compound (III) or compound (IIIa) according to a knownmethod and the like. In the aforementioned Reaction Scheme, the formulas(IIa, IIa′) mean both compound (IIa) and compound (IIa′). When thestarting material is compound (IIa), compound (IV) has a leaving group Xas a substituent of ring B. On the other hand, when the startingmaterial is compound (IIa′), compound (IV) has functional group R as asubstituent of ring B. This reaction is carried out in an organicsolvent which does not adversely influence the reaction. As such organicsolvent, chloroform, methylene chloride, tetrahydrofuran, 1,4-dioxane,N,N-dimethylformamide, N,N-dimethylacetamide, acetone, ethyl acetate, ora mixed solvent thereof and the like can be used, preferablytetrahydrofuran, N,N-dimethylacetamide and the like.

In addition, this reaction is not particularly limited, and can becarried out in the presence of a suitable base (e.g., cesium carbonate,potassium carbonate, sodium carbonate, potassium t-butoxide, sodiumhydride, triethylamine, DBU, DBN (1,5-diazabicyclo[4.3.0]non-5-ene) andthe like). When a base is used, preferred are potassium carbonate,potassium tert-butoxide, sodium hydride and the like.

The reaction temperature is generally about −30 to about 150° C.,preferably about −10 to about 100° C. A temperature not less than or notmore than these temperatures can be employed as necessary. The reactiontime is generally about 10 min-about 48 hr, preferably about 30 min-24hr. A reaction time not less than or not more than the above can beemployed as necessary.

[Step 4]

Compound (IV′) can be produced, in step 4, in the same manner as in step2, by performing hydrolysis, oxidation, reduction, nucleophilicaddition, deprotection and the like with functional group R of compound(IV) to convert same to functional group R′.

That is, the aforementioned Reaction Scheme describes, for convenience,compound (IV) having leaving group X as a substituent of ring B. Inpractice, compound (IV) having leaving group X as a substituent of ringB is not subjected to step 4.

[Step 5]

In step 5, compound (I) is obtained by reacting compound (IV′) withcompound (V) by coupling reaction, addition reaction, substitutionreaction, condensation reaction and the like according to a known methodand the like.

The coupling reaction is carried out using, for example, base, palladiumreagent or copper reagent. Where necessary, a ligand may be used.

Examples of the base used for this reaction include alkali metalhydroxide such as sodium hydroxide, potassium hydroxide and the like;alkali metal hydrogencarbonate such as sodium hydrogen carbonate and thelike; alkali metal carbonate such as sodium carbonate, potassiumcarbonate and the like; cesium salts such as cesium carbonate and thelike; alkali metal phosphates such as tripotassium phosphate and thelike; alkali metal hydrides such as sodium hydride, potassium hydrideand the like; sodium amide; alkali metal alkoxides such as sodiummethoxide, sodium ethoxide and the like; amine such as trimethylamine,triethylamine, N-ethyl-N-isopropylpropan-2-amine, diisopropylamine andthe like; cyclic amine such as pyridine, 4-dimethylaminopyridine,1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) and the like, and the like.

Examples of the palladium reagent include palladium-carbon,tetrakis(triphenylphosphine)palladium(0),bis(triphenylphosphine)palladium(II) dichloride,tris(dibenzylideneacetone)dipalladium(0),trans-dichlorobis(tri-o-tolylphosphine)palladium(II), palladium(II)trifluoroacetate, palladium(II) acetate and the like.

Examples of the copper catalyst include copper iodide, copper bromide,copper chloride, copper acetate and the like.

Examples of the ligand include, in addition to phosphine ligand such astriphenylphosphine, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl,2-(di-tert-butylphosphino)biphenyl, 2-(dicyclohexylphosphino)biphenyl,2-(dicyclohexylphosphino)-2′,6′-dimethoxy-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′,4′,6′-triisopropyl-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl,1,1′-bis(diphenylphosphino)ferrocene, tri-tert-butylphosphine,tricyclohexylphosphine,(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) and the like,2-(dimethylamino)acetic acid, cyclohexyl-1,2-diamine,N,N′-dimethylcyclohexyl-1,2-diamine, or picoline acid and the like.

This reaction can be carried out without solvent or in a known solvent,for example, solvents such as water; alcohols (methanol, ethanol and thelike); ethers (diethyl ether, 1,4-dioxane, 1,2-dimethoxyethane,tetrahydrofuran and the like); aromatic hydrocarbons (benzene, toluene,xylene and the like); esters (ethyl acetate and the like); halogenatedhydrocarbons (chloroform, dichloromethane and the like); nitriles(acetonitrile and the like); amides (N,N-dimethylformamide,N,N-dimethylacetamide, 1-methyl-2-pyrrolidinone and the like); ketones(acetone, 2-butanone and the like); sulfoxides (dimethylsulfoxide andthe like), and the like. These solvents may be used alone or in amixture at suitable ratio.

In this reaction, molecular sieves may be added as necessary.

This reaction may be performed under microwave irradiation as necessary.

This reaction may be carried out under an atmosphere of, for example,nitrogen, argon and the like, as necessary.

In this reaction, per 1 mol of the starting compound, a nucleophilicreagent is generally used in about 0.5-about 10 mol, preferably about1-about 5 mol, the amount of the base is generally about 0.1-about 100equivalents, preferably about 1-about 5 equivalents, the amount of thepalladium reagent or copper reagent is about 0.01-about 2 equivalents,preferably about 0.01-about 0.5 equivalents, the amount of the phosphineligand is generally about 0.01-about 2 equivalents, preferably about0.01-about 0.5 equivalents, and the amount of the cyclohexyl-1,2-diamineis generally about 0.01-about 2 equivalents, preferably about 0.01-about1 equivalents. The reaction temperature is generally 0° C. 20-200° C.,preferably 50° C.-150° C. The reaction time is about 0.1-about 100 hr,preferably about 0.5-about 50 hr.

The addition reaction and substitution reaction can be carried out usinga nucleophilic reagent such as organic metal (e.g., LDA, butyllithium,methylmagnesium bromide) and the like. These reactions can be carriedout in a suitable solvent such as aprotonic solvent and the like (e.g.,polar compound (e.g., DMF, DMSO, HMPA), nitrile compound (e.g.,acetonitrile, propionitrile), ether compound (THF, dioxane, diethylether, dibutyl ether, dimethoxyethane), a ketone compound (acetone,methyl ethyl ketone, methyl isobutyl ketone), an aromatic hydrocarbon(e.g., benzene, toluene, xylene and the like), a halogenated aromatichydrocarbon (e.g., monochlorobenzene, dichlorobenzene and the like), analiphatic hydrocarbon (hexane, heptane, octane), and a mixed solventthereof, and the like).

These reactions may be carried out under an atmosphere such as nitrogen,argon and the like as necessary.

In these reactions, per 1 mol of the starting compound, the amount ofthe nucleophilic reagent is generally about 1-about 10 mol, preferablyabout 1-about 5 mol, and the amount of the base is about 0.1-about 100equivalents, preferably about 1-about 5 equivalents.

The reaction temperature is generally about −78 to about 60° C.,preferably about −20 to about 20° C. A temperature not less than or notmore than these temperatures can be employed as necessary. The reactiontime is generally about 10 min-about 24 hr, preferably about 30 min-12hr. A reaction time not less than or not more than the above can beemployed as necessary.

In addition, when each of compound (V) and compound (IV′) has primary orsecondary alcohol and a hydroxy group, Mitsunobu reaction can be used.

This reaction can be carried out under conditions generally known. Forexample, this reaction can be carried out in a suitable solvent such asTHF and the like, by adding azodicarboxylic acid derivative such asdiisopropylazodicarboxylate, diethylazodicarboxylate and the like, andorganic phosphorus reagent such as triphenylphosphine and the like tothe above-mentioned two kinds of substrates.

When compound (V) and compound (IV′) have a carboxyl group and an aminogroup, respectively, compound (I), which is a condensation product, canbe produced by condensation reaction.

The condensation reaction can be carried out using a dehydratingcondensing agent.

Examples of the dehydrating condensing agent to be used in this reactioninclude N,N′-dicyclohexylcarbodiimide,1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) or a hydrochloridethereof, N,N′-carbonyldiimidazole,1H-benzotriazol-1-yloxytris(dimethylamino)phosphoniumhexafluorophosphate,O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HATU), 2-chloro-1,3-dimethylimidazolium chloride,and bromotripyrrolidinophosphonium hexafluorophosphate and the like.

This reaction may be carried out, for example, in the presence of a basesuch as 1-hydroxybenzotriazole (HOBt), N,N-diisopropylethylamine,N-methylmorpholine, triethylamine, 4-(N,N-dimethylamino)pyridine and thelike as necessary.

This reaction is preferably carried out in a known solvent, for example,solvents such as amides (N,N-dimethylformamide, N,N-dimethylacetamide,and N-methylpyrrolidone and the like); halogenated hydrocarbons(dichloromethane and the like); esters (ethyl acetate and the like);hydrocarbons (cyclohexane, n-hexane and the like); aromatic hydrocarbons(toluene and the like); ethers (tetrahydrofuran, diethyl ether, dioxane,and 1,2-dimethoxyethane and the like); or nitriles (acetonitrile and thelike), and the like.

In this reaction, per 1 mol of the starting compound, the amount ofcompound (V) is generally about 1-about 5 mol, and the amount of thedehydrating condensing agent is about 1-about 100 equivalents,preferably 1-5 equivalents. The reaction temperature is generally 0°C.-100° C., preferably 0° C.-60° C. The reaction time is about 0.1-about100 hr, preferably about 0.5-about 50 hr.

When compound (I) is an amide compound, compound (I) can also beproduced by activating a carboxyl group of compound (V) or compound(IV′) according to a known activation method, and by reacting thecompound with compound (IV′) or compound (V), each having an aminogroup.

As the activation method of a carboxyl group, a general method isadopted, for example, a method of producing an acid anhydride by usingchloroformic acid ester, pivaloyl chloride, 2,4,6-trichlorobenzoylchloride and the like; a method of producing an acid halide by usingthionyl chloride, oxalyl chloride and the like; and a method ofproducing ester of 1-hydroxybenzotriazole, or pentafluorophenol and thelike by using a dehydrating condensing agent, and the like.

A representative example is a method of producing an acid halide. Forexample, acid halide can be produced by treating carboxylic acid with ahalogenating agent such as thionyl chloride, oxalyl chloride and thelike and, as an additive, for example, N,N-dimethylformamide may beadded.

The method of producing an acid halide is preferably carried out in aknown solvent, for example, solvent such as halogenated hydrocarbons(dichloromethane and the like); ethers (tetrahydrofuran, diethyl etherand the like); or aromatic hydrocarbons (toluene and the like) and thelike, or without solvent.

In this reaction, the amount of the halogenating agent is generallyabout 1-about 100 equivalents, preferably 1-5 equivalents, per 1 mol ofthe starting compound. The reaction temperature is generally −78° C. to100° C., preferably 0° C. to 100° C. The reaction time is about0.1-about 100 hr, preferably about 0.5-about 50 hr.

After activation of a carboxyl group of compound (V) as mentioned above,it is reacted with an amino group of compound (IV′) to give compound(I), which is an amide compound. Alternatively, after activation of acarboxyl group of compound (IV′), it is reacted with an amino group ofcompound (V) to give compound (I), which is an amide compound. Thisreaction is preferably carried out in a known solvent, for example,solvent such as halogenated hydrocarbons (dichloromethane and the like);ethers (tetrahydrofuran, diethyl ether and the like); or amides(N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone andthe like) and the like.

The reaction temperature is generally −78° C. to 150° C., preferably 0°C. to 100° C. The reaction time is about 0.1-about 100 hr, preferablyabout 0.5-about 50 hr.

[Step 6]

In step 6, compound (VIa) is obtained by reacting compound (IIa) or(IIa″) with compound (V) by coupling reaction, addition reaction,substitution reaction and condensation reaction and the like accordingto a known method and the like in the same manner as in step 5.

For example, specific examples include a coupling reaction usingcompound (IIa) and compound (V). This reaction is carried out using abase, and palladium reagent. Where necessary, a phosphine ligand may beused.

Examples of the palladium reagent include palladium-carbon,tetrakis(triphenylphosphine)palladium(0),bis(triphenylphosphine)palladium(II) dichloride,tris(dibenzylideneacetone)dipalladium(0),trans-dichlorobis(tri-o-tolylphosphine)palladium(II), palladium(II)trifluoroacetate, palladium(II) acetate and the like, preferablytetrakis(triphenylphosphine)palladium(0) and the like.

Examples of the base include alkali metal hydroxides such as sodiumhydroxide, potassium hydroxide and the like; alkali metalhydrogencarbonates such as sodium hydrogen carbonate and the like;alkali metal carbonate such as sodium carbonate, potassium carbonate andthe like; cesium salts such as cesium carbonate and the like; alkalimetal phosphates such as tripotassium phosphate and the like; alkalimetal hydrides such as sodium hydride, potassium hydride and the like;sodium amide; alkali metal alkoxides such as sodium methoxide, sodiumethoxide and the like; amines such as trimethylamine, triethylamine,N-ethyl-N-isopropylpropan-2-amine, diisopropylamine and the like; cyclicamines such as pyridine, 4-dimethylaminopyridine,1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) etc. and the like. Preferredare sodium carbonate, cesium carbonate, tripotassium phosphate and thelike.

Examples of the phosphine ligand include triphenylphosphine,2,2′-bis(diphenylphosphino)-1,1′-binaphthyl,2-(di-tert-butylphosphino)biphenyl, 2-(dicyclohexylphosphino)biphenyl,2-(dicyclohexylphosphino)-2′,6′-dimethoxy-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′,-4′,6′-triisopropyl-1,1′-biphenyl,2-(dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl,1,1′-bis(diphenylphosphino)ferrocene, tri-tert-butylphosphine,tricyclohexylphosphine,(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) and the like.

This reaction is carried out in a known solvent, for example, solventssuch as water; alcohols (methanol, ethanol and the like); ethers(diethyl ether, 1,4-dioxane, 1,2-dimethoxyethane, tetrahydrofuran andthe like); aromatic hydrocarbons (benzene, toluene, xylene and thelike); esters (ethyl acetate and the like); halogenated hydrocarbons(chloroform, dichloromethane and the like); nitriles (acetonitrile andthe like); amides (N,N-dimethylformamide, N,N-dimethylacetamide,1-methyl-2-pyrrolidinone and the like); ketones (acetone, 2-butanone andthe like); sulfoxides (dimethyl sulfoxide and the like), and the like.These solvents may be mixed at suitable ratio or may not be used.Preferred are 1,2-dimethoxyethane-water mixed solvent and the like.

This reaction may be carried out under an atmosphere of, for example,nitrogen, argon and the like, as necessary.

In this reaction, per 1 mol of the starting compound, the palladiumreagent is used in about 0.01-about 2 equivalents, preferably about0.01-about 0.5 equivalents, the base is used in about 0.1-about 100equivalents, preferably about 1-about 5 equivalents, and the phosphineligand is used in about 0.01-about 2 equivalents, preferably about0.01-about 0.5 equivalents. The reaction temperature is generally 0° C.to 200° C., preferably 50° C. to 150° C. The reaction time is about0.1-about 100 hr, preferably about 0.5-about 50 hr.

[Step 7]

In step 7, compound (I) is obtained by reacting compound (VIa) withcompound (III) or compound (IIIa) in the same manner as in step 3.

In any step, when further desired, known protection reaction,deprotection, coupling reaction, acylation reaction, alkylationreaction, cycloalkylation reaction, dehydroxylation reaction,hydrogenation reaction, oxidation reaction, reduction reaction,fluorination reaction, carbon chain extension reaction or substituentexchanging reaction and the like can be used alone or in combination oftwo or more thereof.

Specific examples of the synthesis of compound (I) are explained in thefollowing.

[Step 8]

In step 8, compound (Ib) is obtained from compound (Ia) by reducingunsaturated ring (Ba) in the center to form saturated ring (Bb).

Examples of the reduction reaction include a reaction using a metalreducing reagent such as lithium borohydride, lithium aluminum hydrideand the like, and a catalytic reduction using a transition metal(palladium-carbon, platinum-carbon, platinum oxide, Raney-nickel,rhodium, ruthenium etc.) under a hydrogen atmosphere. Of thesereactions, the catalytic reduction using a transition metal(palladium-carbon, platinum(IV) oxide, rhodium) is preferable. Examplesof the organic solvent to be used for the catalytic reduction includemethanol, ethanol, tertiary butyl alcohol, tetrahydrofuran, diethylether, dioxane, acetone, ethyl acetate, acetic acid, benzene, toluene,xylene, dimethylformamide, dimethyl sulfoxide and the like. Preferredare methanol, ethanol, tetrahydrofuran and the like.

The reaction temperature of the reduction reaction is generally −20 to80° C., preferably about 0 to about 40° C. A temperature not less thanor not more than these temperatures can be employed as necessary. Thereaction time of the reduction reaction is generally 5 min-24 hr,preferably about 30 min-12 hr. A reaction time not less than or not morethan the above can be employed as necessary. In addition, the reactionmay be carried out under pressurization as necessary. The pressure to beapplied is generally 1.1-50 atm, preferably 2-10 atm.

[Step 9]

Furthermore, when one of the saturated ring Bb-constituting atoms is anitrogen atom, that is, the structure shown in the formula (Ic-1),compound (Ic-2), wherein the nitrogen atom is modified by alkylation of,acylation, protection reaction and the like of step 9, can be obtained.

The alkylation is carried out using a suitable alkylating agent in asuitable solvent. Examples of the alkylating agent include alkylhalide(iodomethane, iodoethane etc.) and the like.

Examples of the solvent include solvents such as water, methanol,ethanol, diethyl ether, tetrahydrofuran, toluene, ethyl acetate,acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide and the like.These solvents may be mixed at a suitable ratio or may not be used.

In addition, this reaction is not particularly limited, and can also becarried out in the presence of a suitable base (e.g., cesium carbonate,potassium carbonate, sodium carbonate, potassium t-butoxide, sodiumhydride, triethylamine, DBU, DBN (1,5-diazabicyclo[4.3.0]non-5-ene) andthe like). When a base is used, preferred are potassium carbonate,sodium hydride and the like.

The reaction temperature is generally about −30 to about 150° C.,preferably about −10 to about 100° C. The reaction time is generallyabout 10 min-about 48 hr, preferably about 30 min-24 hr.

The acylation can be carried out in the same manner as in thecondensation reaction of [Step 5]. Commercially available acid chloridecan also be used instead of activating carboxylic acid.

The protection reaction can be carried out according to a methodgenerally known, for example, the method described in T. W. Greene,Protective Groups in Organic Synthesis 3rd edition, Wiley, New York,1999 and the like.

[Step 10]

This step can be carried out in the same manner as in the alkylation of[Step 9]. In addition, deuteration (R²=D) can also be carried out byreacting a deuterium source such as deuterium, deuterated methanol andthe like in a suitable solvent in the presence of a base such as sodiumhydride and the like.

[Step 11]

This step can be carried out in the same manner as in (4) deprotectionof protected amino group in [Step 2].

In addition, when ring D has a protected hydroxy group, that is, thestructure shown in the formula (I-5), compound (I-6), (I-7) and (I-8)can be obtained by the deprotection of step 12, alkylation of step 13,and arylation of step 14, respectively. When ring B is saturated ring Bbin step 14, compound (Ib-9) is sometimes obtained as a byproduct.

[Step 12]

A deprotection can be carried out by an appropriate deprotectionreaction of a known protecting group. For example, when protecting groupP is a silicon protecting group such as a t-butyldimethylsilyl group andthe like, the deprotection can be carried out using TBAF as deprotectingagent, and a reagent having a halogen ion such as hydrochloric acid andthe like.

This reaction is carried out in a known solvent, for example, solventssuch as halogenated hydrocarbons (dichloromethane and the like); ethers(tetrahydrofuran, diethyl ether and the like) and the like.

The reaction temperature is generally −78° C. to 150° C., preferably 0°C. to 100° C. The reaction time is about 0.1-about 100 hr, preferablyabout 0.5-about 50 hr.

In addition, the hydroxy-protecting group is not particularly limited aslong as it can be removed easily and selectively. For example, thosedescribed in T. W. Greene, Protective Groups in Organic Synthesis 3rdedition, Wiley, New York, 1999 can be used.

[Step 13]

Step 13 can be carried out under the conditions of the alkylationreaction of step 9, Mitsunobu reaction of step 5 and the like.

[Step 14]

Step 14 can be carried out using the conditions of the coupling reactionof step 5. For example, compound (I-6) and arylhalide, arylboronic acidor arylboroxin as Ar—Y are treated with a base and a copper reagent.Where necessary, a ligand may be used.

Examples of the base used for this reaction include alkali metalhydroxides such as sodium hydroxide, potassium hydroxide and the like;alkali metal hydrogencarbonates such as sodium hydrogen carbonate andthe like; alkali metal carbonate such as sodium carbonate, potassiumcarbonate and the like; cesium salts such as cesium carbonate and thelike; alkali metal phosphates such as tripotassium phosphate and thelike; alkali metal hydrides such as sodium hydride, potassium hydrideand the like; sodium amide; alkali metal alkoxides such as sodiummethoxide, sodium ethoxide and the like; amines such as trimethylamine,triethylamine, N-ethyl-N-isopropylpropan-2-amine, diisopropylamine andthe like; cyclic amines such as pyridine, 4-dimethylaminopyridine,1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) etc., and the like. These basesmay be used alone or in a combination of two or more thereof.

Examples of the copper catalyst include copper iodide, copper bromide,copper chloride, copper acetate and the like.

Examples of the ligand include 2-(dimethylamino)acetic acid, picolineacid and the like.

This reaction can be carried out without solvent or in a known solvent,for example, solvents such as water; alcohols (methanol, ethanol and thelike); ethers (diethyl ether, 1,4-dioxane, 1,2-dimethoxyethane,tetrahydrofuran and the like); aromatic hydrocarbons (benzene, toluene,xylene and the like); esters (ethyl acetate and the like); halogenatedhydrocarbons (chloroform, dichloromethane and the like); nitriles(acetonitrile and the like); amides (N,N-dimethylformamide,N,N-dimethylacetamide, 1-methyl-2-pyrrolidinone and the like); ketones(acetone, 2-butanone and the like); sulfoxides (dimethyl sulfoxide andthe like), and the like. These solvents may be used alone or in amixture at a suitable ratio.

In this reaction, molecular sieves may be added as necessary.

This reaction may be performed under microwave irradiation as necessary.

This reaction may be carried out under an atmosphere of, for example,nitrogen, argon and the like, as necessary.

In this reaction, per 1 mol of the starting compound, arylhalide,arylboronic acid or arylboroxin is generally used in about 0.3-about 10mol, preferably about 1-about 5 mol, the amount of the base is generallyabout 0.1-about 100 equivalents, preferably about 1-about 5 equivalents,the amount of the copper reagent is about 0.01-about 5 equivalents,preferably about 0.01-about 2 equivalents, and the amount of the ligandis generally about 0.01-about 5 equivalents, preferably about 0.01-about2 equivalents. The reaction temperature is generally 0° C. to 200° C.,preferably 20° C. to 150° C. The reaction time is about 0.1-about 100hr, preferably about 0.5-about 50 hr.

Particularly when Y of Ar—Y in step 14 is a fluorine atom or a chlorineatom, this step may be carried out in a solvent suitable for compound(I-6). In this reaction, a base may be used as necessary.

Examples of the solvent include tetrahydrofuran, toluene,N,N-dimethylformamide, dimethyl sulfoxide and the like. Preferred areN,N-dimethylformamide, dimethyl sulfoxide and the like. These solventsmay be used alone or in a mixture at a suitable ratio.

Examples of the base include sodium carbonate, potassium carbonate,cesium carbonate, sodium hydride, triethylamine and the like.

This reaction may be performed under microwave irradiation as necessary.

This reaction may be carried out under an atmosphere of, for example,nitrogen, argon and the like, as necessary.

In this reaction, per 1 mol of the starting compound, Ar—Y is generallyused in about 0.3-about 10 mol, preferably about 1-about 5 mol, and theamount of the base is generally about 0.1-about 100 equivalents,preferably about 1-about equivalents. The reaction temperature isgenerally 0° C. to 200° C., preferably 20° C. to 150° C. The reactiontime is about 0.1-about 100 hr, preferably about 0.5-about 50 hr.

In step 14, when ring D has a halogen atom such as a bromine atom andthe like as X, that is, the structure shown in the formula (I-10),compound (I-8) can be produced by using Ar—OH as Ar—Y.

Compound (I-15) can be synthesized from compounds (I-10) and (I-12),arylboronic acid and arylboronic acid ester, or compounds (I-13) and(I-14) and arylhalide, by the coupling reaction of step 18. Compounds(I-12), (I-13) and (I-14) can be synthesized by step 15-step 17,respectively.

[Step 15]

When ring D has a hydroxy group, compound (I-12) can be obtained byusing a trifluoromethanesulfonylating agent relative to compound (I-6)in a suitable solvent. In this case, a suitable base may also be added.

Examples of the trifluoromethanesulfonylating agent includetrifluoromethanesulfonyl chloride, trifluoromethanesulfonic anhydrideand the like.

Examples of the base include triethylamine, pyridine, potassiumcarbonate and the like.

Examples of the solvent include tetrahydrofuran, acetonitrile, ethylacetate and the like.

[Step 16]

When ring D has a halogen atom, compound (I-13) can be obtained by usingboronic acid ester relative to compound (I-10) in the presence of ametal catalyst in a suitable solvent. In this case, a suitable base mayalso be added. Compound (I-14) may be produced during the reaction. Inaddition, compound (I-14) can be obtained by hydrolyzing isolatedcompound (I-13).

Examples of the boronic acid ester include4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane and the like.

Examples of the base include triethylamine, pyridine, potassiumcarbonate, cesium carbonate and the like.

Examples of the metal catalyst includetris(dibenzylideneacetone)dipalladium(0),[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and thelike.

Examples of the solvent include 1,2-dimethoxyethane, tetrahydrofuran,acetonitrile, ethyl acetate, N,N-dimethylformamide and the like.

[Step 17]

When ring D has a protected boron atom, compound (I-14) can be obtainedby deprotection of compound (I-ii). Examples of the protecting groupinclude 1,8-diaminonaphthalene and the like. In this case, thedeprotection can be carried out using an acid in a suitable solvent.

Examples of the acid include hydrochloric acid and the like, andexamples of the solvent include tetrahydrofuran and the like.

[Step 18]

In step 18, compound (I-15) can be obtained by applying a method similarto the coupling reaction using a palladium reagent in step 6 to compound(I-10), (I-12), (I-13) or (I-14).

In addition, when ring D has a protected nitrogen atom, that is, thestructure shown in the formula (I-16), compounds (I-17) and (I-18) canbe obtained by the deprotection of step 19 and alkylation of step 20,respectively.

[Step 19]

Step 19 can be carried out in the same manner as in the method of (4)deprotection of protected amino group in step 2.

[Step 20]

Step 20 can be carried out in the same manner as in the method of thealkylation of step 9.

Step 9-step 20 mentioned above can also be applied to compound (VIa) inReaction Scheme 1, and thereafter compounds (I) and (Ib) can be obtainedaccording to step 7 and step 8.

For example, compound (I-8) can be produced by applying step 14 and step7 to compound (VIa-19). In addition, when ring B of compound (I-8) isring Ba, compound (Ib-8) can also be produced by further performing step8.

The amino group of compounds (IIa), (IIa′), (IIa″) and (VIa) in ReactionScheme 1 may be a halogen atom, and the corresponding halogen atom canbe converted to amino group in any step.

For example, as shown in the following formulas, compound (VIa) can alsobe produced by, besides as shown in Reaction Scheme 1, applying step 21to compound (VIa-23) obtained by applying step 2 to compound (IIa′-21),and then step 6 to compound (IIa″−22).

[Step 21]

Step 21 can be carried out in the same manner as in the couplingreaction described in step 5 and using an amino source such as1,1-diphenylmethanimine and the like.

As the base to be used in this reaction, sodium t-butoxide and the likecan be mentioned, as the palladium reagent,tris(dibenzylideneacetone)dipalladium(0) and the like can be mentioned,as the ligand, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and the likecan be mentioned, and as the solvent, toluene and the like can bementioned.

When 1,1-diphenylmethanimine is used as an amino source, (4)deprotection of protected amino group described in step 2 needs to beperformed after the coupling reaction.

Compound (IIa″) can also be produced by a route besides as shown inReaction Scheme 1. Compound (IIa) wherein X═H, namely, compound(IIa-24), is subjected to the protection reaction described in step 9 togive compound (IIa-25).

[Step 22]

Then, functionalized compound (IIa″) can be produced by reacting a baseand reacting a suitable functionalizing agent in step 22. In this case,a suitable additive may be added.

For example, when R′═B(OH)₂, n-butyllithium and the like can bementioned as a base, triisopropyl borate and the like can be mentionedas a functionalizing agent, N,N,N′,N′-tetramethylethylenediamine and thelike can be mentioned as an additive, and tetrahydrofuran and the likecan be mentioned as a solvent. Then, (4) deprotection of protected aminogroup described in step 2 needs to be performed. Deprotection mayproceed during this reaction.

Using the thus-produced compound (IIa″), compound (I) can be producedvia, for example, step 14 and step 7. Alternatively, compound (I-8) canalso be produced via step 6, step 14 and step 7 and using compound(IIa″).

In Reaction Schemes 1-9 mentioned above, in a compound having ring A,ring B and ring D, when ring B is ring Bb and the carbon atom of ring Bto be bonded to ring D has a hydrogen atom, a byproduct wherein thecarbon atom of ring B to be bonded to ring D is hydroxylated may beobtained in a step using the compound. One example thereof is thebyproduct (Ib-9) of step 11.

Byproduct may not be indicated in each Reaction Scheme.

In Reaction Schemes 1-9 mentioned above, in a compound having ring B andring A, when ring B is ring Ba, step 8 may be performed at this stage toconvert ring Ba to ring Bb.

The reactants (arylboronic acid, arylhalide and the like) used in theaforementioned steps may be commercially available products, or can alsobe prepared by a known method or a method analogous thereto. Arylhalide(V-29), arylboronic acid (V-30), and arylboronic acid ester (V-31) canalso be prepared by the following method.

Arylhalide derivative (V-29) can be produced in the same manner as instep 14 and using compound (V-28) having the same or different twohalogen atoms and Ar—Y wherein Y is a hydroxy group, or compound (V-28)having a halogen atom and a hydroxy group and Ar—Y wherein Y is ahalogen atom. Then, arylboronic acid (V-30) or arylboronic acid ester(V-31) can be produced by performing step 16.

Compound (I) or an intermediate therefor may also be optically resolvedby a known method or a method analogous thereto to give an opticallyactive form of compound (I) or an optically active form of theintermediate. As a method of the optical resolution, a method known perse can be mentioned, for example, fractional recrystallization, chiralcolumn method, diastereomer method and the like. In the “fractionalrecrystallization”, a salt is formed from a racemate and an opticallyactive compound [e.g., (+)-mandelic acid, (−)-mandelic acid,(+)-tartaric acid, (−)-tartaric acid, (+)-1-phenethylamine,(−)-1-phenethylamine, cinchonine, (−)-cinchonidine, brucine etc.), whichis separated by fractional recrystallization and the like and, whendesired, subjected to a neutralization step to give a free opticalisomer. In the “chiral column method”, a racemate or a salt thereof issubjected to a column for separation of optical isomer (chiral column).For example, in liquid chromatography, a racemate is added to a chiralcolumn such as ENANTIO-OVM (manufactured by TOSO) or CHIRAL seriesmanufactured by DAICEL and the like, and developed with water, a buffer(e.g., phosphate buffer), an organic solvent (e.g., hexane, ethanol,methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine,triethylamine and the like), or a mixed solvent thereof to separate anoptical isomer. For example, in gas chromatography, a chiral column suchas CP-Chirasil-DeX CB (manufactured by GL Sciences Inc.) and the like isused to achieve separation. In the “diastereomer method”, a racemate andan optically active reagent are reacted to give a diastereomer mixture,then subjected to a general separation means (e.g., fractionalrecrystallization, chromatography method etc.) to give one diastereomer,and subjected to a chemical reaction (e.g., acid hydrolysis, basehydrolysis, hydrogenolysis etc.) to dissociate an optically activereagent moiety, whereby the object optical isomer is obtained. Examplesof the “optically active reagent” include optically active organic acidssuch as MTPA [α-methoxy-α-(trifluoromethyl)phenylacetic acid],(−)-menthoxyacetic acid and the like; optically activealkoxymethylhalides such as(1R-endo)-2-(chloromethoxy)-1,3,3-trimethylbicyclo[2.2.1]heptane and thelike, and the like.

Compound (I) or an intermediate therefor obtained by the above methodscan be isolated and purified by, for example, a general separation meanssuch as recrystallization, distillation, chromatography and the like.When compound (I) is obtained as a free compound, it can be converted toa salt by a method known per se or a method analogous thereto (e.g.,neutralization etc.). When compound (I) is obtained as a salt, it can beconverted to a free form or other salt by a method known per se or amethod analogous thereto.

As a salt of compound (I) or an intermediate therefor, apharmacologically acceptable salt and the like are used. For example,salts with inorganic bases, salts with organic bases, salts withinorganic acids, salts with organic acids, salts with basic or acidicamino acids and the like are used. Preferable examples of the salts withinorganic bases include alkali metal salts such as sodium salt,potassium salt and the like, alkaline earth metal salts such as calciumsalt, magnesium salt and the like, aluminum salt, ammonium salt and thelike. Preferable examples of the salts with organic bases include saltswith trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine,ethanolamine, diethanolamine, triethanolamine, cyclohexylamine,dicyclohexylamine, N,N′-dibenzylethylenediamine and the like. Preferableexamples of the salts with inorganic acids include salts withhydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid,phosphoric acid and the like. Preferable examples of the salts withorganic acids include salts with formic acid, acetic acid,trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaricacid, maleic acid, citric acid, succinic acid, malic acid,methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid andthe like. Preferable examples of the salts with basic amino acidsinclude salts with arginine, lysine, ornithine and the like. Preferableexamples of the salts with acidic amino acids include salts withaspartic acid, glutamic acid and the like. Of these, pharmaceuticallyacceptable salt is preferable. When compound (I) or intermediate has abasic functional group, examples thereof include salts with inorganicacids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuricacid, phosphoric acid and the like, salts with organic acids such asacetic acid, phthalic acid, fumaric acid, tartaric acid, maleic acid,citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acidand the like. When compound (I) or intermediate has an acidic functionalgroup, examples thereof include alkali metal salts such as sodium salt,potassium salt and the like, alkaline earth metal salts such as calciumsalt, magnesium salt and the like, ammonium salt and the like.

When compound (I) contains an isomer, such isomer can be obtained assingle products by synthesis method and separation method(concentration, solvent extraction, column chromatography,recrystallization etc.) known per se.

The compound of the present invention is useful as an agent for theprophylaxis or treatment of diseases such as

-   (1) mental diseases [e.g., depression, major depression, bipolar    depression, dysthymic disorder, emotional disorder (seasonal    affective disorder and the like), recurrent depression, postpartum    depression, stress disorder, depression symptom, mania, anxiety,    generalized anxiety disorder, anxiety syndrome, panic disorder,    phobia, social phobia, social anxiety disorder, obsessive disorder,    post-traumatic stress syndrome, post-traumatic stress disorder,    Tourette syndrome, autism, adjustment disorder, bipolar disorder,    neurosis, schizophrenia (e.g., positive symptom, negative symptom,    cognitive impairment), neurosis, chronic fatigue syndrome, anxiety    neurosis, compulsive neurosis, panic disorder, epilepsy, anxiety,    anxious mental state, emotional abnormality, cyclothymia, nervous    erethism, faint, addiction, low sex drive, attention deficit    hyperactivity disorder (ADHD), psychotic major depression,    refractory major depression, treatment-resistant depression],-   (2) neurodegenerative diseases [e.g., Alzheimer's disease,    Alzheimer-type senile dementia, Parkinson's disease, Huntington    chorea, multi-infarct dementia, frontotemporal dementia,    frontotemporal dementia Parkinson's Type, progressive supranuclear    palsy, Pick's syndrome, Niemann-Pick syndrome, corticobasal    degeneration, Down's disease, vascular dementia, postencephalitic    parkinsonism, Lewy body dementia, HIV dementia, amyotrophic lateral    sclerosis (ALS), motor neurogenesis disease (MND), Creutzfeldt-Jakob    disease or prion disease, cerebral palsy, progressive supranuclear    palsy, multiple sclerosis],-   (3) age-related cognition memory disorders [e.g., age-related memory    disorders, senile dementia]-   (4) sleep disorders [e.g., intrinsic sleep disorders (e.g.,    psychophysiological insomnia and the like), extrinsic sleep    disorder, circadian rhythm disorders (e.g., time zone change    syndrome (jet lag), shift work sleep disorder, irregular sleep-wake    pattern, delayed sleep phase, advanced sleep phase syndrome,    non-24-hour sleep-wake and the like), parasomnia, sleep disorders    associated with internal medical or psychiatric disorder (e.g.,    chronic obstructive pulmonary diseases, Alzheimer's disease,    Parkinson's disease, cerebrovascular dementia, schizophrenia,    depression, anxiety neurosis), stress insomnia, insomnia, insomniac    neurosis, sleep apnea syndrome],-   (5) respiratory depression caused by anesthetics, traumatic disease,    or neurodegenerative disease and the like,-   (6) traumatic brain injury, neurotic anorexia, eating disorder,    anorexia nervosa, hyperorexia, other eating disorder, alcohol    dependence, alcohol abuse, alcoholic amnesia, alcohol paranoia,    alcohol preference, alcohol withdrawal, alcoholic insanity, alcohol    poisoning, alcoholic jealousy, alcoholic mania, alcohol-dependent    mental disorder, alcoholic insanity, pharmacophilia, pharmacophobia,    pharmacomania, drug withdrawal, migraine, stress headache, tension    headache, diabetic neuropathy, obesity, diabetes, muscular spasm,    Meniere's disease, autonomic ataxia, alopecia, glaucoma,    hypertension, cardiac disease, tachycardia, cardiac failure,    hyperventilation, bronchial asthma, apnea, sudden infant death    syndrome, inflammatory disease, allergic disease, impotence,    climacteric disorder, infertility, cancer, immunodeficiency syndrome    caused by HIV infection, immunodeficiency syndrome caused by stress,    cerebrospinal meningitis, acromegaly, incontinence, metabolic    syndrome, osteoporosis, peptic ulcer, irritable bowel syndrome,    inflammatory bowel disease, ulcerative colitis, Crohn's disease,    stress gastrointestinal disorder, neurotic vomiting, peptic ulcer,    diarrhea, constipation, postoperative ileus, stress gastrointestinal    disorder,-   and the like in mammals (e.g., mouse, rat, hamster, rabbit, cat,    dog, bovine, sheep, monkey, human and the like).

Since the compound of the present invention has a superior AMPA receptorpotentiating action, it can be expected to provide a superiorprophylactic or therapeutic effect for the above-mentioned diseases.

A prodrug of compound (I′) may be used in the same manner as withcompound (I′) encompassing compound (I). A prodrug of compound (I′)means a compound which is converted to compound (I′) with a reaction dueto an enzyme, gastric acid, etc. under the physiological condition inthe living body, that is, a compound which is converted to compound (I′)by oxidation, reduction, hydrolysis, etc. according to an enzyme; acompound which is converted to compound (I′) by hydrolysis etc. due togastric acid, etc.

A prodrug of compound (I′) may be a compound obtained by subjecting anamino group in compound (I′) to an acylation, alkylation orphosphorylation (e.g., a compound obtained by subjecting an amino groupin compound (I′) to an eicosanoylation, alanylation,pentylaminocarbonylation,(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylation,tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylationand tert-butylation, etc.); a compound obtained by subjecting a hydroxylgroup in compound (I′) to an acylation, alkylation, phosphorylation orboration (e.g., a compound obtained by subjecting a hydroxyl group incompound (1′) to an acetylation, palmitoylation, propanoylation,pivaloylation, succinylation, fumarylation, alanylation,dimethylaminomethylcarbonylation, etc.); a compound obtained bysubjecting a carboxy group in compound (I′) to an esterification oramidation (e.g., a compound obtained by subjecting a carboxy group incompound (I′) to an ethyl esterification, phenyl esterification,carboxymethyl esterification, dimethylaminomethyl esterification,pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification,phthalidyl esterification, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methylesterification, cyclohexyloxycarbonylethyl esterification andmethylamidation, etc.) and the like. Any of these compounds can beproduced from compound (I′) by a method known per se. A prodrug forcompound (I′) may also be one which is converted into compound (I′)under a physiological condition, such as those described in IYAKUHIN noKAIHATSU (Development of Pharmaceuticals), Vol. 7 (Design of Molecules),p. 163-198 (HIROKAWA SHOTEN).

Since the compound of the present invention is superior in in vivokinetics (e.g., plasma drug half-life, brain transfer, metabolismstability), shows low toxicity (e.g., more superior as a medicament interms of acute toxicity, chronic toxicity, genetic toxicity,reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicityand the like), it can be safely administered orally or parenterally tomammals (e.g., human, monkey, bovine, horse, swine, mouse, rat, hamster,rabbit, cat, dog, sheep, goat etc.) directly as a medicament, or apharmaceutical composition containing pharmaceutically acceptablecarrier etc. The “parenteral” includes intravenous, intramuscular,subcutaneous, intraorgan, intranasal, intradermal, instillation,intracerebral, rectal, vaginal, intraperitoneal, intratumor, tumorproximal administration, direct administration to a lesion and the like.

While the daily dose of the compound of the present invention variesdepending on the administration route, symptom and the like, it is, forexample, 0.001-1000 mg/kg body weight, preferably 0.01-100 mg/kg bodyweight, more preferably 0.1-10 mg/kg body weight, by, for example, oraladministration to patients with schizophrenia (adult, body weight 40-80kg, for example, 60 kg). This dose can be administered in one to 3portions a day.

A medicament containing the compound of the present invention can beused singly or in the form of a pharmaceutical composition preparedaccording to a method known per se as a production method ofpharmaceutical preparations (e.g., the method described in the JapanesePharmacopoeia etc.) by mixing the compound of the present invention andpharmaceutically acceptable carriers. A medicament containing thecompound of the present invention can be safely administered orally orparenterally (e.g., intravenous, intramuscular, subcutaneous,intraorgan, intranasal, intradermal, instillation, intracerebral,rectal, vaginal, intraperitoneal, lesion etc.) in the form of, forexample, tablet (including sugar-coated tablet, film-coated tablet,sublingual tablet, orally disintegrable tablet, buccal tablet and thelike), pill, powder, granule, capsule (including soft capsule,microcapsule), troche, syrup, liquid, emulsion, suspension, controlledrelease preparation (e.g., immediate-release preparation,sustained-release preparation, sustained-release microcapsule), aerosol,films (e.g., orally disintegrable films, oral mucosal adhesive film),injection (e.g., subcutaneous injection, intravenous injection,intramuscular injection, intraperitoneal injection), drip infusion,transdermal absorption type preparation, ointment, lotion, adhesivepreparation, suppository (e.g., rectal suppository, vaginalsuppository), pellet, nasal preparation, pulmonary preparation(inhalant), eye drop and the like.

As the aforementioned “pharmacologically acceptable carrier”, variousorganic or inorganic carriers conventionally used as starting materialsof preparations are used. For example, excipient, lubricant, binder,disintegrant and the like for solid preparations are used, and solvent,solubilizing agent, suspending agent, isotonic agent, buffering agent,soothing agent and the like for liquid preparations are used. Wherenecessary, additives for preparations such as preservative, antioxidant,colorant, sweetener and the like can be also used.

Examples of the excipient include lactose, white sugar, D-mannitol,starch, corn starch, crystalline cellulose, light anhydrous silicic acidand the like.

Examples of the lubricant include magnesium stearate, calcium stearate,talc, colloidal silica and the like.

Examples of the binding agent include crystalline cellulose, whitesugar, D-mannitol, dextrin, hydroxypropylcellulose,hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose,gelatin, methylcellulose, carboxymethylcellulose sodium and the like.

Examples of the disintegrant include starch, carboxymethylcellulose,carboxymethylcellulose calcium, carboxymethylstarch sodium,L-hydroxypropylcellulose and the like.

Examples of the solvent include water for injection, alcohol, propyleneglycol, Macrogol, sesame oil, corn oil, olive oil and the like.

Examples of the solubilizing agent include polyethylene glycol,propylene glycol, D-mannitol, benzyl benzoate, ethanol,trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodiumcitrate and the like.

Examples of the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid,lecithin, benzalkonium chloride, benzetonium chloride, glycerinmonostearate and the like; hydrophilic polymers such as polyvinylalcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium,methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose and the like; and the like.

Examples of the isotonic agent include glucose, D-sorbitol, sodiumchloride, glycerin, D-mannitol and the like.

Examples of the buffering agent include buffer solutions such asphosphates, acetates, carbonates, citrates and the like.

Examples of the soothing agent include benzyl alcohol and the like.

Examples of the preservative include paraoxybenzoic acid esters,chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid,sorbic acid and the like.

Examples of the antioxidant include sulfites, ascorbic acid,α-tocopherol and the like.

While the pharmaceutical composition varies depending on the dosageform, the administration method, carrier and the like, the compositioncan be produced by adding the compound of the present invention in aproportion of generally 0.01-100% (w/w), preferably 0.1-95% (w/w), ofthe total amount of the preparation according to a conventional method.

The compound of the present invention may be used in combination withother active ingredients (hereinafter to be abbreviated as concomitantdrug).

As the concomitant drug, for example, the following can be mentioned.

benzodiazepine (chlordiazepoxide, diazepam, potassium clorazepate,lorazepam, clonazepam, alprazolam etc.), L-type calcium channelinhibitor (pregabalin etc.), tricyclic or tetracyclic antidepressant(imipramine hydrochloride, amitriptyline hydrochloride, desipraminehydrochloride, clomipramine hydrochloride etc.), selective serotoninreuptake inhibitor (fluvoxamine maleate, fluoxetine hydrochloride,citalopram hydrobromide, sertraline hydrochloride, paroxetinehydrochloride, escitalopram oxalate etc.), serotonin-noradrenalinereuptake inhibitor (venlafaxine hydrochloride, duloxetine hydrochloride,desvenlafaxine hydrochloride etc.), noradrenaline reuptake inhibitor(reboxetine mesylate etc.), noradrenaline-dopamine reuptake inhibitor(bupropion hydrochloride etc.), mirtazapine, trazodone hydrochloride,nefazodone hydrochloride, bupropion hydrochloride, setiptiline maleate,agonist (buspirone hydrochloride, tandospirone citrate, osemozotanhydrochloride etc.), 5-HT₃ antagonist (cyamemazine etc.), heartnon-selective β inhibitor (propranolol hydrochloride, oxprenololhydrochloride etc.), histamine H₁ antagonist (hydroxyzine hydrochlorideetc.), therapeutic drug for schizophrenia (chlorpromazine, haloperidol,sulpiride, clozapine, trifluoperazine hydrochloride, fluphenazinehydrochloride, olanzapine, quetiapine fumarate, risperidone,aripiprazole etc.), CRF antagonist, other antianxiety drug (meprobamateetc.), tachykinin antagonist (MK-869, saredutant etc.), medicamentacting on metabotropic glutamate receptor, CCK antagonist, β3 adrenalineantagonist (amibegron hydrochloride etc.), GAT-1 inhibitor (tiagabinehydrochloride etc.), N-type calcium channel inhibitor, carbonicanhydrase II inhibitor, NMDA glycine site agonist, NMDA antagonist(memantine etc.), peripheral type benzodiazepine receptor agonist,vasopressin antagonist, vasopressin V1b antagonist, vasopressin V1aantagonist, phospho diesterase inhibitor, opioid antagonist, opioidagonist, uridine, nicotinic acid receptor agonist, thyroid hormone (T3,T4), TSH, TRH, MAO inhibitor (phenelzine sulfate, tranylcyprominesulfate, moclobemide etc.), 5-HT_(2A) antagonist, 5-HT_(2A) inverseagonist, COMT inhibitor (entacapone etc.), therapeutic drug for bipolardisorder (lithium carbonate, sodium valproate, lamotrigine, riluzole,felbamate etc.), cannabinoid CB1 antagonist (rimonabant etc.), FAAHinhibitor, sodium channel inhibitor, anti-ADHD drug (methylphenidatehydrochloride, methamphetamine hydrochloride etc.), therapeutic drug foralcohol dependence, therapeutic drug for autism, therapeutic drug forchronic fatigue syndrome, therapeutic drug for spasm, therapeutic drugfor fibromyalgia syndrome, therapeutic drug for headache, therapeuticdrug for insomnia (etizolam, zopiclone, triazolam, zolpidem, ramelteon,indiplon etc.), therapeutic drug for quit smoking, therapeutic drug formyasthenia gravis, therapeutic drug for cerebral infarction, therapeuticdrug for mania, therapeutic drug for hypersomnia, therapeutic drug forpain, therapeutic drug for dysthymia, therapeutic drug forautonomicataxia, therapeutic drug for male and female sexualdysfunction, therapeutic drug for migraine, therapeutic drug forpathological gambler, therapeutic drug for restless legs syndrome,therapeutic drug for substance addiction, therapeutic drug foralcohol-related disease, therapeutic drug for irritable bowel syndrome,therapeutic drug for Alzheimer's disease (donepezil, galanthamine,memantine etc.), therapeutic drug for Parkinson's disease, therapeuticdrug for ALS (riluzole etc., neurotrophic factor etc.), therapeutic drugfor lipid abnormality like cholesterol-lowering agent (statin series(pravastatin sodium, atrovastatin, simvastatin, rosuvastatin etc.),fibrate (clofibrate etc.), squalene synthetase inhibitor), therapeuticdrug for abnormal behavior or suppressant of dromomania due to dementia(sedatives, antianxiety drug etc.), apoptosis inhibitor, antiobesitydrug, therapeutic drug for diabetes, therapeutic drug for hypertension,therapeutic drug for hypotension, therapeutic drug for rheumatism(DMARD), anti-cancer agent, therapeutic drug for parathyroid (PTH),calcium receptor antagonist, sex hormone or a derivative thereof(progesterone, estradiol, estradiol benzoate etc.), neuronaldifferentiation enhancer, nerve regeneration enhancer, non-steroidalanti-inflammatory drug (meloxicam, tenoxicam, indomethacin, ibuprofen,celecoxib, rofecoxib, aspirin, indomethacin etc.), steroid(dexamethasone, cortisone acetate etc.), anti-cytokine drug (TNFinhibitor, MAP kinase inhibitor etc.), antibody medicament, nucleic acidor nucleic acid derivative, aptamer drug and the like.

By combining the compound of the present invention and a concomitantdrug, a superior effect such as

-   (1) the dose can be reduced as compared to single administration of    the compound of the present invention or a concomitant drug,-   (2) the concomitant drug can be selected according to the condition    of patients (mild case, severe case and the like),-   (3) the period of treatment can be set longer by selecting a    concomitant drug having different action and mechanism from the    compound of the present invention,-   (4) a sustained treatment effect can be designed by selecting a    concomitant drug having different action and mechanism from the    compound of the present invention,-   (5) a synergistic effect can be afforded by a combined use of the    compound of the present invention and a concomitant drug, and the    like, can be achieved.

A combined use of the compound of the present invention and aconcomitant drug is referred to as “combination agent of the presentinvention”.

When using the combination agent of the present invention, theadministration time of the compound of the present invention and theconcomitant drug is not restricted, and the compound of the presentinvention or a pharmaceutical composition thereof and the concomitantdrug or a pharmaceutical composition thereof can be administered to anadministration subject simultaneously, or may be administered atdifferent times. The dosage of the concomitant drug may be determinedaccording to the dose clinically used, and can be appropriately selecteddepending on an administration subject, administration route, disease,combination and the like.

The administration mode of the combination agent of the presentinvention is not particularly restricted, and it is sufficient that thecompound of the present invention and the concomitant drug are combinedin administration. Examples of such administration mode include thefollowing:

(1) administration of a single preparation obtained by simultaneouslyprocessing the compound of the present invention and the concomitantdrug, (2) simultaneous administration of two kinds of preparations ofthe compound of the present invention and the concomitant drug, whichhave been separately produced, by the same administration route, (3)administration of two kinds of preparations of the compound of thepresent invention and the concomitant drug, which have been separatelyproduced, by the same administration route in a staggered manner, (4)simultaneous administration of two kinds of preparations of the compoundof the present invention and the concomitant drug, which have beenseparately produced, by different administration routes, (5)administration of two kinds of preparations of the compound of thepresent invention and the concomitant drug, which have been separatelyproduced, by different administration routes in a staggered manner(e.g., administration in the order of the compound of the presentinvention and the concomitant drug, or in the reverse order) and thelike.

The combination agent of the present invention has low toxicity, and forexample, the compound of the present invention or (and) theabove-mentioned concomitant drug can be mixed, according to a methodknown per se, with a pharmacologically acceptable carrier to givepharmaceutical compositions, for example, tablets (including asugar-coated tablet, film-coated tablet), powders, granules, capsules(including a soft capsule), solutions, injections, suppositories,sustained release agents and the like which can be safely administeredorally or parenterally (e.g., administration to local, rectum, vein, andthe like). An injection can be administered intravenously,intramuscularly, subcutaneously or intraorganly or directly to thelesion.

As the pharmacologically acceptable carrier usable for the production ofthe combination agent of the present invention, various organic orinorganic carrier substances conventionally used as preparationmaterials can be mentioned. For example, excipient, lubricant, binderand disintegrant can be used for solid preparations. Solvent,solubilizing agent, suspending agent, isotonic agent, buffering agentand soothing agent and the like can be used for liquid preparations.Where necessary, suitable amounts of general additives such aspreservative, antioxidant, colorant, sweetening agent, adsorbent,wetting agent and the like can also be used as appropriate.

Examples of the excipient include lactose, white sugar, D-mannitol,starch, corn starch, crystalline cellulose, light anhydrous silicic acidand the like.

Examples of the lubricant include magnesium stearate, calcium stearate,talc, colloidal silica and the like.

Examples of the binding agent include crystalline cellulose, whitesugar, D-mannitol, dextrin, hydroxypropylcellulose,hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose,gelatin, methylcellulose, carboxymethylcellulose sodium and the like.

Examples of the disintegrant include starch, carboxymethylcellulose,carboxymethylcellulose calcium, carboxymethylstarch sodium,L-hydroxypropylcellulose and the like.

Examples of the solvent include water for injection, alcohol, propyleneglycol, Macrogol, sesame oil, corn oil, olive oil and the like.

Examples of the solubilizing agent include polyethylene glycol,propylene glycol, D-mannitol, benzyl benzoate, ethanol,trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodiumcitrate and the like.

Examples of the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid,lecithin, benzalkonium chloride, benzetonium chloride, glycerinmonostearate and the like; hydrophilic polymers such as polyvinylalcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium,methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose and the like; and the like.

Examples of the isotonic agent include glucose, D-sorbitol, sodiumchloride, glycerin, D-mannitol and the like.

Examples of the buffering agent include buffer solutions such asphosphates, acetates, carbonates, citrates and the like.

Examples of the soothing agent include benzyl alcohol and the like.

Examples of the preservative include paraoxybenzoic acid esters,chlorobutanol, benzyl alcohol, phenylethyl alcohol, dehydroacetic acid,sorbic acid and the like.

Examples of the antioxidant include sulfites, ascorbic acid,α-tocopherol and the like.

The compounding ratio of the compound of the present invention to theconcomitant drug in the combination agent of the present invention canbe appropriately selected depending on an administration subject,administration route, diseases and the like.

For example, the content of the compound of the present invention in thecombination agent of the present invention varies depending on the formof a preparation, and usually from about 0.01 to 100 wt %, preferablyfrom about 0.1 to 50 wt %, further preferably from about 0.5 to 20 wt %,based on the whole preparation.

While the content of the concomitant drug in the combination agent ofthe present invention varies depending on the form of a preparation, itis usually from about 0.01 to 100 wt %, preferably from about 0.1 to 50wt %, further preferably from about 0.5 to 20 wt %, based on the wholepreparation.

While the content of the additives such as carrier and the like in thecombination agent of the present invention varies depending on the formof a preparation, it is generally about 1 to 99.99 wt %, preferablyabout 10 to 90 wt %, based on the whole preparation.

Similar contents can be employed for individual preparations of thecompound of the present invention and the concomitant drug.

EXAMPLES

The present invention is explained in detail in the following byreferring to Reference Examples, Examples, Experimental Examples andFormulation Examples, which are not to be construed as limitative, andthe invention may be changed within the scope of the present invention.

In the following Examples, the “room temperature” generally shows about10° C. to about 35° C. The ratios for mixed solvents show, unlessotherwise specified, volume mixing ratios. Unless otherwise specified, %shows wt %.

In silica gel column chromatography, basic NH means use ofaminopropylsilane-bound silica gel. The ratios of elution solvents arevolume mixing ratios, unless otherwise specified.

In the following Reference Examples and Examples, the followingabbreviations are used.

-   mp: melting point-   DMF: N,N-dimethylformamide-   THF: tetrahydrofuran-   EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-   DMSO: dimethyl sulfoxide-   HOBt: 1-hydroxybenzotriazole-   DIEA: N,N-diisopropylethylamine-   DEAD: diethyl azodicarboxylate-   IPE: diisopropyl ether-   aq.: aqueous solution-   TEA: triethylamine-   sat.: saturated-   4A MS: 4 angstrom molecular sieves-   DME: 1,2-dimethoxyethane-   Pd(dppf)Cl₂:    [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-   NaH: sodium hydride-   BSA: bovine serum albumin-   EDTA: ethylenediaminetetraacetic acid-   HBSS: Hanks' balanced salt solution-   HEPES: 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid-   HMPA: hexamethylphosphoric triamide-   D-MEM: Dulbecco's Modified Eagle Medium-   N: normal-   % wet: wet weight

¹H-NMR (proton nuclear magnetic resonance spectrum) was measuredFourier-transform type NMR. For the analysis, ACD/SpecManager (tradename) and the like were used. Peaks with very mild protons such as ahydroxyl group, an amino group, hydrochloride, hydrobromide and the likeare not described. In addition, peaks that matched with signals ofwater, deuterated solvents or other solvents are not described.

For indication of the measurement results of ¹H NMR, the followingabbreviations are used.

s: singlet, d: doublet, dd: double doublet, dt: double triplet, t:triplet, q: quartet, dq: double quartet, m: multiplet, brs: broadsinglet, spt: septet, quin: quintet, sxt: sextet, J: coupling constant,Hz: hertz

MS (mass spectrum) was measured by LC/MS (liquid chromatography massspectrometer). As the ionization method, atmospheric pressure ionization(API) method was used. The API method includes ESI (ElectroSprayIonization) method, APCI (Atomospheric Pressure Chemical Ionization)method and ESI+APCI mixed ion mode method.

The data indicates those found. Generally, a molecular ion peak isobserved; however, it may not be observed in some cases. In the case ofa compound having a tert-butoxycarbonyl group (-Boc), a peak afterelimination of a tert-butoxycarbonyl group or tert-butyl group may beobserved as a fragment ion. In the case of a salt, a molecular ion peakor fragment ion peak of free form is generally observed. In addition,plural molecular ion peaks of isotope may be described.

For elemental analysis values (Anal.), those calculated (Calcd) andthose found (Found) are described.

When preparative HPLC was performed for purification and described asC18, an octadecyl-bound silica gel column was used.

Example 1N-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine-9-carboxamide2,2-dioxide A) methyl3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine-9-carboxylate 2,2-dioxide

To a suspension of sodium hydride (60%, 2.0 g) in dry THF (100 mL) wereadded under ice-cooling methyl 3-aminopyrazine-2-carboxylate (1.53 g)and 2-chloroethanesulfonyl chloride (2.1 mL), and the mixture wasstirred at room temperature overnight. To the reaction mixture was added2-chloroethanesulfonyl chloride (2.1 mL), and the mixture was stirred atroom temperature for 3 days. 2-Chloroethanesulfonyl chloride (2.1 mL)was added, and the mixture was stirred at room temperature for 3 days.The reaction mixture was added dropwise to aqueous sodium hydrogencarbonate (15.1 g) solution (400 mL) under ice-cooling, and the mixturewas stirred at the same temperature for 1 hr. The precipitated wascollected by filtration, washed successively with water and a smallamount of methanol, and dried to give the title compound (1.62 g) as apale-yellow solid.

MS(ESI+), found:244.1.

B)N-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine-9-carboxamide2,2-dioxide

To a suspension of methyl3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine-9-carboxylate 2,2-dioxide(1.58 g) in methanol (13 mL) were added 1N aqueous sodium hydroxidesolution (13 mL), and the mixture was stirred at room temperature for 1hr. To the reaction mixture was added 1N hydrochloric acid (13.2 mL),and methanol was evaporated under reduced pressure. The precipitated wascollected by filtration, washed successively with water and methanol,and dried to give a brown solid (866 mg). The obtained solid (734 mg)was dissolved in DMF (20 ml), 4-sec-butylaniline (0.70 mL), HOBt (686mg) and EDCI HCl (859 mg) were added and the mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with ethylacetate, washed successively with 5% aqueous sodium hydrogen carbonatesolution and saturated brine, dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue was purified by basicsilica gel column chromatography (methanol/ethyl acetate), andrecrystallized from water-containing ethanol to give the title compound(332 mg) as pale-yellow crystals.

Example 27-methyl-N-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine-9-carboxamide2,2-dioxide A) 2-amino-5-methylpyridine-3-carbonitrile

To a solution of 2-amino-3-bromo-5-methylpyridine (3.74 g) in DMF (30mL) was added copper(I) cyanide (4.48 g), and the mixture was stirredunder microwave irradiation at 180° C. for 30 min. To the reactionmixture were added ethyl acetate and water, 1N aqueous sodium hydroxidesolution (50 mL) was added and the mixture was stirred. Insolublematerial was filtered off through celite. The aqueous layer and organiclayer were separated, and the aqueous layer was extracted with ethylacetate. The extract was collected, washed with saturated brine, driedover anhydrous sodium sulfate and concentrated under reduced pressure.The residue was purified by silica gel column chromatography (ethylacetate/hexane) to give the title compound (357 mg) as a colorlesssolid.

MS(ESI+), found:134.1.

B) ethyl 2-amino-5-methylpyridine-3-carboxylate

To a solution of 2-amino-5-methylpyridine-3-carbonitrile (353 mg) inethanol (10 mL) was added concentrated sulfuric acid (5 mL), and themixture was stirred at 80° C. for 4 hr. The reaction mixture was addeddropwise to a mixture of sodium carbonate (10.6 g), water (50 mL) andethyl acetate (50 mL) under ice-cooling with stirring. The organic layerwas separated, washed with saturated brine, dried over anhydrous sodiumsulfate, and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography (ethyl acetate/hexane) togive the title compound (373 mg) as a colorless solid.

MS(ESI+), found:181.1.

C) ethyl7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxylate2,2-dioxide

To a solution of ethyl 2-amino-5-methylpyridine-3-carboxylate (368 mg)in DMF (20 mL) were added pyridine (0.66 mL) and 2-chloroethanesulfonylchloride (0.32 ml), and the mixture was stirred at room temperature for3 hr. To the reaction mixture were added water (50 mL) and sodiumcarbonate (1 g), sodium chloride was saturated and the mixture was isextracted 3 times with ethyl acetate. The extracts were collected, driedover anhydrous sodium sulfate, and concentrated under reduced pressure.The residue was purified by silica gel column chromatography(methanol/ethyl acetate) to give the title compound (111 mg) as a brownsolid.

MS(ESI+), found:271.1.

D) 7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxylic acid2,2-dioxide

To a solution of ethyl7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxylate2,2-dioxide (106 mg) in methanol (1 ml) was added 1N aqueous sodiumhydroxide solution (1 mL), and the mixture was stirred at roomtemperature for 1 hr. To the reaction mixture were added 1N hydrochloricacid (1.05 mL) and water (1 mL), and the resulting precipitate wascollected by filtration, washed successively with water and a smallamount of THF, and dried to give the title compound (79 mg) as apale-yellow solid.

MS(ESI+), found:243.1.

E)7-methyl-N-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxamide2,2-dioxide

To a suspension of7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxylic acid2,2-dioxide (76 mg) in DMF (3 mL) were added 4-sec-butylaniline (0.069mL), HOBt (67 mg), and EDCI HCl (84 mg) and the mixture was stirred atroom temperature overnight. To the reaction mixture was added water (10ml), and the resulting precipitate was collected by filtration. Theobtained solid was recrystallized from DMSO-ethanol to give the titlecompound (114 mg) as pale-yellow crystals.

Example 3

In the same manner as in Example 1, the compound of Example 3 wasproduced.

Example 4N-(4-cyclopropylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxamide2,2-dioxide

3,4-Dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carboxylic acid 2,2-dioxide(150 mg) was dissolved in DMF (5 ml), 4-cyclopropylaniline (131 mg),HOBt (151 mg), EDCI HCl (189 mg) and DIEA (0.23 mL) were added and themixture was stirred at room temperature overnight. The reaction mixturewas diluted with ethyl acetate, washed successively with water andsaturated brine, dried over anhydrous sodium sulfate, and concentratedunder reduced pressure. The residue was suspended in ethyl acetate, andinsoluble crystals were collected by filtration to give the titlecompound (168 mg) as pale-yellow crystals.

¹H NMR(300 MHz, DMSO-d₆) δ 0.42-0.78(2H,m), 0.78-1.09(2H,m),1.72-2.06(1H,m), 3.47-3.85(2H,m), 4.65-4.85(2H,m), 6.71-6.98(1H,m),6.99-7.32(2H,m), 7.32-7.70(2H,m), 8.09(1H,dd,J=6.4,1.9 Hz),8.52(1H,dd,J=7.6,1.9 Hz), 12.01(1H,s).

Anal. Calcd for C₁₇H₁₇N₃O₃S:C,59.46; H,4.99; N,12.24. Found: C,59.23;H,4.91; N,12.19.

Examples 5-12

In the same manner as in Example 4, the compounds of Examples 5, 6, 7,8, 9, 10, 11 and 12 were produced.

Example 13N-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,3-dihydro-1,4-benzodioxine-6-carboxamideA) 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide

To a solution of 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (3.54g) in DMF (80 mL) were added HOBt-NH₃ (4.48 g) and EDCI HCl (5.65 g) atroom temperature. The reaction mixture was stirred at room temperaturefor 3 days, water was added, and the mixture was extracted with ethylacetate. The extract was washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure and theresidue was washed with hexane to give the title compound (1.10 g).

¹H NMR(300 MHz,DMSO-d₆) δ 4.18-4.35(4H,m), 6.89(1H,d,J=8.3 Hz),7.19(1H,brs), 7.34-7.44(2H,m), 7.80(1H,brs).

B) 9-bromo-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

A mixture of 3-bromopyridin-2-amine (3 g) in dehydrated THF (30 mL) wasadded to a mixture of 2-chloroethanesulfonyl chloride (7.07 g) andsodium hydride (60%, 3.47 g) in dehydrated THF (30 mL) at roomtemperature, and the reaction mixture was stirred at room temperatureovernight. Water was added to the reaction mixture, and THF was removedunder reduced pressure. The resulting precipitate was collected byfiltration, and washed with water and diethyl ether to give the titlecompound (3.41 g) as a white solid.

MS(ESI+), found:262.9.

C)N-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,3-dihydro-1,4-benzodioxine-6-carboxamide

To a solution of 9-bromo-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (100 mg) in DMF (1 mL) were added toluene (2 mL),2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (74.9 mg), cesiumcarbonate (248 mg), 9,9-dimethyl-4,5-(diphenylphosphino)xanthene (33.0mg) and tris(dibenzylideneacetone)dipalladium(0) (34.8 mg) at roomtemperature. The reaction mixture was stirred under a nitrogenatmosphere at 100° C. for 5 hr, and purified by silica gel columnchromatography (methanol/ethyl acetate) and recrystallized from(methanol/diisopropyl ether) to give the title compound (25.4 mg).

Example 14 9-biphenyl-4-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-biphenyl-4-ylpyridin-2-amine

A mixture of 2M aqueous sodium carbonate solution (6.64 mL),tetrakis(triphenylphosphine)palladium(0) (0.512 g), biphenyl-4-ylboronicacid (2.28 g) and 3-bromopyridin-2-amine (1.532 g) in dehydrated THF (30mL) was heated under reflux overnight. The reaction mixture was added towater, and the mixture was extracted with ethyl acetate. The organiclayer was washed with saturated brine, dried over anhydrous magnesiumsulfate, and concentrated under reduced pressure to give a solid. Theobtained solid was crystallized from toluene, diisopropyl ether andacetonitrile to give the title compound (1.428 g) as a white solid.

MS(ESI+), found:247.4.

B) 9-biphenyl-4-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-biphenyl-4-ylpyridin-2-amine (700 mg) in dehydrated THF(30 mL) was added to a mixture of sodium hydride (60%, 568 mg) and2-chloroethanesulfonyl chloride (1390 mg) in dehydrated THF (30 mL)under ice-cooling. The reaction mixture was stirred at room temperatureovernight, and water and hexane were added. The resulting precipitatewas collected by filtration, and washed with water and ethyl acetate togive the title compound (652 mg) as a white solid.

¹H NMR(300 MHz,DMSO-d₆) δ 3.42-3.54(2H,m), 4.60-4.76(2H,m),6.73(1H,t,J=6.8 Hz), 7.34-7.42(1H,m), 7.44-7.54(2H,m), 7.59-7.66(2H,m),7.66-7.76(5H,m), 7.80(1H,dd,J=6.6,1.7 Hz).

mp 315-316° C.

MS (API+), found:337.0

Anal. Calcd for C₁₉H₁₆N₂O₂S-0.2H₂O:C,66.94; H,4.88; N,8.22. Found:C,67.25; H,4.82; N,8.15.

Example 159-[4-(1-methylethyl)phenoxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(1-methylethyl)phenoxy]pyridin-2-amine

A mixture of 3-bromopyridin-2-amine (1200 mg), tripotassium phosphate(2945 mg), 4-isopropylphenol (1134 mg), copper iodide(I) (132 mg) andpicoline acid (171 mg) in DMSO (40 ml) was stirred under a nitrogenatmosphere at 80° C. overnight. The reaction mixture was added tosaturated aqueous ammonium chloride solution, filtered through celite,and the filtrate was extracted with ethyl acetate. The organic layer waswashed with saturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/hexane) to give the titlecompound (180.4 mg) as a pale-brown solid.

MS(ESI+), found:229.1.

B)₉-[4-(1-methylethyl)phenoxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned A).

Example 169-{[4-(1-methylethyl)phenyl]sulfanyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-{[4-(1-methylethyl)phenyl]sulfanyl}pyridin-2-amine

A mixture of 4-isopropylbenzenethiol (2.288 g), 3-bromopyridin-2-amine(2.0 g), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine)(0.669 g), tris(dibenzylideneacetone)dipalladium(0) (0.529 g) and DIEA(7.47 mL) in toluene (57.8 mL) was stirred overnight under a nitrogenatmosphere at 120° C. The reaction mixture was added to water, filteredthrough celite, and the filtrate was extracted with ethyl acetate. Theorganic layer was washed with saturated brine, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (2508 mg) as a pale-yellow solid.

MS(ESI+), found:245.3.

B)9-{[4-(1-methylethyl)phenyl]sulfanyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned A).

Example 17

The compound of Example 17 was produced in the same manner as in Example16.

Example 18

The compound of Example 18 was produced in the same manner as in Example15.

Example 199-{[4-(1-methylethyl)phenyl]sulfinyl}-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide

To a mixture of9-{[4-(1-methylethyl)phenyl]sulfanyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (137.4 mg) in dehydrated DMF (3 mL) was added a mixture of3-chloroperbenzoic acid (75%, 99 mg) in dehydrated DMF (3 mL) underice-cooling, and the mixture was stirred at room temperature overnight.To the reaction mixture was added saturated aqueous sodium sulfitesolution, and the mixture was extracted with ethyl acetate. The organiclayer was washed with saturated aqueous sodium hydrogen carbonatesolution and saturated brine, dried over anhydrous magnesium sulfate,and concentrated under reduced pressure. The residue was purified bysilica gel column chromatography (ethyl acetate/methanol) to give thetitle compound (67.6 mg) as a white solid.

Example 209-{[4-(1-methylethyl)phenyl]sulfonyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-{[4-(1-methylethyl)phenyl]sulfanyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (125.5 mg) and 3-chloroperbenzoic acid (75%, 190 mg) indehydrated DMF (5 mL) was stirred at room temperature overnight. To thereaction mixture was added saturated aqueous sodium sulfite solution,and the mixture was extracted with ethyl acetate. The organic layer waswashed with saturated aqueous sodium hydrogen carbonate solution andsaturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/methanol) to give the titlecompound (48.4 mg) as a white solid.

Example 21 9-(benzylsulfinyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 19, the title compound (112.2 mg) wasobtained from9-(benzylsulfanyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (220 mg).

Example 22 9-(benzylsulfonyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 20, the title compound (40.3 mg) wasobtained from9-(benzylsulfanyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (220 mg).

Example 239-[4-(1-methylethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)₃-[4-(1-methylethyl)phenyl]pyridin-2-amine

A mixture of 2M aqueous sodium carbonate solution (8.67 mL),tetrakis(triphenylphosphine)palladium(0) (668 mg),4-isopropylphenylboronic acid (2844 mg) and 3-bromopyridin-2-amine (2.0g) in 1,2-dimethoxyethane (30 mL) was heated under reflux overnight. Thereaction mixture was added to water, and the mixture was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate, and concentrated under reducedpressure. The residue was purified by silica gel column chromatography(ethyl acetate/hexane) to give the title compound (2267 mg) as a whitesolid.

MS(ESI+), found:213.4

B)9-[4-(1-methylethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-[4-(1-methylethyl)phenyl]pyridin-2-amine (700 mg) indehydrated THF (15 mL) was added to a mixture of sodium hydride (60%,659 mg) and 2-chloroethanesulfonyl chloride (1613 mg) in dehydrated THF(15 mL) under ice-cooling. The reaction mixture was stirred at roomtemperature overnight, and saturated aqueous sodium hydrogen carbonatesolution and ethyl acetate were added. The resulting precipitate wascollected by filtration, and washed with water and ethyl acetate to givethe title compound (738 mg) as a white solid. The obtained solid wascrystallized from acetonitrile and diisopropyl ether to give a whitesolid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.23(6H,d,J=7.2 Hz), 2.92(1H,spt,J=6.9 Hz),3.37-3.51(2H,m), 4.55-4.72(2H,m), 6.70(1H,t,J=6.8 Hz), 7.22-7.34(2H,m),7.40-7.49(2H,m), 7.60(1H,dd,J=7.2,1.9 Hz), 7.76(1H,dd,J=6.6,1.7 Hz).

mp 239-241° C.

Anal. Calcd for C₁₆H₁₈N₂O₂S:C,63.55; H,6.00; N,9.26. Found: C, 63.37; H,6.00; N, 9.28.

Example 24

The compound of Example 24 was produced in the same manner as in Example15.

Example 259-{2-[4-(1-methylethyl)phenyl]ethyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-{[4-(1-methylethyl)phenyl]ethynyl}pyridin-2-amine

A mixture of bis(triphenylphosphine)palladium(0)dichloride (0.811 g),3-bromopyridin-2-amine (2 g), 1-ethynyl-4-isopropylbenzene (1.667 g) andcopper iodide(I) (0.22 g) in triethylamine (38.6 mL) was heated underreflux. Water was added to the reaction mixture, the mixture wasfiltered through celite, and the filtrate was extracted with ethylacetate. The organic layer was washed with saturated brine, dried overanhydrous magnesium sulfate, and concentrated under reduced pressure.The residue was purified by silica gel column chromatography (ethylacetate/hexane) to give the title compound (1273 mg) as a pale-yellowsolid.

MS(ESI+), found:237.4.

B) 3-{2-[4-(1-methylethyl)phenyl]ethyl}pyridin-2-amine

A mixture of 10% palladium-carbon (50% wet, 50 mg) and3-{[4-(1-methylethyl)phenyl]ethynyl}pyridin-2-amine (662.8 mg) inmethanol (15 mL) was stirred under a hydrogen atmosphere at roomtemperature for 3 hr. The reaction mixture was filtered, a saturatedaqueous sodium hydrogen carbonate solution was added to the filtrate,and the mixture was extracted with ethyl acetate. The organic layer waswashed with saturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/hexane) to give the titlecompound (246.6 mg) as a colorless oil.

MS(ESI+), found:241.4.

C)9-{2-[4-(1-methylethyl)phenyl]ethyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-{2-[4-(1-methylethyl)phenyl]ethyl}pyridin-2-amine (150mg) in dehydrated THF (5 mL) was added to a mixture of sodium hydride(60%, 125 mg) and 2-chloroethanesulfonyl chloride (305 mg) in dehydratedTHF (5 mL) under ice-cooling. The reaction mixture was stirred at roomtemperature for 2 hr, and saturated aqueous sodium hydrogen carbonatesolution and ethyl acetate were added. The resulting precipitate wascollected by filtration, and washed with water and ethyl acetate to givethe title compound (149 mg) as a white solid. The obtained solid wascrystallized from acetonitrile and diisopropyl ether to give a whitesolid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.18(6H,d,J=7.2 Hz), 2.63-2.96(5H,m),3.37-3.50(2H,m), 4.50-4.68(2H,m), 6.56(1H,t,J=6.8 Hz), 7.03-7.30(4H,m),7.45(1H,dd,J=7.2,1.5 Hz), 7.65(1H, dd, J=6.8,1.5 Hz).

Anal. Calcd for C₁₈H₂₂N₂O₂S-0.25H₂O:C,64.55; H,6.77; N,8.36. Found:C,64.46; H,6.65; N,8.34.

Example 269-{[4-(1-methylethyl)phenyl]ethynyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-{[4-(1-methylethyl)phenyl]ethynyl}pyridin-2-amine (150mg) in dehydrated THF (5 mL) was added to a mixture of sodium hydride(60%, 127 mg) and 2-chloroethanesulfonyl chloride (310 mg) in dehydratedTHF (5 mL) under ice-cooling. The reaction mixture was stirred at roomtemperature for 2 hr, and saturated aqueous sodium hydrogen carbonatesolution and ethyl acetate were added. The resulting precipitate wascollected by filtration, and washed with water and ethyl acetate to givethe title compound (110 mg) as a white solid. The obtained solid wascrystallized from acetonitrile and diisopropyl ether to give a whitesolid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.21(6H,d,J=7.2 Hz), 2.81-3.07(1H,m),3.39-3.56(2H,m), 4.56-4.67(2H,m), 6.64(1H,t,J=7.0 Hz), 7.25-7.36(2H,m),7.40-7.49(2H,m), 7.79(1H, dd, J=6.8,1.5 Hz), 7.87(1H,dd,J=7.2,1.5 Hz).

mp 258-262° C.

Anal. Calcd for C₁₈H₁₈N₂O₂S-0.125H₂O: C, 65.78; H, 5.60; N, 8.52. Found:C, 65.75; H, 5.63; N, 8.51.

Example 27N-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxine-6-carboxamideA) 2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide

To 2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxine-6-carbonitrile(200 mg) were added concentrated sulfuric acid (2 mL) and water (0.3 mL)at room temperature. The reaction mixture was stirred at 40° C. for 3hr, water was added and the mixture was stirred for 40 min at roomtemperature. The resulting solid was collected by filtration, washedwith purified water, and dried under reduced pressure to give the titlecompound (190.6 mg).

¹H NMR(300 MHz, CDCl₃) δ 5.80(2H,brs), 7.23(1H,d,J=8.3 Hz),7.58-7.70(2H,m).

B)N-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxine-6-carboxamide

In the same manner as in Example 13, step B, the title compound wasobtained from the compound of the above-mentioned A).

Example 289-biphenyl-4-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 10% palladium-carbon (50% wet, 12 mg) and9-biphenyl-4-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide(115 mg) in THF (50 mL) was stirred under a hydrogen atmosphereovernight. The reaction mixture was filtered, and the filtrate wasconcentrated to give the title compound (122 mg) as a white solid. Theobtained solid was crystallized from acetonitrile, diisopropyl ether andhexane to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ1.64-1.91(3H,m), 1.94-2.15(1H,m),3.18-3.38(2H,m), 3.39-3.67(2H,m), 3.70-4.06(3H,m), 7.25-7.32(2H,m),7.32-7.40(1H,m), 7.41-7.52(2H,m), 7.56-7.63(2H,m), 7.63-7.69(2H,m).

mp 238-239° C.

Anal. Calcd for C₁₉H₂₀N₂O₂S:C,67.03; H,5.92; N,8.23. Found: C,66.75;H,5.91; N,8.14.

Example 299-{5-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-3-yl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 2-amino-N′-hydroxypyridine-3-carboxyamide

To a mixture of 2-aminopyridine-3-carbonitrile (4800 mg) andhydroxyamine hydrochloride (4200 mg) in ethanol (125 mL) was added asolution of sodium carbonate (6406 mg) in water (25 ml) underice-cooling, and the mixture was stirred at room temperature overnight.The reaction mixture was concentrated under reduced pressure, theresidue was added to water, and the mixture was extracted with ethylacetate. The organic layer was washed with saturated brine, dried overanhydrous magnesium sulfate, and concentrated under reduced pressure togive the title compound (5442 mg) as a white solid.

MS(ESI+), found:153.4.

B)₃-{5-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-3-yl}pyridin-2-amine

A mixture of 2-amino-N′-hydroxypyridine-3-carboxyamide (1070 mg),HOBt.H₂O (1185 mg), EDCI HCl (1483 mg) and 4-isopropylbenzoic acid (1270mg) in dehydrated DMF (40 mL) was stirred at room temperature overnightand at 80° C. for 24 hr. To the reaction mixture was added saturatedaqueous sodium hydrogen carbonate solution, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated aqueous sodium hydrogen carbonate solution and saturatedbrine, dried over anhydrous magnesium sulfate, and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography (ethyl acetate/hexane) to give the title compound (302mg) as a white solid.

MS(ESI+), found:281.1.

C)9-{5-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-3-yl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned B).

Example 309-(4-cyclohexylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-cyclohexylphenyl)pyridin-2-amine

A mixture of 2M aqueous sodium carbonate solution (0.396 mL),tetrakis(triphenylphosphine)palladium(0) (30.5 mg),4-cyclohexylphenylboronic acid (140 mg) and 3-bromopyridin-2-amine (91mg) in 1,2-dimethoxyethane (20 mL) and water (5 ml) was stirredovernight under a nitrogen atmosphere at 80° C. The reaction mixture wasadded to water, and the mixture was extracted with ethyl acetate. Theorganic layer was washed with saturated brine, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (57.4 mg) as a pale-yellow solid.

MS(ESI+), found:253.2.

B) 9-(4-cyclohexylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-(4-cyclohexylphenyl)pyridin-2-amine (57 mg) in dehydratedTHF (5 mL) was added to a mixture of sodium hydride (60%, 45.2 mg) and2-chloroethanesulfonyl chloride (110 mg) in dehydrated THF (5 mL) underice-cooling. The reaction mixture was stirred at room temperatureovernight, and water was added. The resulting precipitate was collectedby filtration, and washed with water and diisopropyl ether to give thetitle compound (40.3 mg) as a white solid. The obtained solid wascrystallized from acetonitrile and diisopropyl ether to give a whitesolid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.11-1.57(5H,m), 1.62-1.93(5H,m),2.39-2.58(1H,m), 3.36-3.54(2H,m), 4.55-4.70(2H,m), 6.69(1H,t,J=6.8 Hz),7.20-7.30(2H,m), 7.37-7.46(2H,m), 7.60(1H,d,J=6.4 Hz), 7.75(1H,d,J=6.4Hz).

mp 294-298° C.

Example 319-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (1.905 g),tetrakis(triphenylphosphine)palladium(0) (519 mg),4-phenoxyphenylboronic acid (2.5 g) and 3-bromopyridin-2-amine (1.555 g)in 1,2-dimethoxyethane (60 mL) and water (12 mL) was stirred overnightat 80° C. The reaction mixture was added to water, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/hexane) to give the titlecompound (2.289 g) as a pale-yellow solid.

MS(ESI+), found:263.1.

B) 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-(4-phenoxyphenyl)pyridin-2-amine (47 mg) in dehydratedTHF (5 mL) was added to a mixture of sodium hydride (60%, 35.8 mg) and2-chloroethanesulfonyl chloride (88 mg) in dehydrated THF (5 mL) underice-cooling. The reaction mixture was stirred at room temperatureovernight, and water and hexane were added. The resulting precipitatewas collected by filtration, and washed with water and ethyl acetate togive the title compound (53.2 mg) as a white solid. The obtained solidwas crystallized from THF and diisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 3.40-3.54(2H,m), 4.59-4.73(2H,m),6.65-6.79(1H,m), 6.96-7.14(4H,m), 7.14-7.27(1H,m), 7.34-7.50(2H,m),7.50-7.60(2H,m), 7.60-7.71(1H,m), 7.74-7.83(1H,m).

mp 252-253° C.

Anal. Calcd for C₁₉H₁₆N₂O₃S-0.25H₂O:C,63.94; H,4.66; N,7.85. Found:C,63.93; H,4.55; N,7.78.

Example 329-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(1-methylpropyl)phenyl]pyridin-2-amine

A mixture of sodium carbonate (412 mg),tetrakis(triphenylphosphine)palladium(0) (112 mg),4-(1-methylpropyl)phenylboronic acid (450 mg) and 3-bromopyridin-2-amine(336 mg) in 1,2-dimethoxyethane (15 mL) and water (3 mL) was stirredunder a nitrogen atmosphere at 80° C. overnight. The reaction mixturewas added to water, and the mixture was extracted with ethyl acetate.The organic layer was washed with saturated brine, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (392 mg) as a pale-yellow solid.

MS(ESI+), found:227.3.

B)₉-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-[4-(1-methylpropyl)phenyl]pyridin-2-amine (300 mg) indehydrated THF (5 mL) was added to a mixture of sodium hydride (60%, 265mg) and 2-chloroethanesulfonyl chloride (648 mg) in dehydrated THF (5mL) under ice-cooling. The reaction mixture was stirred at roomtemperature overnight, and water and hexane were added. The resultingprecipitate was collected by filtration, and washed with water anddiisopropyl ether to give the title compound (376 mg) as a white solid.The obtained solid was crystallized from THF, acetonitrile anddiisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 0.81(3H,t,J=7.3 Hz), 1.21(3H,d,J=7.2 Hz),1.59(2H,quin,J=7.3 Hz), 2.62(1H,sxt,J=7.1 Hz), 3.39-3.50(2H,m),4.57-4.72(2H,m), 6.70(1H,t,J=7.0 Hz), 7.19-7.29(2H,m), 7.40-7.49(2H,m),7.61(1H,dd,J=7.3,1.7 Hz), 7.76(1H,dd,J=6.6,1.7 Hz).

mp 237-239° C.

Anal. Calcd for C₁₇H₂₀N₂O₂S-0.1H₂O:C,64.16; H,6.40; N,8.80. Found:C,64.21; H,6.39; N,8.73.

Example 339-[4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)₃-[4-(1-methylethoxy)phenyl]pyridin-2-amine

A mixture of sodium carbonate (906 mg),tetrakis(triphenylphosphine)palladium(0) (247 mg),4-(1-methylethoxy)phenylboronic acid (1000 mg) and3-bromopyridin-2-amine (0.739 g) in 1,2-dimethoxyethane (50 mL) andwater (10 mL) was stirred under a nitrogen atmosphere at 80° C.overnight. The reaction mixture was added to water, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/hexane) to give the titlecompound (883 mg) as a pale-yellow solid.

MS(ESI+), found:229.1.

B)₉-[4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-[4-(1-methylethoxy)phenyl]pyridin-2-amine (350 mg) indehydrated THF (5 mL) was added to a mixture of sodium hydride (60%, 307mg) and 2-chloroethanesulfonyl chloride (750 mg) in dehydrated THF (5mL) under ice-cooling. The reaction mixture was stirred at roomtemperature overnight, and water and hexane were added. The resultingprecipitate was collected by filtration, and washed with water anddiisopropyl ether to give the title compound (360 mg) as a white solid.The obtained solid was crystallized from THF, acetonitrile anddiisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ1.28(6H,d,J=6.0 Hz), 3.38-3.55(2H,m),4.54-4.79(3H,m), 6.68(1H,t,J=7.0 Hz), 6.88-7.01(2H,m), 7.39-7.52(2H,m),7.58(1H,dd,J=7.2,1.9 Hz), 7.73(1H,dd,J=6.8,1.5 Hz).

mp 245-247° C.

Anal. Calcd for C₁₆H₁₈N₂O₃S:C,60.36; H,5.70; N,8.80. Found: C,60.13;H,5.57; N,8.84.

Example 349-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(trifluoromethoxy)phenyl]pyridin-2-amine

A mixture of sodium carbonate (0.903 g),tetrakis(triphenylphosphine)palladium(0) (0.246 g),4-(trifluoromethoxy)phenylboronic acid (1.14 g) and3-bromopyridin-2-amine (0.737 g) in 1,2-dimethoxyethane (50 mL) andwater (10 mL) was stirred under a nitrogen atmosphere at 80° C.overnight. The reaction mixture was added to water, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated brine, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (ethyl acetate/hexane) to give the titlecompound (1.069 g) as a pale-yellow solid.

MS(ESI+), found:255.1.

B)9-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-[4-(trifluoromethoxy)phenyl]pyridin-2-amine (350 mg) indehydrated THF (5 mL) was added to a mixture of sodium hydride (60%, 275mg) and 2-chloroethanesulfonyl chloride (673 mg) in dehydrated THF (5ml) under ice-cooling. The reaction mixture was stirred at roomtemperature overnight, and water and hexane were added. The resultingprecipitate was collected by filtration, and washed with water anddiisopropyl ether to give the title compound (333 mg) as a white solid.The obtained solid was crystallized from THF, acetonitrile anddiisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 3.39-3.53(2H,m), 4.56-4.75(2H,m),6.73(1H,t,J=7.0 Hz), 7.35-7.49(2H,m), 7.58-7.75(3H,m),7.81(1H,dd,J=6.8,1.5 Hz).

mp 249-251° C.

Anal. Calcd for C₁₄H₁₁F₃N₂O₃S-0.2H₂O:C,48.33; H,3.30; N,8.05. Found:C,48.43; H,3.12; N,8.09.

Example 359-(4-tert-butylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-tert-butylphenyl)pyridin-2-amine

A mixture of sodium carbonate (1.31 g),tetrakis(triphenylphosphine)palladium(0) (0.357 g),4-tert-butylphenylboronic acid (1.43 g) and 3-bromopyridin-2-amine(1.069 g) in 1,2-dimethoxyethane (50 mL) and water (10 mL) was stirredunder a nitrogen atmosphere at 80° C. overnight. The reaction mixturewas added to water, and the mixture was extracted with ethyl acetate.The organic layer was washed with saturated brine, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (1.274 g) as a pale-yellow solid.

MS(ESI+), found:227.0.

B)₉-(4-tert-butylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-(4-tert-butylphenyl)pyridin-2-amine (350 mg) indehydrated THF (5 mL) was added to a mixture of sodium hydride (60%, 309mg) and 2-chloroethanesulfonyl chloride (756 mg) in dehydrated THF (5mL) under ice-cooling. The reaction mixture was stirred at roomtemperature overnight, and water and hexane were added. The resultingprecipitate was collected by filtration, and washed with water anddiisopropyl ether to give the title compound (376 mg) as a white solid.The obtained solid was crystallized from THF, acetonitrile anddiisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.31(9H,s), 3.38-3.52(2H,m), 4.52-4.75(2H,m),6.70(1H,t,J=6.8 Hz), 7.35-7.53(4H,m), 7.61(1H,dd,J=7.2,1.5 Hz),7.76(1H,dd,J=6.8,1.5 Hz).

mp 291-292° C.

Anal. Calcd for C₁₇H₂₀N₂O₂S:C,64.53; H,6.37; N,8.85. Found: C,64.26;H,6.38; N,8.86.

Example 36N′-{[4-(1-methylethyl)phenyl]carbonyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carbohydrazide2,2-dioxide A) methyl 4-(1-methylethyl)benzoate

A mixture of 4-isopropylbenzoic acid (10 g) and sulfuric acid (5 mL) inmethanol (50 mL) was heated under reflux overnight, hydrazinemonohydrate (3.66 g) was added, and the mixture was heated under refluxovernight. The reaction mixture was added to a saturated aqueous sodiumhydrogen carbonate solution, and the mixture was extracted with ethylacetate. The organic layer was washed with saturated aqueous sodiumhydrogen carbonate solution and saturated brine, dried over anhydrousmagnesium sulfate and concentrated under reduced pressure to give thetitle compound (10.32 g) as a yellow oil.

MS(ESI+), found:179.0.

B) 4-(1-methylethyl)benzohydrazide

A mixture of methyl 4-(1-methylethyl)benzoate (10 g) and hydrazinemonohydrate (5.62 g) in methanol (50 mL) was heated under refluxovernight. To the reaction mixture was added toluene (50 mL), and themixture was heated at 120° C. overnight. The reaction mixture was addedto a saturated aqueous sodium hydrogen carbonate solution, and themixture was extracted with ethyl acetate. The organic layer was washedwith saturated brine, dried over anhydrous magnesium sulfate andconcentrated under reduced pressure. The residue was washed with hexaneand diisopropyl ether to give the title compound (9.22 g) as a whitesolid.

MS(ESI+), found:179.0.

C) 2-aminopyridine-3-carboxylic acid

A mixture of methyl 2-aminonicotinate (4 g) and 2M aqueous sodiumhydroxide solution (35 mL) in THF (50 mL) was stirred at roomtemperature overnight. The reaction mixture was neutralized with 1Mhydrochloric acid, and extracted with ethyl acetate. The aqueous layerwas acidified with 1M hydrochloric acid, and extracted with THF. Theorganic layers were combined, washed with water and saturated brine,dried over anhydrous magnesium sulfate and concentrated under reducedpressure to give the title compound (1.78 g) as a white solid.

MS(ESI+), found:139.3.

D)2-amino-N′-{[4-(1-methylethyl)phenyl]carbonyl}pyridine-3-carbohydrazide

A mixture of 4-(1-methylethyl)benzohydrazide (2194 mg), HOBt.H₂O (2073mg), EDCI HCl (2595 mg) and 2-aminopyridine-3-carboxylic acid (1700 mg)in dehydrated DMF (50 mL) was stirred at 60° C. overnight. The reactionmixture was added to a saturated aqueous sodium hydrogen carbonatesolution, and the mixture was extracted with ethyl acetate. The organiclayer was washed with saturated aqueous sodium hydrogen carbonatesolution and saturated brine, dried over anhydrous magnesium sulfate andconcentrated under reduced pressure. The residue was crystallized from amixture of ethyl acetate and diisopropyl ether to give the titlecompound (2.4489 g) as a white solid. The mother liquor was purified bysilica gel column chromatography (ethyl acetate/hexane) to give thetitle compound (276.1 mg) as a white solid.

MS(ESI+), found:299.3.

E)N′-{[4-(1-methylethyl)phenyl]carbonyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9-carbohydrazide2,2-dioxide

A mixture of Lawesson reagent (746 mg) and2-amino-N′-{[4-(1-methylethyl)phenyl]carbonyl}pyridine-3-carbohydrazide(1000 mg) in toluene (50 mL) and dehydrated THF (50 mL) was stirred at80° C. overnight. The resulting precipitate was collected by filtration,and washed with THF to give a white solid (1082.2 mg). A mixture of theobtained solid (80 mg) in DMSO (15 mL) was added to a mixture of sodiumhydride (60%, 32.4 mg) and 2-chloroethanesulfonyl chloride (220 mg) indehydrated THF (15 mL) under ice-cooling, and the reaction mixture wasstirred at room temperature under a nitrogen atmosphere overnight. Thereaction mixture was added to water, and the mixture was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The residue was purified by aminopropyl silica-bound silicagel column chromatography (ethyl acetate/methanol) to give the titlecompound (27.3 mg) as a white solid.

Example 37

The compound of Example 37 was produced in the same manner as in Example13.

Example 389-(4-tert-butylphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 10% palladium-carbon (50% wet, 15 mg) and9-(4-tert-butylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (150 mg) in THF (25 mL) and ethanol (25 mL) was stirredunder a hydrogen atmosphere at room temperature, and stirred under ahydrogen atmosphere (3.5 atm) for 1 hr. To the reaction mixture wasadded 5% rhodium-carbon (50% wet, 15 mg), and the mixture was stirredunder a hydrogen atmosphere (3.5 atm) for 4 hr. To the reaction mixturewas added platinum dioxide (15 mg) and the mixture was stirred under ahydrogen atmosphere for 2 hr. The reaction mixture was filtered, thefiltrate was concentrated, and the residue was crystallized from THF anddiisopropyl ether to give the title compound (35 mg) as a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.28(9H,s), 1.61-1.83(3H,m), 1.83-2.09(1H,m),3.22-3.30(2H,m), 3.38-3.56(2H,m), 3.66-3.93(3H,m), 7.06-7.18(2H,m),7.28-7.37(2H,m).

mp 232-236° C.

Anal. Calcd for C₁₇H₂₄N₂O₂S-0.125H₂O:C,63.27; H,7.57; N,8.68. Found:C,63.11; H,7.71; N,8.44.

Example 399-[4-(1-methylpropyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 5% rhodium-carbon (50% wet, 15 mg) and9-[4-(1-methylpropyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (150 mg) in THF (30 mL) and ethanol (30 mL) was stirredunder a hydrogen atmosphere (3 atm) at room temperature for 7 hr. Thereaction mixture was filtered, and the filtrate was concentrated to givethe title compound (132 mg) as a brown solid. The obtained solid wascrystallized from THF and diisopropyl ether to give a brown solid.

¹H NMR(300 MHz, DMSO-d₆) δ 0.78(3H,t,J=7.4 Hz), 1.18(3H,d,J=7.2 Hz),1.54(2H,quin,J=7.2 Hz), 1.62-1.81(3H,m), 1.87-2.11(1H,m),2.50-2.67(1H,m), 3.15-3.36(2H,m), 3.37-3.56(2H,m), 3.66-3.98(3H,m),7.03-7.22(4H,m).

Anal. Calcd for C₁₇H₂₄N₂O₂S-0.25H₂O:C,62.83; H,7.60; N,8.62. Found:C,62.85; H,7.56; N,8.37.

Example 409-[4-(1-methylethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 5% rhodium-carbon (50% wet, 10 mg) and9-[4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (110 mg) in THF (30 mL) and ethanol (30 ml) was stirredunder a hydrogen atmosphere (3 atm) at room temperature for 7 hr. Thereaction mixture was filtered, the filtrate was concentrated to give thetitle compound (121 mg) as a white solid. The obtained solid wascrystallized from THF and diisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.25(6H,d,J=6.1 Hz), 1.61-1.81(3H,m),1.84-2.07(1H,m), 3.17-3.30(2H,m), 3.36-3.55(2H,m), 3.64-3.72(1H,m),3.72-3.94(2H,m), 4.57(1H,quin,J=6.1 Hz), 6.76-6.90(2H,m),7.02-7.15(2H,m).

mp 191-192° C.

Anal. Calcd for C₁₆H₂₂N₂O₃S-0.25H₂O:C,58.78; H,6.94; N,8.57. Found:C,58.82; H,6.93; N,8.52.

Example 419-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 5% rhodium-carbon (50% wet, 15 mg) and9-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (150 mg) in THF (30 mL) and ethanol (30 mL) was stirredunder a hydrogen atmosphere at room temperature for 7 hr. The reactionmixture was filtered, the filtrate was concentrated to give the titlecompound (153 mg) as a gray white solid. The obtained solid wascrystallized from THF and diisopropyl ether to give a gray white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.64-1.87(3H,m), 2.02(1H,d,J=6.0 Hz),3.22-3.30(2H,m), 3.38-3.60(2H,m), 3.70-3.94(3H,m), 7.24-7.40(4H,m).

mp 207-208° C.

Anal. Calcd for C₁₄H₁₅N₂O₃SF₃-0.2H₂O:C,47.78; H,4.41; N,7.96. Found:C,47.89; H,4.38; N,7.96.

Example 429-[4-(1-methylethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 5% rhodium-carbon (50% wet, 15 mg) and9-[4-(1-methylethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (150 mg) in THF (30 mL) and ethanol (30 mL) was stirredunder a hydrogen atmosphere at room temperature for 7 hr. The reactionmixture was filtered, and the filtrate was concentrated to give thetitle compound (143 mg) as a gray white solid. The obtained solid wascrystallized from THF and diisopropyl ether to give a white solid.

¹H NMR(300 MHz, DMSO-d₆) δ 1.20(6H,d,J=7.2 Hz), 1.61-1.82(3H,m),1.86-2.09(1H,m), 2.86(1H,quin,J=6.9 Hz), 3.22-3.30(2H,m),3.37-3.58(2H,m), 3.64-3.96(3H,m), 7.03-7.14(2H,m), 7.14-7.24(2H,m).

mp 198-203° C.

Anal. Calcd for C₁₆H₂₂N₂O₂S-0.125H₂O:C,62.26; H,7.27; N,9.08. Found:C,62.19; H,7.34; N,8.99.

Example 439-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (173 mg) and 5% rhodium-carbon (50% wet, 17 mg) in THF (50mL) and ethanol (20 mL) was stirred under a hydrogen atmosphere at roomtemperature overnight. To the reaction mixture was added platinumdioxide (17 mg), and the mixture was stirred under a hydrogen atmosphereat room temperature for 7 hr. The reaction mixture was filtered throughcelite, and the filtrate was concentrated under reduced pressure. Theresidue was purified by aminopropyl silica-bound silica gel columnchromatography (ethyl acetate/methanol) to give the title compound (153mg) as a white solid. The obtained solid was crystallized fromacetonitrile and diisopropyl ether.

¹H NMR(300 MHz, DMSO-d₆) δ1.63-1.84(3H,m), 1.86-2.07(1H,m),3.28(2H,t,J=6.4 Hz), 3.48(2H,dq,J=12.4, 6.4 Hz), 3.66-3.90(3H,m),6.89-6.98(2H,m), 6.98-7.05(2H,m), 7.10-7.18(1H,m), 7.18-7.27(2H,m),7.34-7.46(2H,m).

Example 44 9-biphenyl-4-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (32.9 mg) was added to amixture of 2M aqueous sodium carbonate solution (0.428 mL),9-bromo-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide (150 mg)and biphenyl-4-ylboronic acid (135 mg) in 1,2-dimethoxyethane (5.701ml). The reaction mixture was stirred under a nitrogen atmosphere at100° C. overnight, added to water, and the mixture was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The residue was purified by silica gel column chromatography(ethyl acetate/hexane, then ethyl acetate/methanol) to give the titlecompound (44.5 mg) as a pale-brown solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.37-3.53 (2H, m), 4.60-4.74 (2H, M) 6.74(1H, t, J=7.0 Hz), 7.34-7.44 (1H, m), 7.44-7.54 (2H, m), 7.58-7.67 (2H,m), 7.67-7.76 (5H, m), 7.80 (1H, dd, J=6.8, 1.5 Hz).

MS (API+), found: 337.3

Example 45

The compound of Example 45 was produced in the same manner as in Example44.

Example 46 9-naphthalen-2-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(naphthalen-2-yl)pyridin-2-amine

To a solution of 3-bromopyridin-2-amine (1.0 g) in 1,2-dimethoxyethane(50 mL) were added naphthalen-2-ylboronic acid (1.292 g), sodiumcarbonate (1.225 g), tetrakis(triphenylphosphine)palladium(0) (0.334 g)and water (10 mL) at room temperature. The reaction mixture was stirredunder a nitrogen atmosphere at 80° C. for 5 hr, water was added, and themixture was extracted with ethyl acetate. The extract was washed withsaturated brine, dried over anhydrous sodium sulfate and the solvent wasevaporated under reduced pressure. The residue was washed withacetonitrile to give the title compound (0.876 g).

¹H NMR(300 MHz, DMSO-d₆) δ 5.65(2H,s), 6.70(1H, dd, J=7.2, 4.9 Hz),7.44(1H,dd,J=7.2,1.9 Hz), 7.51-7.60(3H,m), 7.91-8.03(5H,m).

B) 9-naphthalen-2-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of 60% sodium hydride (0.79 g) in THF (20 mL) was added2-chloroethanesulfonyl chloride (1.93 g) under ice-cooling. The reactionmixture was stirred under ice-cooling for 5 min. Then, a solution of3-(naphthalen-2-yl)pyridin-2-amine (0.87 g) in THF (20 mL) was added.The reaction mixture was stirred at room temperature overnight and at50° C. for 1 hr, and water and hexane were added under ice-cooling. Theresulting solid was collected by filtration, washed with diisopropylether, and dried under reduced pressure to give the title compound (0.88g).

¹H NMR(300 MHz, DMSO-d₆) δ 3.43-3.56(2H,m), 4.62-4.74(2H,m),6.76(1H,t,J=7.0 Hz), 7.50-7.59(2H,m), 7.68(1H, dd, J=8.7,1.5 Hz),7.75(1H,dd,J=7.2,1.1 Hz), 7.83(1H,dd,J=6.6,0.9 Hz), 7.88-8.01(4H,m).

Example 479-(3-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(3-fluorobiphenyl-4-yl)pyridin-2-amine

To a solution of 3-bromopyridin-2-amine (1.0 g) in 1,2-dimethoxyethane(50 mL) were added 3-fluorobiphenyl-4-ylboronic acid (1.623 g), sodiumcarbonate (1.225 g), tetrakis(triphenylphosphine)palladium(D) (0.334 g),and water (10 mL) at room temperature. The reaction mixture was stirredunder a nitrogen atmosphere at 80° C. for 4 hr, water was added, and themixture was extracted with ethyl acetate. The extract was washed withsaturated brine, and dried over anhydrous sodium sulfate. The solventwas evaporated under reduced pressure. The residue was purified byrecrystallization (THF/diisopropyl ether) to give the title compound(1.528 g).

¹H NMR(300 MHz, DMSO-d₆) δ 5.74(2H,brs), 6.68(1H,dd,J=7.2,4.9 Hz),7.35-7.46(4H,m), 7.47-7.55(2H,m), 7.56-7.65(3H,m), 7.98(1H,dd,J=4.9,1.9Hz).

B) 9-(3-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of 60% sodium hydride (0.76 g) in THF (20 mL) was added2-chloroethanesulfonyl chloride (1.85 g) under ice-cooling. The reactionmixture was stirred under ice-cooling for 5 min, and a solution of3-(3-fluorobiphenyl-4-yl)pyridin-2-amine (1.0 g) in THF (20 mL) wasadded. The reaction mixture was stirred at room temperature overnight,and water and hexane were added under ice-cooling. The resulting solidwas collected by filtration, washed with diisopropyl ether, and driedunder reduced pressure to give the title compound (1.06 g).

¹H NMR(300 MHz, DMSO-d₆) δ 3.46-3.54(2H,m), 4.63-4.72(2H,m),6.75(1H,t,J=7.0 Hz), 7.39-7.64(8H,m), 7.76(1H, dd, J=7.2,1.9 Hz),7.83(1H,dd,J=6.8,1.5 Hz).

Example 489-(3-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a solution of9-(3-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (200 mg) in THF/methanol (30 ml/30 mL) was added 10%palladium carbon (50 mg). The reaction mixture was stirred under ahydrogen atmosphere at 50° C. for 1 day. 5% Rhodium carbon (100 mg) wasadded, and the reaction mixture was stirred under a hydrogen atmosphereat room temperature for 7 hr, and insoluble material was filtered offthrough celite. The filtrate was concentrated under reduced pressure,and the obtained residue was purified by recrystallization(methanol-THF/diisopropyl ether) to give the title compound (154.4 mg).

¹H NMR(300 MHz, DMSO-d₆) δ 1.66-1.92(3H,m), 1.94-2.13(1H,m),3.40-3.67(3H,m), 3.72-3.99(3H,m), 7.05-7.28(2H,m), 7.30-7.70(7H,m).

Example 499-naphthalen-2-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a solution of9-naphthalen-2-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide(150 mg) in THF/methanol (30 mL/30 mL) was added platinum (IV) oxide (50mg). The reaction mixture was stirred under a hydrogen atmosphere atroom temperature for 7 hr, and insoluble material was filtered offthrough celite. The filtrate was concentrated under reduced pressure,and the obtained residue was purified by recrystallization(methanol-THF/diisopropyl ether) to give the title compound (104.7 mg).

¹H NMR(300 MHz, CDCl₃) δ 1.74-2.29(4H,m), 3.26-3.37(2H,m),3.40-3.60(2H,m), 3.87-4.10(3H,m), 7.30(1H,d,J=1.9 Hz), 7.42-7.51(2H,m),7.56-7.63(1H,m), 7.75-7.85(3H,m).

Example 509-(5-phenylthiophen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(5-phenylthiophen-2-yl)pyridin-2-amine

A mixture of sodium carbonate (799 mg),tetrakis(triphenylphosphine)palladium(0) (218 mg),3-bromopyridin-2-amine (652 mg) and 5-phenylthiophen-2-ylboronic acid(1000 mg) in water (10 mL) and 1,2-dimethoxyethane (50 mL) was stirredunder a nitrogen atmosphere at 80° C. overnight. The reaction mixturewas added to water, and the mixture was extracted with ethyl acetate.The organic layer was washed with saturated brine, dried over anhydrousmagnesium sulfate and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (579 mg) as a dark yellow solid.

MS(ESI+), found:253.2.

B) 9-(5-phenylthiophen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-(5-phenylthiophen-2-yl)pyridin-2-amine (250 mg) indehydrated THF (10 mL) was added to a mixture of sodium hydride (60%,198 mg) and 2-chloroethanesulfonyl chloride (485 mg) in dehydrated THF(10 mL) under ice-cooling, and the mixture was stirred at roomtemperature overnight. The reaction mixture was added to water, and theresulting precipitate was washed with water and diisopropyl ether togive the title compound (262 mg) as a yellow solid. The obtained solidwas crystallized from acetonitrile to give a yellow solid.

¹H NMR(300 MHz, DMSO-d₆) δ 3.46-3.63(2H,m), 4.63-4.76(2H,m),6.77(1H,dd,J=7.6,6.8 Hz), 7.27-7.39(1H,m), 7.39-7.50(2H,m),7.52(1H,d,J=4.2 Hz), 7.65-7.75(2H,m), 7.76-7.85(2H,m),8.25(1H,dd,J=7.6,1.5 Hz).

mp 241-242° C.

Anal. Calcd for C₁₇H₁₄N₂O₂S₂:C,59.63; H,4.12; N,8.18. Found: C,59.37;H,4.12; N,8.03.

Example 519-{(E)-2-[4-(1-methylethyl)phenyl]ethenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)4,4,5,5-tetramethyl-2-{(E)-2-[4-(1-methylethyl)phenyl]ethenyl}-1,3,2-dioxaborolane

A mixture of triethylamine (246 mg), 1-ethynyl-4-isopropylbenzene (3500mg), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3417 mg) and zirconocenechloride hydride (626 mg) was stirred at 80° C. overnight. To thereaction mixture was added hexane, and the mixture was filtered. Thefiltrate was concentrated under reduced pressure, and the residue waspurified by silica gel column chromatography (ethyl acetate/hexane) togive the title compound (6030 mg) as a yellow solid.

¹H NMR(300 MHz, CDCl₃) δ 1.24(6H,d,J=7.2 Hz), 1.31(12H, s),2.78-3.02(1H,m), 6.11(1H,d,J=18.1 Hz), 7.20(2H,d,J=7.9 Hz),7.31-7.47(3H,m).

B)9-{(E)-2-[4-(1-methylethyl)phenyl]ethenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned A).

Example 529-{[4-(1-methylethyl)benzyl]oxy}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-{[4-(1-methylethyl)benzyl]oxy}pyridin-2-amine

A mixture of cesium carbonate (2.82 g), 1,10-phenanthrolin (0.208 g),(4-isopropylphenyl)methanol (8.68 g), 3-bromopyridin-2-amine (1 g) andcopper (I) iodide (0.110 g) in toluene (10 mL) was stirred under anitrogen atmosphere at 110° C. overnight, and at 130° C. for 5 hr. Thereaction mixture was added to saturated brine, and the mixture wasextracted with ethyl acetate. The organic layer was washed withsaturated brine, dried over anhydrous magnesium sulfate and concentratedunder reduced pressure. The residue was purified by silica gel columnchromatography (ethyl acetate/hexane) to give the title compound (0.92g) as a pale-yellow solid.

MS(ESI+), found:243.1.

B)9-{[4-(1-methylethyl)benzyl]oxy}-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned A).

Example 539-(5-phenylfuran-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-furan-2-ylpyridin-2-amine

In the same manner as in Example 14, step A, the title compound (2600mg) was obtained as a yellow solid from furan-2-boronic acid (2500 mg)and 3-bromopyridin-2-amine (2974 mg).

MS(ESI+), found:161.0.

B) 3-(5-bromofuran-2-yl)pyridin-2-amine hydrobromide

A mixture of bromine (1425 mg) in acetic acid (30 mL) was added to amixture of 3-furan-2-ylpyridin-2-amine (1500 mg) in acetic acid (30 mL)under ice-cooling, and the reaction mixture was stirred at roomtemperature overnight. To the reaction mixture was added a mixture ofhexane and ethyl acetate. The resulting precipitate was collected byfiltration and washed with ethyl acetate to give the title compound(2674 mg) as a brown solid.

¹H NMR(300 MHz, CDCl₃) δ 6.86(1H,d,J=3.8 Hz), 7.03(1H,dd,J=7.7,6.2 Hz),7.10(1H,d,J=3.4 Hz), 7.79(2H,brs), 8.06(1H,dd,J=6.2,1.7 Hz),8.19(1H,dd,J=7.5,1.5 Hz).

C) 3-(5-phenylfuran-2-yl)pyridin-2-amine

In the same manner as in Example 14, step A, the title compound (1.19 g)was obtained as a yellow solid from 3-(5-bromofuran-2-yl)pyridin-2-aminehydrobromide and phenylboronic acid.

D) 9-(5-phenylfuran-2-yl)-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from the compound of the above-mentioned C).

Example 549-(2-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(2-fluorobiphenyl-4-yl)pyridin-2-amine

To a solution of 3-bromopyridin-2-amine (1.0 g) in 1,2-dimethoxyethane(50 mL) were added 2-fluorobiphenyl-4-ylboronic acid (1.623 g), sodiumcarbonate (1.225 g), tetrakis(triphenylphosphine)palladium(0) (0.334 g),and water (10 mL) at room temperature. The reaction mixture was stirredunder a nitrogen atmosphere at 80° C. overnight, water was added, andthe mixture was extracted with ethyl acetate. The extract was washedwith saturated brine, dried over anhydrous sodium sulfate and thesolvent was evaporated under reduced pressure. The residue was purifiedby recrystallization (THF/diisopropyl ether) to give the title compound(1.175 g).

¹H NMR(300 MHz, DMSO-d₆) δ5.74(2H,s),6.68(1H,dd,J=7.2,4.9 Hz),7.35-7.46(4H,m), 7.48-7.55(2H,m), 7.56-7.65(3H,m), 7.98(1H,dd,J=4.9,1.9Hz).

B) 9-(2-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of 60% sodium hydride (0.76 g) in THF (20 mL) was added2-chloroethanesulfonyl chloride (1.85 g) under ice-cooling. The reactionmixture was stirred under ice-cooling for 5 min, and a solution of3-(2-fluorobiphenyl-4-yl)pyridin-2-amine (1.0 g) in THF (20 mL) wasadded. The reaction mixture was stirred at room temperature overnight,and water and hexane were added under ice-cooling. The resulting solidwas collected by filtration, washed with ethyl acetate, and dried underreduced pressure to give the title compound (0.724 g).

¹H NMR(300 MHz, DMSO-d₆) δ 3.45-3.54(2H,m), 4.64-4.72(2H,m),6.75(1H,t,J=7.0 Hz), 7.39-7.63(8H,m), 7.75(1H,dd,J=7.2,1.9 Hz),7.83(1H,dd,J=6.8,1.5 Hz).

Example 559-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a solution of9-(2-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (200 mg) in THF/methanol (30 mL/30 mL) was added 5% rhodiumcarbon (50 mg). The reaction mixture was stirred under a hydrogenatmosphere at room temperature for 1 day. Platinum (IV) oxide (40 mg)was added, and the mixture was stirred under a hydrogen atmosphere atroom temperature for 9 hr, and insoluble material was filtered offthrough celite. The filtrate was concentrated under reduced pressure,the obtained residue was purified by recrystallization (THF-ethylacetate/diisopropyl ether) to give the title compound (121.2 mg).

¹H NMR(300 MHz, DMSO-d₆) δ 1.81-2.25(4H,m), 3.25-3.38(2H,m),3.40-3.58(2H,m), 3.86-3.99(3H,m), 6.92-7.06(2H,m), 7.32-7.48(4H,m),7.49-7.57(2H,m).

Example 569-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A suspension of9-(4-chlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (224 mg), potassium carbonate (149 mg),bis(pinacolato)diboron (232 mg), tricyclohexylphosphine (43 mg), andtris(dibenzylideneacetone)dipalladium(0) (35 mg) in 1,2-dimethoxyethane(5 mL) was stirred at 70° C. overnight. The reaction mixture was cooledto room temperature, purified by silica gel column chromatography (ethylacetate/hexane), and recrystallized from ethanol/ethyl acetate to givethe title compound (142 mg) as a white solid.

Example 579-(5-phenylthiophen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 10% palladium-carbon (50% wet, 12 mg) and9-(5-phenylthiophen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (120 mg) in ethanol (10 mL) and dehydrated THF (60 mL) wasstirred under a hydrogen atmosphere at room temperature for 4 hr. To thereaction mixture was added 5% rhodium-carbon (50% wet, 12 mg) and themixture was stirred under a hydrogen atmosphere at room temperatureovernight, and under a hydrogen atmosphere (4 atm) for 6 hr. To thereaction mixture was added 5% ruthenium-alumina (12 mg) and the mixturewas stirred under a hydrogen atmosphere at room temperature overnight.To the reaction mixture was added platinum dioxide (12 mg), and themixture was stirred under a hydrogen atmosphere at room temperature for24 hr. The reaction mixture was filtered through celite, and thefiltrate was concentrated under reduced pressure. The residue waspurified by aminopropyl silica-bound silica gel column chromatography(ethyl acetate/methanol) to give the title compound (42.3 mg) as a whitesolid. The obtained solid was crystallized from acetonitrile anddiisopropyl ether.

¹H NMR(300 MHz, CDCl₃) δ 1.71-2.04(3H,m), 2.04-2.21(1H,m),3.20-3.32(2H,m), 3.46(2H,t,J=6.1 Hz), 3.80(2H,t,J=6.6 Hz),4.03(1H,t,J=5.7 Hz), 6.96(1H,d,J=3.8 Hz), 7.25-7.33(1H,m),7.35(1H,d,J=3.8 Hz), 7.37-7.46(2H,m), 7.57-7.65(2H,m).

Example 589-{2-[4-(1-methylethyl)phenyl]ethyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 38.

The compounds of Examples 1-58 produced by the above-mentioned methodsor methods analogous thereto are shown in the following Tables. In theTables, MS means Found.

TABLE 1 Ex. No. IUPAC Name Structure Salt MS 1N-[4-(1-methylpropyl)phenyl]- 3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

361.2 2 7-methyl-N-[4-(1- methylpropyl)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

374.2 3 N-[4-(1-methylpropyl)phenyl]-7- (trifluoromethyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

428.1 4 N-(4-cyclopropylphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

344.2 5 N-[6-(trifluoromethyl)pyridin-3- yl]-3,4-dihydropyrido[2,1-c][l,2,4]thiadiazine-9- carboxamide 2,2-dioxide

373.2 6 N-[4-(trifluoromethyl)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

372.2 7 N-[5-(trifluoromethyl)pyridin-2- yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

373.2 8 N-[4-(trifluoromethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

388.2

TABLE 2  9 N-(4-cyanophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

329.2 10 N-(4-acetylphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

346.2 11 N-[4-(dimethylcarbamoyl)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

375.2 12 N-methyl-N-[4-(1- methylethyl)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carboxamide 2,2-dioxide

360.0 13 N-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,3- dihydro-1,4-benzodioxine-6- carboxamide

362.3 14 9-biphenyl-4-yl-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

337.0 15 9-[4-(1-methylethyl)phenoxy]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

319.3 16 9-{[4-(1- methylethyl)phenyl]sulfanyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

335.3 17 9-(benzylsulfanyl)-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

307.3

TABLE 3 18 9-(biphenyl-4-yloxy)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.3 19 9-{[4-(1- methylethyl)phenyl]sulfinyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

351.2 20 9-{[4-(1- methylethyl)phenyl]sulfonyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.3 21 9-(benzylsulfinyl)-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

323.2 22 9-(benzylsulfonyl)-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

339.2 23 9-[4-(1-methylethyl)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

302.9 24 9-[(2-methyl-1,3-benzothiazol-5- yl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.9 25 9-{2-[4-(1- methylethyl)phenyl]ethyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

331.2 26 9-{[4-(1- methylethyl)phenyl]ethynyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

327.1

TABLE 4 27 N-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)- 2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxine-6-carboxamide

434.0 28 9-biphenyl-4-yl-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.0 29 9-{5-[4-(1-methylethyl)phenyl]- 1,2,4-oxadiazol-3-yl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

1H NMR (300 MHz, DMSO-d6) δ 1.26 (6H, d, J = 6.8 Hz), 3.03 (1H, spt, J =6.8 Hz), 3.43-3.61 (2H, m), 4.61-4.77 (2H, m), 6.78 (1H, t, J = 7.0 Hz),7.50-7.60 (2H, m), 7.99 (1H, dd, J = 6.8, 1.9 Hz), 8.05-8.14 (2H, m),8.19 (1H, dd, J = 7.4, 1.7 Hz). 30 9-(4-cyclohexylphenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

343.3 31 9-(4-phenoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.3 32 9-[4-(1-methylpropyl)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

317.2 33 9-[4-(1-methylethoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

319.4 34 9-[4-(trifluoromethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.2

TABLE 5 35 9-(4-tert-butylphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

317.3 36 N′-{[4-(1- methylethyl)phenyl]carbonyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine-9- carbohydrazide 2,2-dioxide

389.3 37 N-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-4-(1- methylethyl)benzamide

346.1 38 9-(4-tert-butylphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

321.3 39 9-[4-(1-methylpropyl)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

321.3 40 9-[4-(1-methylethoxy)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

323.3 41 9-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

349.2 42 9-[4-(1-methylethyl)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

307.2 43 9-(4-phenoxyphenyl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.1

TABLE 6 44 9-biphenyl-4-yl-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

337.3 45 9-(4-chlorophenyl)-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

295.0 46 9-naphthalen-2-yl-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

311.1 47 9-(3-fluorobiphenyl-4-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 48 9-(3-fluorobiphenyl-4-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 49 9-naphthalen-2-yl-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.1 50 9-(5-phenylthiophen-2-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

343.3 51 9-{(E)-2-[4-(1- methylethyl)phenyl]ethenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

329.1 52 9-{[4-(1-methylethyl)benzyl]oxy}- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 53 9-(5-phenylfuran-2-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

327.1

TABLE 7 54 9-(2-fluorobiphenyl-4-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 55 9-(2-fluorobiphenyl-4-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 56 9-[4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

387.1 57 9-(5-phenylthiophen-2-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.0 58 9-{2-[4-(1- methylethyl)phenyl]ethyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

335.2

Example 599-[(7-methoxynaphthalen-2-yl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[(7-methoxynaphthalen-2-yl)oxy]pyridin-2-amine

A mixture of picoline acid (0.427 g), tripotassium phosphate (11.04 g),copper (I) iodide (0.660 g), 7-methoxynaphthalen-2-ol (6.04 g),3-bromopyridin-2-amine (3 g) and DMSO(50 mL) was stirred under anitrogen atmosphere at 140° C. overnight. Water was added, and themixture was filtered through celite, and the filtrate was extracted withethyl acetate. The organic layer was washed with saturated brine, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The residue was purified by silica gel column chromatography(ethyl acetate/hexane) and basic silica gel column chromatography (ethylacetate/hexane) to give the title compound (1.667 g) as a pale-yellowsolid.

MS (API+), found: 267.1

B)9-[(7-methoxynaphthalen-2-yl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of sodium hydride (60%, 375 mg), 2-chloroethanesulfonylchloride (612 mg) and dehydrated THF (15 mL) was added a mixture of3-[(7-methoxynaphthalen-2-yl)oxy]pyridin-2-amine (500 mg) and dehydratedTHF (15 mL) at room temperature. The reaction mixture was stirred for 2hr, water was added, and THF was evaporated under reduced pressure.

The resulting precipitate was washed with water and diisopropyl ether togive the title compound (348 mg) as a pale-brown solid. The obtainedsolid was crystallized from acetonitrile and diisopropyl ether to give apale-brown solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.61 (2H, m), 3.84 (3H, s), 4.56-4.83(2H, m), 6.61 (1H, t, J=7.2 Hz), 7.03-7.18 (2H, m), 7.20-7.27 (2H, m),7.29 (1H, dd, J=7.8, 1.3 Hz), 7.66 (1H, dd, J=6.8, 1.1 Hz), 7.81 (1H, d,J=9.1 Hz), 7.86 (1H, d, J=8.7 Hz).

mp 235-237° C.

Anal. Calcd for C₁₈H₁₆N₂O₄S-1/3H₂O:C,59.66;H,4.64;N,7.73. Found:C,59.73; H,4.55;N,7.80.

Example 609-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-[(7-methoxynaphthalen-2-yl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (120 mg), platinum (IV) oxide (76 mg) and acetic acid (10mL) was stirred under a hydrogen atmosphere at room temperatureovernight. The reaction mixture was filtered, and concentrated underreduced pressure. To the residue was added a saturated aqueous sodiumhydrogen carbonate solution and the mixture was extracted with ethylacetate. The organic layer was washed with saturated aqueous sodiumhydrogen carbonate solution and saturated brine, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuewas crystallized from ethyl acetate and hexane to give the titlecompound (27.4 mg) as a gray white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.77-2.13 (4H, m), 3.22-3.38 (2H, m),3.38-3.61 (2H, m), 3.76-3.91 (5H, m), 5.03 (1H, t, J=3.8 Hz), 7.01 (1H,dd, J=8.9, 2.5 Hz), 7.06 (1H, dd, J=8.9, 2.5 Hz), 7.19 (1H, d, J=2.3Hz), 7.40 (1H, d, J=2.3 Hz), 7.75 (2H, dd, J=9.1, 3.8 Hz).

Example 619-{[4-(1-methylethyl)phenoxy]methyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) (2-chloropyridin-3-yl)methanol

To a mixture of methyl 2-chloronicotinate (5 g), dehydrated THF (30 mL)and ethanol (30 mL) was added sodium borohydride (4.41 g) at 0° C. Thereaction mixture was stirred at room temperature overnight, poured intowater, and the mixture was extracted with ethyl acetate. The organiclayer was washed with saturated brine, dried over anhydrous magnesiumsulfate, and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography (ethyl acetate/hexane) togive the title compound (3.22 g) as a white solid.

MS (API+), found: 144.0

B) 2-chloro-3-{[4-(1-methylethyl)phenoxy]methyl}pyridine

To a mixture of triphenylphosphine (2740 mg), 4-isopropylphenol (1138mg), (2-chloropyridin-3-yl)methanol (1000 mg) and dehydrated THF (20 mL)was added DEAD (40% toluene solution, 4549 mg) at room temperature over30 min. The reaction mixture was stirred at room temperature for 2 hr,DEAD (40% toluene solution, 919 mg) was added at room temperature, andthe mixture was stirred for 1 hr. The reaction mixture was concentratedunder reduced pressure, and the residue was purified by silica gelcolumn chromatography (ethyl acetate/hexane) to give the title compound(1623 mg) as an orange oil.

MS (API+), found: 262.1

C) 3-{([4-(1-methylethyl)phenoxy]methyl}pyridin-2-amine

A mixture of sodium tert-butoxide (0.617 g),2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.160 g),1,1-diphenylmethanimine (1.008 g),2-chloro-3-{[4-(1-methylethyl)phenoxy]methyl}pyridine (1.12 g),tris(dibenzylideneacetone)dipalladium(0) (0.118 g) and toluene (20 mL)was stirred at 110° C. for 6 hr. To the reaction mixture was added THF,and the mixture was filtered through celite, and the filtrate wasconcentrated under reduced pressure. To the residue were added THF (25mL) and 1M hydrochloric acid (25 mL) at room temperature, and themixture was stirred overnight. The reaction mixture was neutralized withsaturated aqueous sodium hydrogen carbonate solution, and extracted withethyl acetate. The organic layer was washed with water and saturatedbrine, dried over anhydrous magnesium sulfate and concentrated underreduced pressure. The residue was purified by basic silica gel columnchromatography (ethyl acetate/hexane) to give the title compound (902.2mg) containing impurity as a pale-yellow oil.

MS (API+), found: 243.1

D)9-{([4-(1-methylethyl)phenoxy]methyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-{[4-(1-methylethyl)phenoxy]methyl}pyridin-2-amine (600mg) and dehydrated THF (10 mL) was added to a mixture of sodium hydride(60%, 495 mg), 2-chloroethanesulfonyl chloride (1211 mg) and dehydratedTHF (10 mL) at room temperature. The reaction mixture was stirred for 1hr, water was added, and the mixture was extracted with ethyl acetate.The organic layer was washed with water and saturated brine, dried overanhydrous magnesium sulfate, and concentrated under reduced pressure.The residue was purified by basic silica gel column chromatography(methanol/ethyl acetate) to give the title compound (303 mg) as a whitesolid. The obtained solid was crystallized from THF-diisopropyl ether togive a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.17 (6H, d, J=7.2 Hz), 2.74-3.00 (1H, m),3.40-3.57 (2H, m), 4.57-4.74 (2H, m), 4.85 (2H, s), 6.68 (1H, t, J=7.0Hz), 6.86-6.95 (2H, m), 7.12-7.23 (2H, m), 7.68 (1H, dd, J=7.0, 1.3 Hz),7.76 (1H, d, J=6.4 Hz).

mp 212-214° C.

Anal. Calcd for C₁₇H₂₀N₂O₃S-1/10H₂O:C,61.09;H,6.09;N,8.38. Found:C,61.10;H,6.12;N,8.36.

Example 62(9R)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (603 mg) of9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol=100) to give the title compound (296 mg) with a shorterretention time.

¹H NMR(300 MHz, DMSO-d₆) δ 1.60-1.85 (3H, m), 1.87-2.11 (1H, m),3.20-3.31 (2H, m), 3.36-3.62 (2H, m), 3.63-3.96 (3H, m), 6.90-6.98 (2H,m), 6.98-7.08 (2H, m), 7.09-7.18 (1H, m), 7.18-7.29 (2H, m), 7.33-7.45(2H, m).

mp 171-176° C.

Anal. Calcd for C₁₉H₂₀N₂O₃S:C,64.02;H,5.66;N,7.86. Found:C,63.86;H,5.78;N,7.81.

Example 63(9S)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (603 mg) of9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol=100) to give the title compound (288 mg) with a longerretention time.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.84 (3H, m), 1.89-2.10 (1H, m),3.22-3.30 (2H, m), 3.38-3.61 (2H, m), 3.68-3.95 (3H, m), 6.90-6.99 (2H,m), 6.99-7.09 (2H, m), 7.11-7.18 (1H, m), 7.18-7.29 (2H, m), 7.34-7.46(2H, m).

mp 174-175° C.

Anal. Calcd for C₁₉H₂₀N₂O₃S:C,64.02;H,5.66;N,7.86. Found:C,63.92;H,5.78;N,7.82.

Example 649-biphenyl-4-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-Biphenyl-4-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (300 mg) was separated by SFC (column: CHIRALPAK ADH(KG010), 20 mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES,LTD., mobile phase:carbon dioxide/methanol/acetonitrile=660/170/170(v/v/v)) to give the title compound (140 mg) with a shorter retentiontime.

¹H NMR (300 MHz, DMSO-d₆) δ 1.62-1.89 (3H, m), 1.93-2.14 (1H, m),3.25-3.31 (2H, m), 3.39-3.66 (2H, m), 3.71-4.00 (3H, m), 7.26-7.40 (3H,m), 7.41-7.51 (2H, m), 7.56-7.63 (2H, m), 7.63-7.71 (2H, m).

mp 220-222° C.

Anal. Calcd for C₁₉H₂₀N₂O₂S:C,67.03;H,5.92;N,8.23. Found:C,66.84;H,5.92;N,8.17.

Example 659-biphenyl-4-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-Biphenyl-4-yl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (300 mg) was separated by SFC (column: CHIRALPAK ADH(KG010), 20 mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES,LTD., mobile phase:carbon dioxide/methanol/acetonitrile=660/170/170(v/v/v)) to give the title compound (138 mg) with a longer retentiontime.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.88 (3H, m), 1.92-2.13 (1H, m),3.24-3.31 (2H, m), 3.41-3.62 (2H, m), 3.71-3.96 (3H, m), 7.26-7.40 (3H,m), 7.41-7.52 (2H, m), 7.57-7.63 (2H, m), 7.63-7.71 (2H, m).

mp 224-227° C.

Anal. Calcd for C₁₉H₂₀N₂O₂S-1/5H₂O:C,66.33;H,5.98;N,8.14. Found:C,66.50;H,5.93;N,8.10.

Example 669-[4-(cyclopentyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (450 mg), iodocyclopentane (639 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (3 mL) was stirred at 130° C. overnight. Theniodocyclopentane (639 mg) was added and the mixture was stirred at 150°C. for 5 hr. The mixture was poured into 1N NaOH aq. and extracted withEtOAc. The organic layer was separated, washed with 1N NaOH aq. andbrine, dried over anhydrous magnesium sulfate and concentrated in vacuo.The residue was purified by column chromatography (NH silica gel, elutedwith MeOH in EtOAc) to give crude product (81.1 mg). The crude productwas purified by preparative HPLC (C18, eluted with H₂O in acetonitrilecontaining 0.1% TFA). The desired fraction was neutralized withsat.NaHCO₃ aq. and extracted with EtOAc. The organic layer wasseparated, dried over anhydrous magnesium sulfate and concentrated invacuo to give the title compound (52.3 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.44-1.84 (6H, m), 1.82-2.04 (2H, m),3.38-3.52 (2H, m), 4.54-4.74 (2H, m), 4.75-4.94 (1H, m), 6.68 (1H, t,J=7.0 Hz), 6.87-7.04 (2H, m), 7.37-7.52 (2H, m), 7.58 (1H, dd, J=7.2,1.5 Hz), 7.74 (1H, dd, J=6.6, 1.7 Hz).

mp 254-256° C.

Anal. Calcd for C₁₈H₂₀N₂O₃S-1/4H₂O:C,61.96;H,5.92;N,8.03. Found:C,62.20;H,5.86;N,7.98.

Example 679-[4-(2,2-dimethylpropoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (300 mg), 1-iodo-2,2-dimethylpropane(430 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(200 mg) in DMSO (5 mL) was stirred at 150° C. for 1 hr. Water was addedto give a precipitate. The precipitate was collected by filtration andwashed with Et₂O-water. The precipitate was crystallized from CH₃CN-IPEto give the title compound (182 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.01 (9H, s), 3.37-3.56 (2H, m), 3.67 (2H,s), 4.53-4.74 (2H, m), 6.69 (1H, t, J=6.8 Hz), 6.90-7.03 (2H, m),7.39-7.51 (2H, m), 7.58 (1H, dd, J=7.2, 1.5 Hz), 7.74 (1H, dd, J=6.8,1.5 Hz).

mp 258-259° C.

Anal. Calcd for C₁₈H₂₂N₂O₃S-1/4H₂O:C,61.60;H,6.46;N,7.98. Found:C,61.61;H,6.33;N,7.95.

Example 689-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(cyclohexyloxy)phenyl]pyrazin-2-amine

A mixture of sodium carbonate (491 mg),tetrakis(triphenylphosphine)palladium(0) (80 mg),4-(cyclohexyloxy)phenylboronic acid (612 mg) and 3-chloropyrazin-2-amine(300 mg) in water (3 mL) and DME (15 mL) was stirred at 80° C. for 4 hr.Silica gel was added and the mixture was concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give 3-[4-(cyclohexyloxy)phenyl]pyrazin-2-amine (485mg) as a white solid.

MS (API+), found: 270.1

B)9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-[4-(cyclohexyloxy)phenyl]pyrazin-2-amine (470 mg) in THF(dry) (25.00 mL) was added to a mixture of NaH (60%, 349 mg) and2-chloroethanesulfonyl chloride (853 mg) in THF (dry) (25 mL) at roomtemperature. The mixture was stirred at room temperature overnight and80° C. for 3 hr. Water was added and THF was removed in vacuo. Aprecipitate was collected by filtration and washed with water-Et₂O togive the title compound (522 mg) as a yellow solid. The solid wascrystallized from CH₃CN-IPE to give a yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.11-1.61 (6H, m), 1.61-1.82 (2H, m),1.82-2.03 (2H, m), 3.43-3.61 (2H, m), 4.30-4.52 (1H, m), 4.53-4.69 (2H,m), 6.86-7.07 (2H, m), 7.53-7.65 (1H, m), 7.65-7.76 (1H, m), 7.90-8.05(2H, m).

mp 239-240° C.

Anal. Calcd for C₁₈H₂₁N₃O₃S:C,60.15;H,5.89;N,11.69. Found:C,60.00;H,5.90;N,11.66.

Example 699-[4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (602 mg),4-(bromomethyl)tetrahydro-2H-pyran (780 mg),4-(bromomethyl)tetrahydro-2H-pyran (780 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(602 mg) in DMSO (5 mL) was stirred at 130° C. for 3 hr. The mixture waspoured into 1N NaOH aq. and extracted with EtOAc. The organic layer wasseparated, washed with 1N NaOH aq. and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was passedthrough column chromatography (NH silica gel, eluted with MeOH) to givethe title compound (357 mg) as a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.16-1.45 (2H, m), 1.58-1.77 (2H, m),1.87-2.11 (1H, m), 3.25-3.40 (2H, m), 3.39-3.52 (2H, m), 3.80-3.94 (4H,m), 4.53-4.74 (2H, m), 6.69 (1H, t, J=7.0 Hz), 6.91-7.02 (2H, m),7.40-7.50 (2H, m), 7.58 (1H, dd, J=7.0, 1.7 Hz), 7.74 (1H, dd, J=6.8,1.5 Hz). mp 268-269° C.

Anal. Calcd for C₁₉H₂₂N₂O₄S-1/8H₂O:C,60.58;H,5.95;N,7.44. Found:C,60.49;H,5.91;N,7.79.

Example 709-[4-(cyclopropyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (450 mg), bromocyclopropane (394 mg)and 4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (3 mL) was stirred at 130° C. overnight. Thenbromocyclopropane (788 mg) and sodium iodide (488 mg) were added and themixture was stirred at 150° C. for 5 hr. The mixture was poured into 1NNaOH aq. and extracted with EtOAc. The organic layer was separated,washed with 1N NaOH aq. and brine, dried over anhydrous magnesiumsulfate and concentrated in vacuo to give a brown solid. The solid waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) to give 50.9 mg of yellow solid. The solid was purified bypreparative HPLC (C18, eluted with H₂O in acetonitrile containing 0.1%TFA). The desired fraction was neutralized with sat.NaHCO₃ aq. andextracted with EtOAc. The organic layer was separated, dried overanhydrous magnesium sulfate and concentrated in vacuo to give the titlecompound (26.8 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.57-0.88 (4H, m), 3.39-3.52 (2H, m), 3.87(1H, tt, J=6.1, 3.0 Hz), 4.50-4.74 (2H, m), 6.69 (1H, t, J=7.0 Hz),6.92-7.16 (2H, m), 7.42-7.53 (2H, m), 7.53-7.66 (1H, m), 7.74 (1H, d,J=6.4 Hz).

Example 719-[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (750 mg), 4-bromotetrahydro-2H-pyran(896 mg), sodium iodide (814 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (5 mL) was stirred at 150° C. overnight and 160° C. for24 hr. The mixture was poured into 1N NaOH aq. and extracted with EtOAc.The organic layer was separated, washed with 1N NaOH aq. and brine,dried over anhydrous magnesium sulfate and concentrated in vacuo. Theresidue was purified by column chromatography (NH silica gel, elutedwith MeOH in EtOAc) to give a white solid (66.6 mg). The solid waspurified by preparative HPLC (C18, eluted with H₂O in acetonitrilecontaining 0.1% TFA). The desired fraction was neutralized with sat.NaHCO₂aq. and extracted with EtOAc. The organic layer was separated,dried over anhydrous magnesium sulfate and concentrated in vacuo to givethe title compound (17.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.46-1.73 (2H, m), 1.99 (2H, dd, J=13.1, 4.0Hz), 3.38-3.58 (4H, m), 3.76-3.99 (2H, m), 4.56-4.75 (3H, m), 6.69 (1H,t, J=6.8 Hz), 6.95-7.08 (2H, m), 7.40-7.52 (2H, m), 7.59 (1H, dd, J=7.2,1.5 Hz), 7.74 (1H, dd, J=6.4, 1.5 Hz).

Example 729-[4-(1-ethylpropoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (750 mg), 3-bromopentane (820 mg),sodium iodide (814 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (5 mL) was stirred at 150° C. for 3 hr. The mixture waspoured into 1N NaOH aq. and extracted with EtOAc. The organic layer wasseparated, washed with 1N NaOH aq. and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (NH silica gel, eluted with MeOH in EtOAc) to givea solid. This material was purified by preparative HPLC (C18, elutedwith H₂O in acetonitrile containing 0.1% TFA). The desired fraction wasneutralized with sat.NaHCO₃aq. and extracted with EtOAc. The organiclayer was separated, dried over anhydrous magnesium sulfate andconcentrated in vacuo to give the title compound (36.1 mg) as a paleyellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.92 (6H, t, J=7.4 Hz), 1.51-1.76 (4H, m),3.38-3.55 (2H, m), 4.17-4.37 (1H, m), 4.55-4.73 (2H, m), 6.69 (1H, t,J=7.0 Hz), 6.87-7.02 (2H, m), 7.37-7.51 (2H, m), 7.59 (1H, d, J=7.2 Hz),7.74 (1H, d, J=6.8 Hz).

Example 737-chloro-9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-chloro-3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine

A mixture of sodium carbonate (307 mg),tetrakis(triphenylphosphine)palladium(0) (50.1 mg),4-(cyclohexyloxy)phenylboronic acid (414 mg) and3-bromo-5-chloropyridin-2-amine (300 mg) in DME (15 mL) and water (3 mL)was stirred at 80° C. for 5 hr. Silica gel was added and the mixture wasconcentrated in vacuo. The residue was purified by column chromatography(silica gel, eluted with EtOAc in hexane) to give the title compound(212 mg) as a yellow gum.

MS (API+), found:303.1

B)7-chloro-9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 5-chloro-3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine (210mg) in THF (dry) (10 mL) was added to a mixture of NaH (60%, 139 mg) and2-chloroethanesulfonyl chloride (339 mg) in THF (dry) (10.0 mL) at roomtemperature. The mixture was stirred at room temperature overnight.Water was added and the mixture was concentrated in vacuo. The residuewas washed with water and IPE to give the title compound (232 mg) as apale yellow solid. The solid was crystallized from EtOAc-hexane to givea pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.16-1.61 (6H, m), 1.63-1.83 (2H, m),1.83-2.04 (2H, m), 3.40-3.54 (2H, m), 4.27-4.49 (1H, m), 4.51-4.72 (2H,m), 6.87-7.09 (2H, m), 7.38-7.59 (2H, m), 7.65 (1H, d, J=2.6 Hz), 8.05(1H, d, J=2.3 Hz).

mp 284-287° C.

Anal. Calcd for C₁₉H₂₁N₂O₃SCl:C,58.08;H,5.39;N,7.13. Found:C,57.82;H,5.41;N,7.06.

Example 749-[4-(cyclopentylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (450 mg), (iodomethyl)cyclopentane (684mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (5 mL) was stirred at 130° C. for 2 hr. The mixture waspoured into water and extracted with EtOAc. The organic layer wasseparated, washed with 1N NaOH aq. and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was washed withEt₂O to give the title compound (311 mg) as a pale yellow solid. Thesolid was crystallized from CH₃CN-IPE to give a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.43 (2H, m), 1.46-1.69 (4H, m),1.69-1.91 (2H, m), 2.32 (1H, dt, J=14.7, 7.4 Hz), 3.39-3.56 (2H, m),3.88 (2H, d, J=6.8 Hz), 4.50-4.76 (2H, m), 6.68 (1H, t, J=7.0 Hz),6.90-7.03 (2H, m), 7.35-7.53 (2H, m), 7.58 (1H, dd, J=7.2, 1.9 Hz), 7.74(1H, dd, J=6.8, 1.5 Hz).

mp 258-259° C.

Anal. Calcd for C₁₉H₂₂N₂O₃S:C,63.66;H,6.19;N,7.82. Found:C,63.45;H,6.13;N,7.81.

Example 759-[4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of potassium carbonate (450 mg), sodium iodide (488 mg),2-(bromomethyl)tetrahydrofuran (538 mg) and4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) in DMSO (10 mL) was stirred at 130° C. for 5 hr. The mixturewas poured into water and extracted with EtOAc. The organic layer wasseparated, washed with 1N NaOH aq. and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was washed withIPE to give the title compound (332 mg) as a pale yellow solid. Thesolid was crystallized from CH₃CN-IPE to give a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.51-2.16 (4H, m), 3.39-3.52 (2H, m),3.59-3.74 (1H, m), 3.73-3.88 (1H, m), 3.88-4.08 (2H, m), 4.08-4.25 (1H,m), 4.52-4.78 (2H, m), 6.69 (1H, t, J=7.0 Hz), 6.86-7.11 (2H, m),7.36-7.52 (2H, m), 7.58 (1H, dd, J=7.0, 1.7 Hz), 7.74 (1H, dd, J=6.6,1.7 Hz).

mp 222-223° C.

Anal. Calcd for C₁₈H₂₀N₂O₄S.0.25H₂O:C,59.24;H,5.66;N,7.68. Found:C,59.32;H,5.54;N,7.71.

Example 767-chloro-9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-(2-amino-5-chloropyridin-3-yl)phenol

A mixture of sodium carbonate (4.09 g),tetrakis(triphenylphosphine)palladium(0) (0.668 g),4-(tert-butyldimethylsilyloxy)phenylboronic acid (6.32 g) and3-bromo-5-chloropyridin-2-amine (4.00 g) in DME (100 mL) and water (20mL) was stirred at 80° C. overnight. Silica gel was added and themixture was concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) to give4-(2-amino-5-chloropyridin-3-yl)phenol (3.05 g) as a pale yellow solidand 3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-5-chloropyridin-2-amine(1.55 g) as a yellow solid.

4-(2-amino-5-chloropyridin-3-yl)phenol

MS (API+), found: 221.1

3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-5-chloropyridin-2-amine

MS (API+), found:335.2

B)5-chloro-3-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)pyridin-2-amine

A mixture of potassium carbonate (376 mg),2-fluoro-4-(trifluoromethyl)pyridine (269 mg) and4-(2-amino-5-chloropyridin-3-yl)phenol (300 mg) in DMSO (5 mL) wasstirred at 120° C. for 2 hr. The mixture was neutralized with sat.NaHCO₃aq. and extracted with EtOAc. The organic layer was separated, washedwith 1N NaOH aq. and brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with EtOAc in hexane) to give the title compound(484 mg) as a pale yellow solid.

MS (API+), found: 366.1

C)7-chloro-9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

5-Chloro-3-(4-(4-(trifluoromethyl)pyridin-2-yloxy)phenyl)pyridin-2-amine(470 mg) was added to a mixture of NaH (60%, 257 mg) and2-chloroethanesulfonyl chloride (628 mg) in THF (dry) (10 mL) at roomtemperature. The mixture was stirred at room temperature overnight and80° C. for 3 hr. Water was added and the mixture was concentrated invacuo. The residue was washed with IPE to give the title compound (502mg) as a yellow solid. The solid was crystallized from CH₃CN-IPE to givea pale yellow solid (1st crop impure, 2nd crop (254 mg)). The 1st cropwas purified by column chromatography (NH silica gel, eluted with MeOHin EtOAc) to give the title compound (263 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.44-3.61 (2H, m), 4.57-4.72 (2H, m),7.17-7.29 (2H, m), 7.46-7.57 (2H, m), 7.57-7.66 (2H, m), 7.77 (1H, d,J=2.3 Hz), 8.11 (1H, d, J=2.7 Hz), 8.45 (1H, d, J=5.3 Hz).

mp 238-239° C.

Anal. Calcd for C₁₉H₁₃N₃O₃SClF₃-0.2EtOAc:C,50.23;H,3.11;N,8.88. Found:C,49.97;H,3.26;N,8.86.

Example 777-chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)5-chloro-3-{4-[(5-chloropyridin-2-yl)oxy]phenyl}pyridin-2-amine

A mixture of potassium carbonate (376 mg), 5-chloro-2-fluoropyridine(215 mg) and 4-(2-amino-5-chloropyridin-3-yl)phenol (300 mg) in DMSO (10mL) was stirred at 120° C. for 5 hr. The mixture was poured into waterand extracted with EtOAc. The organic layer was separated, washed with1N NaOH aq. and brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with EtOAc in hexane) to give the title compound(450 mg) as a pale yellow solid.

MS (API+), found: 332.0

B)7-chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of5-chloro-3-{4-[(5-chloropyridin-2-yl)oxy]phenyl}pyridin-2-amine (440 mg)in THF (dry) (10 mL) was added to a mixture of NaH (60%, 265 mg) and2-chloroethanesulfonyl chloride (648 mg) in THF (dry) (10 mL) at roomtemperature. The mixture was stirred at room temperature overnight and80° C. for 3 hr. Water was added and the mixture was concentrated invacuo. The residue was washed with water and Et₂O to give an off-whitesolid. The solid was purified by column chromatography (NH silica gel,eluted with MeOH in EtOAc) to give the title compound (520 mg) as anoff-white solid. The solid was crystallized from CH₃CN-IPE to give awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.55 (2H, m), 4.52-4.70 (2H, m),7.13-7.24 (3H, m), 7.55-7.66 (2H, m), 7.76 (1H, d, J=2.3 Hz), 7.98 (1H,dd, J=8.7, 2.7 Hz), 8.11 (1H, d, J=2.7 Hz), 8.25 (1H, d, J=2.7 Hz).

mp 228-229° C.

Anal. Calcd for C₁₈H₁₃N₃O₃SCl₂:C,51.20;H,3.10; N,9.95. Found:C,51.16;H,3.17;N,9.95.

Example 787-chloro-9-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)5-chloro-3-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)pyridin-2-amine

A mixture of potassium carbonate (376 mg),2-fluoro-3-(trifluoromethyl)pyridine (269 mg) and4-(2-amino-5-chloropyridin-3-yl)phenol (300 mg) in DMSO (10 mL) wasstirred at 120° C. for 3 hr. The mixture was poured into water andextracted with EtOAc. The organic layer was separated, washed with 1NNaOH aq. and brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with EtOAc in hexane) to give the title compound(470 mg) as a pale yellow solid.

MS (API+), found: 366.0

B)7-chloro-9-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of5-chloro-3-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)pyridin-2-amine(450 mg) in THF (dry) (10 mL) was added to a mixture of NaH (60%, 246mg) and 2-chloroethanesulfonyl chloride (602 mg) in THF (dry) (10.0 mL)at room temperature. The mixture was stirred at 70° C. for 3 hr. Waterwas added and the mixture was concentrated in vacuo. The residue waswashed with water and Et₂O to give an off-white solid. The solid waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) to give the title compound (315 mg) as a white solid. The solidwas crystallized from CH₃CN-IPE to give a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.38-3.62 (2H, m), 4.53-4.78 (2H, m),7.14-7.30 (2H, m), 7.36 (1H, dd, J=7.6, 4.9 Hz), 7.51-7.68 (2H, m), 7.77(1H, d, J=2.3 Hz), 8.12 (1H, d, J=2.6 Hz), 8.29 (1H, dd, J=7.6, 1.1 Hz),8.45 (1H, dd, J=4.9, 1.1 Hz).

mp 264-265° C.

Anal. Calcd for C₁₉H₁₃N₃O₃SClF₃—CH₃CN:C,50.76;H,3.25;N,11.28. Found:C,50.67;H,3.27;N,11.21.

Example 797-chloro-9-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)5-chloro-3-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-1,2-dihydropyridin-2-amine

A mixture of 4-bromo-2-(trifluoromethyl)pyridine (282 mg), tripotassiumphosphate (481 mg), picolinic acid (27.9 mg), copper(I) iodide (21.58mg) and 4-(2-amino-5-chloropyridin-3-yl)phenol (250 mg) in DMSO (5 mL)was stirred at 140° C. under N₂ overnight. The mixture was poured intosat.NH₄Cl aq. and extracted with EtOAc. The organic layer was separated,washed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with EtOAc in hexane) to give the title compound(230 mg) as a pale yellow solid.

MS (API+), found: 366.0

B)7-chloro-9-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of5-chloro-3-(4-(2-(trifluoromethyl)pyridin-4-yloxy)phenyl)pyridin-2-amine(220 mg) in THF (dry) (10 mL) was added to a mixture of NaH (60%, 120mg) and 2-chloroethanesulfonyl chloride (294 mg) in THF (dry) (10 mL) atroom temperature. The mixture was stirred at 70° C. for 1 hr. MeOH andNH silica gel were added and the mixture was concentrated in vacuo. Theresidue was purified by column chromatography (NH silica gel, elutedwith MeOH in EtOAc) to give the titled compound (253 mg) as a whitesolid. The solid was crystallized from CH₃CN-IPE to give a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.44-3.56 (2H, m), 4.54-4.73 (2H, m), 7.22(1H, dd, J=5.7, 2.3 Hz), 7.29-7.41 (2H, m), 7.50 (1H, d, J=2.3 Hz),7.67-7.76 (2H, m), 7.80 (1H, d, J=2.3 Hz), 8.13 (1H, d, J=2.3 Hz), 8.67(1H, d, J=5.7 Hz).

mp 239-240° C.

Anal. Calcd for C₁₉H₃N₃O₃SClF₃:C,50.06;H,2.87;N,9.22. Found: C,50.08;H,3.13;N,9.08.

Example 809-(4-pyrrolidin-1-ylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 1-(4-iodophenyl)pyrrolidin-2-one

A mixture of 4-bromobutanoyl chloride (15.0 g) in THF (dry) (150 mL) wasadded to a mixture of 4-iodoaniline (7.50 g) and Et₃N (9.55 mL) in THF(dry) (150 mL) at 0° C. The mixture was stirred at 60° C. overnight. Amixture of NaH (60%, 4.11 g) in DMF (dry) (50 mL) was added to themixture at 0° C. The mixture was stirred at 120° C. overnight. Themixture was poured into water and extracted with EtOAc. The organiclayer was separated, washed with brine, dried over anhydrous magnesiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) to give thetitle compound (3.84 g) as a white solid.

MS (API+), found: 287.9

B) 1-(4-iodophenyl)pyrrolidine

A mixture of borane-tetrahydrofuran complex (1.2 M in THF, 5.81 mL) and1-(4-iodophenyl)pyrrolidin-2-one (1.00 g) in THF (dry) (20 mL) wasstirred at 70° C. under N₂ for 3 hr. The mixture was poured into 1N HClaq., sat.NaHCO₃ aq. was added and the mixture was extracted with EtOAc.The organic layer was separated, washed with brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo to give the title compound(0.954 g) as a white solid.

MS (API+), found: 274.0

C) 3-(4-pyrrolidin-1-ylphenyl)-1,2-dihydropyridin-2-amine

n-Butyllithium (1.6 M in hexane, 48.3 mL) was added dropwise to asolution of N,N,N′,N′-tetramethylethane-1,2-diamine (8.08 g) andtert-butyl pyridin-2-ylcarbamate (5.00 g) in THF (dry) (50 mL) at −78°C. The mixture was stirred at 0° C. under N₂ for 2 hr. Triisopropylborate (17.0 g) was added to the mixture at −78° C. The mixture wasstirred at 0° C. under N₂ for 30 min. The mixture was quenched withsat.NH₄Cl aq. at 0° C. and added with Et₂O to give a yellow precipitate(11.7 g, wet). A mixture of the precipitate (349 mg), sodium carbonate(155 mg), tetrakis(triphenylphosphine)palladium(0) (42.3 mg) and1-(4-iodophenyl)pyrrolidine (200 mg) in DME (25 mL) and water (5 mL) wasstirred at 80° C. under N₂ overnight. NH silica gel was added and themixture was concentrated in vacuo. The residue was purified by columnchromatography (NH silica gel, eluted with EtOAc in hexane) to give thetitle compound (17.1 mg) as a white solid.

MS (API+), found: 240.1

D)9-(4-pyrrolidin-1-ylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-(4-(pyrrolidin-1-yl)phenyl)pyridin-2-amine (17.0 mg) inTHF (dry) (5 mL) was added to a mixture of NaH (60%, 14.2 mg) and2-chloroethanesulfonyl chloride (34.7 mg) in THF (dry) (5.00 mL) at roomtemperature. The mixture was stirred at 50° C. for 1 hr. Water and NHsilica gel were added and the mixture was concentrated in vacuo. Theresidue was purified by column chromatography (NH silica gel, elutedwith MeOH in EtOAc) to give the title compound (14.8 mg) as a paleyellow solid.

¹H NMR (300 MHz, CDCl₃) δ 1.89-2.09 (4H, m), 3.27-3.35 (4H, m),3.35-3.44 (2H, m), 4.55-4.71 (2H, m), 6.46-6.64 (3H, m), 7.10 (1H, dd,J=6.8, 1.5 Hz), 7.43 (1H, dd, J=7.2, 1.5 Hz), 7.48-7.57 (2H, m).

Example 817-chloro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-chloro-3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate decahydrate (20.7 g),tetrakis(triphenylphosphine)palladium(0) (0.836 g),4-phenoxyphenylboronic acid (9.28 g) and 4-phenoxyphenylboronic acid(9.28 g) in DME (150 mL) and water (30 mL) was stirred at 80° C. underN₂ overnight. NH silica gel was added and the mixture was concentratedin vacuo. The residue was purified by column chromatography (NH silicagel, eluted with EtOAc in hexane) to give the title compound (10.6 g) asa yellow solid.

MS (API+), found: 297.1

B)7-chloro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of NaH (60%, 2.59 g) and 2-chloroethanesulfonyl chloride(6.33 g) in THF (dry) (50 mL) was added a solution of5-chloro-3-(4-phenoxyphenyl)pyridin-2-amine (3.84 g) in THF (dry) (50mL) at room temperature. The mixture was stirred at room temperatureovernight. Water and NH silica gel were added and the mixture wasconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with MeOH in EtOAc) to give the title compound(3.07 g) as a pale yellow solid. The solid was is crystallized fromDMSO(15 mL)-EtOH(90 mL) to give a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.38-3.58 (2H, m), 4.50-4.72 (2H, m),6.88-7.14 (4H, m), 7.14-7.28 (1H, m), 7.29-7.49 (2H, m), 7.50-7.64 (2H,m), 7.71 (1H, d, J=2.6 Hz), 8.09 (1H, d, J=2.3 Hz).

mp 248-249° C.

Anal. Calcd for C₁₉H₁₅N₂O₃SCl-0.25H₂O:C,58.31;H,3.99;N,7.16. Found:C,58.32;H,3.97;N,7.13.

Example 829-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-(2-aminopyridin-3-yl)phenol

Tetrakis(triphenylphosphine)palladium(0) (0.967 g) was added to asuspension of 3-bromopyridin-2-amine (4.82 g), 4-hydroxyphenylboronicacid (5.00 g) and sodium carbonate (5.91 g) in DME (250 mL) and water(50.0 mL) and the mixture was stirred at 80° C. under nitrogen for 4 hr.Water and EtOAc were added and the organic layer was separated, washedwith brine, dried over anhydrous sodium sulfate and concentrated invacuo. The residue was purified by column chromatography (silica gel,eluted with EtOAc in hexane) and washed with IPE to give the titlecompound (2.80 g) as a white solid.

MS (ESI+), found: 187.0.

B) 3-{4-[(3-fluorobenzyl)oxy]phenyl}pyridin-2-amine

Diisopropylazadicarboxylate (1.19 mL) was added dropwise to a solutionof triphenylphosphine (1585 mg), 4-(2-aminopyridin-3-yl)phenol (750 mg)and (3-fluorophenyl)methanol (0.434 mL) in THF (dry) (15 mL) at roomtemperature and the mixture was stirred overnight and concentrated invacuo. The residue was purified by column chromatography (1st; NH-silicagel, eluted with EtOAc in hexane, 2nd; silica gel, eluted with EtOAc inhexane) to give the title compound (210 mg) as a white powder.

MS (ESI+), found: 295.1.

C)9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 136 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.214 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-{4-[(3-fluorobenzyl)oxy]phenyl}pyridin-2-amine (200 mg) in THF (dry)(10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen overnight. The mixture was quenched withwater at 0° C. carefully. Water was added to form precipitates whichwere washed with water, hexane and collected. The precipitate wassonicated in EtOAc and the insoluble material was collected to give9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (317.7 mg) as an off-white solid. This was crystallized fromMeOH-THF/IPE to give an off-white crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 3.43-3.55 (2H, m), 4.58-4.73 (2H, m), 5.18(2H, s), 6.69 (1H, t, J=7.0 Hz), 7.05 (2H, d, J=9.0 Hz), 7.16 (1H, td,J=8.7, 2.6 Hz), 7.25-7.36 (2H, m), 7.40-7.52 (3H, m), 7.59 (1H, dd,J=7.2, 1.5 Hz), 7.74 (1H, dd, J=6.8, 1.9 Hz).

Example 839-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide Example 849-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-ol2,2-dioxide

Diisopropylazadicarboxylate (0.241 mL) was added to a suspension oftriphenylphosphine (321 mg),2,2-dioxido-4-(3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(229 mg) and (3-fluorophenyl)methanol (0.106 mL) in THF (dry) (80 mL) atroom temperature and the mixture was stirred overweekend andconcentrated in vacuo. The residue was washed with EtOAc-THF (1:1) andthe insoluble material was removed by filtration, and the filtrate wasconcentrated in vacuo (starting phenol was recovered, 95.6 mg). Theresidue was purified by column chromatography (1st; silica gel, elutedwith EtOAc in hexane and MeOH in EtOAc, 2nd; NH-silica gel, eluted withMeOH in EtOAc, 3rd; silica gel, eluted with EtOAc in hexane) to give9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide and9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-ol2,2-dioxide.9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was recrystallized from THF/IPE to give colorless crystals(40.3 mg).9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-ol2,2-dioxide was recrystallized from THF/IPE to give a white solid (1.4mg).9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.81 (3H, m), 1.88-2.09 (1H, m),3.21-3.29 (2H, m), 3.41-3.55 (2H, m), 3.67-3.74 (1H, m), 3.76-3.88 (2H,m), 5.06-5.16 (2H, m), 6.92-7.00 (2H, m), 7.08-7.19 (3H, m), 7.24-7.33(2H, m), 7.39-7.49 (1H, m).9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-ol2,2-dioxide

¹H NMR (300 MHz, DMSO-d₆) δ 1.44-1.61 (1H, m), 1.76-2.02 (3H, m),3.41-3.55 (4H, m), 3.78-3.96 (2H, m), 5.13 (2H, s), 5.72 (1H, s),6.91-7.01 (2H, m), 7.10-7.19 (1H, m), 7.24-7.34 (4H, m), 7.44 (1H, td,J=8.0, 5.8 Hz).

Example 859-[4-(3-chlorophenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3-chlorophenoxy)phenyl)pyridin-2-amine

To a mixture of 4-(2-aminopyridin-3-yl)phenol (400 mg),1-chloro-3-iodobenzene (615 mg), picoline acid (52.9 mg) andtripotassium phosphate (1368 mg) in DMSO (6 mL) was added copper (I)iodide (82.0 mg). The reaction mixture was stirred under a nitrogenatmosphere at 120° C. for 4 hr. To the reaction mixture was added water,and the mixture was extracted with ethyl acetate. The extract was washedwith saturated brine, dried over anhydrous sodium sulfate, and thesolvent was evaporated under reduced pressure. The residue was purifiedby silica gel column chromatography (ethyl acetate/hexane) andconcentrated under reduced pressure to give the title compound (307 mg)as a yellow solid.

MS (ESI+), found: 297.0.

B)9-[4-(3-chlorophenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 202 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.319 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(3-chlorophenoxy)phenyl)pyridin-2-amine (300 mg) in THF (dry) (10mL) was added at 0° C. and the mixture was stirred at room temperatureunder nitrogen overnight. The mixture was quenched with water at 0° C.carefully. Water was added to form precipitates which were washed withwater, hexane and collected. The precipitate was sonicated in EtOAc andthe insoluble material was collected to give the title compound (248 mg)as an off-white solid. This was crystallized from THF-MeOH/IPE to givecolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.51 (2H, m), 4.61-4.70 (2H, m), 6.71(1H, t, J=7.0 Hz), 7.01-7.06 (1H, m), 7.07-7.12 (2H, m), 7.14 (1H, t,J=2.1 Hz), 7.21-7.26 (1H, m), 7.41-7.47 (1H, m), 7.55-7.61 (2H, m), 7.65(1H, dd, J=7.2, 1.9 Hz), 7.78 (1H, dd, J=6.8, 1.5 Hz).

Example 869-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (20.0 mg) was added to a solution of9-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (100 mg) in THF (dry) (10 mL) and MeOH (10 mL) and themixture was stirred at room temperature under hydrogen overnight. Theinsoluble solid was removed by filtration through Celite-pad (elutedwith EtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give9-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (77.3 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ1.69-1.82 (3H, m), 1.93-2.09 (1H, m),3.26-3.31 (2H, m), 3.43-3.55 (2H, m), 3.76-3.89 (3H, m), 7.00 (2H, d,J=8.7 Hz), 7.06 (1H, d, J=7.9 Hz), 7.26 (2H, d, J=8.7 Hz), 7.29-7.36(1H, m), 7.62-7.69 (1H, m), 7.79 (1H, d, J=7.6 Hz).

Example 874-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol A)3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (1.38 g) was added to asuspension of 3-bromopyridin-2-amine (20.6 g),4-(tert-butyldimethylsilyloxy)phenylboronic acid (39.0 g) and sodiumcarbonate (25.2 g) in DME (650 mL) and water (130 mL) and the mixturewas stirred at 100° C. under nitrogen 6 hr. Volatiles were removed invacuo, water and EtOAc were added and the organic layer was separated,washed with brine, dried over anhydrous sodium sulfate and concentratedin vacuo. The residue was crystallized from EtOAc-hexane to give4-(2-aminopyridin-3-yl)phenol (7.90 g) as yellow crystals. The filtrateof crystallization was purified by column chromatography (silica gel,eluted with EtOAc in hexane) to give3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)pyridin-2-amine (23.4 g) asa white powder.

MS (ESI+), found: 301.3.

B)9-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 6.66 g) in THF (dry) (200 mL) was added2-chloroethanesulfonyl chloride (7.00 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)pyridin-2-amine (10 g) inTHF (dry) (200 mL) was added at 0° C. and the mixture was stirred atroom temperature under nitrogen overnight. The mixture was quenched withwater at 0° C. carefully. Water was added to form precipitates whichwere washed with water and EtOAc, and collected to give9-(4-{[(tert-butyl(dimethyl)silyl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (11.2 g) as an off-white solid.

MS (ESI+), found: 391.2.

C) 4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol

TBAF (1 M in THF) (40.0 mL) was added to a solution of9-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (14.9 g) in THF (dry)(2.0 L) at 0° C. and the mixture wasstirred at ambient temperature for 30 min. The mixture was neutralizedwith sat. NH₄Cl aq. and extracted with EtOAc. The organic layer wasseparated, dried over anhydrous sodium sulfate and concentrated invacuo. The residue was washed with EtOAc/hexane to give the titlecompound (10.2 g) as an off-white crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 3.36-3.54 (2H, m), 4.57-4.74 (2H, m), 6.67(1H, t, J=6.8 Hz), 6.78 (2H, d, J=8.7 Hz), 7.35 (2H, d, J=8.7 Hz), 7.54(1H, dd, J=7.2, 1.5 Hz), 7.71 (1H, dd, J=6.8, 1.5 Hz), 9.58 (1H, s).

Example 889-[4-(cycloheptyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg), potassium carbonate (390 mg) in DMSO (5 mL) was addedbromocycloheptane (250 mg). The mixture was stirred at 130° C. for 1 hr.Another bromocycloheptane (100 uL) was added and the mixture was stirredat room temperature overnight. 0.5 N NaOH aq., EtOAc and THF were addedand the extracted organic layer was washed with water and brine, driedover anhydrous sodium sulfate and concentrated in vacuo. The residue wascrystallized from MeCN/IPE to give the title compound (144 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.40-1.79 (10H, m), 1.90-2.05 (2H, m),3.40-3.49 (2H, m), 4.49-4.59 (1H, m), 4.60-4.68 (2H, m), 6.65-6.72 (1H,m), 6.92 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7 Hz), 7.58 (1H, dd, J=7.2,1.5 Hz), 7.73 (1H, dd, J=6.8, 1.5 Hz).

Example 899-[4-(cyclohexyloxy)phenyl]-7-fluoro-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(cyclohexyloxy)phenyl]-5-fluoropyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (54.5 mg) was added to asuspension of 3-bromo-5-fluoropyridin-2-amine (300 mg),4-(cyclohexyloxy)phenylboronic acid (449 mg) and sodium carbonate (333mg) in DME (15 mL) and water (3 mL) and the mixture was stirred at 100°C. under nitrogen for 2 hr. Water and EtOAc were added and the organiclayer was separated, washed with brine, dried over anhydrous sodiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) and washed withIPE to give the title compound (366 mg) as a yellow solid.

MS (ESI+), found: 287.2.

B)9-[4-(cyclohexyloxy)phenyl]-7-fluoro-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 153 mg) in THF (dry) (15 mL) was added2-chloroethanesulfonyl chloride (0.403 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(cyclohexyloxy)phenyl)-5-fluoropyridin-2-amine (366 mg) in THF(dry) (15 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 15 hr and at 50° C. for 1 hr. The mixturewas quenched with water at 0° C. carefully and water was added to formprecipitates. The precipitate was crystallized from THF-MeOH/IPE to givethe title compound (170 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.58 (6H, m), 1.65-1.80 (2H, m),1.89-2.04 (2H, m), 3.39-3.51 (2H, m), 4.34-4.47 (1H, m), 4.54-4.67 (2H,m), 6.97 (2H, d, J=8.7 Hz), 7.51 (2H, d, J=8.7 Hz), 7.77 (1H, dd, J=8.5,2.8 Hz), 8.04 (1H, dd, J=4.3, 2.8 Hz).

Example 909-[4-(3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(3-methoxyphenoxy)phenyl]pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-iodo-3-methoxybenzene (754 mg) and DMSO (8 mL). The mixturewas stirred at 120° C. under nitrogen for 6 hr. The insoluble materialwas removed by silica-filtration with EtOAc, and the filtrate wasextracted with EtOAc. The organic layer was separated, washed with waterand brine, dried over anhydrous sodium sulfate and concentrated invacuo. The residue was purified by column chromatography (NH silica gel,eluted with EtOAc in hexane) to give the title compound (349 mg) as ayellow solid.

MS (ESI+), found: 293.3.

B)9-[4-(3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 143 mg) in THF (dry) (15 mL) was added2-chloroethanesulfonyl chloride (0.376 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(3-methoxyphenoxy)phenyl)pyridin-2-amine (348 mg) in THF (dry) (15mL) was added at 0° C. and the mixture was stirred at room temperatureunder nitrogen for 15 hr. The mixture was quenched with water at 0° C.carefully and water was added to form precipitates. The precipitate wascrystallized from MeCN-THF-MeOH/IPE to give the title compound (304 mg)as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.51 (2H, m), 3.75 (3H, s), 4.61-4.70(2H, m), 6.58-6.79 (4H, m), 7.03 (2H, d, J=8.7 Hz), 7.27-7.36 (1H, m),7.54 (2H, d, J=8.7 Hz), 7.63 (1H, dd, J=7.2, 1.5 Hz), 7.77 (1H, dd,J=6.8, 1.5 Hz).

Example 919-[4-(cyclobutyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg), potassium carbonate (390 mg) and bromocyclobutane (191 mg) inDMSO (5 mL) was stirred at 130° C. for 1 hr. Bromocyclobutane (100 mg)was added, and the mixture was stirred at room temperature overnight.0.5N Aqueous sodium hydroxide solution, ethyl acetate and THF were addedand the mixture was extracted. The extract was washed with water andsaturated brine, dried over anhydrous sodium sulfate, and the solventwas evaporated under reduced pressure. The residue was separated by HPLC(C18, mobile phase: water/acetonitrile (0.1% TFA containing system)). Tothe obtained fraction was added a saturated aqueous sodium hydrogencarbonate solution, and the mixture was extracted with ethyl acetate,dried over anhydrous sodium sulfate, and concentrated under reducedpressure. The residue was crystallized from acetonitrile, THF anddiisopropyl ether to give the title compound (71.9 mg) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.62-1.76 (1H, m), 1.81-1.93 (1H, m),2.12-2.26 (2H, m), 2.41-2.53 (2H, m), 3.36-3.44 (2H, m), 4.61-4.72 (3H,m), 6.56 (1H, t, J=6.8 Hz), 6.82 (2H, d, J=8.7 Hz), 7.16 (1H, dd, J=6.8,1.5 Hz), 7.45 (1H, dd, J=7.2, 1.5 Hz), 7.52 (2H, d, J=8.7 Hz).

Example 927-chloro-9-[6-(cyclohexyloxy)pyridin-3-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-bromo-2-(cyclohexyloxy)pyridine

Cyclohexanol (3.99 mL) was added to a mixture of NaH (60%, 1.50 g) inN,N-dimethylacetoamide (10 mL) at 0° C. The mixture was stirred at roomtemperature for 30 min. The solution of 5-bromo-2-chloropyridine (6.00g) in N,N-dimethylacetoamide (10 mL) was added and the mixture wasstirred at 100° C. for 1.5 hr. The mixture was quenched with water atroom temperature and extracted with EtOAc. The organic layer wasseparated, washed with brine, dried over anhydrous sodium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(silica gel, eluted with EtOAc in hexane) to give the title compound(7.67 g) as colorless oil.

MS (ESI+), found: 256.0, 258.0.

B) 5-chloro-6′-(cyclohexyloxy)-3,3′-bipyridin-2-amine

n-Butyllithium (1.6 M in hexane) (20.5 mL) was dropwised to a mixture of5-bromo-2-(cyclohexyloxy)pyridine (7.00 g) and THF (dry) (75 mL) at −78°C. and the mixture was stirred at the same temperature under nitrogenfor 40 min. Triisopropyl borate (7.71 g) was dropwised to the mixture at−78° C. and the mixture was stirred at the same temperature for 5 min.Then the mixture was warmed up to room temperature and stirred foradditional 30 min. The mixture was poured into 1N NaOH aq. (75 mL)/water(120 mL) and stirred for 1 hr. The organic layer was separated and theaqueous phase was washed with Et₂O (100 mL×2) and neutralized by 1N HClaq. The mixture was extracted with EtOAc, dried over anhydrous sodiumsulfate and concentrated in vacuo to give[6-(cyclohexyloxy)pyridin-3-yl]boronic acid (5.15 g) as pale yellowsolid. Tetrakis(triphenylphosphine)palladium(0) (107 mg) was added to asuspension of 3-bromo-5-chloropyridin-2-amine (640 mg),[6-(cyclohexyloxy)pyridin-3-yl]boronic acid (750 mg) and sodiumcarbonate (654 mg) in DME (15 mL) and water (3 mL) and the mixture wasstirred at 100° C. under nitrogen for 2.5 hr. Water and EtOAc were addedand the organic layer was separated, washed with brine, dried overanhydrous sodium sulfate and concentrated in vacuo. The residue waspurified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (846 mg) as colorless gum.

MS (ESI+), found: 304.1.

C)7-chloro-9-[6-(cyclohexyloxy)pyridin-3-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 553 mg) in THF (dry) (30 mL) was added2-chloroethanesulfonyl chloride (0.582 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of5-chloro-6′-(cyclohexyloxy)-3,3′-bipyridin-2-amine (840 mg) in THF (dry)(30 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen overnight. The mixture was quenched withwater at 0° C. carefully. EtOAc and THF were added and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane). The residuewas crystallized from THF/IPE to give the title compound (336 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.18-1.61 (6H, m), 1.69-1.79 (2H, m),1.94-2.01 (2H, m), 3.42-3.58 (2H, m), 4.55-4.68 (2H, m), 4.94-5.14 (1H,m), 6.81 (1H, d, J=9.1 Hz), 7.78 (1H, d, J=2.6 Hz), 7.88 (1H, dd, J=8.7,2.6 Hz), 8.10 (1H, d, J=2.3 Hz), 8.27 (1H, d, J=2.3 Hz).

Example 939-[6-(cyclohexyloxy)pyridin-3-yl]-7-fluoro-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 6′-(cyclohexyloxy)-5-fluoro-3,3′-bipyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (36.3 mg) was added to asuspension of 3-bromo-5-fluoropyridin-2-amine (200 mg),6-(cyclohexyloxy)pyridin-3-ylboronic acid (255 mg) and sodium carbonate(222 mg) in DME (5 mL) and water (1 mL) and the mixture was stirred at90° C. under nitrogen for 3 hr. Water and EtOAc were added and theorganic layer was separated, washed with brine, dried over anhydroussodium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with EtOAc in hexane) andwashed with IPE to give the title compound (280 mg) as a yellow solid.

MS (ESI+), found: 288.1.

B)9-[6-(cyclohexyloxy)pyridin-3-yl]-7-fluoro-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 195 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.307 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of6′-(cyclohexyloxy)-5-fluoro-3,3′-bipyridin-2-amine (280 mg) in THF (dry)(10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 1 day. The mixture was quenched withwater at 0° C. carefully. EtOAc and THF were added and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The residue was crystallized fromMeCN-THF/IPE to give the title compound (81.1 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.26-1.60 (6H, m), 1.68-1.78 (2H, m),1.92-2.03 (2H, m), 3.43-3.51 (2H, m), 4.50-4.69 (2H, m), 4.94-5.11 (1H,m), 6.82 (1H, d, J=8.7 Hz), 7.84-7.97 (2H, m), 8.10 (1H, dd, J=4.3, 2.8Hz), 8.30 (1H, d, J=1.9 Hz).

Example 949-[6-(cyclohexyloxy)pyridin-3-yl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[6-(cyclohexyloxy)pyridin-3-yl]pyrazin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (53.5 mg) was added to asuspension of 3-chloropyrazin-2-amine (200 mg),6-(cyclohexyloxy)pyridin-3-ylboronic acid (375 mg) and sodium carbonate(327 mg) in DME (5 mL) and water (1 ml) and the mixture was stirred at90° C. under nitrogen for 3 hr. Water and EtOAc were added and theorganic layer was separated, washed with brine, dried over anhydroussodium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with EtOAc in hexane) andwashed with IPE to give the title compound (332 mg) as brown gum.

MS (ESI+), found: 271.1.

B)9-[6-(cyclohexyloxy)pyridin-3-yl]-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 246 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.388 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-[6-(cyclohexyloxy)pyridin-3-yl]pyrazin-2-amine (332 mg) in THF (dry)(10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 1 day. The mixture was quenched withwater at 0° C. carefully. EtOAc and THF were added and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The residue was crystallized fromMeCN-THF/IPE to give the title compound (104 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.62 (6H, m), 1.65-1.83 (2H, m),1.85-2.11 (2H, m), 3.49-3.65 (2H, m), 4.51-4.73 (2H, m), 4.97-5.20 (1H,m), 6.84 (1H, d, J=8.7 Hz), 7.58-7.76 (2H, m), 8.27 (1H, dd, J=8.7, 2.6Hz), 8.82 (1H, d, J=2.3 Hz).

Example 959-[6-(cyclohexyloxy)pyridin-3-yl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[6-(cyclohexyloxy)pyridin-3-yl]-5-methylpyrazin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (48.3 mg) was added to asuspension of 3-chloro-5-methylpyrazin-2-amine (200 mg),6-(cyclohexyloxy)pyridin-3-ylboronic acid (339 mg) and sodium carbonate(295 mg) in DME (5 mL) and water (1 mL) and the mixture was stirred at90° C. under nitrogen for 3 hr. Water and EtOAc were added and theorganic layer was separated, washed with brine, dried over anhydroussodium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with EtOAc in hexane) to givethe title compound (339 mg) as light brown gum.

MS (ESI+), found: 285.1.

B)9-[6-(cyclohexyloxy)pyridin-3-yl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 238 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.375 ml) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-[6-(cyclohexyloxy)pyridin-3-yl]-5-methylpyrazin-2-amine (338 mg) inTHF (dry) (10 ml) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 1 day. The mixture was quenched withwater at 0° C. carefully. EtOAc and THF were added and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The residue was crystallized fromMeCN-THF/IPE to give the title compound (84.5 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.20-1.62 (6H, m), 1.63-1.83 (2H, m),1.92-2.07 (2H, m), 2.30 (3H, s), 3.43-3.58 (2H, m), 4.48-4.69 (2H, m),4.96-5.16 (1H, m), 6.84 (1H, d, J=8.7 Hz), 7.58 (1H, s), 8.27 (1H, dd,J=8.7, 1.9 Hz), 8.85 (1H, d, J=1.9 Hz).

Example 969-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (357 mg) of9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (00006),mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/ethanol/acetonitrile=600/200/200) to give the titlecompound (156 mg) with a shorter retention time. Crystallization fromacetonitrile and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.69-1.87 (3H, m), 1.94-2.15 (1H, m),3.20-3.26 (2H, m), 3.41-3.59 (2H, m), 3.75-3.91 (3H, m), 7.10-7.27 (2H,m), 7.34-7.63 (6H, m).

Example 979-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (357 mg) of9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (00006),mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/ethanol/acetonitrile=600/200/200) to give the titlecompound (158 mg) with a longer retention time. Crystallization fromacetonitrile and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.91 (3H, m), 1.91-2.17 (1H, m),3.19-3.28 (2H, m), 3.39-3.62 (2H, m), 3.69-3.91 (3H, m), 7.10-7.27 (2H,m), 7.31-7.60 (6H, m).

Example 989-[4-(3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (37 mg) was added to a solution of9-[4-(3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (129 mg) in THF (dry) (20 mL) and MeOH (20 mL) and themixture was stirred at room temperature under hydrogen overnight. Theinsoluble material was removed by filtration, and the filtrate wasconcentrated in vacuo. The residue was crystallized from THF/IPE to givethe title compound (70.2 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.82 (3H, m), 1.91-2.09 (1H, m),3.24-3.29 (2H, m), 3.41-3.54 (2H, m), 3.72-3.87 (6H, m), 6.51-6.62 (2H,m), 6.72 (1H, dd, J=7.6, 2.3 Hz), 6.90-6.98 (2H, m), 7.17-7.33 (3H, m).

Example 997-methyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-methyl-3-(4-phenoxyphenyl)pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (40.8 mg) was added to asuspension of 3-bromo-5-methylpyridin-2-amine (220 mg),4-phenoxyphenylboronic acid (327 mg) and sodium carbonate (249 mg) inDME (8 mL) and water (1.5 mL) and the mixture was stirred at 85° C.under nitrogen overnight. Silica-gel was added and the volatiles wereremoved in vacuo. The mixture supported on silica-gel was purified bycolumn chromatography (NH-silica gel, eluted with EtOAc in hexane) togive the title compound (315 mg) as a white solid.

MS (ESI+), found: 277.1.

B)7-methyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 229 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.361 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of5-methyl-3-(4-phenoxyphenyl)pyridin-2-amine (316 mg) in THF (dry) (20mL) was added at 0° C. and the mixture was stirred at room temperaturefor 30 min. The mixture was quenched with water. Water and EtOAc wereadded and the extracted organic layer was washed with brine. Silica-gelwas added and the volatiles were removed in vacuo. The mixture supportedon silica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc) to give7-methyl-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (158.2 mg) as a white solid. Platinum(IV) oxide (30.0 mg)was added to a solution of7-methyl-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (141 mg) in THF (dry) (15 mL) and MeOH (15 mL) and themixture was stirred at 50° C. under hydrogen overnight. Platinum(IV)oxide (30.0 mg) was added and the mixture was stirred at 50° C. underhydrogen for 1 day. The insoluble material was removed by filtration,silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(silica gel, eluted with MeOH in EtOAc) and crystallized from THF/IPE togive the title compound (35.4 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.85-1.01 (3H, m), 1.41-1.58 (1H, m),1.64-2.18 (3H, m), 3.17-3.26 (2H, m), 3.38-3.48 (1H, m), 3.74-3.87 (3H,m), 6.88-6.98 (2H, m), 6.99-7.05 (2H, m), 7.10-7.24 (3H, m), 7.36-7.44(2H, m).

Example 1009-(2′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)9-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-(4-Chlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (224 mg), potassium acetate (149 mg),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (232 mg),tricyclohexylphosphine (42.6 mg), andtris(dibenzylideneacetone)dipalladium(0) (34.8 mg) in DME (5 mL) wasstirred at 70° C. overnight. After cooling to room temperature, themixture was purified by column chromatography (silica gel with Celite,eluted with EtOAc in hexane then MeOH in EtOAc) then recrystallized fromEtOH-EtOAc to give the title compound (142 mg) as white powder.

MS (ESI+), found: 387.1.

B)9-(2′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (18.0 mg) was added to asuspension of 1-fluoro-2-iodobenzene (69.0 mg),9-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (60.0 mg) and cesium carbonate (152 mg) in toluene (3 mL)and EtOH (3 mL) and the mixture was stirred at 80° C. under nitrogen for24 hr. Silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) and dissolved in THF (dry)(5 mL) and MeOH (5 mL) and platinum(IV) oxide (6.00 mg) was added andthe mixture was stirred at room temperature under hydrogen for 2 days.The insoluble solid was removed by filtration through Celite-pad (elutedwith EtOAc). Silica-gel was added and the volatiles were removed invacuo. The mixture supported on silica-gel was purified by columnchromatography (NH silica gel, eluted with MeOH in EtOAc) andcrystallized from THF/IPE to give the title compound (0.80 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.91 (4H, m), 1.98-2.12 (1H, m),3.24-3.28 (1H, m), 3.43-3.56 (2H, m), 3.76-3.87 (3H, m), 7.18-7.61 (8H,m).

Example 1019-(2-methylbiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(2-methylbiphenyl-4-yl)pyridin-2-amine

Pd(dppf)Cl₂ (0.089 g) was added to a mixture of 4-bromo-2-methylbiphenyl(1.5 g), potassium acetate (1.787 g) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.312 g) inDME (25 mL) and DMSO (1.25 mL). The mixture was stirred at 80° C. undernitrogen overnight. Activated-carbon powder was added and the mixturewas stirred for 5 min. The insoluble material was removed by filtration,and the filtrate was concentrated in vacuo to give crude4,4,5,5-tetramethyl-2-(2-methylbiphenyl-4-yl)-1,3,2-dioxaborolane.Tetrakis(triphenylphosphine)palladium(0) (173 mg) was added to asuspension of 3-bromopyridin-2-amine (865 mg), the prepared4,4,5,5-tetramethyl-2-(2-methylbiphenyl-4-yl)-1,3,2-dioxaborolane andsodium carbonate decahydrate (2861 mg) in DME (30 mL) and water (6 mL)and the mixture was stirred at 80° C. under nitrogen for 6 hr.Silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) to give the title compound(1.25 g) as a light yellow solid.

MS (ESI+), found: 261.1.

B) 9-(2-methylbiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 1.163 g) in THF (dry) (30 mL) was added2-chloroethanesulfonyl chloride (1.22 ml.) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(2-methylbiphenyl-4-yl)pyridin-2-amine (1.51 g) in THF (dry) (50 mL)was added at 0° C. and the mixture was stirred at room temperatureovernight. The mixture was quenched with water at 0° C. carefully. Waterand EtOAc were added and the precipitates were collected and washed withwater and EtOAc, dried in vacuo to give the title compound (339 mg) as awhite solid. A part of this was recrystallized from MeCN-THF/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.26 (3H, s), 3.42-3.54 (2H, m), 4.60-4.73(2H, m), 6.72 (1H, t, J=7.0 Hz), 7.24 (1H, d, J=8.3 Hz), 7.33-7.51 (7H,m), 7.66 (1H, dd, J=7.2, 1.9 Hz), 7.79 (1H, dd, J=6.8, 1.5 Hz).

Example 1029-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (60 mg) was added to a solution of9-(2-methylbiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (265 mg) in THF (dry) (75 mL), MeOH (75 mL) and the mixturewas stirred at room temperature under hydrogen for 12 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). The filtrate wasconcentrated and the residue was crystallized from MeCN-THF/IPE to givethe title compound (200 mg) as a colorless crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.91 (3H, m), 1.91-2.11 (1H, m), 2.22(3H, s), 3.25-3.30 (2H, m), 3.43-3.63 (2H, m), 3.73-3.96 (3H, m),7.02-7.20 (3H, m), 7.28-7.51 (5H, m).

Example 1039-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (166.3 mg) of9-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol 100%) to give the title compound (75.4 mg) with a longerretention time. Crystallization from acetonitrile and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.87 (3H, m), 1.96-2.11 (1H, m), 2.22(3H, s), 3.25-3.29 (2H, m), 3.39-3.59 (2H, m), 3.71-3.94 (3H, m),7.01-7.18 (3H, m), 7.29-7.48 (5H, m).

Example 1049-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (166.3 mg) of9-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol 100%) to give the title compound (76.4 mg) with a shorterretention time. Crystallization from acetonitrile and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.87 (3H, m), 1.89-2.12 (1H, m), 2.22(3H, s), 3.25-3.29 (2H, m), 3.37-3.60 (2H, m), 3.67-3.94 (3H, m),7.01-7.20 (3H, m), 7.27-7.51 (5H, m).

Example 1059-(4′-methylbiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Trifluoromethanesulfonyl chloride (0.035 mL) was added to a mixture of4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(46 mg) in DMF (dry) (1 mL) at 0° C. The mixture was stirred at 0° C.for 5 min and at room temperature for 2 hr. Water and EtOAc were addedand the extracted organic layer was washed with brine, dried overanhydrous sodium sulfate and concentrated in vacuo. EtOH (3 mL), water(1.5 mL) and DMF (dry) (2 mL) was added to the residue.Tetrakis(triphenylphosphine)palladium(0) (16 mg), p-tolylboronic acid(59.3 mg) and sodium carbonate decahydrate (125 mg) was added and themixture was stirred at 50° C. under nitrogen overnight. Water and EtOAcwere added and the extracted organic layer was washed with brine.Silica-gel was added to the organic phase and the volatiles were removedin vacuo. The mixture supported on silica-gel was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) andcrystallized from MeCN/IPE to give the title compound (7.3 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.88 (3H, m), 1.88-2.10 (1H, m), 2.34(3H, s), 3.24-3.29 (2H, m), 3.41-3.60 (2H, m), 3.73-3.91 (3H, m),7.17-7.35 (4H, m), 7.47-7.64 (4H, m).

Example 1069-(3′-methoxybiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (9.7 mg) was added to a solution of9-(3′-methoxybiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (17.4 mg) in THF (dry) (15 mL) and MeOH (15 mL) and themixture was stirred at 50° C. under hydrogen overnight. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Silica-gel was added tothe filtrate and the volatiles were removed in vacuo. The mixturesupported on silica-gel was purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) to give the title compound (6.5 mg) ascolorless gum.

¹H NMR (300 MHz, CDCl₃) δ 1.78-2.02 (3H, m), 2.08-2.23 (1H, m),3.25-3.35 (2H, m), 3.40-3.56 (2H, m), 3.86 (3H, s), 3.89-4.01 (3H, m),6.89 (1H, dd, J=8.1, 2.5 Hz), 7.08-7.11 (1H, m), 7.12-7.17 (1H, m), 7.22(2H, d, J=8.3 Hz), 7.32-7.38 (1H, m), 7.53 (2H, d, J=8.3 Hz).

Example 1079-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-methylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (0.507 g) was added to a mixture of picolinic acid(0.328 g), 4-(2-aminopyridin-3-yl)phenol (2.48 g), tripotassiumphosphate (8.48 g), 1-iodo-4-methylbenzene (3.19 g) and DMSO (150 mL).The mixture was stirred at 130° C. under nitrogen for 4.5 hr. Theinsoluble solid was removed by filtration through NH-silica gel/Celitepad (eluted with EtOAc). Water was added and the mixture was extracted.The extracted organic layer was washed with brine. Silica-gel was addedto the organic phase and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) to give the title compound(2.17 g) as a yellow solid.

MS (ESI+), found: 277.1.

B)9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 1.57 g) in THF (dry) (60 mL) was added2-chloroethanesulfonyl chloride (1.652 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(4-methylphenoxy)phenyl)pyridin-2-amine (2.17 g) in THF (dry) (40mL) was added at 0° C. and the mixture was stirred at room temperatureunder nitrogen overnight. The mixture was quenched with water at 0° C.Water, EtOAc and IPE were added and the precipitates were collected,washed with water/EtOAc, and dried in vacuo. The precipitates werecrystallized from DMSO (15 ml)/EtOH (200 mL) at 80° C. to roomtemperature to give the title compound (1.91 g) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 2.30 (3H, s), 3.39-3.51 (2H, m), 4.59-4.71(2H, m), 6.70 (1H, t, J=7.0 Hz), 6.94-7.03 (4H, m), 7.22 (2H, d, J=8.3Hz), 7.47-7.54 (2H, m), 7.61 (1H, dd, J=7.2, 1.5 Hz), 7.76 (1H, dd,J=6.8, 1.5 Hz).

mp 248-249° C.

Anal. Calcd for C₂₀H₁₈N₂O₃S:C,65.55;H,4.95;N,7.64. Found:C,65.46;H,5.00;N,7.55.

Example 1089-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (278 mg) in THF (dry) (30 mL) and MeOH (30 mL) and themixture was stirred at 50° C. under hydrogen for 3 hr. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). The filtrate wasconcentrated and the residue was crystallized from MeCN/IPE to give thetitle compound (195.4 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.80 (3H, m), 1.90-2.07 (1H, m), 2.29(3H, s), 3.24-3.30 (2H, m), 3.47 (2H, q, J=6.4 Hz), 3.70-3.89 (3H, m),6.84-6.97 (4H, m), 7.14-7.24 (4H, m).

Example 1099-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (160.7 mg) of9-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (79.9 mg) with ashorter retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.56-1.84 (3H, m), 1.87-2.11 (1H, m), 2.29(3H, s), 3.23-3.29 (2H, m), 3.38-3.59 (2H, m), 3.63-4.01 (3H, m),6.81-7.04 (4H, m), 7.07-7.31 (4H, m).

Example 1109-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (160.7 mg) of9-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (78 mg) with alonger retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.84 (3H, m), 1.90-2.11 (1H, m), 2.29(3H, s), 3.23-3.29 (2H, m), 3.36-3.56 (2H, m), 3.65-3.95 (3H, m),6.78-7.01 (4H, m), 7.11-7.28 (4H, m).

Example 1119-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-fluoro-3-methylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 4-bromo-1-fluoro-2-methylbenzene (609 mg) and DMSO (8 mL).The mixture was stirred at 130° C. under nitrogen for 5 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). Water was addedand the extracted organic layer was washed with brine. Silica-gel wasadded to the organic layer and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) to give the title compound(362.3 mg) as a pale-yellow solid.

MS (ESI+), found: 295.1.

B)9-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 245 mg) in THF (dry) (15 mL) was added2-chloroethanesulfonyl chloride (0.386 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(4-fluoro-3-methylphenoxy)phenyl)pyridin-2-amine (360 mg) in THF(dry) (20 ml) was added at 0° C. and the mixture was stirred at roomtemperature for 5 hr. The mixture was quenched with water at 0° C.Water, EtOAc and IPE were added and the precipitates were collected,washed with water/EtOAc, dried in vacuo to give the title compound(359.2 mg) as a white solid. A part of this was recrystallized fromMeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.24 (3H, d, J=1.9 Hz), 3.41-3.52 (2H, m),4.58-4.71 (2H, m), 6.70 (1H, t, J=7.0 Hz), 6.88-7.02 (3H, m), 7.06 (1H,dd, J=6.4, 3.0 Hz), 7.18 (1H, t, J=9.3 Hz), 7.47-7.55 (2H, m), 7.61 (1H,dd, J=7.2, 1.5 Hz), 7.77 (1H, dd, J=6.8, 1.5 Hz).

Example 1129-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (256 mg) in THF (dry) (30 mL) and MeOH (30 mL) and themixture was stirred at 50° C. under hydrogen for 3 hr. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). The filtrate wasconcentrated and the residue was crystallized from MeCN/IPE to give thetitle compound (169.3 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.81 (3H, m), 1.93-2.06 (1H, m), 2.22(3H, d, J=1.9 Hz), 3.25-3.30 (2H, m), 3.39-3.54 (2H, m), 3.69-3.89 (3H,m), 6.83-6.94 (3H, m), 7.01 (1H, dd, J=6.4, 3.0 Hz), 7.08-7.23 (3H, m).

Example 1139-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (135 mg) of9-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=700/150/150) to give the titlecompound (56.8 mg) with a shorter retention time. Crystallization fromTHF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.61-1.81 (3H, m), 1.88-2.07 (1H, m), 2.22(3H, d, J=1.9 Hz), 3.24-3.30 (2H, m), 3.41-3.55 (2H, m), 3.68-3.89 (3H,m), 6.83-6.94 (3H, m), 7.01 (1H, dd, J=6.0, 3.4 Hz), 7.09-7.23 (3H, m).

Example 1149-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (135 mg) of9-[4-(4-fluoro-3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=700/150/150) to give the titlecompound (56.8 mg) with a longer retention time. Crystallization fromTHF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.82 (3H, m), 1.89-2.06 (1H, m), 2.22(3H, d, J=1.9 Hz), 3.24-3.30 (2H, m), 3.47 (2H, dq, J=12.4, 6.4 Hz),3.70-3.88 (3H, m), 6.83-6.94 (3H, m), 7.01 (1H, dd, J=6.4, 3.0 Hz),7.12-7.23 (3H, m).

Example 1159-[4-(2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(2-methylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-iodo-2-methylbenzene (703 mg) and DMSO (8 mL). The mixturewas stirred at 130° C. under nitrogen for 5 hr. Activated carbon wasadded and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Water was added and theextracted organic layer was washed with brine. Silica-gel was added tothe organic layer and the volatiles were removed in vacuo. The mixturesupported on silica-gel was purified by column chromatography (NH-silicagel, eluted with EtOAc in hexane) to give the title compound (392.8 mg)as a yellow solid.

MS (ESI+), found: 277.1.

B)9-[4-(2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 284 mg) in THF (dry) (15 mL) was added2-chloroethanesulfonyl chloride (0.448 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(2-methylphenoxy)phenyl)pyridin-2-amine (392 mg) in THF (dry) (20mL) was added at 0° C. and the mixture was stirred at room temperaturefor 5 hr. The mixture was quenched with water at 0° C. Water, EtOAc andIPE were added and the precipitates were collected, washed withwater/EtOAc, dried in vacuo to give the title compound (415.4 mg) as awhite solid. A part of this was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.19 (3H, s), 3.40-3.51 (2H, m), 4.59-4.69(2H, m), 6.70 (1H, t, J=7.0 Hz), 6.86-6.93 (2H, m), 6.99 (1H, dd, J=7.9,1.1 Hz), 7.10-7.18 (1H, m), 7.21-7.29 (1H, m), 7.35 (1H, d, J=7.2 Hz),7.47-7.53 (2H, m), 7.61 (1H, dd, J=7.2, 1.5 Hz), 7.76 (1H, dd, J=6.6,1.7 Hz).

Example 1169-[4-(2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (281 mg) in THF (dry) (150 ml) and MeOH (150 mL) and themixture was stirred at 50° C. under hydrogen overnight. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). The filtrate wasconcentrated and the residue was crystallized from MeCN/IPE to give thetitle compound (144.1 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.80 (3H, m), 1.91-2.09 (1H, m), 2.18(3H, s), 3.25-3.29 (2H, m), 3.47 (2H, q, J=5.7 Hz), 3.70-3.86 (3H, m),6.82 (2H, d, J=8.7 Hz), 6.91 (1H, d, J=7.6 Hz), 7.06-7.25 (4H, m), 7.32(1H, dd, J=7.4, 0.9 Hz).

Example 1179-[4-(3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3-methylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-iodo-3-methylbenzene (703 mg) and DMSO (8 mL). The mixturewas stirred at 130° C. under nitrogen for 5 hr. Activated carbon wasadded and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Water was added and theextracted organic layer was washed with brine. Silica-gel was added tothe organic layer and the volatiles were removed in vacuo. The mixturesupported on silica-gel was purified by column chromatography (NH-silicagel, eluted with EtOAc in hexane) to give the title compound (511.5 mg)as a yellow solid.

MS (ESI+), found: 277.1.

B)9-[4-(3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 370 mg) in THF (dry) (25 mL) was added2-chloroethanesulfonyl chloride (0.583 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(3-methylphenoxy)phenyl)pyridin-2-amine (511 mg) in THF (dry) (40mL) was added at 0° C. and the mixture was stirred at room temperatureovernight. The mixture was quenched with water at 0° C. Water, EtOAc andIPE were added and the precipitates were collected, washed withwater/EtOAc, dried in vacuo to give the title compound (514 mg) as awhite solid. A part of this was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.31 (3H, s), 3.42-3.50 (2H, m). 4.61-4.69(2H, m), 6.71 (1H, t, J=7.0 Hz), 6.83-6.95 (2H, m), 6.96-7.05 (3H, m),7.30 (1H, t, J=7.8 Hz), 7.53 (2H, d, J=8.3 Hz), 7.64 (1H, d, J=1.1 Hz),7.77 (1H, dd, J=6.6, 1.3 Hz).

Example 1189-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (357 mg) in THF (dry) (80 mL) and MeOH (80 mL) and themixture was stirred at 50° C. under hydrogen for 6 hr. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc) and the filtrate wasconcentrated in vacuo. The residue was crystallized from MeCN-THF/IPE togive the title compound (243.5 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.80 (3H, m), 1.90-2.09 (1H, m), 2.29(3H, s), 3.25-3.31 (2H, m), 3.41-3.53 (2H, m), 3.72-3.88 (3H, m),6.77-7.00 (5H, m), 7.14-7.31 (3H, m).

Example 1199-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (200.3 mg) of9-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (94.9 mg) with ashorter retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.83 (3H, m), 1.92-2.09 (1H, m), 2.29(3H, s), 3.24-3.28 (2H, m), 3.38-3.56 (2H, m), 3.69-3.88 (3H, m),6.75-7.00 (5H, m), 7.13-7.32 (3H, m).

Example 1209-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (200.3 mg) of9-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (93.2 mg) with alonger retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.82 (3H, m), 1.92-2.09 (1H, m), 2.29(3H, s), 3.24-3.29 (2H, m), 3.38-3.57 (2H, m), 3.70-3.90 (3H, m),6.76-6.99 (5H, m), 7.15-7.32 (3H, m).

Example 1219-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-(4-(2-methyl-4-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-2-methyl-4-(trifluoromethyl)benzene (770 mg) and DMSO(8 mL). The mixture was stirred at 130° C. under nitrogen for 5 hr.Activated carbon was added and the insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc). Waterwas added and the extracted organic layer was washed with brine.Silica-gel was added to the organic layer and the volatiles were removedin vacuo. The mixture supported on silica-gel was purified by columnchromatography (NH-silica gel, eluted with EtOAc in hexane) to give thetitle compound (489 mg) as a yellow solid.

MS (ESI+), found: 345.1.

B)9-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 284 mg) in THF (dry) (25 mL) was added2-chloroethanesulfonyl chloride (0.448 ml) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(2-methyl-4-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine (489mg) in THF (dry) (40 mL) was added at 0° C. and the mixture was stirredat room temperature overnight. The mixture was quenched with water at 0°C. Water, EtOAc and THF were added and the extracted organic layer waswashed with brine. Silica-gel was added to the organic layer and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) and washed with IPE to give the title compound (390 mg) as awhite solid. A part of this was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.33 (3H, s), 3.41-3.51 (2H, m), 4.58-4.71(2H, m), 6.71 (1H, t, J=6.8 Hz), 7.00-7.10 (3H, m), 7.53-7.67 (4H, m),7.72-7.81 (2H, m).

Example 1229-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (315 mg) in THF (dry) (10 mL) and MeOH (10 ml.) and themixture was stirred at room temperature under hydrogen for 4 hr.Activated carbon was added and the insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc) and thefiltrate was concentrated in vacuo. The residue was crystallized fromTHF/IPE to give the title compound (206.1 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.81 (3H, m), 1.93-2.12 (1H, m), 2.32(3H, s), 3.26-3.31 (2H, m), 3.38-3.54 (2H, m), 3.72-3.90 (3H, m),6.90-7.03 (3H, m), 7.25 (2H, d, J=8.7 Hz), 7.54 (1H, dd, J=8.7, 2.3 Hz),7.71 (1H, d, J=1.9 Hz).

Example 1239-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (166 mg) of9-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ODH (OG010), 20mmID×250 mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=800/100/100) to give the titlecompound (62.8 mg) with a shorter retention time. Crystallization fromTHF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.82 (3H, m), 1.93-2.10 (1H, m), 2.31(3H, s), 3.26-3.29 (2H, m), 3.43-3.54 (2H, m), 3.71-3.89 (3H, m),6.91-7.02 (3H, m), 7.25 (2H, d, J=8.7 Hz), 7.54 (1H, dd, J=8.7, 1.9 Hz),7.71 (1H, d, J=1.9 Hz).

Example 1249-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (166 mg) of9-{4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ODH(OG010), 20mmID×250 mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=800/100/100) to give the titlecompound (76.8 mg) with a longer retention time. Crystallization fromTHF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.82 (3H, m), 1.92-2.10 (1H, m), 2.31(3H, s), 3.25-3.30 (2H, m), 3.39-3.56 (2H, m), 3.69-3.91 (3H, m),6.89-7.04 (3H, m), 7.25 (2H, d, J=8.7 Hz), 7.54 (1H, dd, J=8.9, 2.1 Hz),7.71 (1H, d, J=2.3 Hz).

Example 1259-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-4-(trifluoromethyl)benzene (725 mg) and DMSO (8 mL).The mixture was stirred at 130° C. under nitrogen for 5 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). Water was addedand the extracted organic layer was washed with brine. Silica-gel wasadded to the organic layer and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) to give the title compound(690.4 mg) as a yellow solid.

MS (ESI+), found: 331.1.

B)9-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 418 mg) in THF (dry) (25 mL) was added2-chloroethanesulfonyl chloride (0.659 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(4-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine (690 mg) in THF(dry) (40 mL) was added at 0° C. and the mixture was stirred at roomtemperature overnight. The mixture was quenched with water at 0° C.Water, EtOAc and THF were added and the extracted organic layer waswashed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was washed with IPE/EtOAc, dried invacuo to give9-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (579.1 mg) as a slightly yellow solid. Platinum(IV) oxide(30 mg) was added to a solution of9-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (505 mg) in THF (dry) (15 mL) and NeOH (15 mL) and themixture was stirred at room temperature under hydrogen for 6 hr.Platinum(IV) oxide (30 mg), NeOH (15 mL) and THF (dry) (15 mL) wereadded and the mixture was stirred at 50° C. under hydrogen overnight.Activated carbon was added and the insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc) and thefiltrate was concentrated in vacuo. The residue was crystallized fromTHF/IPE to give the title compound (297.2 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.83 (3H, m), 1.92-2.12 (1H, m),3.25-3.30 (2H, m), 3.40-3.56 (2H, m), 3.74-3.90 (3H, m), 7.02-7.19 (4H,m), 7.29 (2H, d, J=8.7 Hz), 7.74 (2H, d, J=8.7 Hz).

mp 191-193° C.

Anal. Calcd for C₂₀H₁₉N₂O₃SF₃:C,56.60;H,4.51;N,6.60. Found:C,56.51;H,4.59;N,6.59.

Example 1269-(6-methoxynaphthalen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(6-methoxynaphthalen-2-yl)pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (95 mg) was added to asuspension of 3-bromopyridin-2-amine (713.7 mg),6-methoxynaphthalen-2-ylboronic acid (1000 mg) and sodium carbonatedecahydrate (2361 mg) in DME (15 mL) and water (3 mL) and the mixturewas stirred at 80° C. under nitrogen for 3 hr and at 70° C. overnight.Activated carbon was added and the insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc) and thevolatiles were removed in vacuo to give the title compound (1194 mg) asa crude orange solid. This product was subjected to the next reactionwithout further purification.

MS (ESI+), found: 251.1.

B)9-(6-methoxynaphthalen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 951 mg) in THF (dry) (40 mL) was added2-chloroethanesulfonyl chloride (1.50 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(6-methoxynaphthalen-2-yl)pyridin-2-amine (1190 mg) in THF (dry) (25mL) was added at 0° C. and the mixture was stirred at room temperatureovernight. The mixture was quenched with water. Water and EtOAc wereadded and the precipitates were collected, washed with water/EtOAc,dried in vacuo to give the title compound (835.3 mg). A part of this wasrecrystallized from MeCN-THF/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 3.43-3.51 (2H, m), 3.89 (3H, s), 4.62-4.71(2H, m), 6.75 (1H, t, J=7.0 Hz), 7.18 (1H, dd, J=8.9, 2.5 Hz), 7.35 (1H,d, J=2.6 Hz), 7.64 (1H, dd, J=8.7, 1.9 Hz), 7.72 (1H, dd, J=7.0, 1.7Hz), 7.78-7.87 (3H, m), 7.91 (1H, s).

Example 1279-(6-methoxynaphthalen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-(6-methoxynaphthalen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (218 mg) in THF (dry) (75 mL) and MeOH (75 mL) and themixture was stirred at room temperature under hydrogen overnight and at50° C. overnight. Activated carbon was added and the insoluble solid wasremoved by filtration through NH-silica gel/Celite pad (eluted withEtOAc). The filtrate was concentrated and the residue was crystallizedfrom MeCN-THF/IPE to give the title compound (153 mg) as colorlesscrystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.75-1.90 (3H, m), 1.95-2.13 (1H, m),3.27-3.30 (2H, m), 3.43-3.66 (2H, m), 3.75-3.95 (6H, m), 7.15 (1H, dd,J=9.1, 2.6 Hz), 7.24-7.39 (2H, m), 7.61 (1H, s), 7.77 (2H, dd, J=8.7,3.8 Hz).

Example 1289-(6-methoxynaphthalen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (114 mg) of9-(6-methoxynaphthalen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (KG010),mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=800/100/100) to give the titlecompound (52 mg) with a shorter retention time. Crystallization fromacetonitrile and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.75-1.90 (3H, m), 1.95-2.13 (1H, m),3.27-3.30 (2H, m), 3.43-3.66 (2H, m), 3.75-3.95 (6H, m), 7.15 (1H, dd,J=9.1, 2.6 Hz), 7.24-7.39 (2H, m), 7.61 (1H, s), 7.77 (2H, dd, J=8.7,3.8 Hz).

Example 1299-(6-methoxynaphthalen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (114 mg) of9-(6-methoxynaphthalen-2-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (KG010),mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=800/100/100) to give the titlecompound (56 mg) with a longer retention time. Crystallization fromacetonitrile and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.73-1.90 (3H, m), 1.98-2.11 (1H, m),3.29-3.31 (2H, m), 3.44-3.62 (2H, m), 3.77-3.94 (6H, m), 7.15 (1H, dd,J=8.9, 2.5 Hz), 7.29-7.34 (2H, m), 7.61 (1H, s), 7.77 (2H, dd, J=8.7,3.8 Hz).

Example 1309-[4-(3-ethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3-ethylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-3-ethylbenzene (596 mg) and DMSO (8 mL). The mixturewas stirred at 130° C. under nitrogen for 4 hr. Activated carbon wasadded and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Water and EtOAc were addedand the extracted organic layer was washed with brine. Silica-gel wasadded to the organic layer and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) to give the title compound(312.5 mg) as a pale yellow crystalline solid.

MS (ESI+), found: 291.1.

B)9-[4-(3-ethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 215 mg) in THF (dry) (20 mL) was added2-chloroethanesulfonyl chloride (0.339 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(3-ethylphenoxy)phenyl)pyridin-2-amine (312 mg) in THF (dry) (30mL) was added at 0° C. and the mixture was stirred at room temperaturefor 1 hr. The mixture was quenched with water at 0° C. Water andEtOAc/THF were added and the extracted organic layer was washed withbrine. Silica-gel was added to the organic layer and the volatiles wereremoved in vacuo. The mixture supported on silica-gel was purified bycolumn chromatography (NH silica gel, eluted with MeOH in EtOAc) andwashed with IPE/EtOAc to give the title compound (295 mg) as a whitesolid. A part of this was recrystallized from THF/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 1.18 (3H, t, J=7.6 Hz), 2.62 (2H, q, J=7.6Hz), 3.40-3.51 (2H, m), 4.57-4.71 (2H, m), 6.70 (1H, t, J=7.0 Hz), 6.87(1H, dd, J=7.7, 2.1 Hz), 6.93-7.06 (4H, m), 7.27-7.36 (1H, m), 7.50-7.57(2H, m), 7.62 (1H, dd, J=7.2, 1.5 Hz), 7.76 (1H, dd, J=6.6, 1.7 Hz).

Example 1319-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(3-ethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (247 mg) in THF (dry) (20 mL) and MeOH (20 mL). The mixturewas stirred at 50° C. under hydrogen for 40 min and at room temperatureunder hydrogen for 4 h. Activated carbon was added and the insolublesolid was removed by filtration through NH-silica gel/Celite pad (elutedwith EtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (167.0 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.16 (3H, t, J=7.7 Hz), 1.62-1.82 (3H, m),1.89-2.09 (1H, m), 2.60 (2H, q, J=7.7 Hz), 3.23-3.29 (2H, m), 3.38-3.55(2H, m), 3.69-3.91 (3H, m), 6.80 (1H, dd, J=8.1, 1.7 Hz), 6.87-6.95 (3H,m), 6.99 (1H, d, J=7.6 Hz), 7.15-7.23 (2H, m), 7.29 (1H, t, J=7.9 Hz).

Example 1329-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (140 mg) of9-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (OC006),mmID×250 mmL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=700/150/150) to give the titlecompound (73 mg) with a shorter retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.16 (3H, t, J=7.5 Hz), 1.64-1.84 (3H, m),1.91-2.11 (1H, m), 2.60 (2H, q, J=7.5 Hz), 3.22-3.28 (2H, m), 3.38-3.56(2H, m, J=6.2, 6.2, 6.2 Hz), 3.69-3.91 (3H, m), 6.80 (1H, dd, J=7.5, 2.3Hz), 6.86-6.95 (3H, m), 7.00 (1H, d, J=7.5 Hz), 7.20 (2H, d, J=8.7 Hz),7.29 (1H, t, J=7.7 Hz).

Example 1339-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (140 mg) of9-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (OC006),mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=700/150/150) to give the titlecompound (56 mg) with a longer retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.16 (3H, t, J=7.7 Hz), 1.64-1.84 (3H, m),1.91-2.11 (1H, m), 2.60 (2H, q, J=7.5 Hz), 3.23-3.28 (2H, m), 3.38-3.57(2H, m), 3.70-3.88 (3H, m), 6.80 (1H, dd, J=7.7, 2.1 Hz), 6.88-6.95 (3H,m), 7.00 (1H, d, J=6.8 Hz), 7.20 (2H, d, J=8.3 Hz), 7.29 (1H, t, J=7.9Hz).

Example 1349-[4-(3,4-dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3,4-dimethylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 4-bromo-1,2-dimethylbenzene (596 mg) and DMSO (8 mL). Themixture was stirred at 130° C. under nitrogen for 3 hr and at 110° C.under nitrogen overnight. Activated carbon was added and the insolublesolid was removed by filtration through NH-silica gel/Celite pad (elutedwith EtOAc). Water and EtOAc were added and the extracted organic layerwas washed with brine. Silica-gel was added to the organic layer and thevolatiles were removed in vacuo. The mixture supported on silica-gel wasis purified by column chromatography (NH-silica gel, eluted with EtOAcin hexane) to give the title compound (144 mg) as a pale yellowcrystalline solid.

MS (ESI+), found: 291.1.

B)9-[4-(3,4-dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 99 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.156 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(3,4-dimethylphenoxy)phenyl)pyridin-2-amine (144 mg) in THF (dry)(10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen overnight. The mixture was quenched withwater at 0° C. and extracted with EtOAc/THF. Silica-gel was added to theorganic phase and the volatiles were removed in vacuo. The mixturesupported on silica-gel was purified by column chromatography (silicagel, eluted with MeOH in EtOAc) to give the title compound (119.7 mg). Apart of product was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.21 (6H, s), 3.40-3.52 (2H, m), 4.58-4.71(2H, m), 6.70 (1H, t, J=7.0 Hz), 6.81 (1H, dd, J=8.3, 2.6 Hz), 6.91 (1H,d, J=2.6 Hz), 6.92-6.99 (2H, m), 7.17 (1H, d, J=8.3 Hz), 7.45-7.53 (2H,m), 7.61 (1H, dd, J=7.2, 1.5 Hz), 7.76 (1H, dd, J=6.6, 1.7 Hz).

Example 1359-[4-(3,4-dimethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (25 mg) was added to a solution of9-[4-(3,4-dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide (93.8 mg) in THF (dry) (10 mL) and NeOH (10 mL). The mixturewas stirred at room temperature under hydrogen for 3 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc) and the filtratewas concentrated in vacuo. The residue was crystallized from THF/IPE togive the title compound (71.8 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.81 (3H, m), 1.86-2.06 (1H, m), 2.20(6H, s), 3.24-3.29 (2H, m), 3.39-3.56 (2H, m), 3.67-3.91 (3H, m), 6.75(1H, dd, J=8.3, 2.6 Hz), 6.80-6.96 (3H, m), 7.05-7.30 (3H, m).

Example 1369-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) (4-bromophenyl)(4-methylphenyl)methanone

To a mixture of N,O-dimethylhydroxylamine hydrochloride (8.20 g) in THF(dry) (75 mL) was added TEA (23.4 mL) at 0° C. After being stirred at 0°C. for 20 min, 4-methylbenzoyl chloride (10 g) in THF (dry) (20 mL) wasadded to the reaction mixture. The mixture was stirred at roomtemperature for 2 days. The mixture was quenched with water at roomtemperature and extracted with EtOAc. The organic layer was separated,washed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo to give N-methoxy-N, 4-dimethylbenzamide (11.7 g)as a yellow oil. n-Butyllithium (1.6 M in hexane) (25.1 mL) was addeddropwise to a mixture of 1,4-dibromobenzene (8.29 g) in THF (dry) (105mL) at −78° C. for 10 min. The mixture was stirred at the sametemperature under nitrogen for 30 min to form white precipitates. Asolution of N-methoxy-N, 4-dimethylbenzamide (6 g) in THF (dry) (20 mL)was added to the reaction mixture at −78° C. and the mixture was stirredat the same temperature under nitrogen for 30 min and then at roomtemperature under a dry atmosphere with anhydrous calcium chloride tubeovernight. The mixture was quenched with sat. NH₄Cl aq. at roomtemperature and extracted with EtOAc. The organic layer was separated,washed with water and brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(silica gel, eluted with EtOAc in hexane) to give the title compound(7.18 g) as a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 2.41 (3H, s), 7.38 (2H, d, J=7.9 Hz), 7.65(4H, d, J=7.9 Hz), 7.74-7.80 (2H, m).

B) 1-bromo-4-(difluoro(4-methylphenyl)methyl)benzene

Bis(2-methoxyethyl)aminosulfur trifluoride (4.79 mL) was added dropwiseunder nitrogen to (4-bromophenyl)(4-methylphenyl)methanone (3 g) at roomtemperature. The mixture was stirred at 75° C. under nitrogen for 10min. Toluene (1.5 mL) was added and the mixture was stirred at 75° C.under nitrogen overnight. The mixture was quenched with sat. NaHCO₃ aq.at room temperature and extracted with EtOAc. The organic layer wasseparated, washed with water and brine, dried over anhydrous magnesiumsulfate and concentrated in vacuo. The residue was washed with hexaneand the insoluble material was removed by filtration, and the filtratewas concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) to give thetitle compound (646.4 mg) as pale yellow oil.

¹H NMR (300 MHz, DMSO-d₆) δ 2.34 (3H, s), 7.27-7.33 (2H, m), 7.37-7.42(2H, m), 7.42-7.50 (2H, m), 7.70 (2H, d, J=8.3 Hz).

C) 3-(4-(difluoro(4-methylphenyl)methyl)phenyl)pyridin-2-amine

Pd(dppf)Cl₂ (31.8 mg) was added to a mixture of1-bromo-4-(difluoro(4-methylphenyl)methyl)benzene (646 mg), potassiumacetate (640 mg) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (828 mg) inDME (20 mL) and DMSO (1 mL). The mixture was stirred at 80° C. undernitrogen overnight. Activated-carbon powder was added and the mixturewas stirred for 5 min. The insoluble material was removed by filtration.The filtrate was concentrated in vacuo. To the residual brown oil wasadded potassium acetate (640 mg),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (828 mg),Pd(dppf)Cl₂ (60 mg) and DME (20 mL), and the mixture was stirred at 80°C. under nitrogen for 5 hr. Activated-carbon powder was added and themixture was stirred for 5 min. The insoluble material was removed byfiltration. Silica-gel was added and the volatiles were removed invacuo. The mixture supported on silica-gel was purified by columnchromatography (NH silica gel, eluted with EtOAc in hexane) to givecrude of2-(4-(difluoro(4-methylphenyl)methyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolaneas a pale yellow amorphous solid.Tetrakis(triphenylphosphine)palladium(0) (62.8 mg) was added to asuspension of 3-bromopyridin-2-amine (313 mg), the prepared2-(4-(difluoro(4-methylphenyl)methyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolaneand sodium carbonate decahydrate (1036 mg) in DME (20 ml) and water (4mL) and the mixture was stirred at 80° C. under nitrogen for 4 hr.Silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(silica gel, eluted with EtOAc in hexane) to give a pale yellow solid(1.12 g) including the title compound. This was used for the next stepwithout further purification.

MS (ESI+), found: 311.1.

D)9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 362 mg) in THF (dry) (20 mL) was added2-chloroethanesulfonyl chloride (0.571 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(difluoro(4-methylphenyl)methyl)phenyl)pyridin-2-amine obtained bystep C of Example 136 in THF (dry) (10 mL) was added at 0° C. and themixture was stirred at room temperature under a dry atmosphere withanhydrous calcium chloride tube overnight. The mixture was quenched withwater/THF then water at 0° C. and extracted with EtOAc/THF. Silica-gelwas added to the organic phase and the volatiles were removed in vacuo.The mixture supported on silica-gel was purified by columnchromatography (silica gel, eluted with MeOH in EtOAc) and concentratedin vacuo and washed with IPE to give the title compound (197 mg) as anoff-white powder. A part of product was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 2.35 (3H, s), 3.41-3.51 (2H, m), 4.58-4.73(2H, m), 6.72 (1H, t, J=7.0 Hz), 7.27-7.36 (2H, m), 7.44 (2H, d, J=8.3Hz), 7.49-7.58 (2H, m), 7.59-7.70 (3H, m), 7.80 (1H, dd, J=6.8, 1.5 Hz).

Example 1379-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (156 mg) in THF (dry) (20 mL) and MeOH (20 mL). The mixturewas stirred at room temperature under hydrogen for 3 h. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Platinum(IV) oxide (30 mg)was added and the mixture was stirred at room temperature under hydrogenovernight. Activated carbon was added and the insoluble solid wasremoved by filtration through NH-silica gel/Celite pad (eluted withEtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (72.0 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.80 (3H, m), 1.95-2.04 (1H, m), 2.34(3H, s), 3.25-3.28 (2H, m), 3.40-3.55 (2H, m), 3.82 (3H, q, J=6.4 Hz),7.25-7.36 (4H, m), 7.36-7.47 (4H, m).

mp 190-191° C.

Anal. Calcd for C₂₁H₂₂N₂O₂SF₂:C,62.36;H,5.48;N,6.93. Found:C,62.35;H,5.59;N,6.80.

Example 1389-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (33 mg) of9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AY-H (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=740/130/130) to give the titlecompound (15 mg) with a shorter retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.81 (3H, m), 1.90-2.10 (1H, m), 2.34(3H, s), 3.24-3.30 (2H, m), 3.42-3.54 (2H, m), 3.76-3.89 (3H, m),7.27-7.35 (4H, m), 7.38-7.47 (4H, m).

Example 1399-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (33 mg) of9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AY-H (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=740/130/130) to give the titlecompound (16.8 mg) with a longer retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.83 (3H, m), 2.00 (1H, s), 2.34 (3H,s), 3.23-3.30 (2H, m), 3.40-3.57 (2H, m), 3.73-3.89 (3H, m), 7.25-7.35(4H, m), 7.37-7.46 (4H, m).

Example 1409-{4-[difluoro(4-fluoro-3-methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-{4-[difluoro(4-fluoro-3-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (148 mg) in THF (dry) (50 mL) and MeOH (50 mL). The mixturewas stirred at room temperature under hydrogen for 3 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc) and the filtratewas concentrated in vacuo. The residue was crystallized from THF/IPE togive the title compound (46.5 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.83 (3H, m), 1.92-2.07 (1H, m), 2.27(3H, d, J=1.9 Hz), 3.24-3.28 (2H, m), 3.40-3.55 (2H, m), 3.74-3.89 (3H,m), 7.19-7.55 (7H, m).

Example 1419-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (20 mg) was added to a solution of9-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (100 mg) in THF (dry) (50 mL) and MeOH (50 mL). The mixturewas stirred at room temperature under hydrogen for 3 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). Platinum(IV) oxide(20 mg) was added and the mixture was stirred at room temperature underhydrogen overnight. Activated carbon was added and the insoluble solidwas removed by filtration through NH-silica gel/Celite pad (eluted withEtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (68.8 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.83 (3H, m), 1.92-2.07 (1H, m), 3.14(2H, t, J=8.7 Hz), 3.24-3.27 (2H, m), 3.38-3.56 (2H, m, J=5.7 Hz),3.70-3.86 (3H, m), 4.56 (2H, t, J=8.7 Hz), 6.38-6.51 (2H, m), 6.91 (2H,d, J=8.7 Hz), 7.12-7.24 (3H, m).

Example 1429-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of platinum (IV) oxide (30 mg) and9-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (192 mg) in THF (20 mL) was stirred under a hydrogenatmosphere overnight. To the reaction mixture was added activatedcarbon, and the mixture was filtered through basic silica gel andcelite. To the filtrate was added silica gel and the mixture wasconcentrated under reduced pressure. The residue was purified by silicagel column chromatography (methanol/ethyl acetate) and concentratedunder reduced pressure. The residue was separated by HPLC (C18, mobilephase: water/acetonitrile (0.1% TFA containing system)). To the obtainedfraction was added a saturated aqueous sodium hydrogen carbonatesolution, and the mixture was extracted with ethyl acetate, dried overanhydrous magnesium sulfate, and concentrated under reduced pressure.The obtained residue was crystallized from THF and diisopropyl ether togive the title compound (30 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.85 (3H, m), 1.90-2.12 (1H, m),3.25-3.29 (2H, m), 3.48 (2H, dq, J=12.8, 6.3 Hz), 3.74-3.89 (3H, m),7.07 (2H, d, J=8.7 Hz), 7.19 (1H, dd, J=8.9, 2.8 Hz), 7.28 (2H, d, J=8.7Hz), 7.46 (1H, d, J=3.0 Hz), 7.86 (1H, d, J=8.7 Hz).

Example 1439-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-fluoro-2-methylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 4-fluoro-1-iodo-2-methylbenzene (761 mg) and DMSO (8 mL). Themixture was stirred at 130° C. under nitrogen for 5 hr. Activated carbonwas added and the insoluble solid was removed by filtration throughNH-silica gel/Celite pad (eluted with EtOAc). Water was added and theextracted organic layer was washed with brine. Silica-gel was added tothe organic layer and the volatiles were removed in vacuo. The mixturesupported on silica-gel was purified by column chromatography (NH-silicagel, eluted with EtOAc in hexane) to give the title compound (354 mg) asa yellow solid.

MS (ESI+), found: 295.1.

B)9-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 241 mg) in THF (dry) (25 mL) was added2-chloroethanesulfonyl chloride (0.380 ml) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(4-fluoro-2-methylphenoxy)phenyl)pyridin-2-amine (354 mg) in THF(dry) (40 mL) was added at 0° C. and the mixture was stirred at roomtemperature overnight. The mixture was quenched with water at 0° C.Water, EtOAc and THF were added and the extracted organic layer waswashed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was washed with IPE/EtOAc, dried invacuo to give the title compound (375 mg) as a slightly yellow solid. Apart of this was recrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ2.18 (3H, s), 3.41-3.49 (2H, m), 4.58-4.70(2H, m), 6.70 (1H, t, J=6.8 Hz), 6.88 (2H, d, J=8.7 Hz), 7.03-7.10 (2H,m), 7.23 (1H, dd, J=9.1, 1.9 Hz), 7.50 (2H, d, J=8.7 Hz), 7.60 (1H, dd,J=7.2, 1.5 Hz), 7.76 (1H, dd, J=6.4, 1.5 Hz).

mp 240-242° C.

Anal. Calcd for C₂₀H₁₇N₂O₃SF-0.2H₂O:C,61.91; H,4.52;N,7.22. Found:C,61.94;H,4.60;N,7.37.

Example 1449-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide (303 mg) in THF (dry) (30 mL) andMeOH (30 mL) and the mixture was stirred at 50° C. under hydrogen for 4hr. The starting material was purified by column chromatography (NHsilica gel, eluted with MeOH in EtOAc) and recovered. Platinum(IV) oxide(30 mg) was added to a solution of the purified starting material in THF(dry) (30 mL) and MeOH (30 mL) and the mixture was stirred at 50° C.under hydrogen overnight. Activated carbon was added and the insolublesolid was removed by filtration through NH-silica gel/Celite pad (elutedwith EtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from MeCN/IPE to give the title compound (115 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.80 (3H, m), 1.89-2.06 (1H, m), 2.17(3H, s), 3.27 (2H, t, J=6.4 Hz), 3.37-3.54 (2H, m), 3.69-3.88 (3H, m),6.73-6.84 (2H, m), 6.92-7.10 (2H, m), 7.13-7.25 (3H, m).

Example 1459-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (140 mg) of9-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=740/130/130) to give the titlecompound (42 mg) with a shorter retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.81 (3H, m), 1.90-2.05 (1H, m), 2.17(3H, s), 3.24-3.28 (2H, m), 3.39-3.55 (2H, m), 3.67-3.88 (3H, m), 6.80(2H, d, J=8.7 Hz), 6.91-7.09 (2H, m), 7.10-7.26 (3H, m).

Example 1469-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (140 mg) of9-[4-(4-fluoro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK AYH (OC006), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/ethanol=740/130/130) to give the titlecompound (32 mg) with a longer retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.82 (3H, m), 1.89-2.07 (1H, m), 2.17(3H, s), 3.23-3.28 (2H, m), 3.41-3.56 (2H, m), 3.67-3.90 (3H, m),6.76-6.87 (2H, m), 6.93-7.10 (2H, m), 7.12-7.26 (3H, m).

Example 1479-[4-(4-chlorophenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 4-chlorophenylboronic acid (407 mg),4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(240 mg), diacetoxycopper (316 mg), triethylamine (0.604 mL), andpowdered 4A MS (1.5 g) in DMF (10 mL) was stirred at room temperatureovernight. The mixture was added with NH silica gel, concentrated invacuo, and purified by column chromatography (NH silica gel, eluted withMeOH in EtOAc) to give the title compound (132 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.43-3.50 (2H, m), 4.62-4.69 (2H, m), 6.71(1H, t, J=7.0 Hz), 7.03-7.13 (4H, m), 7.43-7.49 (2H, m), 7.53-7.59 (2H,m), 7.63 (1H, dd, J=7.2, 1.5 Hz), 7.78 (1H, dd, J=6.8, 1.9 Hz).

mp 232-234° C.

Anal. Calcd for C₁₉H₁₅N₂O₃SCl:C,58.99;H,3.91;N, 7.24. Found:C,58.83;H,4.02;N,7.11.

Example 1489-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-(2-aminopyridin-3-yl)phenol

A mixture of sodium carbonate decahydrate (86.0 g),tetrakis(triphenylphosphine)palladium(0) (7.76 g),(4-((tert-butyldimethylsilyl)oxy)phenyl)boronic acid (40 g) and3-bromopyridin-2-amine (26.9 g) in DME (500 mL) and water (50 mL) wasstirred at 90° C. for 24 hr. After cooling to room temperature, theaqueous layer was removed. The organic layer was filtered with NH-silicagel cartridge, and washed with EtOAc. The filtrate was concentrated invacuo. The residue was recrystallized from EtOAc-IPE to give the titlecompound (25.0 g) as a pale yellow solid.

MS (ESI+), found: 187.1.

B) 3-(4-((tert-butyl(dimethyl)silyl)oxy)phenyl)pyridin-2-amine

A mixture of 4-(2-aminopyridin-3-yl)phenol (19.8 g),tert-butyldimethylchlorosilane (21.8 mL) and 1H-imidazol (8.69 g) in DMF(200 mL) was stirred at room temperature for 20 hr. To the mixture wasadded water, and the resulting precipitate was collected by filtration,and then washed with water to give the title compound (30.5 g) as awhite solid.

MS (ESI+), found: 301.1.

C)9-(4-((tert-butyl(dimethyl)silyl)oxy)phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 42.0 g) in THF (dry) (350 mL) was added2-chloroethanesulfonyl chloride (44.5 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-((tert-butyl(dimethyl)silyl)oxy)phenyl)pyridin-2-amine (78.8 g) inTHF (dry) (350 mL) was added at 0° C. and the mixture was stirred atroom temperature under N₂ overnight. The mixture was quenched with waterat 0° C. carefully. Additional water was added to form precipitateswhich were washed with water and EtOAc and collected to give the titlecompound (65.5 g) as an off-white solid.

MS (ESI+), found: 391.2.

D)9-(4-((tert-butyl(dimethyl)silyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (2.0 g) was added to a solution of9-(4-((tert-butyl(dimethyl)silyl)oxy)phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (20.0 g) in THF (dry) (500 mL) and MeOH (300 mL) and themixture was stirred at room temperature under H₂ for 4 hr. The mixturewas passed through NH silica gel cartridge with Celite (eluted withTHF). The filtrate was concentrated in vacuo. The residual solid wasrecrystallized from THF (100 mL)-IPE (300 mL) to give the title compound(17.3 g).

MS (ESI+), found: 395.2.

E)4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol

A mixture of9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (6.97 g) and 6 M HCl aq. (10.0 mL) in AcOH (100 mL) wasstirred at 60° C. for 2 hr. After cooling to room temperature, thesolvent was removed in vacuo. The residual solid was recrystallized fromMeOH-IPE to give the title compound (5.01 g) as a white solid.

MS (ESI+), found: 281.1.

F)9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 4-chlorophenylboronic acid (167 mg),4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(100 mg), pyridine (0.087 mL), diacetoxycopper (130 mg), and cesiumcarbonate (116 mg) in DMSO (3.0 mL) was stirred at room temperature for24 hr. The mixture was diluted with water, and extracted with EtOAc (40mL). The organic layer was washed with 0.1N NaOH aq. (2×40 mL) and thenbrine, dried over anhydrous magnesium sulfate, and concentrated invacuo. The residue was purified by column chromatography (silica gel,eluted with MeOH in EtOAc) to give the title compound (23.0 mg) as awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.82 (3H, m), 1.96-2.06 (1H, m),3.23-3.29 (2H, m), 3.44-3.52 (2H, m), 3.75-3.86 (3H, m), 6.95-7.07 (4H,m), 7.23 (2H, d, J=8.3 Hz), 7.39-7.47 (2H, m).

mp 215-216° C.

Anal. Calcd for C₁₉H₁₉N₂O₃SCl:C,58.38;H,4.90;N,7.17. Found:C,58.38;H,4.97;N,6.89.

Example 149(9S)-9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Diacetoxycopper (1037 mg) was added to a mixture of triethylamine (1.983mL), 4-chlorophenylboronic acid (1339 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(800 mg) and in DMF (dry) (30 mL). The mixture was stirred at roomtemperature under a dry atmosphere with anhydrous calcium chloride tubefor 15 hr. Then 4-chlorophenylboronic acid (1339 mg) and diacetoxycopper(1037 mg) were added and the mixture was stirred at room temperatureunder a dry atmosphere with anhydrous calcium chloride tube for 2 days.The insoluble material was removed by filtration, and the filtrate wasdiluted with water, and extracted with EtOAc. The organic layer waswashed with 0.1N NaOH aq., dried over anhydrous magnesium sulfate.Silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH silica gel, eluted with MeOH in EtOAc) then crystallized fromTHF/IPE to give the title compound (177 mg) as an off-white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.83 (3H, m), 1.93-2.09 (1H, m),3.25-3.30 (2H, m), 3.40-3.55 (2H, m), 3.71-3.89 (3H, m), 6.93-7.08 (4H,m), 7.23 (2H, d, J=8.7 Hz), 7.37-7.48 (2H, m).

X-ray powder diffraction pattern with specific peaks at d value (ord-spacing)=15.60, 7.80, 5.21, 5.06, 4.64, 3.97, 3.90 and 3.75 Å.

Example 1509-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (214 mg) of9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (101 mg) with alonger retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.62-1.85 (3H, m), 1.89-2.10 (1H, m),3.25-3.28 (2H, m), 3.41-3.56 (2H, m), 3.69-3.89 (3H, m), 6.92-7.09 (4H,m), 7.23 (2H, d, J=8.3 Hz), 7.38-7.48 (2H, m).

mp 183-185° C.

Anal. Calcd for C₁₉H₁₉N₂O₃SCl:C,58.38;H,4.90;N,7.17. Found:C,58.42;H,5.01;N,6.93.

Example 1519-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of2,4,6-tris(3,4-dichlorophenyl)-1,3,5,2,4,6-trioxatriborinane (277 mg),4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(100 mg), pyridine (0.087 mL), diacetoxycopper (130 mg), and cesiumcarbonate (116 mg) in MeCN (10 mL) was stirred at room temperature for16 hr. The mixture was filtered by Celite.

The filtrate was diluted with water, and extracted with EtOAc (40 mL).The organic layer was washed with 0.1N NaOH aq. (2×40 mL) and thenbrine, dried over anhydrous magnesium sulfate, and concentrated invacuo. The residue was purified by column chromatography (NH silica gel,eluted with MeOH in EtOAc) and then recrystallized from EtOAc-IPE togive the title compound (37.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.81 (3H, m), 1.95-2.08 (1H, m),3.24-3.29 (2H, m), 3.48 (2H, dq, J=12.8, 6.4 Hz), 3.75-3.90 (3H, m),6.97-7.08 (3H, m), 7.26 (2H, d, J=8.7 Hz), 7.31 (1H, d, J=3.0 Hz), 7.63(1H, d, J=8.7 Hz).

mp 195-197° C.

Anal. Calcd for C₁₉H₈N₂O₃SCl₂-0.25H₂O:C,53.09;H,4.34;N,6.52.Found:C,53.18;H,4.29;N,6.34.

Example 1529-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (312 mg) of9-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (145 mg) with ashorter retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.73-1.79 (3H, m), 1.93-2.08 (1H, m),3.25-3.29 (2H, m), 3.40-3.55 (2H, m), 3.72-3.91 (3H, m), 6.95-7.10 (3H,m), 7.21-7.36 (3H, m), 7.63 (1H, d, J=9.1 Hz).

Example 1539-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (312 mg) of9-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK IC (ME001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:acetonitrile 100%) to give the title compound (143 mg) with alonger retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.73-1.78 (3H, m), 1.92-2.08 (1H, m),3.25-3.29 (2H, m), 3.40-3.54 (2H, m), 3.74-3.88 (3H, m), 6.94-7.08 (3H,m), 7.21-7.34 (3H, m), 7.63 (1H, d, J=9.1 Hz).

Example 1549-[4-(4-chloro-3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-chloro-3-methoxyphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 4-bromo-1-chloro-2-methoxybenzene (714 mg) and DMSO (8 mL).The mixture was stirred at 130° C. under nitrogen for 4 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). Silica-gel wasadded to the filtrate and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH-silica gel, eluted with EtOAc in hexane) and concentrated. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give the title compound (359 mg) as pale yellow oil.

MS (ESI+), found: 327.1.

B)9-[4-(4-chloro-3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 220 mg) in THF (dry) (20 mL) was added2-chloroethanesulfonyl chloride (0.347 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(4-chloro-3-methoxyphenoxy)phenyl)pyridin-2-amine (359 mg) in THF(dry) (10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under a dry atmosphere with anhydrous calcium chloride tubeovernight. The mixture was quenched with water/THF then water at 0° C.and extracted with EtOAc/THF. Silica-gel was added to the organic phaseand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc) and concentrated in vacuo and washed with IPE togive the title compound (306 mg) as a white solid. A part of product wasrecrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.49 (2H, m), 3.85 (3H, s), 4.62-4.68(2H, m), 6.59 (1H, dd, J=8.7, 2.7 Hz), 6.71 (1H, t, J=7.0 Hz), 6.97 (1H,q, J=3.2 Hz), 7.06 (2H, d, J=8.7 Hz), 7.42 (1H, d, J=8.7 Hz), 7.52-7.58(2H, m), 7.63 (1H, dd, J=7.2, 1.5 Hz), 7.77 (1H, d, J=5.3 Hz).

Example 1559-[4-(4-chloro-3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(4-chloro-3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (262.3 mg) in THF (dry) (60 mL) and MeOH (30 mL). Themixture was stirred at room temperature under hydrogen for 3 hr.Platinum(IV) oxide (30 mg) was added and the mixture was stirred at roomtemperature under hydrogen for 4 hr. The insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc) and thefiltrate was concentrated in vacuo. MeCN (13 mL) was added and thismixture was purified by preparative HPLC (C18, eluted with water inacetonitrile containing 0.1% TFA). The desired fractions wereneutralized with sat.NaHCO₃ aq. and the mixture was extracted withEtOAc. The combined organic layer was dried over anhydrous magnesiumsulfate and concentrated in vacuo. The residue was crystallized fromTHF/IPE to give the title compound (80.1 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.85 (3H, m), 1.93-2.08 (1H, m),3.22-3.28 (2H, m), 3.39-3.56 (2H, m), 3.74-3.89 (6H, m), 6.51 (1H, dd,J=8.7, 2.7 Hz), 6.91 (1H, d, J=2.7 Hz), 6.98 (2H, d, J=8.7 Hz), 7.23(2H, d, J=8.7 Hz), 7.39 (1H, d, J=8.7 Hz).

Example 1569-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3-(1,1-difluoroethyl)phenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-3-(1,1-difluoroethyl)benzene (712 mg) and DMSO (8mL). The mixture was stirred at 130° C. under nitrogen for 10 hr.Activated carbon was added and the insoluble solid was removed byfiltration through NH-silica gel/Celite pad (eluted with EtOAc).Silica-gel was added to the filtrate and the volatiles were removed invacuo. The mixture supported on silica-gel was purified by columnchromatography (NH-silica gel, eluted with EtOAc in hexane) andconcentrated. The residue was purified by column chromatography (silicagel, eluted with EtOAc in hexane) to give the title compound (499 mg) aspale yellow oil.

MS (ESI+), found: 327.1.

B)9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 306 mg) in THF (dry) (25 mL) was added2-chloroethanesulfonyl chloride (0.483 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(3-(1,1-difluoroethyl)phenoxy)phenyl)pyridin-2-amine (499 mg) inTHF (dry) (15 mL) was added at 0° C. and the mixture was stirred at roomtemperature under a dry atmosphere with anhydrous calcium chloride tubeovernight. The mixture was quenched with water/THF then water at 0° C.and extracted with EtOAc/THF. Silica-gel was added to the organic phaseand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc) and concentrated in vacuo and washed with IPE togive the title compound (254 mg) as a white solid. A part of product wasrecrystallized from MeCN/IPE.

¹H NMR (300 MHz, DMSO-d₆) δ 1.97 (3H, t, J=18.9 Hz), 3.41-3.50 (2H, m),4.61-4.70 (2H, m), 6.71 (1H, t, J=7.0 Hz), 7.07 (2H, d, J=8.7 Hz),7.14-7.21 (1H, m), 7.23-7.28 (1H, m), 7.36 (1H, d, J=7.6 Hz), 7.49-7.54(1H, m), 7.57 (2H, d, J=8.7 Hz), 7.64 (1H, dd, J=7.2, 1.9 Hz), 7.77 (1H,dd, J=6.6, 1.7 Hz).

Example 1579-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (230 mg) in THF (dry) (20 mL) and MeOH (20 mL). The mixturewas stirred at room temperature under hydrogen overnight. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc) and the filtratewas concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with MeOH in EtOAc) and concentrated.The residue was crystallized from EtOAc/hexane to give the titlecompound (79.4 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.83 (3H, m), 1.87-2.08 (4H, m),3.23-3.29 (2H, m), 3.41-3.55 (2H, m), 3.72-3.89 (3H, m), 6.93-7.02 (2H,m), 7.07-7.14 (1H, m), 7.18-7.27 (3H, m), 7.33 (1H, d, J=8.0 Hz),7.45-7.55 (1H, m).

mp 117-118° C.

Anal. Calcd for C₂₁H₂₂N₂O₃SF₂:C,59.99;H,5.27;N,6.66. Found:C,60.00;H,5.30;N,6.66.

Example 1589-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (49 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (KG010), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/methanol=740/260) to give the title compound (21mg) with a shorter retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.82 (3H, m), 1.85-2.07 (4H, m),3.22-3.29 (2H, m), 3.38-3.57 (2H, m), 3.72-3.91 (3H, m), 6.99 (2H, d,J=8.7 Hz), 7.11 (1H, d, J=8.3 Hz), 7.18-7.27 (3H, m), 7.33 (1H, d, J=7.5Hz), 7.45-7.55 (1H, m).

Example 1599-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (49 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK ADH (KG010), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/methanol=740/260) to give the title compound (20mg) with a longer retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.82 (3H, m), 1.85-2.09 (4H, m),3.24-3.30 (2H, m), 3.40-3.57 (2H, m), 3.72-3.90 (3H, m), 6.99 (2H, d,J=8.7 Hz), 7.11 (1H, d, J=8.3 Hz), 7.16-7.28 (3H, m), 7.33 (1H, d, J=7.5Hz), 7.46-7.55 (1H, m).

Example 160(9S)-9-{4-[2-chloro-5-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Diacetoxycopper (907 mg) was added to a mixture of pyridine (0.606 mL),2-chloro-5-(trifluoromethyl)phenylboronic acid (459 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(700 mg) and cesium carbonate (814 mg) in MeCN (25 mL). The mixture wasstirred at room temperature under a dry atmosphere with anhydrouscalcium chloride tube for 2 days. The insoluble material was removed byfiltration, and the filtrate was diluted with water, and extracted withEtOAc. The organic layer was washed with brine and dried over anhydrousmagnesium sulfate. Silica-gel was added and the volatiles were removedin vacuo. The mixture supported on silica-gel was purified by columnchromatography (NH silica gel, eluted with MeOH in EtOAc) andconcentrated in vacuo to give the title compound (5.9 mg) as pale yellowgum.

¹H NMR (300 MHz, CDCl₃) δ 1.79-2.03 (3H, m), 2.05-2.19 (1H, m),3.24-3.33 (2H, m), 3.40-3.53 (2H, m), 3.82-3.99 (3H, m), 6.88-6.97 (2H,m), 7.13-7.19 (2H, m), 7.24 (1H, d, J=1.5 Hz), 7.34 (1H, dd, J=8.3, 1.5Hz), 7.58 (1H, d, J=8.3 Hz).

Example 1619-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-ethylphenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-4-ethylbenzene (596 mg) and DMSO (8 mL). The mixturewas stirred at 130° C. under nitrogen for 4 hr. Activated carbon wasadded and the insoluble solid was removed by filtration through silicagel/Celite pad (eluted with EtOAc). Silica-gel was added to the filtrateand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (NH-silica gel, elutedwith EtOAc in hexane) and concentrated to give the title compound (117mg) as an off-white solid.

MS (ESI+), found: 291.1.

B)9-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 81 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.085 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(4-ethylphenoxy)phenyl)pyridin-2-amine (117 mg) in THF (dry) (10mL) was added at 0° C. and the mixture was stirred at room temperatureunder nitrogen for 4 hr. The mixture was quenched with water at 0° C.Water, EtOAc and THF were added and the mixture was extracted.Silica-gel was added to the organic phase and the volatiles were removedin vacuo. The mixture supported on silica-gel was purified by columnchromatography (silica gel, eluted with MeOH in EtOAc) and concentratedin vacuo to give9-[4-(4-ethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide as a white solid. Platinum(IV) oxide (20 mg) was added to asolution of9-[4-(4-ethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (153 mg) in THF (dry) (20 mL) and MeOH (20 mL). The mixturewas stirred at room temperature under hydrogen for 3 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough silica gel/Celite pad (eluted with EtOAc). Platinum(IV) oxide(20 mg) was added and the mixture was stirred at room temperature underhydrogen overnight. Activated carbon was added and the insoluble solidwas removed by filtration through silica gel/Celite pad (eluted withEtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (46.7 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.18 (3H, t, J=7.6 Hz), 1.64-1.84 (3H, m),1.90-2.09 (1H, m), 2.59 (2H, q, J=7.6 Hz), 3.28 (2H, t, J=6.2 Hz),3.40-3.55 (2H, m), 3.70-3.89 (3H, m), 6.86-6.99 (4H, m), 7.13-7.28 (4H,m).

Example 1629-{4-[difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 1-bromo-4-(difluoro(phenyl)methyl)benzene

Bis(2-methoxyethyl)aminosulfur trifluoride (2.02 mL) was added dropwiseunder nitrogen to (4-bromophenyl)(phenyl)methanone (1 g) at roomtemperature. The mixture was stirred at 75° C. under nitrogen for 11 hrand at room temperature for 2 days. The mixture was quenched with sat.NaHCO₃ aq. at room temperature and extracted with EtOAc. The organiclayer was separated, washed with water and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with EtOAc in hexane) to givethe title compound (436 mg) as a colorless amorphous solid.

¹H NMR (300 MHz, DMSO-d₆) δ 7.37-7.58 (7H, m), 7.71 (2H, d, J=8.3 Hz).

B) 3-(4-(difluoro(phenyl)methyl)phenyl)pyridin-2-amine

Pd(dppf)Cl₂ (19.4 mg) was added to a mixture of1-bromo-4-(difluoro(phenyl)methyl)benzene (376 mg), potassium acetate(391 mg) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)(506 mg) in DME (10 mL) and DMSO (0.5 mL). The mixture was stirred at80° C. under nitrogen overnight. Activated-carbon powder was added andthe mixture was stirred for 5 min. The insoluble material was removed byfiltration. The filtrate was concentrated in vacuo to give a brown oilof2-(4-(difluoro(phenyl)methyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.Tetrakis(triphenylphosphine)palladium(0) (38.4 mg) was added to asuspension of 3-bromopyridin-2-amine (192 mg), the prepared2-(4-(difluoro(phenyl)methyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolaneand sodium carbonate decahydrate (634 mg) in DME (10 mL) and water (2mL) and the mixture was stirred at 80° C. under nitrogen for 3 hr.Silica-gel was added and the volatiles were removed in vacuo. Themixture supported on silica-gel was purified by column chromatography(NH silica gel, eluted with EtOAc in hexane) to give the title compound(291 mg) as a colorless oil.

MS (ESI+), found: 297.1.

C)9-{4-[difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 196 mg) in THF (dry) (20 mL) was added2-chloroethanesulfonyl chloride (0.310 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(difluoro(phenyl)methyl)phenyl)pyridin-2-amine (291 mg) in THF(dry) (10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under a dry atmosphere with anhydrous calcium chloride tubefor 2 hr. The mixture was quenched with water/THF then water at 0° C.and extracted with EtOAc/THF. Silica-gel was added to the organic phaseand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc) and concentrated in vacuo. The residue was washedwith IPE to give the title compound (49 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.51 (2H, m), 4.60-4.70 (2H, m), 6.72(1H, t, J=6.8 Hz), 7.45-7.70 (10H, m), 7.80 (1H, dd, J=6.8, 1.5 Hz).

Example 1639-{4-[difluoro(phenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (14 mg) was added to a solution of9-{4-[difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (49 mg) in THF (dry) (10 mL) and MeOH (10 ml). The mixturewas stirred at room temperature under hydrogen for 4 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc) and the filtratewas concentrated in vacuo. The residue was crystallized from THF/IPE togive the title compound (18.8 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.82 (3H, m), 1.91-2.10 (1H, m),3.24-3.28 (2H, m), 3.42-3.53 (2H, m), 3.74-3.89 (3H, m), 7.28-7.37 (2H,m), 7.42-7.58 (7H, m).

Example 1649-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-(2-amino-5-methylpyridin-3-yl)phenol

Tetrakis(triphenylphosphine)palladium(0) (0.716 g) was added to asuspension of 3-bromo-5-methylpyridin-2-amine (3.86 g),4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (5 g) and sodiumcarbonate (2.19 g) in DME (150 mL) and water (30 mL) and the mixture wasstirred at 80° C. under nitrogen for 5 hr. Silica-gel was added and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (1.99 g) as a pale yellow solid.

MS (ESI+), found: 201.1.

B) 3-(4-(4-fluoro-3-methoxyphenoxy)phenyl)-5-methylpyridin-2-amine

Copper(I) iodide (95 mg) was added to a mixture of picolinic acid (61.5mg), 4-(2-amino-5-methylpyridin-3-yl)phenol (500 mg), tripotassiumphosphate (1590 mg), 4-bromo-1-fluoro-2-methoxybenzene (614 mg) and DMSO(8 mL). The mixture was stirred at 130° C. under nitrogen for 10 hr. Theinsoluble solid was removed by filtration through silica gel/Celite pad(eluted with EtOAc). Silica-gel was added to the filtrate and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH-silica gel, eluted with EtOAc inhexane) to give the title compound (361 mg) as pale yellow oil.

MS (ESI+), found: 325.1.

C)9-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 222 mg) in THF (dry) (20 mL) was added2-chloroethanesulfonyl chloride (0.233 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(4-fluoro-3-methoxyphenoxy)phenyl)-5-methylpyridin-2-amine (360 mg)in THF (dry) (20 mL) was added at 0° C. and the mixture was stirred atroom temperature under nitrogen overnight. The mixture was quenched withwater at 0° C. Water, EtOAc and THF were added to the mixture and theorganic phase was separated. Silica-gel was added to the organic phaseand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc) and concentrated in vacuo to give9-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide as a white solid. This product was subjected to the nextreaction without further purification. A part of the product wascrystallized from EtOAc/IPE to give the title compound as a colorlesssolid.

MS (ESI+), found: 415.1.

D)9-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (30 mg) was added to a solution of9-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (400 mg) in THF (dry) (15 mL) and MeOH (15 mL). The mixturewas stirred at room temperature under hydrogen for 3 hr. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough silica gel/Celite pad (eluted with EtOAc). Platinum(IV) oxide(30 mg) was added and the mixture was stirred at room temperature underhydrogen overnight. AcOH (10 mL) and platinum(IV) oxide (30 mg) wereadded and the mixture was stirred at room temperature under hydrogen for1 day and at 50° C. for 1 day. Activated carbon was added and theinsoluble solid was removed by filtration through silica gel/Celite pad(eluted with EtOAc) and the filtrate was concentrated in vacuo. Theresidue was purified by column chromatography (NH silica gel, elutedwith MeOH in EtOAc) and concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (30.3 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.83-0.99 (3H, m), 1.49 (1H, q, J=12.3 Hz),1.70-2.17 (2H, m), 3.04-3.25 (3H, m), 3.37-3.63 (1H, m), 3.74-3.87 (6H,m), 6.52 (1H, dt, J=9.1, 3.2 Hz), 6.87-6.98 (3H, m), 7.15-7.26 (3H, m).

Example 1659-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 1-bromo-4-(cyclohexyloxy)benzene

Boron trifluoride etherate (5.83 mL) was added to a mixture of4-bromophenol (39.8 g) and cyclohexene (187 mL) in toluene (160 mL) toform bright orange-red solution. The mixture was stirred at 40° C. undernitrogen for 5 hr. The mixture was quenched with 2N NaOH aq. (40 mL) andwater at room temperature and extracted with EtOAc. The organic layerwas separated, washed with water and brine, dried over anhydrous sodiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with hexane) to give the titlecompound (46.3 g) as pale yellow oil.

¹H NMR (300 MHz, DMSO-d₆) δ 1.22-1.53 (6H, m), 1.70-1.85 (2H, m), 1.95(2H, dt, J=6.5, 3.3 Hz), 4.14-4.24 (1H, m), 6.77 (2H, d, J=9.0 Hz), 7.34(2H, d, J=9.0 Hz).

B) 3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine

n-Butyllithium (1.6 M in hexane) (136 mL) was dropwised to a mixture of1-bromo-4-(cyclohexyloxy)benzene (46.3 g) and THF (dry) (500 mL) at −78°C. and the mixture was stirred at the same temperature under nitrogenfor 40 min. Triisopropyl borate (51.2 g) was dropwised to the mixture at−78° C. for 15 min and the mixture was stirred at the same temperaturefor 5 min. Then the mixture was warmed up to room temperature andstirred for additional 30 min. The mixture was poured into 1N NaOH aq.(250 mL) and water (750 mL) and the mixture was further stirred for 30min. The organic layer was separated and the aqueous phase was washedwith Et₂O (300 mL×2) and acidified by 6N HCl aq. The mixture wasextracted with EtOAc, dried over anhydrous sodium sulfate andconcentrated in vacuo to give 4-(cyclohexyloxy)phenylboronic acid (29.5g) as a white powder. Tetrakis(triphenylphosphine)palladium(0) (0.656 g)was added to a suspension of 3-bromopyridin-2-amine (9.83 g),4-(cyclohexyloxy)phenylboronic acid (15.0 g) and sodium carbonate (12.0g) in DME (325 mL) and water (65.0 mL) and the mixture was stirred at100° C. under nitrogen for 3 hr and at 90° C. for 12 hr. Volatiles wereremoved in vacuo with silica-gel. The silica-supported mixture waspurified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (14.1 g) as a white powder.

MS (ESI+), found: 269.1.

C)9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 10.5 g) in THF (dry) (200 mL) was added2-chloroethanesulfonyl chloride (11.0 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine (14.1 g) in THF (dry) (150mL) was added at 0° C. and the mixture was stirred at room temperatureunder nitrogen for 14 hr. The mixture was quenched with water at 0° C.carefully. Water and hexane were added to form precipitates which werewashed with EtOAc and collected to give9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (17.4 g) as an off-white solid. To9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (16.0 g) was added DMSO (280 mL) under heating with oil bath(ca. 90° C.). After being stirred for 10 min., EtOH (520 mL) wasdropwised at 85° C. to form precipitates. The mixture was stirred forfurther 15 min at same temperature and then cooled to room temperature(the oil bath was removed and stirred for 50 min and stirred for 60 minin water bath). The precipitates were collected, washed with EtOH (40mL) and dried in air for 2 days to give the title compound (13.1 g) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.59 (6H, m), 1.63-1.80 (2H, m),1.88-2.01 (2H, m), 3.41-3.49 (2H, m), 4.32-4.44 (1H, m), 4.59-4.68 (2H,m), 6.68 (1H, t, J=7.0 Hz), 6.96 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7Hz), 7.58 (1H, dd, J=7.3, 1.7 Hz), 7.71-7.76 (1H, m).

mp 275-277° C.

Anal. Calcd for C₁₉H₂₂N₂O₃S:C,63.66;H,6.19;N,7.82. Found:C,63.63;H,6.30;N,7.86.

X-ray powder diffraction pattern with specific peaks at d value (ord-spacing)=12.48, 9.63, 7.65, 6.63, 6.22, 5.23, 4.90, 4.85, 4.65 and4.52 Å.

Example 1669-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of sodium carbonate (121 mg),tetrakis(triphenylphosphine)palladium(0) (13.18 mg),(4-phenoxyphenyl)boronic acid (98 mg) and9-bromo-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide (100 mg)in DMF (dry) (10 mL) and water (2 mL) was stirred at 80° C. under N₂overnight. NH silica gel was added and the mixture was concentrated invacuo. The residue was purified by column chromatography (NH silica gel,eluted with MeOH in EtOAc) to give9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (116 mg) as a white solid. The solid was crystallized fromDMSO (1.5 mL)-EtOH (3 mL) to give the title compound (90.7 mg) as awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.37-3.52 (2H, m), 4.55-4.76 (2H, m), 6.70(1H, t, J=7.0 Hz), 6.96-7.13 (4H, m), 7.14-7.23 (1H, m), 7.36-7.48 (2H,m), 7.49-7.58 (2H, m), 7.63 (1H, dd, J=7.2, 1.5 Hz), 7.77 (1H, dd,J=6.6, 1.7 Hz).

mp 251-252° C.

Anal. Calcd for C₁₉H₁₆N₂O₃S:C,64.76;H,4.58;N,7.95. Found:C,64.63;H,4.65;N,7.88.

Example 1679-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of 4-phenoxyphenylboronic acid (40.2 g),3-bromopyridin-2-amine (25 g), tetrakis(triphenylphosphine)palladium(0)(5.01 g) and sodium carbonate (30.6 g) in DME (722 mL) and water (145mL) was stirred at 80° C. under N₂ for 20 hr. NH silica gel was addedand the mixture was concentrated in vacuo. The residue was purified bycolumn chromatography (NH silica gel, eluted with EtOAc in hexane) togive a white solid. The solid was crystallized from EtOAc and hexane togive the title compound (33.8 g) as a white solid.

MS (API+), found: 263.1

B) 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 20.4 g) in THF (dry) (250 mL) was added2-chloroethanesulfonyl chloride (32.2 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-phenoxyphenyl)pyridin-2-amine (29.09 g) in THF (dry) (150 ml) wasdropwised at 0° C. and the mixture was stirred at room temperature underN₂ for 2 days. The mixture was quenched with THF/water (v/v=5/1) at 0°C. under N₂ carefully. Water (500 mL) and EtOAc (400 mL) were added toform precipitates (stirred for 30 min) which were washed with water andEtOAc, collected and crystallized from DMSO/EtOH (500 mL/1000 ml, at 90°C.) to give the title compound (36.0 g) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 3.40-3.53 (2H, m), 4.60-4.71 (2H, m), 6.71(1H, t, J=6.8 Hz), 6.96-7.05 (2H, m), 7.05-7.13 (2H, m), 7.13-7.23 (1H,m), 7.38-7.47 (2H, m), 7.50-7.57 (2H, m), 7.63 (1H, dd, J=7.2, 1.5 Hz),7.77 (1H, dd, J=6.8, 1.5 Hz).

mp 253-255° C.

MS (API+), found: 353.1

X-ray powder diffraction pattern with specific peaks at d value (ord-spacing)=10.99, 7.23, 5.83, 5.05, 4.95, 4.69, 4.57, 4.19, 4.14 and4.01 Å.

Example 1689-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 1-bromo-4-(4-methylphenoxy)benzene

A mixture of 4-methylphenol (30.0 g), 1,4-dibromobenzene (54.5 g),copper(I) iodide (4.40 g), potassium carbonate (5.11 g) andN,N-dimethylglycine (2.86 g) in DMF (300 mL) was stirred at 100° C.under N₂ for 18 hr. The mixture was diluted with sat. NH₄Cl aq. at 0° C.and extracted with EtOAc. The organic layer was separated, washed withsat: NH₄Cl aq., 1N NaOH aq. and brine, dried over anhydrous magnesiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with hexane) to give the titlecompound (39.5 g) as a colorless solid.

¹H NMR (300 MHz, CDCl₃) δ 2.34 (3H, s), 6.83-6.91 (4H, m), 7.14 (2H, d,J=8.3 Hz), 7.40 (2H, d, J=9.0 Hz).

B) 4,4,5,5-tetramethyl-2-[4-(4-methylphenoxy)phenyl]-1,3,2-dioxaborolane

A mixture of 1-bromo-4-(4-methylphenoxy)benzene (37.0 g),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (42.8 g),potassium acetate (27.6 g) and[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (5.14 g) inDMF (370 mL) was stirred at 100° C. under N₂ for 16 hr. The mixture wasneutralized with sat. NaHCO₃ aq. at 0° C. and the solid was removed byfiltration, and the filtrate was extracted with EtOAc. The organic layerwas separated, washed with brine, dried over anhydrous magnesium sulfateand concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) to give thetitle compound (43.5 g) as an off-white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.33 (12H, s), 2.34 (3H, s), 6.88-6.99 (4H,m), 7.15 (2H, d, J=8.3 Hz), 7.76 (2H, d, J=8.7 Hz).

C) 3-[4-(4-methylphenoxy)phenyl]pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (12.5 g) was added to asuspension of 3-bromopyridin-2-amine (31.2 g),4,4,5,5-tetramethyl-2-[4-(4-methylphenoxy)phenyl]-1,3,2-dioxaborolane(72.8 g) and sodium carbonate (38.3 g) in 1,2-dimethoxyethane (500 mL)and water (250 mL) and the mixture was stirred at 100° C. under N₂ for16 hr. The mixture was diluted with water at room temperature andextracted with EtOAc-THF (3:1). The separated organic layer was washedwith brine, dried over anhydrous magnesium sulfate and concentrated invacuo. The residue was purified by column chromatography (NH silica gel,eluted with EtOAc in hexane) to give a crude product, which was washedwith diisopropyl ether to give the title compound (35.2 g) as acolorless solid.

MS (ESI+), found: 277.0.

¹H NMR (300 MHz, CDCl₃) δ 2.35 (3H, s), 4.54 (2H, brs), 6.74 (1H, dd,J=7.3, 5.1 Hz), 6.97 (2H, d, J=8.7 Hz), 7.05 (2H, d, J=8.7 Hz), 7.18(2H, d, J=8.3 Hz), 7.32-7.41 (3H, m), 8.06 (1H, dd, J=4.9, 1.9 Hz).

D)9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

2-Chloroethanesulfonyl chloride (19.5 mL) was added dropwise to amixture of NaH (60%, 12.5 g) in THF (100 mL) at 0° C. in an ice bath.After being stirred at 0° C. for 10 min, a solution of3-[4-(4-methylphenoxy)phenyl]pyridin-2-amine (17.2 g) in THF (100 mL)was added dropwise to the mixture at 0° C. The ice-bath was removed andthe mixture was stirred at room temperature under N₂ for 14 hr. Themixture was quenched with EtOH at 0° C. and water was added dropwise tothe mixture at 0° C. The mixture was stirred at room temperature for 1h. The precipitate was collected by filtration, and washed with waterand EtOAc to give the title compound (8.68 g) as colorless powder.

E)9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-[4-(4-Methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (10.4 g) was crystallized from DMSO-EtOH to give the titlecompound (8.04 g) as colorless crystals.

MS (ESI+), found: 367.1.

¹H NMR (300 MHz, DMSO-d₆) δ 2.29 (3H, s), 3.38-3.50 (2H, m), 4.58-4.68(2H, m), 6.68 (1H, t, J=7.0 Hz), 6.92-7.00 (4H, m), 7.21 (2H, d, J=8.0Hz), 7.45-7.53 (2H, m), 7.59 (1H, dd, J=7.1, 1.6 Hz), 7.75 (1H, dd,J=6.6, 1.6 Hz).

mp 248-250° C.

Anal. Calcd for C₂₀H₁₈N₂O₃S:C,65.55;H,4.95;N,7.64; S, 8.75. Found:C,65.56;H,5.02;N,7.63; S, 8.69.

X-ray powder diffraction pattern with specific peaks at d value (ord-spacing)=12.62, 7.78, 7.34, 6.96, 6.25, 5.89, 5.53, 5.16 Å.

Example 1699-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(cyclohexyloxy)phenyl)-5-methylpyrazin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (0.922 g) was added to asuspension of 3-bromo-5-methylpyrazin-2-amine (5 g),4-(cyclohexyloxy)phenylboronic acid (7.61 g) and sodium carbonatedecahydrate (15.2 g) in DME (200 mL) and water (40 mL) and the mixturewas stirred at 80° C. under nitrogen overnight. The insoluble materialwas removed by filtration (eluted with EtOAc), and silica-gel was addedand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith EtOAc in hexane) to give the title compound (7.5 g) as a paleorange solid.

MS (ESI+), found: 284.1.

B)9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 5.29 g) in THF (dry) (100 mL) was added2-chloroethanesulfonyl chloride (5.57 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(cyclohexyloxy)phenyl)-5-methylpyrazin-2-amine (7.5 g) in THF (dry)(75 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 2 days. The mixture was quenched withwater/THF at 0° C. carefully and water was added to form precipitateswhich were washed with EtOAc and water and dried in vacuo to give crudetitle compound (4.7 g). The part of this material (ca. 4.3 g) wascrystallized from DMSO (200 mL)-EtOH (40 ml)/water (400 mL) to give9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide as light-yellow crystals (3.6 g), which was recrystallizedfrom DMSO (100 mL)-EtOH (15 mL)/water (100 mL) at 80° C. to roomtemperature to give the title compound (3.09 g) as light-yellowcrystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.17-1.59 (6H, m), 1.62-1.82 (2H, m),1.85-2.03 (2H, m), 2.29 (3H, s), 3.42-3.55 (2H, m), 4.34-4.50 (1H, m),4.51-4.62 (2H, m), 6.99 (2H, d, J=8.7 Hz), 7.52 (1H, s), 8.00 (2H, d,J=8.7 Hz).

X-ray powder diffraction pattern with specific peaks at d value (ord-spacing)=23.99, 7.98, 5.99, 4.60, 3.99 and 3.42 Å.

Example 1709-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (15 mg) was added to a mixture of9-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (300 mg) in THF (dry) (10 mL) and MeOH (10 mL). The mixturewas stirred at room temperature under hydrogen overnight. The insolublesolid was removed by filtration through silica gel/Celite pad (elutedwith EtOAc) and the filtrate was concentrated in vacuo. The residue wascrystallized from THF/IPE to give the title compound (77.7 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.83 (3H, m), 1.85-2.12 (4H, m),3.24-3.29 (2H, m), 3.41-3.55 (2H, m), 3.74-3.90 (3H, m), 6.93-7.16 (4H,m), 7.25 (2H, d, J=8.3 Hz), 7.57 (2H, d, J=8.7 Hz). mp 171-172° C.

Anal. Calcd for C₂₁H₂₂N₂O₃SF₂:C,59.99;H,5.27;N,6.66. Found:C,60.06;H,5.51;N,6.44.

Example 1719-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-(4-(3-(1,1-difluoroethyl)phenoxy)phenyl)-5-methylpyridin-2-amine

Copper(I) iodide (39.2 mg) was added to a mixture of picolinic acid(25.4 mg), 4-(2-aminopyridin-3-yl)phenol (206 mg), tripotassiumphosphate (656 mg), 1-bromo-3-(1,1-difluoroethyl)benzene (239 mg) andDMSO (3 mL). The mixture was stirred at 130° C. under nitrogen for 10hr. The insoluble solid was removed by filtration through silicagel/Celite pad (eluted with EtOAc). Silica-gel was added to the filtrateand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (NH-silica gel, elutedwith EtOAc in hexane) to give the title compound (165 mg) as a yellowamorphous solid.

MS (ESI+), found: 341.1.

B)9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 96 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.101 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-(3-(1,1-difluoroethyl)phenoxy)phenyl)-5-methylpyridin-2-amine (164mg) in THF (dry) (10 mL) was added at 0° C. and the mixture was stirredat room temperature under nitrogen overnight. The mixture was quenchedwith water at 0° C. Water, EtOAc and THF were added and the mixture wasextracted. Silica-gel was added to the organic phase and the volatileswere removed in vacuo. The mixture supported on silica-gel was purifiedby column chromatography (silica gel, eluted with MeOH in EtOAc) andconcentrated in vacuo to give9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide as a white solid. Platinum(IV) oxide (30 mg) was added to asolution of the prepared9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide in THF (dry) (15 mL) and MeOH (15 mL). The mixture wasstirred at room temperature under hydrogen for 3 hr. Activated carbonwas added and the insoluble solid was removed by filtration throughsilica gel/Celite pad (eluted with EtOAc, to remove catalytic poison).Platinum(IV) oxide (30 mg) was added and the mixture was stirred at roomtemperature under hydrogen overnight. Activated carbon was added and theinsoluble solid was removed by filtration through silica gel/Celite pad(eluted with EtOAc) and the filtrate was concentrated in vacuo. Theresidue was crystallized from THF/IPE to give the title compound (47.6mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.95 (3H, d, J=6.4 Hz), 1.51 (1H, q, J=12.2Hz), 1.86-2.18 (5H, m), 3.19-3.26 (3H, m), 3.42 (1H, dd, J=12.1, 4.5Hz), 3.74-3.86 (3H, m), 6.97 (2H, d, J=8.7 Hz), 7.11 (1H, dd, J=8.1, 2.1Hz), 7.17-7.28 (3H, m), 7.33 (1H, d, J=7.2 Hz), 7.46-7.55 (1H, m).

Example 1729-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A diastereomer mixture (30 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (C18, mobile phase:water/acetonitrile(5 mM ammonium acetate-containing system)), a saturated aqueous sodiumhydrogen carbonate solution was added to a fraction having a longerretention time, and the mixture was extracted with ethyl acetate, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The obtained racemate (27 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (MB001), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/methanol=740/260) to give the title compound (14mg) with a shorter retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.95 (3H, d, J=6.4 Hz), 1.51 (1H, q, J=12.4Hz), 1.84-2.19 (5H, m), 3.13-3.26 (3H, m), 3.42 (1H, dd, J=11.9, 4.7Hz), 3.72-3.87 (3H, m), 6.97 (2H, d, J=8.3 Hz), 7.11 (1H, d, J=7.5 Hz),7.17-7.26 (3H, m), 7.33 (1H, d, J=7.9 Hz), 7.45-7.55 (1H, m).

Example 1739-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A diastereomer mixture (30 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (C18, mobile phase: water/acetonitrile(5 mM ammonium acetate-containing system)), a saturated aqueous sodiumhydrogen carbonate solution was added to a fraction having a longerretention time, and the mixture was extracted with ethyl acetate, driedover anhydrous magnesium sulfate and concentrated under reducedpressure. The obtained racemate (27 mg) of9-{4-[3-(1,1-difluoroethyl)phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (MB001), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/methanol=740/260) to give the title compound (14mg) with a longer retention time as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.95 (3H, d, J=6.4 Hz), 1.51 (1H, q, J=12.2Hz), 1.82-2.19 (5H, m), 3.13-3.26 (3H, m), 3.36-3.48 (1H, m), 3.69-3.88(3H, m), 6.97 (2H, d, J=8.3 Hz), 7.11 (1H, d, J=7.9 Hz), 7.17-7.26 (3H,m), 7.33 (1H, d, J=7.5 Hz), 7.45-7.56 (1H, m).

Example 1749-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (45 mg) was added to a mixture of9-(4-(1,1-difluoroethyl)phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (207 mg) in THF (dry) (120 mL) and MeOH (120 mL). Themixture was stirred at room temperature under hydrogen overnight.Activated carbon powder was added and the insoluble solid was removed byfiltration through silica gel/Celite pad (eluted with EtOAc) and thefiltrate was concentrated in vacuo. The residue was crystallized fromTHF/IPE to give the title compound (80.4 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-1.82 (3H, m), 1.86-2.09 (4H, m),3.23-3.29 (2H, m), 3.38-3.58 (2H, m), 3.72-3.91 (3H, m), 7.32 (2H, d,J=8.3 Hz), 7.50 (2H, d, J=8.3 Hz).

Example 1759-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (250 mg) and platinum(IV) oxide (25.9 mg) in MeOH (10 mL)was stirred at room temperature under H₂ for 20 hr. The reaction mixturewas filtered by Celite and the filtrate was concentrated in vacuo. Theresidue was recrystallized from EtOAc-MeOH to give the title compound(68.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.72-1.80 (3H, m), 1.97-2.06 (1H, m),3.25-3.32 (2H, m), 3.43-3.59 (2H, m), 3.78-3.96 (3H, m), 7.46 (2H, d,J=8.3 Hz), 7.68 (2H, d, J=8.3 Hz).

mp 226-227° C.

Anal. Calcd for C₁₄H₅N₂O₂SF₃-0.75H₂O:C,48.62;H,4.81;N,8.10. Found:C,48.29;H,4.39;N,7.99.

Example 1769-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45.3 mg) of9-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:hexane/ethanol=200/800) to give the title compound (23.3 mg) witha shorter retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.83-2.02 (3H, m), 2.07-2.23 (1H, m),3.24-3.33 (2H, m), 3.40-3.57 (2H, m), 3.84-4.03 (3H, m), 7.28 (2H, d,J=7.9 Hz), 7.58 (2H, d, J=7.9 Hz).

Example 1779-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45.3 mg) of9-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:hexane/ethanol=200/800) to give the title compound (21.3 mg) witha longer retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.79-2.01 (3H, m), 2.05-2.24 (1H, m), 3.30(2H, t, J=6.4 Hz), 3.49 (2H, q, J=6.4 Hz), 3.87-4.05 (3H, m), 7.27-7.32(2H, m), 7.59 (2H, d, J=8.3 Hz).

Example 1789-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (85.4 mg) of9-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:hexane/ethanol=500/500) to give the title compound (43.6 mg) witha shorter retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.79-2.01 (3H, m), 2.06-2.20 (1H, m),3.23-3.33 (2H, m), 3.39-3.54 (2H, m), 3.82-4.03 (3H, m), 7.11-7.23 (4H,m).

Example 1799-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (85.4 mg) of9-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:hexane/ethanol=500/500) to give the title compound (42.8 mg) witha longer retention time. Crystallization from THF and diisopropyl ethergave a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.80-2.01 (3H, m), 2.06-2.21 (1H, m),3.24-3.35 (2H, m), 3.41-3.55 (2H, m), 3.83-4.02 (3H, m), 7.13-7.22 (4H,m).

Example 1809-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(cyclohexyloxy)phenyl)-5-methylpyrazin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (55.3 mg) was added to asuspension of 3-bromo-5-methylpyrazin-2-amine (300 mg),4-(cyclohexyloxy)phenylboronic acid (456 mg) and sodium carbonate (338mg) in DME (15 mL) and water (3 mL) and the mixture was stirred at 100°C. under nitrogen for 2 hr. Water and EtOAc were added and the organiclayer was separated, washed with brine, dried over anhydrous sodiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) and washed withhexane/IPE to give the title compound (236 mg) as a white powder.

MS (ESI+), found: 284.3.

B)9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 100 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.263 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(cyclohexyloxy)phenyl)-5-methylpyrazin-2-amine (236 mg) in THF(dry) (10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 15 hr and at 50° C. for 1 hr. The mixturewas quenched with water at 0° C. carefully and water was added to formprecipitates. The precipitate was crystallized from THF/IPE to give thetitle compound (128 mg) as yellow crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.21-1.60 (6H, m), 1.62-1.79 (2H, m),1.88-2.01 (2H, m), 2.29 (3H, s), 3.45-3.55 (2H, m), 4.36-4.48 (1H, m),4.52-4.62 (2H, m), 6.99 (2H, d, J=8.7 Hz), 7.52 (1H, s), 8.00 (2H, d,J=8.7 Hz).

mp 216-217° C.

Anal. Calcd for C₁₉H₂₃N₃O₃S:C,61.10;H,6.21;N,11.25. Found:C,61.10;H,6.33;N,11.04.

Example 1819-[4-(2-methylpropoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(200 mg), potassium carbonate (260 mg) in DMSO (4 mL) was added1-iodo-2-methylpropane (173 mg). The mixture was stirred at 130° C. for1 hr. Another 1-iodo-2-methylpropane (0.10 mL) was added and the mixturewas stirred at room temperature overnight. 0.5N NaOHaq, EtOAc and THFwere added and the extracted organic layer was washed with water andbrine, dried over anhydrous sodium sulfate and concentrated in vacuo.The residue was crystallized from THF-MeOH/IPE to give the titlecompound (104 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.99 (6H, d, J=6.4 Hz), 1.95-2.11 (1H, m),3.41-3.51 (2H, m), 3.78 (2H, d, J=6.8 Hz), 4.60-4.71 (2H, m), 6.65-6.72(1H, m), 6.96 (2H, d, J=8.7 Hz), 7.45 (2H, d, J=8.7 Hz), 7.58 (1H, dd,J=7.2, 1.5 Hz), 7.74 (1H, dd, J=6.6, 1.5 Hz).

Example 182 9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide A)3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine

DEAD (in toluene) (1.57 mL) was added dropwise to a solution oftriphenylphosphine (909 mg), 4-(2-aminopyridin-3-yl)phenol (430 mg) andcyclohexanol (0.369 mL) in THF (dry) (15 mL) at room temperature and themixture was stirred for 2 hr. Another DEAD, triphenylphosphine andcyclohexanol were added (0.5 eq, respectively) and the mixture wasstirred at room temperature for 2 hr. The mixture was concentrated invacuo and the residue was purified by column chromatography (NH silicagel, eluted with EtOAc in hexane, and silica gel, eluted with EtOAc inhexane) to give the title compound (172 mg) as a white solid.

MS (ESI+), found: 269.1.

B)9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 127 mg) in THF (dry) (5 mL) was added2-chloroethanesulfonyl chloride (0.200 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine (170 mg) in THF (dry) (5 mL)was added at 0° C. and the mixture was stirred at room temperature undernitrogen overnight. The mixture was quenched with water at 0° C.carefully. Water was added to form precipitates which were washed withwater and hexane, collected and dried in vacuo to give the titlecompound (148 mg) as a white powder. A part of this product wascrystallized from MeCN-THF/IPE to give a colorless crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.59 (6H, m), 1.67-1.80 (2H, m),1.88-2.01 (2H, m), 3.39-3.50 (2H, m), 4.31-4.45 (1H, m), 4.58-4.70 (2H,m), 6.68 (1H, t, J=7.0 Hz), 6.95 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7Hz), 7.58 (1H, dd, J=7.2, 1.5 Hz), 7.70-7.79 (1H, m).

mp 272-274° C.

Anal. Calcd for C₁₉H₂₂N₂O₃S-0.2H₂O:C,63.03; H,6.24;N,7.74. Found:C,63.01;H,6.29;N,7.58.

Example 1832-chloro-4-[(4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]benzonitrile

Potassium carbonate (73.9 mg) was added to a mixture of4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(50 mg) and 2-chloro-4-fluorobenzonitrile (41.6 mg) in DMF (dry) (1 mL).The mixture was stirred at 60° C. under atmosphere overnight. Themixture was quenched with water and extracted with EtOAc. The organiclayer was separated, washed with water and brine, dried over anhydrousmagnesium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with MeOH in EtOAc) andconcentrated. The residue was crystallized from MeCN-THF/IPE to give thetitle compound (32.2 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.83 (3H, m), 1.99-2.07 (1H, m),3.23-3.28 (2H, m), 3.42-3.55 (2H, m), 3.78-3.89 (3H, m, J=4.5 Hz), 7.04(1H, dd, J=8.7, 2.3 Hz), 7.15 (2H, d, J=8.7 Hz), 7.28-7.37 (3H, m), 7.96(1H, d, J=9.1 Hz).

mp 219-220° C.

Anal. Calcd for C₂₀H₁₈N₃O₃SCl:C,57.76;H,4.36;N,10.10. Found:C,57.73;H,4.47;N,9.90.

Example 1842-chloro-4-[4-(9-hydroxy-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]benzonitrile

Crude title compound was obtained as a byproduct of Example 183. Thetitle compound (2.1 mg) was obtained as a white solid by crystallizationfrom THF and diisopropyl ether.

¹H NMR (300 MHz, DMSO-d₆) δ 1.48-1.67 (1H, m), 1.85-2.04 (3H, m), 3.51(2H, t, J=5.9 Hz), 3.77-3.93 (2H, m), 5.96-6.05 (1H, m), 7.03 (1H, dd,J=8.7, 2.3 Hz), 7.16 (2H, d, J=9.1 Hz), 7.30 (1H, d, J=2.3 Hz), 7.48(2H, d, J=8.7 Hz), 7.97 (1H, d, J=9.1 Hz). 2 protons were hidden in apeak of water.

Example 1859-(4-phenylcyclohexyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) tert-butyl (3-bromopyridin-2-yl)carbamate

A solution of 3-bromopyridin-2-amine (5.8 g) in t-BuOH (25 mL) was addedto a solution of di-tert-butyl dicarbonate (8.78 g) in t-BuOH (45 mL) at0° C. The mixture was stirred at room temperature overnight and 65° C.overweekend. The reaction mixture was concentrated in vacuo. The residuewas purified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (5.99 g) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.55 (9H, s), 6.89 (1H, dd, J=7.9, 4.9 Hz),7.30 (1H, brs), 7.82 (1H, dd, J=7.7, 1.7 Hz), 8.41 (1H, dd, J=4.9, 1.5Hz).

B) tert-butyl [3-(1-hydroxy-4-phenylcyclohexyl)pyridin-2-yl]carbamate

To a solution of tert-butyl (3-bromopyridin-2-yl)carbamate (4 g) in THF(dry) (20 mL) was added dropwise n-butyllithium (1.6 M in hexane) (20.1mL) at −78° C. and the mixture was stirred at the same temperature undernitrogen for 1 hr to give a yellow suspension. A solution of4-phenylcyclohexanone (3.06 g) in THF (dry) (30 mL) was added dropwiseat −78° C. and the mixture was stirred at room temperature undernitrogen overnight. The mixture was quenched with water at 0° C. andextracted with EtOAc. The organic layer was separated, washed with brineand dried over anhydrous sodium sulfate and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give the title compound (560 mg) as a pale yellowsolid.

MS (ESI+), found: 369.2.

C) 1-(2-aminopyridin-3-yl)-4-phenylcyclohexanol

4N HCl-EtOAc (5 mL) was added to tert-butyl[3-(1-hydroxy-4-phenylcyclohexyl)pyridin-2-yl]carbamate (450 mg) and themixture was stirred at room temperature overnight. The resultedprecipitates were collected and dried in vacuo to give1-(2-aminopyridin-3-yl)-4-phenylcyclohexanol hydrochloride.

1-(2-aminopyridin-3-yl)-4-phenylcyclohexanol hydrochloride

¹H NMR (300 MHz, DMSO-d₆) δ 1.44-1.71 (2H, m), 1.77-2.03 (4H, m),2.23-2.38 (2H, m), 2.69-2.85 (1H, m), 5.80-6.05 (1H, m), 6.83-6.98 (1H,m), 7.07-7.38 (5H, m), 7.61-7.89 (2H, m), 7.91-8.12 (2H, m), 13.34-13.80(1H, m).

This material was resolved in EtOAc and washed with sat. NaHCO₃aq. andNaOH aq. The organic layer was separated, washed with brine, dried overanhydrous magnesium sulfate and concentrated in vacuo to give1-(2-aminopyridin-3-yl)-4-phenylcyclohexanol (246 mg) as a colorlessoil.

D) 3-(4-phenylcyclohexyl)pyridin-2-amine

TFA (3 mL) was added to 1-(2-aminopyridin-3-yl)-4-phenylcyclohexanol(246 mg) and the mixture was stirred at 40° C. under nitrogen for 6 hr.TFA was removed in vacuo and this product was subjected to the nextreaction without further purification. MeOH (1 mL) and Pd/C (10 mg) wereadded and the mixture was stirred at room temperature under hydrogen for2 days. The insoluble solid was removed by filtration through Celite-pad(eluted with EtOAc) and the filtrate was concentrated in vacuo. Theresidue was purified by column chromatography (NH silica gel, elutedwith EtOAc in hexane) to give the title compound (38.6 mg) as colorlessoil.

¹H NMR (300 MHz, CDCl₃) δ 1.63-1.92 (5H, m), 1.95-2.14 (2H, m),2.28-2.43 (2H, m), 2.53-2.67 (1H, m), 5.52 (2H, brs), 6.62 (1H, dd,J=7.9, 4.9 Hz), 7.18-7.25 (1H, m), 7.28-7.37 (4H, m), 7.40 (1H, dd,J=7.6, 1.5 Hz), 7.98 (1H, dd, J=4.9, 1.9 Hz).

E) 9-(4-phenylcyclohexyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 29.2 mg) in THF (dry) (2 mL) was added2-chloroethanesulfonyl chloride (0.046 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-phenylcyclohexyl)pyridin-2-amine (36.8 mg) in THF (dry) (2 mL) wasadded at 0° C. and the mixture was stirred at room temperature undernitrogen overnight. The mixture was quenched with water at 0° C.carefully and extracted with EtOAc. The organic layer was separated,washed with brine, dried over anhydrous sodium sulfate and concentratedin vacuo. The residue was purified by column chromatography (silica gel,eluted with EtOAc in hexane) and crystallized from EtOAc-hexane to givethe title compound (15.7 mg) as an off-white crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.52-2.13 (8H, m), 2.85-3.11 (2H, m),3.37-3.53 (2H, m), 4.50-4.69 (2H, m), 6.52-6.69 (1H, m), 7.11-7.25 (1H,m), 7.27-7.38 (4H, m), 7.44-7.58 (1H, m), 7.58-7.72 (1H, m).

Example 1869-{[4-(1-methylpropyl)phenoxy]methyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-{[4-(1-methylpropyl)phenoxy]methyl}pyridin-2-amine

The solution of (2-aminopyridin-3-yl)methanol (1.0 g) in THF (dry) (10mL) was added dropwise to a solution of thionyl chloride (0.736 mL) inTHF (dry) (30 mL) at 0° C. The mixture was stirred at room temperaturefor 30 min and concentrated in vacuo to give3-(chloromethyl)pyridin-2-amine hydrochloride as a yellow gum. NaH (60%,147 mg) was added to a mixture of 4-(1-methylpropyl)phenol (503 mg) inDMF (dry) (7 mL) at 0° C. The mixture was stirred at the sametemperature for 20 min, then was added with the prepared3-(chloromethyl)pyridin-2-amine hydrochloride (300 mg) at the sametemperature. The mixture was stirred at 0° C. for 20 min, roomtemperature for 1 hr and 60° C. for 1 hr. Silica-gel was added to themixture and the volatiles were removed in vacuo. The mixture supportedon silica-gel was purified by column chromatography (silica gel, elutedwith EtOAc in hexane) to give the title compound (151 mg) as pale yellowcrystals.

MS (ESI+), found: 257.1.

B)9-{[4-(1-methylpropyl)phenoxy]methyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 117 mg) in THF (dry) (4 mL) was added2-chloroethanesulfonyl chloride (0.185 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-{[4-(1-methylpropyl)phenoxy]methyl}pyridin-2-amine (150 mg) in THF(dry) (4 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen for 1 day. The mixture was quenched withwater at 0° C. carefully. EtOAc and THF were added and the organic layerwas separated, washed with brine, dried over anhydrous sodium sulfateand concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane) andcrystallized from THF/IPE to give the title compound (34.9 mg) ascolorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (3H, t, J=7.4 Hz), 1.15 (3H, d, J=6.8Hz), 1.43-1.60 (2H, m), 2.54-2.57 (1H, m), 3.39-3.54 (2H, m), 4.53-4.68(2H, m), 4.85 (2H, s), 6.63-6.76 (1H, m), 6.91 (2H, d, J=8.7 Hz), 7.12(2H, d, J=8.7 Hz), 7.69 (1H, d, J=7.2 Hz), 7.76 (1H, d, J=6.8 Hz).

Example 1879-{4-[3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(3-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine

Copper(I) iodide (61.4 mg) was added to a mixture of tripotassiumphosphate (1026 mg), picolinic acid (39.7 mg),4-(2-aminopyridin-3-yl)phenol (300 mg) and1-iodo-3-(trifluoromethyl)benzene (526 mg) in DMSO (6 mL). The mixturewas stirred at 120° C. under nitrogen for 2 hr. The mixture was purifiedby column chromatography (silica gel, eluted with EtOAc in hexane) togive the title compound (348 mg) as a pale yellow solid.

MS (ESI+), found: 331.2.

B)9-{4-[3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 210 mg) in THF (dry) (10 mL) was added2-chloroethanesulfonyl chloride (0.331 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(4-(3-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine (347 mg) in THF(dry) (10 mL) was added at 0° C. and the mixture was stirred at roomtemperature under nitrogen overnight. The mixture was quenched withwater at 0° C. carefully. Water was added to form precipitates whichwere washed with water and hexane, collected and dried in vacuo to givethe title compound (234 mg) as a white powder. A part of this productwas crystallized from MeCN-THF/IPE as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.53 (2H, m), 4.59-4.71 (2H, m), 6.72(1H, t, J=7.0 Hz), 7.12 (2H, d, J=9.1 Hz), 7.33-7.44 (2H, m), 7.49-7.56(1H, m), 7.57-7.69 (4H, m), 7.79 (1H, dd, J=6.6, 1.7 Hz).

Example 1889-{4-[(4,4-dimethylcyclohex-1-en-1-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-(4-((4,4-dimethylcyclohex-1-en-1-yl)oxy)phenyl)pyridin-2-amine

Copper(I) iodide (102 mg) was added to a mixture of picolinic acid (66.1mg), 4-(2-aminopyridin-3-yl)phenol (500 mg), tripotassium phosphate(1710 mg), 1-bromo-4,4-dimethylcyclohex-1-ene (609 mg) and DMSO (8 mL).The mixture was stirred at 130° C. under nitrogen for 16 hr. Theinsoluble solid was removed by filtration through silica gel/Celite pad(eluted with EtOAc). Silica-gel was added to the filtrate and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH-silica gel, eluted with EtOAc inhexane) to give the title compound (563 mg) as an off-white amorphoussolid.

MS (ESI+), found: 295.1.

B)9-{4-[(4,4-dimethylcyclohex-1-en-1-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 382 mg) in THF (dry) (30 mL) was added2-chloroethanesulfonyl chloride (0.402 mL) at 0° C. and the mixture wasstirred for 10 min at the same temperature. A solution of3-(4-((4,4-dimethylcyclohex-1-en-1-yl)oxy)phenyl)pyridin-2-amine (563mg) in THF (dry) (30 mL) was added at 0° C. and the mixture was stirredat room temperature under nitrogen for 3 hr. The mixture was quenchedwith water at 0° C. Water and EtOAc were added and the mixture wasextracted. Silica-gel was added to the organic phase and the volatileswere removed in vacuo. The mixture supported on silica-gel was purifiedby column chromatography (silica gel, eluted with MeOH in EtOAc) andconcentrated in vacuo to give the title compound (369 mg) as a paleyellow solid. A part of the product was crystallized from MeCN/IPE togive a pale yellow crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 0.97 (6H, s), 1.49 (2H, t, J=6.4 Hz),1.83-1.94 (2H, m), 2.07-2.18 (2H, m), 3.40-3.51 (2H, m), 4.59-4.70 (2H,m), 5.03 (1H, t, J=3.8 Hz), 6.70 (1H, t, J=7.0 Hz), 6.99 (2H, d, J=8.7Hz), 7.50 (2H, d, J=8.7 Hz), 7.60 (1H, d, J=6.4 Hz), 7.76 (1H, d, J=5.7Hz).

Example 1899-{4-[(4,4-dimethylcyclohexyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Platinum(IV) oxide (40 mg) was added to a solution of9-{4-[(4,4-dimethylcyclohex-1-en-1-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (340 mg) in THF (dry) (30 mL), NeOH (30 mL) and AcOH (10mL). The mixture was stirred at room temperature under hydrogenovernight. Activated carbon was added and the insoluble solid wasremoved by filtration through silica gel/Celite pad (eluted with EtOAc,to remove catalytic poison). Platinum(IV) oxide (40 mg) was added andthe mixture was stirred at 50° C. under hydrogen for 6 hr. Platinum(IV)oxide was added and the mixture was stirred 50° C. under hydrogen for 12hr. The insoluble solid was removed by filtration through silicagel/Celite pad (eluted with EtOAc) and the filtrate was concentrated invacuo with silica-gel. The mixture supported on silica-gel was purifiedby column chromatography (silica gel, eluted with MeOH in EtOAc) andconcentrated in vacuo. The residue was crystallized from EtOAc/hexane.This was dissolved in THF, silica-gel was added to the solution and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (silica gel, eluted with MeOH inEtOAc). The residue was crystallized from THF-EtOAc/IPE to give thetitle compound (37.6 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 0.83-1.02 (6H, m), 1.19-1.34 (2H, m),1.37-2.14 (10H, m), 3.22-3.29 (2H, m), 3.38-3.55 (2H, m, J=12.7, 6.4,6.4, 6.4 Hz), 3.63-3.90 (3H, m), 4.21-4.34 (1H, m), 6.81-6.92 (2H, m),7.02-7.18 (2H, m).

Example 1909-(4-propoxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-(4-propoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (300 mg) and platinum(IV) oxide (32.1 mg) in MeOH (10 mL)was stirred at room temperature under H₂ for 20 hr. The reaction mixturewas filtered by Celite and the filtrate was concentrated in vacuo. Theresidue was recrystallized from EtOAc-MeOH to give the title compound(114 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.97 (3H, t, J=7.4 Hz), 1.67-1.78 (5H, m),1.90-2.03 (1H, m), 3.23-3.29 (2H, m), 3.41-3.51 (2H, m), 3.69 (1H, t,J=5.3 Hz), 3.81 (2H, q, J=5.8 Hz), 3.90 (2H, t, J=6.4 Hz), 6.86 (2H, d,J=8.7 Hz), 7.09 (2H, d, J=8.7 Hz).

mp 169-170° C.

Anal. Calcd for C₁₆H₂₂N₂O₃S-0.75H₂O:C,57.21; H,7.05;N,8.34. Found:C,57.21;H,6.56;N,8.33.

Example 1919-(6-phenoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 6′-fluoro-3,3′-bipyridin-2-amine

A mixture of sodium carbonate (5.79 g),tetrakis(triphenylphosphine)palladium(0) (0.631 g),6-fluoropyridin-3-ylboronic acid (5 g) and 3-bromopyridin-2-amine (4.72g) in DME (75 mL) and water (15 mL) was stirred at 80° C. overnight. Themixture was poured into water and extracted with EtOAc. The organiclayer was separated, washed with brine, dried over anhydrous magnesiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica gel, eluted with EtOAc in hexane, then NH silicagel, eluted with EtOAc in hexane) to give the title compound (4.53 g) asa colorless solid.

MS (API+), found: 190.0

B) 6′-phenoxy-3,3′-bipyridin-2-amine

A mixture of potassium carbonate (3287 mg), phenol (821 mg) and6′-fluoro-3,3′-bipyridin-2-amine (1500 mg) in DMSO (15 mL) was stirredfor 1 hr at 150° C. The mixture was poured into water and extracted withEtOAc. The organic layer was separated, washed with brine, dried overanhydrous magnesium sulfate and concentrated in vacuo. The residue waspurified by column chromatography (NH silica gel, eluted with EtOAc inhexane) to give the title compound (1750 mg) as a yellow solid.

MS (API+), found: 264.1

C) 9-(6-phenoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 6′-phenoxy-3,3′-bipyridin-2-amine (350 mg) in THF (dry) (15mL) was added to a mixture of NaH (60%, 266 mg) and2-chloroethanesulfonyl chloride (542 mg) in THF (dry) (15.0 ml) at roomtemperature. The mixture was stirred at 50° C. overnight. The mixturewas poured into water and extracted with EtOAc. The organic layer wasseparated, washed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(NH silica gel, eluted with MeOH in EtOAc) to give the title compound(419 mg) as a pale yellow solid. The solid was crystallized fromCH₃CN-IPE to give a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.40-3.55 (2H, m), 4.57-4.71 (2H, m), 6.72(1H, t, J=7.0 Hz), 7.08 (1H, d, J=8.7 Hz), 7.14-7.20 (2H, m), 7.20-7.28(1H, m), 7.36-7.50 (2H, m), 7.70 (1H, dd, J=7.2, 1.5 Hz), 7.80 (1H, dd,J=6.8, 1.5 Hz), 8.03 (1H, dd, J=8.5, 2.4 Hz), 8.23 (1H, d, J=2.3 Hz).

mp 244-245° C.

Anal. Calcd for C₁₈H₁₅N₃O₃S:C,61.18;H,4.28;N,11.89. Found:C,60.98;H,4.39;N,11.89.

Example 1929-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 3-(4-phenoxyphenyl)pyridin-2-amine (301 mg) inN,N-dimethylacetoamide (3 mL) was added dropwise to2-chloroethanesulfonyl chloride (382 mg) and additionalN,N-dimethylacetoamide (2 mL) was used to complete the addition of abovesolution. After being stirred at 60° C. for 4 hr, the mixture was cooledto room temperature. Water (10 mL) was added dropwise to the reactionmixture and the whole was stirred at room temperature for 0.5 hr. Theprecipitate was collected by filtration, washed with water (10 mL) andTHF (3 mL), and dried in vacuo at 60° C. to give the title compound(346.7 mg) as an off-white powder.

MS (ESI+), found: 353.2.

¹H NMR (300 MHz, DMSO-d₆) δ 3.40-3.54 (2H, m), 4.59-4.73 (2H, m),6.65-6.79 (1H, m), 6.96-7.14 (4H, m), 7.14-7.27 (1H, m), 7.34-7.50 (2H,m), 7.50-7.60 (2H, m), 7.60-7.71 (1H, m), 7.74-7.83 (1H, m).

Example 1939-(4-tert-butylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 3-(4-tert-butylphenyl)pyridin-2-amine (301 mg) inN,N-dimethylacetoamide (4 mL) was added dropwise to2-chloroethanesulfonyl chloride (437 mg) and additionalN,N-dimethylacetoamide (1 mL) was used to complete the addition of abovesolution. After being stirred at 60° C. for 3 hr, the mixture was cooledto room temperature. Water (10 mL) was added dropwise to the reactionmixture and the whole was stirred at room temperature for 0.5 hr. Theprecipitate was collected by filtration, washed with water (10 mL) anddiisopropyl ether (3 mL), and dried in vacuo at 60° C. to give the titlecompound (366 mg) as an off-white powder.

MS (ESI+), found: 317.2.

¹H NMR (300 MHz, DMSO-d₆) δ 1.31 (9H, s), 3.38-3.52 (2H, m), 4.52-4.75(2H, m), 6.70 (1H, t, J=6.8 Hz), 7.35-7.53 (4H, m), 7.61 (1H, dd, J=7.2,1.5 Hz), 7.76 (1H, dd, J=6.8, 1.5 Hz).

Example 1949-(3-fluorobiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 2-chloroethanesulfonyl chloride (208.2 mg) inN,N-dimethylacetoamide (2 mL) was added dropwise to a suspension of3-(3-fluorobiphenyl-4-yl)pyridin-2-amine (149.5 mg) inN,N-dimethylacetoamide (2 mL) and additional N,N-dimethylacetoamide (1mL) was used to complete the addition of above solution. After beingstirred at 60° C. for 3 h, the mixture was cooled to room temperature.Water (10 mL) was added dropwise to the reaction mixture and the wholewas stirred at room temperature for 0.5 hr. The precipitate wascollected by filtration, washed with water (10 mL) and THF (3 mL), anddried in vacuo at 60° C. to give the title compound (143 mg) as anoff-white powder.

MS (ESI+), found: 355.1.

¹H NMR (300 MHz, DMSO-d₆) δ 3.46-3.54 (2H, m), 4.63-4.72 (2H, m), 6.75(1H, t, J=7.0 Hz), 7.39-7.64 (8H, m), 7.76 (1H, dd, J=7.2, 1.9 Hz), 7.83(1H, dd, J=6.8, 1.5 Hz).

Example 1959-(6-phenoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 2-chloroethanesulfonyl chloride (386 mg) inN,N-dimethylacetoamide (2 mL) was added dropwise to a solution of6′-phenoxy-3,3′-bipyridin-2-amine (302 mg) in N,N-dimethylacetoamide (2mL) and additional N,N-dimethylacetoamide (1 mL) was used to completethe addition of above solution. After being stirred at 60° C. for 4 h,the mixture was cooled to room temperature. Water (10 mL) was addeddropwise to the reaction mixture and the whole was stirred at roomtemperature for 0.5 hr. The precipitate was collected by filtration,washed with water (10 mL) and diisopropyl ether (3 mL), and dried invacuo at 60° C. to give the title compound (323 mg) as an off-whitepowder.

MS (ESI+), found: 354.2.

¹H NMR (300 MHz, DMSO-d₆) δ3.40-3.55 (2H, m), 4.57-4.71 (2H, m), 6.72(1H, t, J=7.0 Hz), 7.08 (1H, d, J=8.7 Hz), 7.14-7.20 (2H, m), 7.20-7.28(1H, m), 7.36-7.50 (2H, m), 7.70 (1H, dd, J=7.2, 1.5 Hz), 7.80 (1H, dd,J=6.8, 1.5 Hz), 8.03 (1H, dd, J=8.5, 2.4 Hz), 8.23 (1H, d, J=2.3 Hz).

Example 1969-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 2-chloroethanesulfonyl chloride (381 mg) inN,N-dimethylacetoamide (2 mL) was added dropwise to a suspension of3-[4-(cyclohexyloxy)phenyl]pyridin-2-amine (301 mg) inN,N-dimethylacetoamide (2 mL) and additional N,N-dimethylacetoamide (1mL) was used to complete the addition of above solution. After beingstirred at 60° C. for 3 hr, the mixture was cooled to room temperature.Water (10 mL) was added dropwise to the reaction mixture and the wholewas stirred at room temperature for 0.5 hr. The precipitate wascollected by filtration, washed with water (10 mL) and diisopropyl ether(3 mL), and dried in vacuo at 60° C. to give the title compound (342 mg)as an off-white powder.

MS (ESI+), found: 359.2.

¹H NMR (300 MHz, DMSO-d₆) δ 1.19-1.59 (6H, m), 1.67-1.80 (2H, m),1.88-2.01 (2H, m), 3.39-3.50 (2H, m), 4.31-4.45 (1H, m), 4.58-4.70 (2H,m), 6.68 (1H, t, J=7.0 Hz), 6.95 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7Hz), 7.58 (1H, dd, J=7.2, 1.5 Hz), 7.70-7.79 (1H, m).

Example 1979-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

2-Chloroethanesulfonyl chloride (0.885 g) in N,N-dimethylacetoamide (7.0mL) was added dropwise to a solution of3-[4-(4-methylphenoxy)phenyl]pyridin-2-amine (1.00 g) inN,N-dimethylacetoamide (3.0 mL) at 0° C. The mixture was stirred at 70°C. under N₂ overnight. EtOAc and IPE was added dropwise to the mixtureat room temperature. The solid was isolated by filtration and washedwith water, IPE and EtOAc to give the title compound (1.07 g) as a graysolid.

B)9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-[4-(4-Methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was crystallized from DMSO-EtOH to give the title compound(0.870 g) as colorless crystals.

MS (ESI+), found: 367.1.

¹H NMR (300 MHz, DMSO-d₆) δ 2.30 (3H, s), 3.39-3.53 (2H, m), 4.58-4.73(2H, m), 6.70 (1H, t, J=7.0 Hz), 6.98 (4H, dd, J=8.9, 3.2 Hz), 7.22 (2H,d, J=8.3 Hz), 7.51 (2H, d, J=9.0 Hz), 7.61 (1H, dd, J=7.2, 1.5 Hz), 7.76(1H, dd, J=6.8, 1.5 Hz).

Example 1984-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]phenolA)9-[4-(4-{[tert-butyl(dimethyl)silyl]oxy}phenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 4-(tert-butyldimethylsilyloxy)phenylboronic acid (6.11 g),4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(2.23 g), triethylamine (5.61 ml), diacetoxycopper (2.93 g), and 4A MS(2.0 g) in DMF (80 mL) was stirred at room temperature overnight. Themixture was added with silica gel, concentrated in vacuo, and purifiedby column chromatography (silica gel, eluted with EtOAc in hexane) togive the title compound (1.82 g) as a white solid.

MS (ESI+), found: 483.2.

B)4-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]phenol

A solution of9-[4-(4-{[tert-butyl(dimethyl)silyl]oxy}phenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (1.82 g) in THF (dry) (55 mL) was added totetrabutylammonium fluoride(1 M in THF) (6.79 mL) at room temperature.After stirring for 0.5 hr, the mixture was added with sat.NH₄Cl aq. andsilica gel, then concentrated in vacuo. The residue was purified bycolumn chromatography (silica gel, eluted with EtOAc in hexane then MeOHin EtOAc), recrystallized from THF-IPE, then preparative HPLC (C18,eluent; H₂O/MeCN with 0.1% TFA). The collected fraction was concentratedin vacuo. The residue was recrystallized from MeCN—H₂O to give the titlecompound (492 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.49 (2H, m), 4.60-4.68 (2H, m), 6.69(1H, t, J=7.0 Hz), 6.77-6.84 (2H, m), 6.87-6.97 (4H, m), 7.44-7.50 (2H,m), 7.59 (1H, dd, J=7.2, 1.9 Hz), 7.75 (1H, dd, J=6.8, 1.9 Hz), 9.39(1H, s).

mp 289-290° C.

Anal. Calcd for C₁₉H₁₆N₂O₄S:C,61.94;H,4.38;N,7.60. Found:C,61.86;H,4.42;N,7.64.

Example 1999-[4-(4-fluorophenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 4-fluorophenylboronic acid (365 mg),4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(240 mg), diacetoxycopper (316 mg), triethylamine (0.60 mL), andpowdered 4A MS (1.5 g) in DMF (10 mL) was stirred at room temperatureovernight. The mixture was added with NH silica gel, concentrated invacuo, and purified by column chromatography (NH silica gel, eluted withMeOH in EtOAc) to give the title compound (139 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.49 (2H, m), 4.61-4.68 (2H, m),6.67-6.73 (1H, m), 7.00 (2H, d, J=8.7 Hz), 7.10-7.30 (4H, m), 7.53 (2H,d, J=8.7 Hz), 7.62 (1H, dd, J=7.2, 1.5 Hz), 7.73-7.81 (1H, m).

mp 266-267° C.

Anal. Calcd for C₁₉H₁₅N₂O₃SF:C,61.61;H,4.08;N,7.56. Found:C,61.67;H,4.17;N,7.60.

Example 2009-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 4-(trifluoromethyl)phenylboronic acid (495 mg),4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(240 mg), diacetoxycopper (316 mg), triethylamine (0.60 mL), andpowdered 4A MS (1.5 g) in DMF (10 mL) was stirred at room temperatureovernight. The mixture was added with NH silica gel, concentrated invacuo, and purified by column chromatography (NH silica gel, eluted withMeOH in EtOAc) to give the title compound (45 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.43-3.51 (2H, m), 4.62-4.70 (2H, m), 6.72(1H, t, J=7.0 Hz), 7.14-7.26 (4H, m), 7.58-7.69 (3H, m), 7.72-7.82 (3H,m).

mp 253-255° C.

Anal. Calcd for C₂₀H₁₅N₂O₃SF₃:C,57.14;H,3.60;N,6.66. Found:C,57.21;H,3.73;N,6.68.

Example 2019-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-chlorophenylboronic acid (167 mg),4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(100 mg), diacetoxycopper (130 mg), triethylamine (0.248 mL), andpowdered 4A MS (1.00 g) in MeCN (10 mL) was stirred at room temperatureovernight. The mixture was added with NH silica gel, concentrated invacuo, and purified by column chromatography (NH silica gel, eluted withMeOH in EtOAc), and then recrystallized from EtOAc-IPE to give the titlecompound (37.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.83 (3H, m), 1.96-2.08 (1H, m),3.24-3.29 (2H, m), 3.42-3.53 (2H, m), 3.75-3.87 (3H, m), 6.94-7.04 (3H,m), 7.07 (1H, t, J=2.3 Hz), 7.16-7.29 (3H, m), 7.36-7.45 (1H, m).

mp 165-167° C.

Anal. Calcd for C₁₉H₁₉N₂O₃SCl:C,58.38;H,4.90;N,7.17. Found:C,58.38;H,5.03;N,6.96.

Example 202(9R)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)(9S)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide(9R)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

9-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (28.8 g) was separated by preparative HPLC (column;CHIRALPAK AS (CC001), 50 mmID×500 mL, DAICEL CHEMICAL INDUSTRIES, LTD.,eluent; MeCN/2-propanol=100/900) to give(9S)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (13.7 g) as a white solid and(9R)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (11.8 g) as a white solid.

(9S)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

MS (ESI+), found: 395.2.

(9R)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

MS (ESI+), found: 395.2.

B)(9R)-9-(4-hydroxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of(9R)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (11.8 g) and 6 M HCl aq. (15.0 mL) in MeOH (100 mL) wasstirred at 60° C. for 2 hr. After cooling to room temperature, theprecipitate was collected and washed with MeOH to give the titlecompound (8.04 g) as a white solid.

MS (ESI+), found: 281.0.

C)(9R)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of 3-chlorophenylboronic acid (167 mg),(9R)-9-(4-hydroxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (100 mg), diacetoxycopper (130 mg), triethylamine (0.248mL), and powdered 4A MS (1.50 g) in DMF (10 mL) was stirred at roomtemperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) to give the title compound (32.0 mg) asa white solid.

¹H NMR (300 MHz, DMSO-d₆) δ1.70-1.80 (3H, m), 1.95-2.06 (1H, m),3.23-3.29 (2H, m), 3.48 (2H, q, J=6.3 Hz), 3.76-3.86 (3H, m), 6.94-7.03(3H, m), 7.07 (1H, t, J=2.3 Hz), 7.15-7.28 (3H, m), 7.36-7.46 (1H, m).

Example 203(9S)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol

A mixture of(9S)-9-(4-((tert-butyldimethylsilyl)oxy)phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (13.7 g) and 6 M HCl aq. (17.4 mL) in MeOH (350 mL) wasstirred at 60° C. for 2 hr. After cooling to room temperature, theprecipitate was collected and washed with MeOH to give the titlecompound (8.20 g) as a white solid.

MS (ESI+), found: 281.0.

B)(9S)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3-chlorophenyl)boronic acid (167 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(100 mg), diacetoxycopper (130 mg), triethylamine (0.248 mL), andpowdered 4A MS (1.50 g) in DMF (10 mL) was stirred at room temperatureovernight. The mixture was added with NH silica gel, concentrated invacuo, and purified by column chromatography (NH silica gel, eluted withMeOH in EtOAc) to give the title compound (34.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.71-1.80 (3H, m), 2.02 (1H, d, J=6.1 Hz),3.24-3.29 (2H, m), 3.48 (2H, q, J=6.4 Hz), 3.76-3.86 (3H, m), 6.94-7.03(3H, m), 7.07 (1H, t, J=2.3 Hz), 7.17-7.28 (3H, m), 7.36-7.45 (1H, m).

Anal. Calcd for C₁₉H₁₉N₂O₃SCl:C,58.38;H,4.90;N,7.17. Found:C,58.39;H,4.91;N,7.11.

Example 2048-methoxy-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-methoxy-3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (122 mg),tetrakis(triphenylphosphine)palladium(0) (33.2 mg),4-phenoxyphenylboronic acid (160 mg) and 3-iodo-4-methoxypyridin-2-amine(144 mg) in DME (10 mL) and water (3 ml) was stirred at 80° C.overnight. The mixture was added with silica gel, concentrated in vacuo,and purified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (124 mg) as a pale yellow solid.

MS (ESI+), found: 293.1.

B)8-methoxy-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 4-methoxy-3-(4-phenoxyphenyl)pyridin-2-amine (124 mg) inTHF (dry) (5 mL) was added to a suspension of NaH (60%, 85.0 mg) and2-chloroethanesulfonyl chloride (0.133 ml) in THF (dry) (5 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration and washed with water and EtOAc then crystallized fromTHF-IPE to give the title compound (60.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.32-3.39 (2H, m), 3.81 (3H, s), 4.52-4.65(2H, m), 6.79 (1H, d, J=8.0 Hz), 6.96 (2H, d, J=8.7 Hz), 7.05-7.25 (5H,m), 7.36-7.49 (2H, m), 7.87 (1H, d, J=7.6 Hz).

mp 269-270° C.

Anal. Calcd for C₂₀H₁₈N₂O₄S-0.25H₂O:C,62.08; H,4.82;N,7.24. Found:C,62.08;H,4.76;N,7.23.

Example 2058-chloro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-chloro-3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (122 mg),tetrakis(triphenylphosphine)palladium(0) (33.2 mg),4-phenoxyphenylboronic acid (160 mg) and 4-chloro-3-iodopyridin-2-amine(146 mg) in DME (10 mL) and water (3 mL) was stirred at 80° C.overnight. The mixture was added with silica gel, concentrated in vacuo,and purified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (111 mg) as a pale yellow solid.

MS (ESI+), found: 297.1.

B)8-chloro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 4-chloro-3-(4-phenoxyphenyl)pyridin-2-amine (124 mg) inTHF (dry) (5 mL) was added to a suspension of NaH (60%, 84.0 mg) and2-chloroethanesulfonyl chloride (0.131 mL) in THF (dry) (5 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration and washed with water and EtOAc, and then crystallized fromTHF-IPE to give the title compound (60.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.39-3.49 (2H, m), 4.57-4.67 (2H, m), 6.86(1H, d, J=7.2 Hz), 6.99-7.25 (7H, m), 7.39-7.49 (2H, m), 7.80 (1H, d,J=7.6 Hz).

mp 283-284° C.

Anal. Calcd for C₁₉H₁₅ClN₂O₃S-0.25H₂O-0.25AcOEt:C,58.11;H,4.27;N,6.78.

Found: C,58.26;H,4.08;N,6.81.

Example 2067-fluoro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-fluoro-3-(4-phenoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (122 mg),tetrakis(triphenylphosphine)palladium(0) (33.2 mg),4-phenoxyphenylboronic acid (160 mg) and 3-bromo-5-fluoropyridin-2-amine(110 mg) in DME (10 mL) and water (3 mL) was stirred at 80° C.overnight. The mixture was added with silica gel, concentrated in vacuo,and purified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (132 mg) as a pale yellow solid.

MS (ESI+), found: 281.1.

B)7-fluoro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide

A solution of 5-fluoro-3-(4-phenoxyphenyl)pyridin-2-amine (124 mg) inTHF (dry) (5 mL) was added to a suspension of NaH (60%, 88.0 mg) and2-chloroethanesulfonyl chloride (0.139 mL) in THF (dry) (5 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration and washed with water and EtOAc, then recrystallized fromEtOAc-EtOH to give the title compound (29.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.51 (2H, m), 4.57-4.65 (2H, m),7.00-7.12 (4H, m), 7.15-7.24 (1H, m), 7.38-7.48 (2H, m), 7.60 (2H, d,J=8.7 Hz), 7.84 (1H, dd, J=8.3, 3.0 Hz), 8.04-8.14 (1H, m).

mp 91.9-92.0° C.

Anal. Calcd for C₁₉H₁₅N₂O₃SF-1.0H₂O:C,58.75; H,4.41;N,7.21. Found:C,58.85;H,4.05;N,6.82.

Example 2077-methyl-9-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-methyl-3-(4-phenoxyphenyl)pyrazin-2-amine

A mixture of sodium carbonate (122 mg),tetrakis(triphenylphosphine)palladium(0) (33.2 mg),4-phenoxyphenylboronic acid (160 mg) and 3-bromo-5-methylpyrazin-2-amine(108 mg) in DME (10 mL) and water (3 mL) was stirred at 80° C.overnight. The mixture was added with silica gel, concentrated in vacuo,and purified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (148 mg) as a pale yellow solid.

MS (ESI+), found: 278.1.

B)7-methyl-9-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 5-methyl-3-(4-phenoxyphenyl)pyrazin-2-amine (124 mg) inTHF (dry) (5 mL) was added to a suspension of NaH (60%, 89.0 mg) and2-chloroethanesulfonyl chloride (0.140 mL) in THF (dry) (5 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration and washed with water and EtOAc then recrystallized fromEtOAc-EtOH to give the title compound (86.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 2.30 (3H, s), 3.46-3.56 (2H, m), 4.54-4.63(2H, m), 7.01-7.13 (4H, m), 7.16-7.24 (1H, m), 7.39-7.49 (2H, m), 7.57(1H, s), 7.98-8.07 (2H, m).

mp 92.0-92.5° C.

Anal. Calcd for C₁₉H₁₇N₃O₃S-0.5H₂O:C,60.62; H,4.82;N,11.16. Found:C,60.67;H,4.61;N,10.87.

Example 2089-[3-chloro-4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(3-chloro-4-isopropoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (760 mg),tetrakis(triphenylphosphine)palladium(0) (207 mg),3-chloro-4-isopropoxyphenylboronic acid (1.00 g) and3-bromopyridin-2-amine (621 mg) in DME (10 mL) and water (3 mL) wasstirred at 80° C. overnight. The mixture was added with silica gel,concentrated in vacuo, and purified by column chromatography (silicagel, eluted with EtOAc in hexane) to give the title compound (770 mg) asa pale yellow solid.

MS (ESI+), found: 264.2.

B)9-[3-chloro-4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 3-(3-chloro-4-isopropoxyphenyl)pyridin-2-amine (770 mg) inTHF (dry) (10 mL) was added to a suspension of NaH (60%, 586 mg) and2-chloroethanesulfonyl chloride (0.919 mL) in THF (dry) (10 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration, washed with water and EtOAc and crystallized from THF-IPE togive the title compound (600 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.32 (6H, d, J=6.0 Hz), 3.43-3.50 (2H, m),4.60-4.79 (3H, m), 6.70 (1H, t, J=7.0 Hz), 7.21 (1H, d, J=8.7 Hz), 7.44(1H, dd, J=8.7, 2.3 Hz), 7.61 (1H, d, J=2.3 Hz), 7.64 (1H, dd, J=7.2,1.9 Hz), 7.77 (1H, dd, J=6.6, 1.7 Hz).

mp 239-240° C.

Anal. Calcd for C₁₆H₇N₂O₃SCl:C,54.46;H,4.86;N,7.94. Found:C,54.28;H,4.86;N,7.86.

Example 2099-(4-butoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-butoxyphenyl)pyridin-2-amine

A mixture of sodium carbonate (0.978 g),tetrakis(triphenylphosphine)palladium(0) (0.267 g),4-butoxyphenylboronic acid (1.16 g) and 3-bromopyridin-2-amine (0.799g,) in DME (23 mL) and water (4.6 ml) was stirred at 80° C. overnight.The mixture was added with silica gel, concentrated in vacuo, andpurified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (0.690 g) as a pale yellow solid.

MS (ESI+), found: 243.1.

B) 9-(4-butoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 3-(4-butoxyphenyl)pyridin-2-amine (690 mg) in THF (dry) (5ml) was added to a suspension of NaH (60%, 569 mg) and2-chloroethanesulfonyl chloride (0.893 mL) in THF (dry) (5 mL) at 0° C.The mixture was stirred at room temperature overnight. Water and hexanewere added to give a white precipitate. The precipitate was collected byfiltration and washed with water and EtOAc, and then recrystallized fromIPE-EtOH to give the title compound (502 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 0.94 (3H, t, J=7.4 Hz), 1.38-1.52 (2H, m),1.65-1.78 (2H, m), 3.39-3.49 (2H, m), 4.01 (2H, t, J=6.4 Hz), 4.59-4.69(2H, m), 6.68 (1H, t, J=7.0 Hz), 6.93-6.99 (2H, m), 7.42-7.49 (2H, m),7.58 (1H, dd, J=7.2, 1.5 Hz), 7.73 (1H, dd, J=6.8, 1.9 Hz).

mp 230-232° C.

Anal. Calcd for C₁₇H₂₀N₂O₃S-0.1IPE:C,61.69;H,6.30;N,8.18. Found:C,61.85;H,6.34;N,8.01.

Example 2109-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-phenoxyphenyl)pyrazin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (0.268 g) was added to asuspension of 3-chloropyrazin-2-amine (1.00 g), 4-phenoxyphenylboronicacid (2.15 g) and sodium carbonate (1.64 g) in DME (37.5 mL) and water(7.5 mL) and the mixture was stirred at 80° C. under N₂ for 4 hr. Thereaction mixture was added with water and EtOAc. The organic layer wasseparated, washed with brine, dried over anhydrous magnesium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(silica gel, eluted with EtOAc in hexane) to give the title compound(1.97 g) as a white solid.

MS (ESI+), found: 264.1.

B) 9-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A solution of 3-(4-phenoxyphenyl)pyrazin-2-amine (1.97 g) in THF (dry)(20 mL) was added to a suspension of NaH (60%, 1.50 g) and2-chloroethanesulfonyl chloride (2.35 mL) in THF (dry) (20 mL) at 0° C.The mixture was stirred at room temperature overnight then at 80° C. for4 hr. After cooling to room temperature, the mixture was added withwater and EtOAc. The precipitate was collected by filtration, washedwith water and EtOAc, and then recrystallized from EtOH-EtOAc to givethe title compound (1.68 g) as a pale yellow solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.51-3.60 (2H, m), 4.59-4.67 (2H, m),7.02-7.14 (4H, m), 7.17-7.24 (1H, m), 7.39-7.48 (2H, m), 7.65-7.76 (2H,m), 7.99-8.07 (2H, m).

Anal. Calcd for C₁₈H₁₅N₃O₃S-0.5H₂O:C,59.66; H,4.45;N,11.59. Found:C,59.50;H,4.33;N,11.40.

Example 2119-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (96.0 mg), and platinum(IV) oxide (15.0 mg) in EtOH (5 mL)was stirred at room temperature for 2.5 hr under H₂. The mixture wasadded with NH silica gel, concentrated, purified by columnchromatography (NH silica gel, eluted with MeOH in EtOAc), thenrecrystallized from EtOAc-IPE to give the title compound (32.0 mg) aswhite powder.

¹H NMR (300 MHz, DMSO-d₆) δ 2.85-2.95 (2H, m), 3.01-3.09 (1H, m),3.26-3.43 (4H, m), 3.75-3.88 (2H, m), 4.49 (1H, d, J=4.9 Hz), 6.91-7.06(4H, m), 7.10-7.20 (1H, m), 7.30-7.45 (4H, m).

Anal. Calcd for C₁₈H₁₉N₃O₃S-0.2H₂O:C,59.88;H,5.42;N,11.64. Found:C,60.13;H,5.52;N,11.46.

Example 212(9S)-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide Example 213(9R)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1c][1,2,4]thiadiazine2,2-dioxide

A mixture of9-(4-phenoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (1.24 g), and platinum(IV) oxide (124 mg) in EtOH (20 mL)was stirred at room temperature for 20 hr under H₂. The mixture wasfiltered by Celite, and the filtrate was concentrated in vacuo. Theresidue was separated by SFC (column; CHIRALPAK IC (MB001), 20 mmID×250mL, DAICEL CHEMICAL INDUSTRIES, LTD., eluent; CO₂/MeOH=660/340) to givetwo materials (retention time; short (510 mg) and retention time; long(420 mg)). The material (retention time; short) (510 mg) wasrecrystallized from MeOH-IPE to give(9S)-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (386 mg) as a white solid. The material (retention time;long) (420 mg) was recrystallized from MeOH-EtOAc to give(9R)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (149 mg) as a white solid.

(9S)-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

¹H NMR (300 MHz, DMSO-d₆) δ 2.85-2.93 (2H, m), 3.02-3.11 (1H, m),3.25-3.31 (2H, m), 3.35-3.42 (2H, m), 3.76-3.86 (2H, m), 4.48 (1H, d,J=4.5 Hz), 6.93-7.05 (4H, m), 7.11-7.19 (1H, m), 7.32-7.44 (4H, m).

mp 124-125° C.

Anal. Calcd for C₁₈H₁₉N₃O₃S-0.25H₂O:C,59.73;H,5.43;N,11.61. Found:C,59.62;H,5.57;N,11.40.

(9R)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

¹H NMR (300 MHz, DMSO-d₆) δ 2.83-2.94 (2H, m), 3.01-3.10 (1H, m),3.25-3.31 (2H, m), 3.34-3.43 (2H, m), 3.75-3.87 (2H, m), 4.49 (1H, d,J=4.5 Hz), 6.93-7.06 (4H, m), 7.11-7.19 (1H, m), 7.31-7.45 (4H, m).

mp 124-125° C.

Anal. Calcd for C₁₈H₁₉N₃O₃S:C,60.49;H,5.36;N,11.76. Found:C,60.25;H,5.56;N,11.60.

Example 2144-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyltrifluoromethanesulfonate

To a suspension of4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(1.00 g) and potassium carbonate (1.23 g) in DMF (dry) (30 mL) was addedtrifluoromethanesulfonyl chloride (0.939 mL) at 0° C. The mixture wasstirred at 0° C. for 5 min then at room temperature for 2 hr. Themixture was added with water. The resulting precipitate was collected,washed with water, and dried at 60° C. in vacuo to give the titlecompound (1.27 g) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.69-1.84 (3H, m), 2.01 (1H, dd, J=8.7, 5.3Hz), 3.23-3.34 (2H, m), 3.39-3.57 (2H, m), 3.72-3.95 (3H, m), 7.24-7.55(4H, m).

Anal. Calcd for C₁₄H₁₅N₂O₅S₂F₃:C,40.77;H,3.67;N,6.79. Found:C,40.85;H,3.69;N,6.72.

Example 215(9S)-9-[4-(4-chloro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (4-chloro-2-methylphenyl)boronic acid (912 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg) and powdered 4A MS (5.00 g) in MeCN (18 mL) was stirred at roomtemperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) to give the title compound (37.0 mg) asa white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.80 (3H, m), 1.94-2.07 (1H, m), 2.19(3H, s), 3.23-3.30 (2H, m), 3.47 (2H, d, J=5.3 Hz), 3.72-3.87 (3H, m),6.82-6.96 (3H, m), 7.16-7.29 (3H, m), 7.38-7.46 (1H, m).

192-193° C.

Anal. Calcd for C₂₀H₂₁N₂O₃SCl:C,59.33;H,5.23;N,6.92. Found:C,59.09;H,5.30;N,6.67.

Example 216(9S)-9-[4-(3,4-dimethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3,4-dimethylphenyl)boronic acid (802 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg) and powdered 4A MS (5.00 g) in MeCN (18 mL) was stirred at roomtemperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) then recrystallized from EtOAc to givethe title compound (40.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.69-1.79 (3H, m), 1.96-2.05 (1H, m), 2.20(6H, s), 3.24-3.30 (2H, m), 3.43-3.51 (2H, m), 3.69-3.88 (3H, m), 6.75(1H, dd, J=8.1, 2.8 Hz), 6.83-6.92 (3H, m), 7.09-7.21 (3H, m).

mp 170-171° C.

Anal. Calcd for C₂₁H₂₄N₂O₃S-0.1H₂O:C,65.29;H,6.31;N,7.25. Found:C,65.18;H,6.29;N,7.14.

Example 217(9R)-9-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (4-ethylphenyl)boronic acid (1.34 g),(9R)-9-(4-hydroxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (500 mg), diacetoxycopper (648 mg), triethylamine (1.24 mL),and powdered 4A MS (1.50 g) in DMF (20 mL) was stirred at roomtemperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) then recrystallized from EtOAc-IPE togive the title compound (53.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.18 (3H, t, J=7.6 Hz), 1.67-1.81 (3H, m),1.93-2.07 (1H, m), 2.59 (2H, q, J=7.6 Hz), 3.24-3.29 (2H, m), 3.47 (2H,dq, J=12.3, 6.4 Hz), 3.70-3.88 (3H, m), 6.86-6.99 (4H, m), 7.14-7.27(4H, m). mp 152-153° C.

Anal. Calcd for C₂₁H₂₄N₂O₃S:C,65.60;H,6.29;N,7.29. Found:C,65.48;H,6.30;N,7.21.

Example 218(9S)-9-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (4-ethylphenyl)boronic acid (802 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg), and powdered 4A MS (5.00 g) in MeCN (18 mL) was stirred atroom temperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) then recrystallized from EtOAc to givethe title compound (132 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.18 (3H, t, J=7.6 Hz), 1.69-1.80 (3H, m),1.95-2.03 (1H, m), 2.59 (2H, q, J=7.6 Hz), 3.24-3.30 (2H, m), 3.43-3.53(2H, m), 3.72-3.85 (3H, m), 6.87-6.98 (4H, m), 7.15-7.25 (4H, m).

mp 156-157° C.

Anal. Calcd for C₂₁H₂₄N₂O₃S:C,65.60;H,6.29;N,7.29. Found:C,65.39;H,6.30;N,7.17.

Example 219(9S)-9-[4-(3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3-methoxyphenyl)boronic acid (813 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg), and powdered 4A MS (5.00 g) in MeCN (18 mL) was stirred atroom temperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column is chromatography (NHsilica gel, eluted with MeOH in EtOAc) then recrystallized from EtOAc togive the title compound (80.0 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.74 (3H, d, J=3.4 Hz), 1.95-2.06 (1H, m),3.23-3.31 (2H, m), 3.42-3.54 (2H, m), 3.71-3.87 (6H, m), 6.52-6.62 (2H,m), 6.69-6.75 (1H, m), 6.88-7.04 (2H, m), 7.11-7.37 (3H, m).

mp 139-140° C.

Anal. Calcd for C₂₀H₂₂N₂O₄S:C,62.16;H,5.74;N,7.25. Found:C,62.05;H,5.75;N,7.18.

Example 220(9S)-9-(2′-chlorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (16.0 mg) was added to amixture of (2-chlorophenyl)boronic acid (76.0 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyltrifluoromethanesulfonate (100 mg) and sodium carbonate (51.4 mg) inEtOH (3 mL), water (1.5 mL) and DMF (dry) (2 ml). The mixture wasstirred at 50° C. under nitrogen for 19 hr. Silica-gel was added and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc), dissolved in MeCN/DMSO (4700/300 μM) and purified by preparativeHPLC (C18, eluted with water in acetonitrile containing 0.1% TFA). Thedesired fractions were neutralized with sat.NaHCO₃aq., extracted withEtOAc and washed with brine. The organic layer was separated, dried overanhydrous magnesium sulfate and concentrated in vacuo. The residue wascrystallized from MeCN-THF/hexane to give the title compound (38.4 mg)as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.88 (3H, m), 1.93-2.19 (1H, m),3.41-3.65 (2H, m), 3.68-4.02 (3H, m), 7.28-7.35 (2H, m), 7.37-7.46 (5H,m), 7.51-7.65 (1H, m). The peaks of two protons were hidden behindwater.

Example 221

The compound of Example 221 was produced in the same manner as inExample 220.

Example 2229-{4-[(E)-2-phenylethenyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) (E)-3-(4-styrylphenyl)pyridin-2-amine

Pd(dppf)Cl₂ (0.141 g) was added to a mixture of(E)-1-bromo-4-styrylbenzene (1.00 g), potassium acetate (1.14 g) and4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.03 g) inDMF (dry) (10 mL). The mixture was stirred at 90° C. under nitrogen for12 hr. The insoluble solid was removed by filtration through Celite pad(eluted with EtOAc). The organic layer was separated, washed with waterand brine, dried over anhydrous magnesium sulfate. Activated-carbonpowder and silica-gel were added and the mixture was shaken, sonicatedand filtered through silica-gel/Celite pad (eluted with EtOAc). Thefiltrate was concentrated in vacuo to give the crude(E)-4,4,5,5-tetramethyl-2-(4-styrylphenyl)-1,3,2-dioxaborolane.Tetrakis(triphenylphosphine)palladium(0) (0.186 g) was added to asuspension of 3-bromopyridin-2-amine (0.557 g), the prepared(E)-4,4,5,5-tetramethyl-2-(4-styrylphenyl)-1,3,2-dioxaborolane andsodium carbonate (1.02 g) in DME (20 mL) and water (4 mL) and themixture was stirred at 80° C. under nitrogen overnight. Silica-gel wasadded and the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith EtOAc in hexane) to give the title compound (532 mg) as a paleyellow solid.

MS (ESI+), found: 273.1.

B)9-{4-[(E)-2-phenylethenyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

2-Chloroethanesulfonyl chloride (0.410 mL) was added to a mixture of NaH(60%, 390 mg) in THF (dry) (8 mL) at 0° C. under nitrogen flow. Themixture was stirred at 0° C. for 5 min. The mixture of(E)-3-(4-styrylphenyl)pyridin-2-amine (531 mg) in THF (dry) (20 mL) wasadded dropwise and the mixture was stirred at room temperature underatmosphere overnight. The mixture was quenched with water at 0° C., andwater, EtOAc and THF were added. The insoluble material was collected byfiltration and crystallized from DMSO-EtOH to give the title compound(340 mg) as slightly pale yellow crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 3.42-3.53 (2H, m), 4.59-4.72 (2H, m), 6.72(1H, t, J=7.0 Hz), 7.22-7.44 (5H, m), 7.51-7.70 (7H, m), 7.78 (1H, dd,J=6.6, 1.3 Hz).

Example 223(9S)-9-(4′-chlorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (16.0 mg) was added to amixture of (4-chlorophenyl)boronic acid (76.0 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyltrifluoromethanesulfonate (100 mg) and sodium carbonate (51.4 mg) inEtOH (3 mL), water (1.5 mL) and DMF (dry) (2 mL). The mixture wasstirred at 50° C. under nitrogen for 16 hr. Silica-gel was added and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) and crystallized from MeCN-THF/IPE to give the title compound(26.7 mg) as a colorless crystal.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.87 (3H, m), 1.91-2.13 (1H, m),3.26-3.29 (2H, m), 3.41-3.60 (2H, m), 3.75-3.92 (3H, m), 7.31 (2H, d,J=8.3 Hz), 7.51 (2H, d, J=8.7 Hz), 7.61 (2H, d, J=8.7 Hz), 7.70 (2H, d,J=8.3 Hz).

Example 224

The compound of Example 224 was produced in the same manner as inExample 223.

Example 225(9S)-9-(4′-chloro-3′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (16.0 mg) was added to amixture of (4-chloro-3-fluorophenyl)boronic acid (85.0 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyltrifluoromethanesulfonate (100 mg) and sodium carbonate (51.4 mg) inEtOH (3 mL), water (1.5 mL) and DMF (dry) (2 mL). The mixture wasstirred at 50° C. under nitrogen for 16 hr. Silica-gel was added and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) and concentrated. The residue was dissolved in MeCN/DMSO(1900/100 μM) and purified by preparative HPLC (C18, eluted with waterin acetonitrile containing 0.1% TFA). The desired fractions wereneutralized with sat. NaHCO₃ aq., extracted with EtOAc and washed withbrine. The organic layer was separated, dried over anhydrous magnesiumsulfate and concentrated in vacuo to give the title compound (5.00 mg)as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.81-2.03 (3H, m), 2.10-2.22 (1H, m),3.27-3.34 (2H, m), 3.41-3.56 (2H, m), 3.86-4.02 (3H, m), 7.24 (2H, d,J=8.3 Hz), 7.28-7.36 (2H, m), 7.39-7.53 (3H, m).

Example 226(9S)-9-(3′-chloro-4′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Tetrakis(triphenylphosphine)palladium(0) (16 mg) was added to a mixtureof (3-chloro-4-fluorophenyl)boronic acid (85 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyltrifluoromethanesulfonate (100 mg) and sodium carbonate (51.4 mg) inEtOH (3 mL), water (1.5 mL) and DMF (dry) (2 mL). The mixture wasstirred at 50° C. under nitrogen for 16 hr. Silica-gel was added and thevolatiles were removed in vacuo. The mixture supported on silica-gel waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc), dissolved in MeCN/DMSO (2500/300 μM) and purified by preparativeHPLC(C18, eluted with water in acetonitrile containing 0.1% TFA). Thedesired fractions were neutralized with sat. NaHCO₃aq., extracted withEtOAc and washed with brine. The organic layer was separated, dried overanhydrous magnesium sulfate and concentrated in vacuo to give the titlecompound (20 mg) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.81-2.03 (3H, m), 2.08-2.24 (1H, m),3.27-3.34 (2H, m), 3.41-3.57 (2H, m), 3.86-4.03 (3H, m), 7.15-7.25 (3H,m), 7.40 (1H, ddd, J=8.7, 4.5, 2.3 Hz), 7.44-7.49 (2H, m), 7.57 (1H, dd,J=6.8, 2.3 Hz).

Example 227(9S)-9-[4-(3,4,5-trifluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3,4,5-trifluorophenyl)boronic acid (1882 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(1000 mg), pyridine (7.21 mL), cesium carbonate (1162 mg),diacetoxycopper (1296 mg) and powdered 4A MS (10.0 g) in MeCN (36 mL)was stirred at room temperature overnight. The mixture was added with NHsilica gel, concentrated in vacuo, and purified by column chromatography(NH silica gel, eluted with MeOH in EtOAc) then recrystallized fromEtOAc to give the title compound (196 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.83 (3H, m), 1.90-2.09 (1H, m),3.23-3.28 (2H, m), 3.39-3.57 (2H, m), 3.71-3.90 (3H, m), 6.95-7.13 (4H,m), 7.19-7.34 (2H, m).

mp 180-181° C.

Anal. Calcd for C₁₉H₁₇N₂O₃SF₃: C, 55.60; H, 4.18; N, 6.83. Found: C,55.66; H, 4.22; N, 6.68.

Example 228(9S)-9-[4-(4-bromophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

Diacetoxycopper (648 mg) was added to a mixture of pyridine (0.433 mL),(4-bromophenyl)boronic acid (1075 mg), cesium carbonate (581 mg) and4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg) in MeCN (35 mL). The mixture was stirred at room temperatureunder a dry atmosphere (anhydrous calcium chloride tube) for 19 hr. Theinsoluble, light-blue precipitates were removed by filtration throughCelite-pad (eluted with EtOAc). Silica-gel was added to the filtrate andthe volatiles were removed in vacuo. The mixture supported on silica-gelwas purified by column chromatography (NH silica gel, eluted with MeOHin EtOAc) and concentrated in vacuo. The residue was crystallized fromTHF/IPE to give the title compound (50.6 mg) as colorless crystals.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.82 (3H, m), 1.93-2.11 (1H, m),3.25-3.29 (2H, m), 3.41-3.54 (2H, m), 3.74-3.86 (3H, m), 6.94-7.04 (4H,m), 7.24 (2H, d, J=8.7 Hz), 7.51-7.59 (2H, m).

Example 2299-[4-(difluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-sc][1,2,4]thiadiazine 2,2-dioxide

A mixture of9-(4-hydroxyphenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (736 mg) and N-benzyl-N,N-diethylethanaminium chloride (59.8mg) in THF (dry) (20 mL) and 8N NaOH aq. (3.28 mL) was stirred at roomtemperature under CHF₂C1 atmosphere overnight. Et₂O was added and theaqueous phase was removed. Then EtOAc was added and the extractedorganic layer was washed with brine and concentrated. The residue waspurified by column chromatography (NH silica gel, eluted with MeOH inEtOAc) and crystallized from THF/hexane to give the title compound (22.5mg) as colorless crystals.

Example 2309-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45 mg) of9-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (AK001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol/diethylamine=1000/1) to give the title compound (20 mg)with a shorter retention time. Crystallization from THF and diisopropylether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.81 (3H, m), 1.85-2.09 (4H, m),3.24-3.29 (2H, m), 3.43-3.55 (2H, m), 3.72-3.91 (3H, m), 7.32 (2H, d,J=7.6 Hz), 7.50 (2H, d, J=7.6 Hz).

Example 2319-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45 mg) of9-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (AK001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol/diethylamine=1000/1) to give the title compound (21 mg)with a longer retention time. Crystallization from THF and diisopropylether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.83 (3H, m), 1.85-2.09 (4H, m),3.24-3.30 (2H, m), 3.39-3.61 (2H, m), 3.73-3.93 (3H, m), 7.32 (2H, d,J=7.6 Hz), 7.50 (2H, d, J=7.6 Hz).

Example 2329-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (255 mg) of9-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (MB001), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/methanol=770/115/115) to give thetitle compound (115 mg) with a shorter retention time as a white solid.Crystallization from THF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.83 (3H, m), 1.93-2.09 (1H, m),3.25-3.29 (2H, m), 3.39-3.57 (2H, m), 3.74-3.90 (3H, m), 7.03-7.18 (4H,m), 7.29 (2H, d, J=8.7 Hz), 7.74 (2H, d, J=8.7 Hz).

mp 174-176° C.

Anal. Calcd for C₂₀H₁₉N₂O₃SF₃:C,56.60;H,4.51;N,6.60. Found:C,56.51;H,4.59;N,6.43.

Example 2339-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (255 mg) of9-{4-[4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by SFC (column: CHIRALPAK IC (MB001), 20mmID×250 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:carbon dioxide/acetonitrile/methanol=770/115/115) to give thetitle compound (120 mg) with a longer retention time as a white solid.Crystallization from THF and diisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.82 (3H, m), 1.95-2.09 (1H, m),3.26-3.29 (2H, m), 3.39-3.55 (2H, m), 3.75-3.87 (3H, m), 7.03-7.18 (4H,m), 7.29 (2H, d, J=8.7 Hz), 7.74 (2H, d, J=8.7 Hz).

mp 177-179° C.

Anal. Calcd for C₂₀H₁₉N₂O₃SF₃:C,56.60;H,4.51;N,6.60. Found:C,56.53;H,4.53;N,6.50.

Example 2349-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45.0 mg) of9-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (AK001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:isopropanol/diethylamine=1000/1) to give the title compound (20.0mg) with a shorter retention time. Crystallization from THF anddiisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.82 (3H, m), 1.86-2.12 (4H, m),3.26-3.29 (2H, m), 3.39-3.59 (2H, m), 3.66-3.93 (3H, m), 6.95-7.11 (4H,m), 7.25 (2H, d, J=8.7 Hz), 7.57 (2H, d, J=8.7 Hz).

mp 153-154° C.

Example 2359-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (45.0 mg) of9-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (AK001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:isopropanol/diethylamine=1000/1) to give the title compound (22.0mg) with a longer retention time. Crystallization from THF anddiisopropyl ether gave a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.61-1.82 (3H, m), 1.86-2.12 (4H, m),3.23-3.29 (2H, m), 3.38-3.58 (2H, m), 3.69-3.91 (3H, m), 6.95-7.12 (4H,m), 7.25 (2H, d, J=8.7 Hz), 7.57 (2H, d, J=8.7 Hz).

mp 154-155° C.

Example 236(9S)-9-[4-(3-fluoro-5-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3-fluoro-5-methylphenyl)boronic acid (824 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg), and powdered 4A MS (5.0 g) in MeCN (18 mL) was stirred at roomtemperature overnight. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with EtOAc in hexane then MeOH in EtOAc) then recrystallizedfrom EtOAc to give the title compound (267 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.69-1.83 (3H, m), 1.95-2.07 (1H, m), 2.29(3H, s), 3.23-3.30 (2H, m), 3.42-3.55 (2H, m), 3.74-3.90 (3H, m),6.61-6.71 (2H, m), 6.81 (1H, dd, J=9.7, 2.1 Hz), 6.95-7.03 (2H, m),7.13-7.33 (2H, m).

mp 158-159° C.

Anal. Calcd for C₂₀H₂₁N₂O₃SF:C,61.84;H,5.45;N,7.21. Found:C,61.64;H,5.41;N,7.03.

Example 2379-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 15.

Example 2389-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Examples 59 and60.

Example 2399-[4-(1H-pyrazol-1-yl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 14.

Example 2409-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 15.

Example 2419-{[7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]oxy}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 7-[(2-aminopyridin-3-yl)oxy]naphthalen-2-ol

The title compound was obtained in the same manner as in Example 15,step A.

MS (API+), found: 253.1

B) 3-{[7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]oxy}pyridin-2-amine

To a mixture of sodium hydride (60%, 116 mg),7-[(2-aminopyridin-3-yl)oxy]naphthalen-2-ol (477 mg) and dehydrated THF(10 mL) was added a mixture of 2,2,2-trifluoroethyl4-methylbenzenesulfonate (370 mg) and dehydrated THF (5 mL) at roomtemperature. The reaction mixture was stirred at 70° C. over theweekend, DMSO (10.00 mL) was added and the mixture was stirred at 120°C. for 1 hr. The reaction mixture was added to a saturated aqueousammonium chloride solution, and the mixture was extracted with ethylacetate. The organic layer was washed with saturated brine, dried overmagnesium sulfate, and concentrated under reduced pressure. The residuewas purified by silica gel column chromatography (ethyl acetate/hexane)to give the title compound (82 mg) as a pale-yellow viscous product.

MS (API+), found: 335.0

C)9-{[7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]oxy}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 14,step B.

Example 2429-[4-(1-methylpropoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 66.

Example 2439-[4-(1,4-dioxaspiro[4.5]dec-8-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 66.

Example 2444-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]cyclohexanone

A mixture of9-[4-(1,4-dioxaspiro[4.5]dec-8-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (130 mg), 1M hydrochloric acid (15 mL) and dehydrated THF(15 mL) was stirred at room temperature for 8 hr. The reaction mixturewas neutralized with 1M aqueous sodium hydroxide solution, and extractedwith ethyl acetate. The organic layer was washed with saturated brine,dried over magnesium sulfate, and concentrated under reduced pressure.The residue was washed with diethyl ether to give the title compound(109 mg) as a pale-yellow solid.

Example 2459-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-7-chloro-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 14,step B.

Example 2469-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 76.

Example 2479-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 76.

Example 2489-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 76.

Example 2497-chloro-9-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 76.

Example 2509-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 76.

Example 2517-chloro-9-[4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 66.

Example 2527-chloro-9-[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 66.

Example 2537-chloro-9-[4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 66.

Example 2549-(4-{[6-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2559-(4-{[4-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2567-chloro-9-(4-{[6-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2579-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2589-(5-phenoxypyridin-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-bromo-2,3′-bipyridin-2′-amine

n-Butyllithium (1.6 M in hexane, 48.3 mL) was added dropwise to asolution of N1,N1,N2,N2-tetramethylethane-1,2-diamine (8.08 g) andtert-butyl pyridin-2-ylcarbamate (5 g) in THF (dry) (50 mL) at −78° C.The mixture was stirred at 0° C. under N₂ for 2 hr. Triisopropyl borate(16.95 g) was added to the mixture at −78° C. The mixture was stirred at0° C. under N₂ for 30 min. The mixture was quenched with sat. NH₄Cl aq.at 0° C. and added with Et₂O to give a yellow precipitate (11.68 g,wet). A mixture of potassium carbonate (438 mg),tetrakis(triphenylphosphine)palladium(0) (61.0 mg), 2,5-dibromopyridine(250 mg) and the precipitate (250 mg) in toluene (10 mL) and MeOH (5 mL)was stirred at 80° C. under N₂ overnight. NH silica gel was added andthe mixture was concentrated in vacuo. The residue was purified bycolumn chromatography (NH silica gel, eluted with EtOAc in hexane) togive the title compound (132 mg) as a yellow solid.

MS (API+), found: 250.0

B) 9-(5-phenoxypyridin-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was synthesized by following the procedure of example79.

Example 2599-(4-{[5-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2607-chloro-9-(4-{[5-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 79.

Example 2619-[4-(cyclohexyloxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (48.0 mg) wasobtained from9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 1.23-1.53 (6H, m), 1.72-2.14 (8H, m),3.20-3.37 (2H, m), 3.37-3.53 (2H, m), 3.82 (1H, t, J=5.1 Hz), 3.91 (2H,t, J=6.4 Hz), 4.08-4.30 (1H, m), 6.84 (2H, d, J=8.3 Hz), 7.04 (2H, d,J=8.3 Hz).

Example 2629-{4-[3-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (36.5 mg) wasobtained from9-{4-[3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.72-1.83 (3H, m), 1.95-2.10 (1H, m),3.25-3.27 (2H, m), 3.44-3.56 (2H, m), 3.76-3.88 (3H, m), 7.04 (2H, d,J=8.7 Hz), 7.24-7.36 (4H, m), 7.47-7.53 (1H, m), 7.58-7.66 (1H, m).

Example 2639-[4-(pyridin-2-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

2-Chloropyridine (0.132 mL) was added to a solution of4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(300 mg) and potassium carbonate (390 mg) in DMSO (6 mL). The mixturewas stirred at 120° C. under nitrogen overnight. The mixture wasquenched with water and extracted with EtOAc. The organic layer wasseparated, washed with water and brine, dried over anhydrous sodiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (NH silica gel, eluted with MeOH in EtOAc) andcrystallized from THF-IPE to give the title compound (3.3 mg) ascolorless crystals.

¹H NMR (300 MHz, CDCl₃) δ 3.37-3.45 (2H, m), 4.63-4.71 (2H, m),6.54-6.63 (1H, m), 6.90-7.05 (2H, m), 7.12-7.23 (2H, m), 7.30-7.37 (1H,m), 7.51 (1H, dd, J=7.0, 1.7 Hz), 7.60-7.76 (3H, m), 8.22 (1H, dd,J=4.5, 2.3 Hz).

Example 264

The compound of Example 264 was produced in the same manner as inExample 88.

Example 2659-[4-(2,2,2-trifluoroethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (49.7 mg) wasobtained from9-[4-(2,2,2-trifluoroethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.79 (3H, m), 1.93-2.04 (1H, m),3.23-3.28 (2H, m), 3.41-3.52 (2H, m), 3.70-3.76 (1H, m), 3.78-3.87 (2H,m), 4.74 (2H, q, J=8.8 Hz), 6.99 (2H, d, J=8.7 Hz), 7.16 (2H, d, J=8.7Hz).

Example 2669-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(2-(trifluoromethyl)phenoxy)phenyl)pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (206 mg)was obtained from 4-(2-aminopyridin-3-yl)phenol (400 mg) and1-iodo-2-(trifluoromethyl)benzene (701 mg).

MS (ESI+), found: 331.0.

B)9-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.51 (2H, m), 4.59-4.72 (2H, m), 6.71(1H, t, J=7.0 Hz), 7.03-7.12 (2H, m), 7.17 (1H, d, J=8.3 Hz), 7.31-7.43(1H, m), 7.54-7.60 (2H, m), 7.62-7.72 (2H, m), 7.75-7.86 (2H, m).

Example 267-269

The compounds of Examples 267-269 were produced in the same manner as inExample 88.

Example 2709-[4-(2-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(2-methoxyphenoxy)phenyl)pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (113.4mg) was obtained from 4-(2-aminopyridin-3-yl)phenol (500 mg) and1-iodo-2-methoxybenzene (754 mg).

MS (ESI+), found: 293.3.

B)9-[4-(2-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.50 (2H, m), 3.77 (3H, s), 4.60-4.67(2H, m), 6.66-6.72 (1H, m), 6.83 (2H, d, J=8.7 Hz), 6.96-7.29 (4H, m),7.46 (2H, d, J=8.7 Hz), 7.59 (1H, dd, J=7.2, 1.9 Hz), 7.75 (1H, dd,J=6.8, 1.5 Hz).

Example 271

The compound of Example 271 was produced in the same manner as inExample 88.

Example 2729-[(4-cyclopentylphenoxy)methyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-((4-cyclopentylphenoxy)methyl)pyridin-2-amine

Diisopropylazodicarboxylate (0.714 mL) was added to a solution oftriphenylphosphine (951 mg), (2-aminopyridin-3-yl)methanol (300 mg) and4-cyclopentylphenol (392 mg) in THF (dry) (20 mL) at room temperatureand the mixture was stirred for 20 hr. Volatiles were removed in vacuowith silica-gel. The silica-supported mixture was purified by columnchromatography (1st; NH-silica gel, eluted with EtOAc in hexane, 2nd;silica gel, eluted with EtOAc in hexane) to give the title compound(55.4 mg) as a white powder.

MS (ESI+), found: 269.1.

B)9-[(4-cyclopentylphenoxy)methyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ1.38-1.81 (6H, m), 1.87-2.05 (2H, m),2.82-2.99 (1H, m), 3.42-3.55 (2H, m), 4.56-4.72 (2H, m), 4.85 (2H, s),6.68 (1H, t, J=6.8 Hz), 6.90 (2H, d, J=8.7 Hz), 7.17 (2H, d, J=8.7 Hz),7.67 (1H, d, J=7.2 Hz), 7.76 (1H, d, J=5.7 Hz).

Example 273

The compound of Example 273 was produced in the same manner as inExample 186.

Example 274

The compound of Example 274 was produced in the same manner as inExample 88.

Example 275

The compound of Example 275 was produced in the same manner as inExample 92.

Example 2769-[(3-chlorobenzyl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(3-chlorobenzyloxy)pyridin-2-amine

To the mixture of 2-aminopyridin-3-ol (500 mg) and DMF (dry) (15 mL) wasadded NaH (60%, 200 mg) at room temperature and the mixture was stirredat room temperature for 20 min. 1-(Bromomethyl)-3-chlorobenzene (933 mg)was added and the mixture was stirred at the same temperature for 1 hr.Water and EtOAc were added and the extracted organic layer was washedwith brine, dried over anhydrous sodium sulfate and concentrated invacuo. The residue was purified by column chromatography (silica gel,eluted with EtOAc in hexane) to give the title compound (1.01 g) as abrown crystalline solid.

MS (ESI+), found: 235.1.

B) 9-[(3-chlorobenzyl)oxy]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.39-3.47 (2H, m), 4.52-4.66 (2H, m), 5.12(2H, s), 6.56 (1H, dd, J=7.6, 6.8 Hz), 7.13 (1H, dd, J=7.7, 1.3 Hz),7.31-7.58 (5H, m).

Example 2779-{[3,5-bis(trifluoromethyl)benzyl]oxy}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)9-{[3,5-bis(trifluoromethyl)benzyl]oxy}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in

Example 276

MS (ESI+), found: 427.1.

B)9-{[3,5-bis(trifluoromethyl)benzyl]oxy}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (61.4 mg) wasobtained from9-{[3,5-bis(trifluoromethyl)benzyl]oxy}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.63-2.05 (4H, m), 3.20-3.27 (2H, m),3.35-3.44 (2H, m), 3.64-3.79 (2H, m), 4.02 (1H, t, J=4.5 Hz), 4.77-5.03(2H, m), 7.96-8.11 (3H, m).

Example 2787-methyl-9-(3-phenoxyazetidin-1-yl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-methyl-3-(3-phenoxyazetidin-1-yl)pyrazin-2-amine

Potassium carbonate (18.53 mg) was added to a mixture of3-phenoxyazetidine (20 mg) and 3-bromo-5-methylpyrazin-2-amine (25 mg)in DMF (dry) (1 mL). The mixture was stirred at 120° C. for 4 hr. Waterand EtOAc were added and the extracted organic layer was washed withbrine, dried over anhydrous sodium sulfate and concentrated in vacuo.The residue was purified by column chromatography (silica gel, elutedwith EtOAc in hexane) to give the title compound (12 mg) as white solid.

MS (ESI+), found: 257.1.

B)7-methyl-9-(3-phenoxyazetidin-1-yl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 1.97-2.12 (3H, m), 3.40-3.44 (2H, m),4.00-4.20 (2H, m), 4.31-4.44 (2H, m), 4.59-4.80 (2H, m), 4.96-5.14 (1H,m), 6.78-6.90 (3H, m), 6.99 (1H, t, J=7.9 Hz), 7.25-7.40 (2H, m).

Example 279

The compound of Example 279 was produced in the same manner as inExample 278.

Example 280

The compound of Example 280 was produced in the same manner as inExample 14.

Example 2819-(1-methyl-1H-indol-5-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (93.2 mg) wasobtained from9-(1-methyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.87 (3H, m), 1.96-2.09 (1H, m),3.25-3.29 (2H, m), 3.42-3.61 (2H, m), 3.73-3.94 (6H, m), 6.36 (1H, dd,J=3.0, 0.8 Hz), 6.98 (1H, dd, J=8.5, 1.7 Hz), 7.27-7.39 (3H, m).

Example 282

The compound of Example 282 was produced in the same manner as inExample 14.

Example 2839-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (28 mg) wasobtained from9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.72-1.83 (3H, m), 1.95-2.09 (1H, m),3.26-3.30 (2H, m), 3.45-3.54 (2H, m), 3.76-3.89 (3H, m), 7.14 (2H, d,J=8.7 Hz), 7.27 (2H, d, J=8.7 Hz), 7.45-7.51 (2H, m), 8.42 (1H, d, J=5.7Hz).

Example 2859-(1-ethyl-1H-indol-5-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) tert-butyl5-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-1H-indole-1-carboxylate

The title compound was obtained in the same manner as in Example 14.

MS (ESI+), found: 400.2.

B) 9-(1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of tert-butyl5-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-1H-indole-1-carboxylate(500 mg) in THF (dry) (80 mL) was added 8 M NaOH aq. (8 mL). The mixturewas stirred at 50° C. for 30 min. MeOH (20 mL) was added and the mixturewas stirred at 50° C. for 4 hr.

The precipitate was collected by filtration and dried in vacuo to givethe title compound (324.1 mg) as a white solid.

MS (ESI+), found: 300.1.

C) 9-(1-ethyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of9-(1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide(131 mg) in DMF (dry) (15 mL) was added NaH (60%, 18.38 mg) at roomtemperature. The mixture was stirred at the same temperature for 10 min.Iodoethane (0.039 mL) was added and the mixture was stirred at roomtemperature overnight. Water and EtOAc were added and the extractedorganic layer was washed with brine. Silica-gel was added to the organiclayer and the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (NH-silica gel, elutedwith MeOH in EtOAc) to give the title compound (34.6 mg) as a whitesolid.

¹H NMR (300 MHz, CDCl₃) δ 1.47 (3H, t, J=7.2 Hz), 3.36-3.45 (2H, m),4.18 (2H, q, J=7.2 Hz), 4.62-4.71 (2H, m), 6.50 (¹H, d, J=2.3 Hz),6.54-6.64 (1H, m), 7.12 (1H, d, J=3.4 Hz), 7.15-7.20 (1H, m), 7.34 (1H,d, J=8.7 Hz), 7.46-7.55 (2H, m), 7.77 (1H, d, J=1.1 Hz).

D)9-(1-ethyl-1H-indol-5-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (24.1 mg) wasobtained from9-(1-ethyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.35 (3H, t, J=7.2 Hz), 1.64-1.88 (3H, m),1.97-2.12 (1H, m), 3.23-3.28 (2H, m), 3.42-3.56 (2H, m), 3.76-3.90 (3H,m), 4.12-4.25 (2H, m), 6.37 (1H, d, J=3.0 Hz), 6.96 (1H, d, J=8.3 Hz),7.28-7.43 (3H, m).

Example 2867-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-oneA) 7-(2-aminopyridin-3-yl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 267.2.

B)7-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 1.15 (6H, s), 1.96 (2H, t, J=6.2 Hz), 3.00(2H, t, J=6.2 Hz), 3.40-3.52 (2H, m), 4.58-4.71 (2H, m), 6.71 (1H, t,J=7.0 Hz), 7.38 (1H, d, J=8.3 Hz), 7.60-7.71 (2H, m), 7.79 (1H, dd,J=6.6, 1.7 Hz), 7.95 (1H, d, J=1.9 Hz).

Example 2875-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-oneA) 5-(2-aminopyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-one

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 253.1.

B)5-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-one

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 1.17 (6H, s), 3.04 (2H, s), 3.44-3.54 (2H,m), 4.63-4.72 (2H, m), 6.74 (1H, t, J=7.0 Hz), 7.53-7.58 (1H, m), 7.64(1H, s), 7.67-7.72 (2H, m), 7.84 (1H, dd, J=6.8, 1.5 Hz).

Example 2887-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one

In the same manner as in Example 98, the title compound (220.1 mg) wasobtained from7-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one.

¹H NMR (300 MHz, DMSO-d₆) δ 1.13 (6H, s), 1.63-1.86 (3H, m), 1.88-2.05(3H, m), 2.94 (2H, t, J=6.0 Hz), 3.17-3.27 (2H, m), 3.41-3.63 (2H, m),3.70-3.96 (3H, m), 7.19-7.33 (1H, m), 7.33-7.45 (1H, m), 7.71 (1H, d,J=1.9 Hz).

Example 2895-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-one

In the same manner as in Example 98, the title compound (163.3 mg) wasobtained from5-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-one.

¹H NMR (300 MHz, DMSO-d₆) δ 1.14 (6H, s), 1.65-1.86 (3H, m), 1.93-2.13(1H, m), 2.99 (2H, s), 3.26-3.30 (2H, m), 3.41-3.61 (2H, m), 3.68-4.00(3H, m), 7.29 (1H, d, J=7.9 Hz), 7.40 (1H, s), 7.60 (1H, d, J=7.9 Hz).

Example 2909-[4-(1H-pyrazol-1-yl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)9-(4-(1H-pyrazol-1-yl)phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 14.

MS (ESI+), found: 327.1.

B)9-[4-(1H-pyrazol-1-yl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (165.7 mg) wasobtained from9-(4-(1H-pyrazol-1-yl)phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.68-1.87 (3H, m), 1.93-2.13 (1H, m),3.24-3.29 (2H, m), 3.44-3.62 (2H, m), 3.74-3.95 (3H, m), 6.45-6.62 (1H,m), 7.33 (2H, d, J=8.7 Hz), 7.66-7.84 (3H, m), 8.47 (1H, d, J=3.0 Hz).

Example 2911-[4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]ethanoneA)1-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]ethanone

The title compound was obtained in the same manner as in Example 14.

MS (ESI+), found: 303.1.

B)1-[4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]ethanone

In the same manner as in Example 98, the title compound (278.6 mg) wasobtained from1-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]ethanone.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.85 (3H, m), 1.95-2.12 (1H, m), 2.57(3H, s), 3.24-3.31 (2H, m), 3.40-3.60 (2H, m), 3.74-3.96 (3H, m), 7.37(2H, d, J=8.3 Hz), 7.90 (2H, d, J=8.3 Hz).

Example 292

The compound of Example 292 was produced in the same manner as inExample 284.

Example 2939-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 5-bromo-1-isobutyl-1H-indole

To a mixture of 5-bromo-1H-indole (1 g) in DMF (dry) (10 mL) was addedNaH (60%, 0.612 g) at room temperature. The mixture was stirred at 80°C. for 10 min. 1-Iodo-2-methylpropane (0.587 mL) was added at roomtemperature and the mixture was stirred at 80° C. for 1 hr. Another1-iodo-2-methylpropane (0.587 mL) was added and the mixture was stirredat 80° C. for 1 hr. Water and EtOAc were added and the extracted organiclayer was washed with brine. Silica-gel was added to the organic layerand the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith EtOAc in hexane) to give the title compound (554 mg) as colorlessoil.

¹H NMR (300 MHz, DMSO-d₆) δ 0.91 (6H, d, J=6.8 Hz), 2.04-2.27 (1H, m),3.88 (2H, d, J=7.2 Hz), 6.42 (1H, d, J=2.6 Hz), 7.07 (1H, d, J=3.0 Hz),7.16-7.22 (1H, m), 7.24-7.25 (1H, m), 7.74 (1H, d, J=1.5 Hz).

B) 3-(1-isobutyl-1H-indol-5-yl)pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 266.2.

C)9-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 0.86 (6H, d, J=6.4 Hz), 2.16 (1H, d, J=6.8Hz), 3.41-3.50 (2H, m), 3.99 (2H, d, J=7.6 Hz), 4.61-4.71 (2H, m), 6.46(1H, d, J=2.6 Hz), 6.67-6.74 (1H, m), 7.27 (1H, dd, J=8.5, 1.7 Hz), 7.38(1H, d, J=3.0 Hz), 7.49 (1H, d, J=8.3 Hz), 7.59-7.64 (1H, m), 7.67 (1H,s), 7.74 (1H, dd, J=6.8, 1.5 Hz).

Example 2949-(1-butyl-1H-indol-5-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (49.7 mg) wasobtained from9-(1-butyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 0.85-0.92 (3H, m), 1.17-1.31 (2H, m),1.67-1.84 (5H, m), 1.97-2.10 (1H, m), 3.25-3.30 (2H, m), 3.43-3.59 (2H,m), 3.77-3.91 (3H, m), 4.14 (2H, t, J=7.0 Hz), 6.36 (1H, d, J=3.0 Hz),6.96 (1H, dd, J=8.5, 1.7 Hz), 7.30-7.41 (3H, m).

Example 2959-{1-[2-(4-fluorophenyl)ethyl]-1H-indol-5-yl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a mixture of cesium carbonate (435 mg) and9-(1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide(200 mg) in DMSO (5 ml) was added 1-(2-bromoethyl)-4-fluorobenzene (136mg). The mixture was stirred at room temperature for 1 day. Water andEtOAc were added and the extracted organic layer was washed with brine,dried over anhydrous sodium sulfate. Silica-gel was added to the organiclayer and the volatiles were removed in vacuo. The mixture supported onsilica-gel was purified by column chromatography (silica gel, elutedwith MeOH in EtOAc), concentrated and dissolved in THF (dry) (25 mL) andMeOH (25 mL). Then platinum(IV) oxide (46 mg) was added and the mixturewas stirred at room temperature under hydrogen overnight. Activatedcarbon was added and the insoluble solid was removed by filtrationthrough NH-silica gel/Celite pad (eluted with EtOAc). The filtrate wasconcentrated and the residue was purified by column chromatography (1st:NH silica gel, eluted with MeOH in EtOAc, 2nd: silica gel, eluted withEtOAc) to give the title compound (5.7 mg) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.75-2.23 (4H, m), 3.05 (2H, t, J=7.2 Hz),3.24-3.35 (2H, m), 3.36-3.58 (2H, m), 3.88-4.03 (3H, m), 4.29 (2H, t,J=7.2 Hz), 6.36 (1H, d, J=3.0 Hz), 6.84 (1H, d, J=3.0 Hz), 6.87-7.14(5H, m), 7.23 (1H, s), 7.35-7.40 (1H, m).

Example 2969-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (5.3 mg) wasobtained from9-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 0.85 (6H, d, J=6.4 Hz), 1.62-1.87 (3H, m),1.93-2.20 (2H, m), 3.23-3.30 (2H, m), 3.42-3.58 (2H, m), 3.72-3.91 (3H,m), 3.95 (2H, d, J=7.2 Hz), 6.37 (1H, d, J=2.3 Hz), 6.95 (1H, dd, J=8.5,1.7 Hz), 7.26-7.34 (2H, m), 7.39 (1H, d, J=8.7 Hz).

Example 2979-(3′-methoxybiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-(4-(1H-naphtho[1,8-de][1,3,2]diazaborinin-2(3H)-yl)phenyl)pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (57.7 mg) was added to asuspension of 3-bromopyridin-2-amine (432 mg),2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2,3-dihydro-1H-naphtho[1,8-de][1,3,2]diazaborinine(1016 mg) and sodium carbonate decahydrate (1429 mg) in DME (10 mL) andwater (2 ml) and the mixture was stirred at 80° C. under nitrogen for 3hr and at 70° C. overnight. Activated carbon was added and the insolublesolid was removed by filtration through NH-silica gel/Celite pad (elutedwith EtOAc). The filtrate was concentrated and the residue was purifiedby column chromatography (silica gel, eluted with EtOAc in hexane) togive the title compound (397 mg) as a brown solid.

MS (ESI+), found: 337.2.

B) 4-(2-aminopyridin-3-yl)phenylboronic acid

6N HCl aq. (1.1 mL) was added to a mixture of3-(4-(1H-naphtho[1,8-de][1,3,2]diazaborinin-2(3H)-yl)phenyl)pyridin-2-amine(396 mg) in THF (dry) (12 mL). The mixture was stirred at roomtemperature for 3 hr. The mixture was added with sat. NaHCO₃aq, EtOAcand 2N NaOH aq., and the separated aqueous phase was acidified by 6N HClaq., then controlled pH ca.8 by sat. NaHCO₃ aq. The aqueous mixture wasextracted with EtOAc, and the organic layer was separated, washed withbrine dried over anhydrous magnesium sulfate and concentrated in vacuoto give the title compound (52.4 mg) as a white solid.

MS (ESI+), found: 215.1.

C) 3-(3′-methoxybiphenyl-4-yl)pyridin-2-amine

Tetrakis(triphenylphosphine)palladium(0) (8.49 mg) was added to asuspension of 1-iodo-3-methoxybenzene (68.8 mg),4-(2-aminopyridin-3-yl)phenylboronic acid (52.4 mg) and sodium carbonatedecahydrate (210 mg) in DME (5 mL), water (1 mL) and THF (dry) (5 mL).The mixture was stirred at 80° C. under nitrogen overnight. Silica-gelwas added and the volatiles were removed in vacuo. The mixture supportedon silica-gel was purified by column chromatography (NH silica gel,eluted with EtOAc in hexane) to give the title compound (49.1 mg) as awhite solid.

MS (ESI+), found: 277.1.

D)9-(3′-methoxybiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To a suspension of NaH (60%, 35.5 mg) in THF (dry) (5 mL) was added2-chloroethanesulfonyl chloride (0.056 mL) at 0° C. and the mixture wasstirred for 5 min at the same temperature. A solution of3-(3′-methoxybiphenyl-4-yl)pyridin-2-amine (49 mg) in THF (dry) (5 mL)was added at 0° C. and the mixture was stirred at room temperatureovernight. The mixture was quenched with water. Water and EtOAc wereadded and the extracted organic layer was washed with brine, dried overanhydrous magnesium sulfate and concentrated in vacuo. The residue waswashed with EtOAc and dried in vacuo to give the title compound (18 mg)as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.56 (2H, m), 3.84 (3H, s), 4.58-4.76(2H, m), 6.74 (1H, t, J=7.0 Hz), 6.96 (1H, dd, J=7.7, 2.1 Hz), 7.21-7.31(2H, m), 7.35-7.45 (1H, m), 7.56-7.65 (2H, m), 7.65-7.76 (3H, m),7.76-7.86 (1H, m).

Example 298

The compound of Example 298 was produced in the same manner as inExample 14.

Example 2999-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)1-(4-bromophenyl)-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole

1-Cyclopropyl-4,4,4-trifluorobutane-1,3-dione (1.330 g) was added to amixture of (4-bromophenyl)hydrazine hydrochloride (1.65 g) and AcOH (10mL). The mixture was stirred at 120° C. for 1 hr. AcOH was removed invacuo and the residue was purified by column chromatography (NH silicagel, eluted with EtOAc in hexane) to give1-(4-bromophenyl)-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole (2.2059g) as a yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 0.60-0.93 (2H, m), 0.93-1.15 (2H, m),1.68-1.88 (1H, m), 6.22 (1H, s), 7.51 (2H, d), 7.63 (2H, d, J=9.1 Hz).

B)3-(4-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 345.1.

C)9-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 0.79-0.95 (2H, m), 0.95-1.11 (2H, m),1.85-2.00 (1H, m), 3.43-3.58 (2H, m), 4.59-4.76 (2H, m), 6.66 (1H, s),6.75 (1H, t, J=7.0 Hz), 7.60-7.78 (5H, m), 7.83 (1H, dd, J=6.6, 1.7 Hz).

Example 300

The compound of Example 300 was produced in the same manner as inExample 299.

Example 3019-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (60.3 mg) wasobtained from9-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 0.73-0.93 (2H, m), 0.93-1.07 (2H, m),1.68-1.91 (4H, m), 1.99-2.14 (1H, m), 3.26-3.29 (2H, m), 3.44-3.60 (2H,m), 3.76-4.01 (3H, m), 6.62 (1H, s), 7.42 (2H, d, J=8.3 Hz), 7.60 (2H,d, J=8.7 Hz).

Example 3029-{4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (176 mg) wasobtained from9-{4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.73-1.85 (3H, m), 1.94-2.15 (1H, m), 2.36(3H, s), 3.26-3.31 (2H, m), 3.42-3.62 (2H, m), 3.73-3.99 (3H, m), 6.76(1H, s), 7.35-7.46 (2H, m), 7.46-7.56 (2H, m).

Example 3039-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (6.50 mg) wasobtained from9-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 1.67-1.91 (6H, m), 1.96-2.20 (2H, m),2.57-2.80 (4H, m), 2.80-2.96 (1H, m), 3.11-3.29 (2H, m), 3.29-3.49 (2H,m), 3.74-3.90 (2H, m), 4.03-4.25 (1H, m), 4.39 (1H, dd, J=9.4, 3.8 Hz),6.56-6.75 (2H, m), 6.86-7.02 (1H, m).

Example 304[4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl](phenyl)methanone

In the same manner as in Example 98, the title compound (11.3 mg) wasobtained from[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl](phenyl)methanone.

¹H NMR (300 MHz, DMSO-d₆) δ 1.71-1.84 (3H, m), 1.95-2.13 (1H, m),3.32-3.35 (2H, m), 3.42-3.59 (2H, m), 3.76-3.96 (3H, m), 7.41 (2H, d,J=8.3 Hz), 7.51-7.61 (2H, m), 7.64-7.80 (5H, m).

Example 3059-{[4-(trifluoromethyl)phenoxy]methyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (1.40 mg) wasobtained from9-{[4-(trifluoromethyl)phenoxy]methyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 1.73-1.96 (2H, m), 1.97-2.22 (2H, m),2.87-3.00 (1H, m), 3.14-3.33 (2H, m), 3.33-3.51 (2H, m), 3.86 (2H, t,J=6.6 Hz), 4.27 (1H, dd, J=9.4, 7.5 Hz), 4.46 (1H, dd, J=9.4, 3.8 Hz),6.99 (2H, d, J=8.7 Hz), 7.54 (2H, d, J=8.7 Hz).

Example 306[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl](3-methoxyphenyl)methanoneA) (4-bromophenyl)(3-methoxyphenyl)methanone

The title compound was obtained in the same manner as in Example 136,step A.

¹H NMR (300 MHz, CDCl₃) δ 3.86 (3H, s), 7.10-7.18 (1H, m), 7.28-7.84(7H, m).

B) [4-(2-aminopyridin-3-yl)phenyl](3-methoxyphenyl)methanone

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 305.1.

C)[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl](3-methoxyphenyl)methanone

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.54 (2H, m), 3.83 (3H, s), 4.60-4.74(2H, m), 6.75 (1H, t, J=7.0 Hz), 7.22-7.36 (3H, m), 7.45-7.55 (1H, m),7.64-7.90 (6H, m).

Example 3079-{4-[3-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-{4-[3-methyl-4-(trifluoromethyl)phenoxy]phenyl}pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (482 mg)was obtained from 4-(2-aminopyridin-3-yl)phenol (500 mg) and4-bromo-2-methyl-1-(trifluoromethyl)benzene (770 mg).

MS (ESI+), found: 345.1.

B)9-{4-[3-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 2.43 (3H, d, J=1.5 Hz), 3.41-3.52 (2H, m),4.55-4.71 (2H, m), 6.72 (1H, t, J=7.0 Hz), 6.97 (1H, dd, J=8.7, 1.9 Hz),7.08-7.20 (3H, m), 7.53-7.83 (5H, m).

Example 3089-{4-[3-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (187 mg) wasobtained from9-{4-[3-methyl-4-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.86 (3H, m), 1.91-2.09 (1H, m), 2.41(3H, d, J=1.5 Hz), 3.24-3.29 (2H, m), 3.39-3.55 (2H, m, J=6.4, 6.4, 6.4Hz), 3.69-3.92 (3H, m), 6.90 (1H, d, J=8.7 Hz), 6.98-7.16 (3H, m), 7.27(2H, d, J=8.7 Hz), 7.66 (1H, d, J=8.7 Hz).

Example 3099-{4-[2-methyl-5-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-{4-[2-methyl-5-(trifluoromethyl)phenoxy]phenyl}pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (456 mg)was obtained from 4-(2-aminopyridin-3-yl)phenol (500 mg) and2-bromo-1-methyl-4-(trifluoromethyl)benzene (770 mg).

MS (ESI+), found: 345.1.

B)9-{4-[2-methyl-5-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 2.30 (3H, s), 3.40-3.50 (2H, m), 4.60-4.70(2H, m), 6.70 (1H, t, J=7.0 Hz), 6.92-7.04 (2H, m), 7.27 (1H, s),7.47-7.66 (5H, m), 7.77 (1H, dd, J=6.6, 1.7 Hz).

Example 3109-{4-[2-methyl-5-(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (173 mg) wasobtained from9-{4-[2-methyl-5-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.65-1.84 (3H, m), 1.92-2.10 (1H, m), 2.28(3H, s), 3.23-3.29 (2H, m), 3.41-3.55 (2H, m), 3.70-3.90 (3H, m),6.84-6.96 (2H, m, J=8.7 Hz), 7.11-7.29 (3H, m), 7.42-7.51 (1H, m), 7.57(1H, d, J=7.9 Hz).

Example 3119-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}pyridin-2-amine

Tripotassium phosphate (3.42 g) was added to a mixture of4-(2-aminopyridin-3-yl)phenol (1.00 g) and1-bromo-4-fluoro-2-(trifluoromethyl)benzene (1.57 g) in DMSO (15 mL).The mixture was stirred at 140° C. under nitrogen for 7 hr. Water andEtOAc were added and the extracted organic layer was washed with brine.Silica-gel was added to the organic layer and the volatiles were removedin vacuo. The mixture supported on silica-gel was purified by columnchromatography (NH-silica gel, eluted with EtOAc in hexane) andconcentrated to give3-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}pyridin-2-amine (1.52 g)as orange oil.

¹H NMR (300 MHz, DMSO-d₆) δ5.60 (2H, s), 6.66 (1H, dd, J=7.2, 4.9 Hz),7.15-7.23 (2H, m), 7.26 (1H, dd, J=9.0, 3.0 Hz), 7.34 (1H, dd, J=7.2,1.9 Hz), 7.44-7.54 (3H, m), 7.88 (1H, d, J=9.0 Hz), 7.95 (1H, dd, J=4.9,1.9 Hz).

B)9-{4-[4-bromo-3-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.41-3.51 (2H, m), 4.59-4.71 (2H, m), 6.71(1H, t, J=6.8 Hz), 7.12-7.19 (2H, m), 7.26 (1H, dd, J=8.9, 2.8 Hz), 7.53(1H, d, J=3.0 Hz), 7.56-7.69 (3H, m), 7.78 (1H, dd, J=6.8, 1.5 Hz), 7.89(1H, d, J=9.0 Hz).

Example 312

The compound of Example 312 was produced in the same manner as inExample 136.

Example 3139-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-[4-(2,3-dihydrobenzofuran-6-yloxy)phenyl]pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (295 mg)was obtained from 4-(2-aminopyridin-3-yl)phenol (500 mg) and6-bromo-2,3-dihydrobenzofuran (641 mg).

MS (ESI+), found: 305.0.

B)9-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 3.16 (2H, t, J=8.5 Hz), 3.40-3.50 (2H, m,J=6.4 Hz), 4.51-4.71 (4H, m), 6.47-6.55 (2H, m), 6.70 (1H, t, J=7.2 Hz),6.99 (2H, d, J=8.7 Hz), 7.22 (1H, d, J=7.9 Hz), 7.51 (2H, d, J=8.3 Hz),7.62 (1H, d, J=6.8 Hz), 7.76 (1H, d, J=5.3 Hz).

Example 314

The compound of Example 314 was produced in the same manner as inExample 313.

Example 315

The compound of Example 315 was produced in the same manner as inExample 310.

Example 316

The compound of Example 316 was produced in the same manner as inExample 313.

Example 3179-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A)3-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-5-methylpyridin-2-amine

In the same manner as in Example 85, step A, the title compound (361 mg)was obtained from 4-(2-amino-5-methylpyridin-3-yl)phenol (500 mg) and4-bromo-1-fluoro-2-methoxybenzene (614 mg).

MS (ESI+), found: 325.1.

B)9-[4-(4-fluoro-3-methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 2.14 (3H, s), 3.39-3.44 (2H, m), 3.83 (3H,s), 4.56-4.62 (2H, m), 6.58 (1H, dt, J=8.7, 3.2 Hz), 6.97-7.04 (3H, m),7.24 (1H, dd, J=11.2, 8.9 Hz), 7.49-7.56 (3H, m), 7.63 (1H, s).

Example 318

The compound of Example 318 was produced in the same manner as inExample 310.

Example 319

The compound of Example 319 was produced in the same manner as inExample 313.

Example 320

The compound of Example 320 was produced in the same manner as inExample 310.

Example 3219-[4-(1-phenylcyclobutyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 4-[1-(4-hydroxyphenyl)cyclobutyl]phenyltrifluoromethanesulfonate

Trifluoromethanesulfonic anhydride (0.350 mL) was added to a solution of4,4′-(cyclobutane-1,1-diyl)diphenol (500 mg) and pyridine (0.505 mL) inMeCN (10 mL) at 0° C. The mixture was stirred at room temperature for 40min. The mixture was neutralized with 1N HCl at 0° C. and extracted withEtOAc. The organic layer was separated, washed with water and brine,dried over anhydrous magnesium sulfate and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give 4-[1-(4-hydroxyphenyl)cyclobutyl]phenyltrifluoromethanesulfonate (160 mg) as colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 1.89-2.03 (2H, m), 2.59-2.78 (4H, m),4.56-4.61 (1H, m), 6.72-6.80 (2H, m), 7.11-7.19 (4H, m), 7.29-7.36 (2H,m).

B)4,4,5,5-tetramethyl-2-[4-(1-phenylcyclobutyl)phenyl]-1,3,2-dioxaborolane

Pd—C (40.0 mg) was added to a mixture of4-[1-(4-hydroxyphenyl)cyclobutyl]phenyl trifluoromethanesulfonate (160mg) in MeOH (10 mL). The mixture was stirred at room temperature underhydrogen for 2 hr. The insoluble solid was removed by filtration throughsilica gel/Celite pad (eluted with EtOAc) and the filtrate wasconcentrated in vacuo. The residue was dissolved in MeCN (5 mL) and TEA(0.119 mL) and trifluoromethanesulfonyl chloride (0.054 mL) were addedat 0° C. The mixture was stirred at room temperature overnight.Trifluoromethanesulfonyl chloride (0.054 mL) and TEA (0.119 mL) wereadded at 0° C. and the mixture was stirred at room temperature under adry atmosphere (anhydrous calcium chloride tube) for 1 day. MeOH (1 mL)was added and the volatiles were removed in vacuo to give an orangeresidue. This material (153 mg) was dissolved in DMF (dry) (5 mL), andwas added potassium acetate (126 mg),4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (164 mg),and Pd(dppf)Cl₂ (15.7 mg). The mixture was stirred at 90° C. undernitrogen for 6 hr. The mixture was poured into water and extracted withEtOAc. The organic layer was separated, washed with water and brine,dried over anhydrous magnesium sulfate and concentrated in vacuo. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give the title compound (26.7 mg) as a white solid.

¹H NMR (300 MHz, CDCl₃) δ 1.31 (12H, s), 1.87-2.04 (2H, m), 2.75 (4H, t,J=7.6 Hz), 7.07-7.16 (1H, m), 7.20-7.24 (1H, m), 7.26-7.37 (5H, m), 7.73(2H, d, J=8.3 Hz).

C)9-[4-(1-phenylcyclobutyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 31 andExample 98.

¹H NMR (300 MHz, CDCl₃) δ 1.62-2.19 (6H, m), 2.67-2.79 (4H, m),3.21-3.33 (2H, m), 3.35-3.49 (2H, m), 3.77-3.97 (3H, m), 7.04 (2H, d,J=8.3 Hz), 7.13 (1H, s), 7.21-7.25 (2H, m), 7.27-7.32 (4H, m).

Example 322

The compound of Example 322 was obtained in the same manner as inExample 31 and Example 98.

Example 3239-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-(1,1-difluoroethyl)phenoxy)phenyl)pyridin-2-amine

In the same manner as in Example 85, step A, the title compound (347 mg)was obtained from 4-(2-aminopyridin-3-yl)phenol (400 mg) and1-bromo-4-(1,1-difluoroethyl)benzene (570 mg).

MS (ESI+), found: 327.1.

B)9-{4-[4-(1,1-difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 1.97 (3H, t, J=18.9 Hz), 3.40-3.54 (2H, m),4.60-4.71 (2H, m), 6.71 (1H, t, J=7.0 Hz), 7.04-7.18 (4H, m), 7.53-7.67(5H, m), 7.78 (1H, dd, J=6.4, 1.5 Hz).

Example 3249-[4-(4-methylbenzyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(4-methylbenzyl)phenyl)pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 275.1.

B)9-[4-(4-methylbenzyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

MS (ESI+), found: 365.1.

C)9-[4-(4-methylbenzyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (18.4 mg) wasobtained from9-[4-(4-methylbenzyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.61-1.80 (3H, m), 1.86-2.08 (1H, m), 2.25(3H, s), 3.22-3.29 (2H, m), 3.37-3.54 (2H, m), 3.64-3.91 (5H, m),6.91-7.20 (8H, m).

Example 3259-[4-(1-methyl-1-phenylethyl)phenyl]-3,4-dihydropyrido[2,1c][1,2,4]thiadiazine2,2-dioxide A) 4-(2-phenylpropan-2-yl)phenyl trifluoromethanesulfonate

Trifluoromethanesulfonic anhydride (1.99 mL) was added dropwise to asolution of 4-(2-phenylpropan-2-yl)phenol (1.68 g) and pyridine (1.277ml) in MeCN (10 ml) at 0° C. The mixture was stirred at room temperaturefor 2 days. The mixture was quenched with 0.1 N HCl aq. at 0° C. andextracted with EtOAc. The organic layer was separated, washed with waterand brine, dried over anhydrous magnesium sulfate, filtered throughsilica-Celite pad (eluted with EtOAc) and concentrated in vacuo to give4-(2-phenylpropan-2-yl)phenyl trifluoromethanesulfonate (2.65 g) as ayellow oil.

¹H NMR (300 MHz, CDCl₃) δ1.68 (6H, s), 7.11-7.25 (5H, m), 7.26-7.34 (4H,m).

B) 3-(4-(2-phenylpropan-2-yl)phenyl)pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 289.1.

C)9-[4-(1-methyl-1-phenylethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 1.67 (6H, s), 3.37-3.52 (2H, m), 4.55-4.72(2H, m), 6.69 (1H, t, J=7.0 Hz), 7.07-7.35 (7H, m), 7.43 (2H, d, J=8.7Hz), 7.61 (1H, dd, J=7.0, 1.7 Hz), 7.71-7.83 (1H, m).

Example 3269-[4-(1-methyl-1-phenylethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (214 mg) wasobtained from9-[4-(1-methyl-1-phenylethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.64 (6H, s), 1.66-1.75 (3H, m), 1.87-2.08(1H, m), 3.22-3.28 (2H, m), 3.39-3.52 (2H, m), 3.67-3.73 (1H, m),3.75-3.87 (2H, m), 7.03-7.20 (5H, m), 7.20-7.33 (4H, m).

Example 3289-[4-(pentafluorosulfanyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-[4-(pentafluorosulfanyl)phenyl]pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 297.0.

B)9-[4-(pentafluorosulfanyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, CDCl₃) δ 3.44-3.52 (2H, m), 4.62-4.70 (2H, m), 6.75(1H, t, J=6.8 Hz), 7.69-7.77 (3H, m), 7.85 (1H, dd, J=6.8, 1.5 Hz), 7.96(2H, d, J=8.7 Hz).

C)9-[4-(pentafluorosulfanyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (2.7 mg) wasobtained from9-[4-(pentafluorosulfanyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.72-1.84 (3H, m), 1.96-2.11 (1H, m),3.41-3.58 (4H, m), 3.79-3.86 (2H, m), 3.89-3.98 (1H, m), 7.46 (2H, d,J=8.7 Hz), 7.85 (2H, d, J=8.7 Hz).

Example 329

The compound of Example 329 was produced in the same manner as inExample 325.

Example 3309-{4-[1-methyl-1-(4-methylphenyl)ethyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 98, the title compound (63.5 mg) wasobtained from9-{4-[1-methyl-1-(4-methylphenyl)ethyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

¹H NMR (300 MHz, DMSO-d₆) δ 1.61 (6H, s), 1.65-1.78 (3H, m), 1.90-2.07(1H, m), 2.25 (3H, s), 3.22-3.29 (2H, m), 3.39-3.52 (2H, m, J=4.1 Hz),3.70 (1H, t, J=5.5 Hz), 3.75-3.88 (2H, m), 7.03-7.16 (8H, m).

Example 3319-[4-(1,1-difluoroethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(1,1-difluoroethyl)phenyl)pyridin-2-amine

The title compound was obtained in the same manner as in Example 101,step A.

MS (ESI+), found: 235.1.

B)9-[4-(1,1-difluoroethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

The title compound was obtained in the same manner as in Example 85,step B.

¹H NMR (300 MHz, DMSO-d₆) δ 2.00 (3H, t, J=18.8 Hz), 3.41-3.51 (2H, m),4.61-4.70 (2H, m), 6.73 (1H, t, J=7.0 Hz), 7.56-7.69 (5H, m), 7.81 (1H,dd, J=6.8, 1.5 Hz).

Example 332

The compound of Example 332 was produced in the same manner as inExample 186.

Example 333-337

The compounds of Examples 333-337 were produced in the same manner as inExample 67.

Example 338(9S)-8-methyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of(9S)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (129 mg), potassium carbonate (100 mg) and iodomethane(0.022 mL) in DMF (4 mL) was stirred at 0° C. to room temperature for 20hr. The reaction mixture was added with NH silica gel, evaporated, andpurified by column chromatography (NH silica gel, eluted with EtOAc inhexane then 20% MeOH in EtOAc) then preparative HPLC (C18, MeCN in H₂Owith 0.1% TFA). The combined collected fractions were concentrated invacuo. The resulting aqueous solution was added with NaHCO₃ and NaCl,then extracted with EtOAc (2×100 mL). The organic layer was combined,dried over anhydrous magnesium sulfate, and concentrated in vacuo. Theresidue was recrystallized from EtOAc —IPE to give the title compound(18 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 2.11 (3H, s), 2.55-2.67 (1H, m), 2.90-3.01(1H, m), 3.13-3.29 (2H, m), 3.41-3.51 (1H, m), 3.55-3.69 (1H, m),3.79-3.90 (2H, m), 3.96 (1H, s), 6.90-6.99 (2H, m), 7.01-7.08 (2H, m),7.11-7.21 (1H, m), 7.24-7.34 (2H, m), 7.35-7.46 (2H, m).

Example 339

The compound of Example 339 was produced in the same manner as inExample 338.

Example 340(9S)-8-acetyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of(9S)-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (129 mg), triethylamine (0.100 mL) and acetyl chloride(0.026 mL) in THF (4 mL) was stirred at 0° C. to room temperature for 20hr. The reaction mixture was added with water, and the precipitate wasfiltered. The collected solid was purified by recrystallization fromMeOH-EtOAc then preparative HPLC (C18, MeCN in H₂O with 10 mM NH₄HCO₃).The combined collected fractions were concentrated in vacuo. Theresulting solid was recrystallized from EtOAc —IPE to give the titlecompound (60 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 2.07-2.14 (3H, m), 3.34-3.69 (5H, m),3.80-3.96 (3H, m), 5.95 (1H, s), 6.96-7.08 (4H, m), 7.12-7.21 (1H, m),7.30-7.47 (4H, m).

Example 341

The compound of Example 341 was produced in the same manner as inExample 340.

Example 342

The compound of Example 342 was produced in the same manner as inExample 98.

Example 343

The compound of Example 343 was produced in the same manner as inExample 14 and Example 98.

Example 344

The compound of Example 344 was produced in the same manner as inExample 14.

Example 345

The compound of Example 345 was produced in the same manner as inExample 98.

Example 3469-(2-fluorobiphenyl-4-yl)-9-methyl-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide hydrochloride A) tert-butyl9-(2-fluorobiphenyl-4-yl)-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide

A suspension of9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide (1.13 g) and di-tert-butyl dicarbonate (1.59 mL) in THF (200mL) was stirred at room temperature overnight. The mixture was addedwith silica gel, concentrated in vacuo, then purified by columnchromatography (silica gel, eluted with EtOAc in hexane) to give thetitle compound (1.45 g) as a colorless amorphous powder.

MS (ESI+), found: 460.2.

B) tert-butyl9-(2-fluorobiphenyl-4-yl)-9-methyl-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide

A suspension of tert-butyl9-(2-fluorobiphenyl-4-yl)-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide (0.71 g), iodomethane (0.115 mL) and NaH (60%, 93 mg) in DMF(16 mL) was stirred at 0° C. to room temperature overnight. The reactionmixture was added with water and extracted with EtOAc. The organic layerwas washed with brine and water, dried over anhydrous magnesium sulfateand concentrated. The residue was purified by column chromatography(silica gel, eluted with EtOAc in hexane). The obtained material waspurified by column chromatography (silica gel, eluted with EtOAc inhexane) to give the title compound (150 mg) as a white solid.

MS (ESI+), found: 474.2.

C)9-(2-fluorobiphenyl-4-yl)-9-methyl-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide hydrochloride

A suspension of tert-butyl9-(2-fluorobiphenyl-4-yl)-9-methyl-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide (150 mg) and 4 N HCl/EtOAc (5 mL) in EtOAc (5 mL) wasstirred at room temperature overnight. After removing solvent, theresidue was recrystallized from MeOH to give the title compound (65 mg)as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.99 (3H, s), 2.92-3.21 (1H, m), 3.28-4.25(7H, m), 7.31-7.85 (8H, m), 10.77 (2H, brs).

Example 347

The compound of Example 347 was produced in the same manner as inExample 98.

Example 3489-(2-fluorobiphenyl-4-yl)(9-²H)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide hydrochloride A) tert-butyl9-(2-fluorobiphenyl-4-yl)(9-^(2H)-)3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide

A suspension of NaH (60%, 35 mg) and tert-butyl9-(2-fluorobiphenyl-4-yl)-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide (200 mg) in DMF (3 mL) was stirred at 0° C. for 0.5 hr. Tothe reaction mixture was added D₂O (3.0 mL) and the mixture was stirredat 0° C. to room temperature overnight. The mixture was added withwater, and extracted with EtOAc. The organic layer was washed with brineand water, dried over anhydrous magnesium sulfate and concentrated. Theresidue was purified by column chromatography (silica gel, eluted withEtOAc in hexane) to give the title compound (95 mg) as a colorlessamorphous powder.

MS (ESI+), found: 461.2.

B)9-(2-fluorobiphenyl-4-yl)(9-²H)-3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide hydrochloride

A suspension of tert-butyl9-(2-fluorobiphenyl-4-yl)(9-²H)-3,4,6,7-tetrahydropyrazino[2,1-c][1,2,4]thiadiazine-8(9H)-carboxylate2,2-dioxide (95 mg) and 4N HCl/EtOAc (1 mL) in EtOAc (3 mL) was stirredat room temperature for 2 hr. After removing solvent, the residue wasrecrystallized from EtOAc-EtOH to give the title compound (61 mg) as awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 3.31-3.52 (4H, m), 3.64-4.04 (4H, m),7.31-7.81 (8H, m), 9.20-10.64 (2H, m).

Example 3499-(3-fluoro-4-propoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide A) 3-(4-(benzyloxy)-3-fluorophenyl)pyridin-2-amine

A mixture of sodium carbonate (7.18 g),tetrakis(triphenylphosphine)palladium(0) (1.957 g),4-(benzyloxy)-3-fluorophenylboronic acid (10 g), and3-bromopyridin-2-amine (5.86 g) in DME (120 mL) and water (24 mL) wasstirred at 80° C. overnight. The mixture was added with silica gel,concentrated in vacuo, and purified by column chromatography (silicagel, eluted with EtOAc in hexane) to give the title compound (9.97 g) asa pale yellow solid.

MS (ESI+), found: 295.1.

B) 4-(2-aminopyridin-3-yl)-2-fluorophenol

A mixture of 3-(4-(benzyloxy)-3-fluorophenyl)pyridin-2-amine (8.5 g),and platinum(IV) oxide (400 mg) in EtOH (200 mL) was stirred at roomtemperature under hydrogen overweekend. The mixture was added with NHsilica gel, concentrated in vacuo, and purified by column chromatography(NH silica gel, eluted with MeOH in EtQAc) to give the title compound(3.20 g) as a pale yellow solid.

MS (ESI+), found: 205.0.

C) 3-(3-fluoro-4-propoxyphenyl)pyridin-2-amine

In the same manner as in Example 67, the title compound was obtainedfrom 4-(2-aminopyridin-3-yl)-2-fluorophenol and 1-iodopropane.

MS (ESI+), found: 261.1.

D)9-(3-fluoro-4-propoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

In the same manner as in Example 14, step B, the title compound wasobtained from 3-(3-fluoro-4-propoxyphenyl)pyridin-2-amine.

Example 350

The compound of Example 350 was produced in the same manner as inExample 98.

Example 351

The compound of Example 351 was produced in the same manner as inExample 349.

Example 352

The compound of Example 352 was produced in the same manner as inExample 98.

Example 353

The compound of Example 353 was produced in the same manner as inExample 349.

Example 354

The compound of Example 354 was produced in the same manner as inExample 76.

Example 355

The compound of Example 355 was produced in the same manner as inExample 67.

Example 356

The compound of Example 356 was produced in the same manner as inExample 98.

Example 357

The compound of Example 357 was produced in the same manner as inExample 203.

Example 358

The compound of Example 358 was produced in the same manner as inExample 98.

Example 359

The compound of Example 359 was produced in the same manner as inExample 214.

Example 3609-(2,4-dichlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To 9-bromo-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide (26mg) were added a solution of 2,4-dichlorophenylboronic acid (38 mg) inethanol (0.5 mL), toluene (0.5 mL),tetrakis(triphenylphosphine)palladium(0) (11 mg) and cesium carbonate(98 mg), and the mixture was stirred at 100° C. overnight. To thereaction solution were added saturated aqueous sodium hydrogen carbonatesolution (1 mL) and ethyl acetate (3 mL) and the mixture was stirred.The organic layer was passed through a phase separation filter, and thesolvent was evaporated from the separated solution by an air blowingapparatus. The residue was purified by HPLC (C18, mobile phase:acetonitrile/10 mM aqueous ammonium acetate solution) to give the titlecompound (20.7 mg).

MS (ESI+): [M+H]+ 329.

Examples 361-398, 400-403, 405-412, 414-432

The compounds of Examples 361-398, 400-403, 405-412, 414-432 wereproduced in the same manner as in Example 360.

Example 4339-[4-(2-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

To4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol(28 mg) were added a solution of 2-chlorophenylboronic acid (47 mg) inacetonitrile (1 mL), pyridine (0.2 mL), cesium carbonate (32 mg) andcopper(II) acetate (36 mg), and the mixture was stirred at roomtemperature overnight.

To the reaction solution were added aqueous ammonium chloride solution(1 mL) and ethyl acetate (3 mL) and the mixture was stirred. The organiclayer was passed through a phase separation filter, and the solvent wasevaporated from the separated solution by an air blowing apparatus. Theresidue was purified by HPLC (C18, mobile phase: acetonitrile/10 mMaqueous ammonium acetate solution) to give the title compound (4.1 mg).

MS (ESI+): [M+H]⁺ 391.

Example 434-456

The compounds of Examples 434-456 were produced in the same manner as inExample 433.

Example 457(9S)-9-[4-(3-chloro-4-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A mixture of (3-chloro-4-fluorophenyl)boronic acid (933 mg),4-[(9S)-2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenol(500 mg), pyridine (3.60 mL), cesium carbonate (581 mg), diacetoxycopper(648 mg) and powdered 4A MS (4 g) in MeCN (18 mL) was stirred at roomtemperature for 3 days. The mixture was added with NH silica gel,concentrated in vacuo, and purified by column chromatography (NH silicagel, eluted with MeOH in EtOAc) then recrystallized from EtOAc-THF/IPEto give(9S)-9-[4-(3-chloro-4-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide (290.6 mg) as a white solid.

¹H NMR (300 MHz, DMSO-d₆) δ1.64-1.85 (3H, m), 1.88-2.10 (1H, m, J=6.0Hz), 3.23-3.29 (2H, m), 3.38-3.57 (2H, m), 3.71-3.91 (3H, m), 6.94-7.10(3H, m), 7.18-7.34 (3H, m), 7.44 (1H, t, J=9.1 Hz).

mp 154-156° C.

Anal. Calcd for C₁₉H₁₈N₂O₃SClF:C,55.81;H,4.44;N,6.85. Found:C,55.83;H,4.43;N,6.68.

Example 458-460

The compounds of Examples 458-460 were produced in the same manner as inExample 433.

Example 4619-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (67.7 mg) of9-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol 100%) to give the title compound (30.4 mg) with a shorterretention time. Crystallization from THF and diisopropyl ether gave awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.74-1.92 (1H, m), 1.93-2.11 (3H, m),3.38-3.60 (2H, m), 3.70-3.97 (5H, m), 5.03 (1H, t, J=3.4 Hz), 7.04 (2H,ddd, J=17.3, 8.9, 2.4 Hz), 7.18 (1H, d, J=2.3 Hz), 7.40 (1H, d, J=2.3Hz), 7.75 (2H, dd, J=8.9, 4.0 Hz). The 2H peak was hidden behind water.

mp 153-154° C.

Example 4629-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

A racemate (67.7 mg) of9-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide was separated by HPLC (column: CHIRALPAK AD (LF001), 50mmID×500 mL, manufactured by DAICEL CHEMICAL INDUSTRIES, LTD., mobilephase:methanol 100%) to give the title compound (30.5 mg) with a longerretention time. Crystallization from THF and diisopropyl ether gave awhite solid.

¹H NMR (300 MHz, DMSO-d₆) δ 1.75-1.90 (1H, m), 1.94-2.08 (3H, m),3.38-3.58 (2H, m), 3.73-3.91 (5H, m), 4.95-5.07 (1H, m), 7.04 (2H, ddd,J=17.3, 8.9, 2.4 Hz), 7.18 (1H, d, J=2.3 Hz), 7.40 (1H, d, J=2.3 Hz),7.75 (2H, dd, J=8.9, 4.0 Hz). The 2H peak was hidden behind water.

mp 154-155° C.

The compounds of Examples 59-283, 285-326, 328-398, 400-403, 405-412 and414-462 are shown in the following Tables. In the Tables, MS meansFound.

In the structural formulas in the Tables, the indication of hydrogenatom bonded to nitrogen atom may be omitted.

TABLE 8 Ex. No. IUPAC Name Structure Salt MS 599-[(7-methoxynaphthalen-2-yl)oxy]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.1 60 9-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

361.3 61 9-{[4-(1- methylethyl)phenoxy]methyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 62 (9R)-9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.3 63 (9S)-9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.3 64 9-biphenyl-4-yl-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.3 65 9-biphenyl-4-yl-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.3 66 9-[4-(cyclopentyloxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.1 67 9-[4-(2,2-dimethylpropoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.1 68 9-[4-(cyclohexyloxy)phenyl]-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

360.1 69 9-[4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

375.1 70 9-[4-(cyclopropyloxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

317.0

TABLE 9 71 9-[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

361.2 72 9-[4-(1-ethylpropoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.1 73 7-chloro-9-[4-(cyclohexyloxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

393.1 74 9-[4-(cyclopentylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 75 9-[4-(tetrahydrofuran-2- ylmethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

361.1 76 7-chloro-9-(4-{[4- (trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

456.0 77 7-chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1 78 7-chloro-9-(4-{[3- (trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

456.0 79 7-chloro-9-(4-{[2- (trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

456.1 80 9-(4-pyrrolidin-1-ylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.1 81 7-chloro-9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

387.0 82 9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

385.2

TABLE 10 83 9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.2 84 9-{4-[(3-fluorobenzyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazin-9-ol 2,2-dioxide

405.2 85 9-[4-(3-chlorophenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

387.1 86 9-{4-[2- {trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 87 4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenol

277.0 88 9-[4-(cycloheptyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

373.1 89 9-[4-(cyclohexyloxy)phenyl]-7-fluoro- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

377.2 90 9-[4-(3-methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

383.1 91 9-[4-(cyclobutyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

331.1 92 7-chloro-9-[6-(cyclohexyloxy)pyridin-3-yl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

394.1 93 9-[6-(cyclohexyloxy)pyridin-3-yl]-7-fluoro-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

378.2 94 9-[6-(cyclohexyloxy)pyridin-3-yl]-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

361.2

TABLE 11 95 9-[6-(cyclohexyloxy)pyridin-3-yl]-7-methyl-3,4-dihydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

375.2 96 9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.0 97 9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.0 98 9-[4-(3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

387.2 99 7-methyl-9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

371.2 100 9-(2′-fluorobiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 101 9-(2-methylbiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

351.1 102 9-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.2 103 9-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 104 9-(2-methylbiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 105 9-(4′-methylbiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 106 9-(3′-methoxybiphenyl-4-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

371.1

TABLE 12 107 9-[4-(4-methylphenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 108 9-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 109 9-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 110 9-[4-(4-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 111 9-[4-(4-fluoro-3- methylphenoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 112 9-[4-(4-fluoro-3- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 113 9-[4-(4-fluoro-3- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 114 9-[4-(4-fluoro-3- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 115 9-[4-(2-methylphenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 116 9-[4-(2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 117 9-[4-(3-methylphenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 118 9-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1

TABLE 13 119 9-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 120 9-[4-(3-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

371.1 121 9-{4-[2-methyl-4- (trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.1 122 9-{4-[2-methyl-4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

439.1 123 9-{4-[2-methyl-4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

439.1 124 9-{4-[2-methyl-4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

439.1 125 9-{4-[4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 126 9-(6-methoxynaphthalen-2-yl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.0 127 9-(6-methoxynaphthalen-2-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.1 128 9-(6-methoxynaphthalen-2-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.1 129 9-(6-methoxynaphthalen-2-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.1 130 9-[4-(3-ethylphenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

381.1

TABLE 14 131 9-[4-(3-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.2 132 9-[4-(3-ethylphenoxy)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

385.1 133 9-[4-(3-ethylphenoxy)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

385.1 134 9-[4-(3,4-dimethylphenoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

381.1 135 9-[4-(3,4-dimethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 136 9-{4-[difluoro(4- methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

401.1 137 9-{4-[difluoro(4- methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 138 9-{4-[difluoro(4- methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 139 9-{4-[difluoro(4- methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 140 9-{4-[difluoro(4-fluoro-3- methylphenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

423.1 141 9-[4-(2,3-dihydro-1-benzofuran-6- yloxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

399.1 142 9-{4-[4-bromo-3- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

503.0 505.0

TABLE 15 143 9-[4-(4-fluoro-2- methylphenoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 144 9-[4-(4-fluoro-2- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 145 9-[4-(4-fluoro-2- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 146 9-[4-(4-fluoro-2- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 147 9-[4-(4-chlorophenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

387.1 148 9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1 149 (9S)-9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.0 150 9-[4-(4-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.0 151 9-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

426.1 152 9-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.0 427.0 153 9-[4-(3,4-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.0 427.0 154 9-[4-(4-chloro-3- methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

417.0

TABLE 16 155 9-[4-(4-chloro-3- methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 156 9-{4-[3-(1,1- difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

417.1 157 9-{4-[3-(1,1- difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 158 9-{4-[3-(1,1- difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.3 159 9-{4-[3-(1,1- difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.3 160 (9S)-9-{4-[2-chloro-5- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

459.1 161 9-[4-(4-ethylphenoxy)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

385.1 162 9-{4-[difluoro(phenyl)methyl]phenyl}- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

387.1 163 9-{4-[difluoro(phenyl)methyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1 164 9-[4-(4-fluoro-3- methoxyphenoxy)phenyl]-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

419.1 165 9-[4-(cyclohexyloxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 166 9-(4-phenoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.1

TABLE 17 167 9-(4-phenoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.1 168 9-[4-(4-methylphenoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 169 9-[4-(cyclohexyloxy)phenyl]-7- methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

374.1 170 9-{4-[4-(1,1-difluoroethyl)- phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 171 9-{4-[3-(1,1-difluoroethyl)- phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.1 172 9-{4-[3-(1,1-difluoroethyl)- phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.3 173 9-{4-[3-(1,1-difluoroethyl)- phenoxy]phenyl}-7-methyl-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.3 174 9-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

329.1 175 9-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

333.1 176 9-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

333.0 177 9-[4-(trifluoromethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

332.9 178 9-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

348.9

TABLE 18 179 9-[4-(trifluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

349.0 180 9-[4-(cyclohexyloxy)phenyl]-7- methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

374.1 181 9-[4-(2-methylpropoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 182 9-[4-(cyclohexyloxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 183 2-chloro-4-[4-(2,2-dioxido- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]-thiadiazin-9- yl)phenoxy]benzonitrile

416.1 184 2-chloro-4-[4-(9-hydroxy-2,2- dioxido-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazin-9- yl)phenoxy]benzonitrile

432.1 185 9-(4-phenylcyclohexyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

343.1 186 9-{[4-(1- methylpropyl)phenoxy]methyl}- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.1 187 9-{4-[3- (trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 188 9-{4-[(4,4-dimethylcyclohex-1-en-1-yl)oxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 189 9-{4-[(4,4- diinethylcyclohexyl)oxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.2 190 9-(4-propoxyphenyl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

323.1

TABLE 19 191 9-(6-phenoxypyridin-3-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

354.1 192 9-(4-phenoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.2 193 9-(4-tert-butylphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

317.2 194 9-(3-fluorobiphenyl-4-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 195 9-(6-phenoxypyridin-3-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

354.1 196 9-[4-(cyclohexyloxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.2 197 9-[4-(4-methylphenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 198 4-[4-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]phenol

369.1 199 9-[4-(4-fluorophenoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

371.0 200 9-{4-[4- (trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 201 9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1 202 (9R)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1

TABLE 20 203 (9S)-9-[4-(3-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1 204 8-methoxy-9-(4-phenoxyphenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

383.1 205 8-chloro-9-(4-phenoxyphenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

387.1 206 7-fluoro-9-(4-phenoxyphenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

371.1 207 7-methyl-9-(4-phenoxyphenyl)- 3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

368.1 208 9-[3-chloro-4-(1- methylethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

353.2 209 9-(4-butoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 210 9-(4-phenoxyphenyl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

354.1 211 9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

358.1 212 (9S)-9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

358.1 213 (9R)-9-(4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

358.1 214 4-[(9S)-2,2-dioxido-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl]phenyl trifluoromethanesulfonate

413.1

TABLE 21 215 (9S)-9-[4-(4-chloro-2- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 216 (9S)-9-[4-(3,4- dimethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 217 (9R)-9-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.2 218 (9S)-9-[4-(4-ethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

385.1 219 (9S)-9-[4-(3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

387.1 220 (9S)-9-(2′-chlorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

375.1 221 9-(2′-chlorobiphenyl-4-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

375.1 222 9-{4-[(E)-2-phenylethenyl]phenyl}- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

363.1 223 (9S)-9-(4′-chlorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

375.1 224 9-(4′-chlorobiphenyl-4-yl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

375.1 225 (9S)-9-(4′-chloro-3′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

393.1 226 (9S)-9-(3′-chloro-4′-fluorobiphenyl-4-yl)-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

393.1

TABLE 22 227 (9S)-9-[4-(3,4,5- trifluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

411.1 228 (9S)-9-[4-(4-bromophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.0 437.0 229 9-[4-(difluoromethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

331.0 230 9-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

329.1 231 9-[4-(1,1-difluoroethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

329.1 232 9-{4-[4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 233 9-{4-[4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 234 9-{4-[4-(1,1- difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 235 9-{4-[4-(1,1- difluoroethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 236 (9S)-9-[4-(3-fluoro-5- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

389.1 237 9-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

331.1 238 9-(5,6,7,8-tetrahydronaphthalen-2-yloxy)-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

335.1

TABLE 23 239 9-[4-(1H-pyrazol-1-yl)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

327.1 240 9-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

407.0 241 9-{[7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]oxy}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 242 9-[4-(1-methylpropoxy)phenyl]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 243 9-[4-(1,4-dioxaspiro[4.5]dec-8-yloxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

417.1 244 4-[4-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]cyclohexanone

373.1 245 9-(4-{[tert- butyl(dimethyl)silyl]oxy}phenyl)-7-chloro-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1 246 9-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

368.1 247 9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

388..0 248 9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1 249 7-chloro-9-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

402.0 250 9-(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1

TABLE 24 251 7-chloro-9-[4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

395.1 252 7-chloro-9-[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

395.1 253 7-chloro-9-[4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

409.2 254 9-(4-{[6-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1 255 9-(4-{[4-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.0 256 7-chloro-9-(4-{[6- (trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

456.0 257 9-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1 258 9-(5-phenoxypyridin-2-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

354.1 259 9-(4-{[5-(trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

422.1 260 7-chloro-9-(4-{[5- (trifluoromethyl)pyridin-3-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

456.0 261 9-[4-(cyclohexyloxy)phenyl]-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

363.2 262 9-{4-[3-(trifluoromethyl)- phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

425.1

TABLE 25 263 9-[4-(pyridin-2-yloxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

354.1 264 9-[4-(2,2,2-trifluoroethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 265 9-[4-(2,2,2-trifluoroethoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

363.1 266 9-{4-[2-(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 267 9-[4-(benzyloxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 268 9-[4-(cyclohexylmethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

373.1 269 9-[4-(cyclopropylmethoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

331.1 270 9-[4-(2-methoxyphenoxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

383.1 271 9-[4-(cyclohex-2-en-1-yloxy)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.1 272 9-[(4-cyclopentylphenoxy)methyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.0 273 9-[(5,6,7,8-tetrahydronaphthalen-2-yloxy)methyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

345.0 274 2-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9- yl)phenoxy]cyclohexanone

373.2

TABLE 26 275 9-[6-(cyclohexyloxy)pyridin-3-yl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

360.2 276 9-[(3-chlorobenzyl)oxy]-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

325.1 277 9-{[3,5-bis(trifluoromethyl)benzyl]oxy}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

431.2 278 7-methyl-9-(3-phenoxyazetidin-1-yl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

347.2 279 9-(4-phenylpiperidin-1-yl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

345.2 280 9-(4-phenoxyphenyl)-7-(trifluoromethyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

421.1 281 9-(1-methyl-1H-indol-5-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

318.2 282 9-(6-phenylpyridin-3-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

338.1 283 9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4,6,7,8,9- hexahydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

426.2 285 9-(1-ethyl-1H-indol-5-yl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

332.2 286 7-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl- 3,4-dihydronaphthalen-1 (2H)-one

357.2 287 5-(2,2-dioxido-3,4-dihydropyrido[2,1-c][l,2,4]thiadiazin-9-yl)-2,2-dimethyl- 2,3-dihydro-1H-inden-1-one

343.1

TABLE 27 288 7-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-3,4-dihydronaphthalen- 1(2H)-one

361.2 289 5-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-2,2-dimethyl-2,3-dihydro-1H-inden- 1-one

347.2 290 9-[4-(1H-pyrazol-1-yl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

331.1 291 1-[4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin- 9-yl)phenyl]ethanone

307.1 292 9-(1-butyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

356.2 293 9-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

356.1 294 9-(1-butyl-1H-indol-5-yl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

360.1 295 9-{1-[2-(4-fluorophenyl)ethyl]-1H-indol-5-yl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

426.2 296 9-[1-(2-methylpropyl)-1H-indol-5-yl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

360.2 297 9-(3′-methoxybiphenyl-4-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 298 [4-(2,2-dioxido-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazin-9-yl)phenyl](phenyl)methanone

365.1 299 9-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

435.1

TABLE 28 300 9-{4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

409.1 301 9-{4-[5-cyclopropyl-3- (trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-3,4,6,7,8,9-hexahydropyrido- [2,1-c][1,2,4]thiadiazine2,2-dioxide

439.1 302 9-{4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

413.1 303 9-[(5,6,7,8-tetrahydronaphthalen-2- yloxy)methyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

349.1 304 [4-(2,2-dioxido-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazin-9- yl)phenyl](phenyl)methanone

369.1 305 9-{[4-(trifluoromethyl)- phenoxy]methyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

363.1 306 [4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl](3- methoxyphenyl)methanone

395.1 307 9-{4-[3-methyl-4-(trifluoromethyl)-phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

435.1 308 9-{4-[3-methyl-4- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

439.1 309 9-{4-[2-methyl-5- (trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

435.0 310 9-{4-[2-methyl-5- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

439.1 311 9-{4-[4-bromo-3- (trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

499.0 501.0

TABLE 29 312 9-{4-[difluoro(4-fluoro-3- methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

419.1 313 9-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

395.1 314 9-{4-[2,4- bis(trifluoromethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

489.1 315 9-{4-[2,4- bis(trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

493.1 316 9-[4-(4-fluoro-3- methoxyphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

401.1 317 9-[4-(4-fluoro-3- methoxyphenoxy)phenyl]-7-methyl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

415.1 318 9-[4-(4-fluoro-3- methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 319 9-[4-(2,3-dihydro-1-benzofuran-5-yloxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

395.1 320 9-[4-(2,3-dihydro-1-benzofuran-5- yloxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

399.1 321 9-[4-(1-phenylcyclobutyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

395.1 322 9-(3-phenoxyphenyl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

357.1 323 9-{4-[4-(1,1- difluoroethyl)phenoxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

417.1

TABLE 30 324 9-[4-(4-methylbenzyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

369.2 325 9-[4-(1-methyl-1-phenylethyl)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

379.1 326 9-[4-(1-methyl-1-phenylethyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

383.1 328 9-[4-(pentafluoro-lambda⁶- sulfanyl)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.0 329 9-{4-[1-methyl-1-(4- methylphenyl)ethyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

393.2 330 9-{4-[1-methyl-1-(4- methylphenyl)ethyl]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

397.2 331 9-[4-(1,1-difluoroethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

325.1 332 9-{[4-(trifluoromethyl)phenoxy]methyl}- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

359.1 333 9-(4-methoxyphenyl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

292.1 334 9-(4-ethoxyphenyl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

306.0 335 9-(4-propoxyphenyl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

320.1 336 9-[4-(1-methylethoxy)phenyl]-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

320.1

TABLE 31 337 9-[4-(cyclopentyloxy)phenyl]-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

346.1 338 (9S)-8-methyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

372.1 339 (9R)-8-methyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

372.1 340 (9S)-8-acetyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

400.1 341 (9R)-8-acetyl-9-(4-phenoxyphenyl)-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

400.1 342 9-(4-butoxyphenyl)-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

337.1 343 9-(4-morpholin-4-ylphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

350.1 344 9-(2-fluorobiphenyl-4-yl)-3,4- dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

356.1 345 9-(2-fluorobiphenyl-4-yl)-3,4,6,7,8,9- hexahydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

360.1 346 9-(2-fluorobiphenyl-4-yl)-9-methyl-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

374.1 347 9-(3-fluoro-4-phenoxyphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

375.1 348 9-(2-fluorobiphenyl-4-yl)(9-~2~H)-3,4,6,7,8,9-hexahydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

361.1

TABLE 32 349 9-(3-fluoro-4-propoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

337.1 350 9-(3-fluoro-4-propoxyphenyl)- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.1 351 9-(4-butoxy-3-fluorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

351.2 352 9-(4-butoxy-3-fluorophenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

355.1 353 9-(3-fluoro-4-{[4- (trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

440.1 354 9-(4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-3,4-dihydropyrazino[2,1- c][1,2,4]thiadiazine 2,2-dioxide

423.1 355 9-(4-butoxyphenyl)-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide

334.1 356 9-(3-fluoro-4-{[4-(trifluoromethyl)-pyridin-2-yl]oxy}phenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

444.1 357 9-[4-(4-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

375.1 358 9-[4-(cycloheptyloxy)phenyl]- 3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

377.2 359 4-(2,2-dioxido-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazin- 9-yl)phenyltrifluoromethanesulfonate

413.1 360 9-(2,4-dichlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.9

TABLE 33 361 9-[3-fluoro-4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

338.1 362 9-(4-fluorophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

279.1 363 9-(3-chloro-4-fluorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9 364 9-(3-chlorophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

295.0 365 9-(3-fluorophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

279.1 366 9-(2-chlorophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

294.9 367 9-(2-fluorophenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

279.1 368 9-(3,4-difluorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

297.0 369 9-(3,4-dichlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.9 370 9-(2,3-dichlorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.9 371 9-(3,5-difluorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

298.0 372 9-(2,4-difluorophenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

297.0

TABLE 34 373 9-(4-chloro-3-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

314.0 374 9-(2,4,5-trifluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.0 375 9-(2,3,4-trifluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.0 376 9-(2,3-difluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

297.0 377 9-phenyl-3,4- dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

261.1 378 9-(2,5-dichlorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.9 379 9-(1-benzyl-1H-pyrazol-4-yl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

341.0 380 9-(2-chloro-4-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9 381 9-(3-chloro-2-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9 382 9-(5-chloro-2-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9 383 9-(2-chloro-5-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9 384 9-(3-chloro-5-fluorophenyl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

312.9

TABLE 35 385 9-[3-methyl-4-(1-methylethoxy)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

333.1 386 9-[4-(benzyloxy)-3,5-dichlorophenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

437.0 387 9-(4-propoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

319.1 388 9-(2-chloro-4-methoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

325.0 389 9-(2,3-dihydro-1-benzofuran-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

303.1 390 9-(4-ethoxyphenyl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

306.1 391 9-(4-methoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

291.0 392 9-[4-chloro-2-(trifluoromethyl)phenyl]- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

364.0 393 9-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

330.0 394 9-(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

331.1 395 9-(4-methoxy-2,6-dimethylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

319.1 396 9-[4-(3-fluorooxetan-3-yl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

335.1

TABLE 36 397 9-(4-morpholin-4-ylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

346.1 398 9-quinolin-3-yl-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

312.1 400 1-[4-(2,2-dioxido-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]ethanone

303.1 401 9-dibenzo[b,d]thiophen-2-yl-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

367.1 402 9-(1-methyl-1H-benzimidazol-6-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.1 403 9-(1,3-benzodioxol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

305.1 405 9-(1H-indol-5-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

300.1 406 9-(1H-indol-6-yl)-3,4- dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide

300.1 407 9-(5-chloro-6-methoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

327.1 408 9-[4-(methylsulfanyl)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

307.0 409 9-(1,3-benzothiazol-6-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

318.0 410 9-(1-benzofuran-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

302.1

TABLE 37 411 9-(4-tert-butoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

333.1 412 9-(1-methyl-1H-indol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

314.1 414 9-(1H-indazol-6-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

301.1 415 9-(1-methyl-1H-indazol-6-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.1 416 9-(4-chloro-2-methylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

309.0 417 9-(2,3-dihydro-1,4-benzodioxin-6-yl)- 3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

319.1 418 9-quinolin-6-yl-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine2,2-dioxide

312.1 419 9-(2-methyl-2H-indazol-6-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.1 420 9-(2-methyl-2H-indazol-5-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

315.1 421 9-(3,4-dimethylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

289.1 422 9-(6-chloropyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

296.0 423 9-(3-fluoro-4-methylphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

293.1

TABLE 38 424 9-[4-chloro-3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

363.0 425 9-(6-ethoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

306.1 426 4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)-N,N- diethylbenzamide

360.1 427 9-(6-methoxypyridin-3-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

292.1 428 tert-butyl 4-[(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin- 9-yl)methylidene]piperidine-1-carboxylate

280.1 429 9-{(1Z)-3-[4- (trifluoromethyl)piperidin-1-yl]prop-1-en-1-yl}-3,4-dihydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

376.1 430 methyl 1-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenyl]cyclopropanecarboxylate

359.1 431 methyl 2-[4-(2,2-dioxido-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazin- 9-yl)phenyl]-2-methylpropanoate

361.1 432 9-(5-chlorothiophen-2-yl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

300.9 433 9-[4-(2-chlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

391.1 434 9-[4-(3-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

376.1 435 9-[4-(4-tert-butylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

413.2

TABLE 39 436 9-{4-[4- (trifluoromethoxy)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

441.1 437 3-[4-(2,2-dioxido-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazin-9- yl)phenoxy]benzonitrile

382.1 438 9-[4-(2,3-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

426.1 439 9-[4-(3,5-dichlorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

428.1 440 9-{4-[2-chloro-5- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

459.1 441 9-{4-[3-chloro-5- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

459.1 442 9-{4-[4-chloro-3- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

459.1 443 9-{4-[4-chloro-2- (trifluoromethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

459.1 444 9-[4-(5-chloro-2-methylphenoxy)phenyl-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 445 4-[4-(2,2-dioxido-3,4,6,7,8,9- hexahydropyrido[2,1-c][1,2,4]thiadiazin-9-yl)phenoxy]-3- methylbenzonitrile

396.1 446 9-[4-(4-chloro-2-methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

405.1 447 9-[4-(3-chloro-4-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

409.1

TABLE 40 448 9-[4-(3-chloro-5-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

409.1 449 9-[4-(2-chloro-5-fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

409.1 450 (9S)-9-[4-(4-chloro-2- fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

409.1 451 (9S)-9-[4-(4-chloro-2-fluoro-5-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

439.1 452 (9S)-9-[4-(4-chloro-2-fluoro-3-methoxyphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

439.1 453 (9S)-9-[4-(2-fluoro-4- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

389.1 454 (9S)-9-[4-(3-fluoro-4- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

389.1 455 (9S)-9-[4-(2,4,5- trimethylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

399.2 456 (9S)-9-{4-[3-(1- methylethyl)phenoxy]phenyl}-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

400.2 457 (9S)-9-[4-(3-chloro-4- fluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

409.1 458 (9S)-9-[4-(4-methoxy-2- methylphenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide

401.2 459 (9S)-9-[4-(3,4-difluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

393.1

TABLE 41 460 (9S)-9-[4-(2,4,5- trifluorophenoxy)phenyl]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

411.1 461 9-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

360.9 462 9-[(7-methoxynaphthalen-2-yl)oxy]-3,4,6,7,8,9-hexahydropyrido[2,1- c][1,2,4]thiadiazine 2,2-dioxide

361.0

Experimental Example 1

(1) Construction of Expression Gene

Human GluR1 flip cDNA was amplified by PCR using forward primerACTGAATTCGCCACCATGCAGCACATTTTTGCCTTCTTCTGC (SEQ ID NO: 1) and reverseprimer CCGCGGCCGCTTACAATCCCGTGGCTCCCAAG (SEQ ID NO: 2) artificiallysynthesized using human brain-derived cDNA (BD Bio science) as atemplate. The amplified product was digested with restriction enzymesEcoRI, NotI (TAKARA SHUZO CO. LTD.), and incorporated into the same siteof pcDNA3.1(+) (Invitrogen) to construct pcDNA3.1(+)/human GluR1 flipgene. Human stargazin cDNA was amplified by PCR using forward primerGGTCTCGAGGCCACCATGGGGCTGTTTGATCGAGGTGTTCA (SEQ ID NO: 3) and reverseprimer GTTGGATCCTTATACGGGGGTGGTCCGGCGGTTGGCTGTG (SEQ ID NO: 4)artificially synthesized using human hippocampus cDNA as a template. Theamplified product was digested with restriction enzymes XhoI, BamHI(TAKARA SHUZO CO. LTD.), and incorporated into the same site ofpcDNA3.1(−) (Invitrogen) to construct pcDNA3.1 Zeo(−)/human stargazingene.

(2) Construction of GluR1 Flip/Stargazin Expressing Cell

CHO-K1 cells passaged in a culture medium (Ham's F12 medium (Invitrogen)added with 10% inactivated fetal bovine serum (Morgate) and penicillin,streptomycin (Invitrogen)) were detached with 0.05% trypsin, 0.53 mMEDTA (Invitrogen) diluted with D-PBS(−). The detached cells weresuspended in a culture medium, and recovered by a centrifugationoperation at 1,000 rpm. The recovered cells were suspended again inD-PBS(−), and added to a 0.4 cm electroporation cuvette (BioRad).pcDNA3.1(+)/human GluR1 flip gene (5 μg) and pcDNA3.1 Zeo(−)/humanstargazin gene (15 μg) were added, and the mixture was introduced intoCHO-K1 cells using Gene Pulser II (BioRad) under the conditions of 950μFd, 250 mV. The introduced cells were cultured overnight in a culturemedium and, the next day, plated in a 96 well plate at 250 cells/wellusing a selection medium (culture medium added with Zeocin (Invitrogen)to 250 μg/mL). Clones showing drug resistance were selected, and GluR1flip/stargazin expressing clones were selected by an assay method usingcalcium influx as an index as shown below.

(3) Measurement Method of AMPA Receptor Function Enhancing Activity ofCompound Using Calcium Influx as Index

CHO-K1/GluR1 flip/stargazin expressing cells were plated on a 96 wellblack transparent bottom plate (Costar) at 2×10⁴ cells/well, andcultured in a 37° C., CO₂ incubator (SANYO Electric Co., Ltd.) for 2days. The medium in the cell plate was removed, and assay buffer A(D-MEM (Invitrogen), 0.1% BSA (Serogical Protein), 20 mM HEPES(Invitrogen)) was added at 50 RL/well. A calcium indicator (Calcium 4Assay Kit, Invitrogen) added with 2.5 mM probenecid (Invitrogen) wasadded at 50 RL/well and the well was left standing in 37° C., CO₂incubator for 1 hr. The cell plate was set in CellLux (PerkinElmer), amixture (50 μL) of 9 mM glutamic acid diluted with assay buffer B (HBSS(Invitrogen), 0.1% BSA, 20 mM HEPES) (final concentration 3 mM) and atest compound (test compound concentration 30 μM) was added, and theamount of change in fluorescence level in 3 min was measured. In thedefinition here, the amount of change in fluorescence level of welladded with glutamic acid at final concentration 3 mM and 300 μMcyclothiazide (TOCRIS) is 100%, the amount of change in fluorescencelevel of well added only with glutamic acid at final concentration 3 mMis 0%, and the compound activity was calculated according to thefollowing formula.activity(%)=(X−C)/(T−C)×100

-   T: amount of change in fluorescence level of well added with    glutamic acid at final concentration 3 mM and 300 cyclothiazide-   C: amount of change in fluorescence level of well added only with    glutamic acid at final concentration 3 mM-   X: amount of change in fluorescence level of well added with test    compound

The results are shown in the following Tables.

TABLE 42 Example No. activity (%) 1 66 4 85 14 78 23 104 24 78 25 98 2687 28 80 31 79 34 78 37 95 43 81 46 80 51 87 52 67 57 86 59 72 60 63 6175 63 77 64 73 65 78 67 68 68 77 69 71 70 86 72 80 73 75 75 81 78 72 7990 80 88 81 86 82 65 83 57 85 84 86 67 87 51 88 75 89 85

TABLE 43 Example No. activity (%) 90 78 91 81 94 71 96 74 97 86 98 71 9973 101 84 102 71 103 81 105 87 106 98 107 69 108 68 109 88 111 58 112 79113 86 115 80 116 69 117 90 118 79 119 92 121 71 122 58 123 57 125 53126 72 127 79 128 98 129 100 130 69 131 58 132 75 134 77 135 59 136 77137 61 138 71 141 80

TABLE 44 Example No. activity (%) 142 70 143 76 144 76 145 84 147 70 14873 149 77 151 67 152 80 154 75 155 63 156 90 157 89 158 76 159 90 160 78161 57 162 56 163 74 164 69 171 87 172 74 173 68 174 79 175 53 177 69179 69 180 70 182 80 183 91 185 36 187 72 191 74 198 87 199 79 201 74203 85 204 70 205 67 206 84

TABLE 45 Example No. activity (%) 207 78 208 79 210 82 211 71 215 67 21671 218 74 219 83 220 93 221 96 226 79 227 68 228 78 230 59 231 78 232 60235 84 236 74 237 66 238 87 239 88 244 76 246 73 251 81 253 80 254 81255 84 256 86 257 84 258 79 259 90 260 91 261 72 264 80 266 84 274 85282 84 287 73 290 79 292 90

TABLE 46 Example No. activity (%) 293 80 294 82 295 64 298 99 299 88 30093 301 76 303 82 304 87 306 89 313 95 316 89 321 64 323 85 324 63 325 99329 82 344 74 345 63 347 76 348 64 349 83 350 74 352 76 357 77 361 85396 82 397 83 400 83 408 85 411 86 412 91 423 80 433 55 447 78 462 69

Experimental Example 2

(1) Animals

Male ICR mice were supplied by CLEA Japan, Inc (Japan). After arrival tothe vivarium, animals were allowed a minimum of 1 week for acclimation.They were housed under a 12:12-h light/dark cycle in a temperature- andhumidity-controlled laboratory and allowed food and water ad libitum.

(2) Drug Administration

A test compound was suspended in 0.5% methylcellulose in distilled waterand orally administered (p.o.). Methamphetamine (Dainippon SumitomoPharma Co., Ltd.) was dissolved in saline and subcutaneouslyadministered (s.c.). All drugs were dosed in a volume of 10 mL/kg bodyweight for mice.

(3) Inhibition of Methamphetamine (MAP)—Induced Hyperlocomotion

The widely used animal models of psychosis have been the measurement ofthe extent of hyperlocomotion induced by psychostimulants (e.g.,amphetamine, cocaine, methamphetamine, MK-801 and phencyclidine) inrodents (Psychopharmacology 1999, vol. 145: 237-250). 4 compounds (A, B,C, D) were tested for its ability to antagonize MAP-inducedhyperlocomotion in mice. Male ICR mice were habituated in the locomotorchambers with infrared sensors (BrainScienceIdea Co., Ltd. Japan) to theexperiment. After the habituation, animals were treated with eithervehicle or the compounds (10 mg/kg, p.o.), and MAP (2 mg/kg, s.c.) wasadministrated 60 min later. Locomotion activities were measured, andaccumulated counts (120 min after administration of MAP) were calculatedin each treatment group. All data were represented as means plus thestandard errors of the means (n=3-9) and analyzed using Student's t-testwith significance set at **P<0.01 and ***P<0.001 or Welch's t-test withsignificance set at ^($)P<0.05, ^($$)P<0.01 and ^($$$)P<0.001.

Compound A is9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide, compound B is9-[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide, compound C is9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine2,2-dioxide, and compound D is9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine2,2-dioxide.

The graphs of FIG. 1 show inhibition of methamphetamine

(MAP)-induced hyperlocomotion by compound A, B, C and D. By administered60 min before MAP (2 mg/kg, s.c.) treatment, compound A, B, C, and Dproduced significant inhibition of MAP-induced hyperlocomotion (0-120min).

Formulation Example 1

(1) compound of Example 1 50 mg (2) lactose 34 mg (3) cornstarch 10.6 mg(4) cornstarch (paste) 5 mg (5) magnesium stearate 0.4 mg (6) calciumcarboxymethylcellulose 20 mg total 120 mg

The above-mentioned (1) to (6) are mixed according to a conventionalmethod, and the mixture is compressed by a tableting machine to give atablet.

INDUSTRIAL APPLICABILITY

The compound of the present invention has an AMPA receptor functionenhancing action and is useful as a prophylactic or therapeutic drug fordepression, schizophrenia, Alzheimer or attention deficit hyperactivitydisorder (ADHD) and the like.

This application is based on patent application No. 2010-179577 filed inJapan, the contents of which are encompassed in full herein.

SEQUENCE LISTING FREE TEXT

SEQ ID NO: 1 is a forward primer for GluR1 flip cDNA.

SEQ ID NO: 2 is a reverse primer for GluR1 flip cDNA.

SEQ ID NO: 3 is a forward primer for stargazin cDNA cDNA.

SEQ ID NO: 4 is a reverse primer for stargazin cDNA cDNA.

The invention claimed is:
 1. A compound represented by the formula (I):

Wherein a partial structural formula represented by the formula:

ring B is optionally substituted by substituent selected from a halogen atom; hydroxy; C₁₋₆ alkyl optionally substituted by a halogen atom; C₁₋₆ alkoxy; and C₁₋₆ alkyl-carbonyl, ring D is C₃₋₇ cycloalkane, C₆₋₁₄ arene, dihydronaphthalene, tetrahydronaphthalene, dihydroinden, thiophene, azetidine, piperidine, furan, pyridine, pyrazole, 1,2,4-oxadiazole, dihydrobenzodioxin, dihydrobenzofuran, benzodioxole, benzofuran, indole, quinoline, benzimidazole, benzothiazole, indazole or dibenzothiophene, optionally substituted by 1-4 substituents selected from (1) a halogen atom; (2) cyano; (3) hydroxy; (4) oxo; (5) C₁₋₆ alkyl optionally substituted by substituent(s) selected from 1) a halogen atom, 2) phenyl optionally substituted by substituent(s) selected from a halogen atom and C₁₋₆ alkyl and 3) C₁₋₆ alkoxycarbonyl; (6) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or phenyl; (7) C₁₋₆ alkyl-carbonyl; (8) phenyl-carbonyl optionally substituted by C₁₋₆ alkoxy; (9) C₂₋₆ alkenyl substituted by phenyl; (10) phenyl optionally substituted by 1 to 3 substituents selected from a halogen atom, C₁₋₆ alkyl, C₃₋₇ cycloalkyl and C₁₋₆ alkoxy; (11) pyrazole optionally substituted by 1 to 3 substituents selected from C₁₋₆ alkyl optionally substituted by a halogen atom, and C₃₋₇ cycloalkyl; (12) pyrrolidine; (13) dihydrobenzofuran; (14) morpholine; (15) oxetane substituted by a halogen atom; (16) sulfanyl substituted by a halogen atom or C₁₋₆ alkyl; (17) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom; (18) di-C₁₋₆ alkylcarbamoyl; (19) 4,4,5,5-tetramethyl-1,3,2-dioxaborolane; (20) C₁₋₆ alkoxy optionally substituted by substituent(s) selected from a halogen atom, C₃₋₇ cycloalkyl, phenyl optionally substituted by a halogen atom, tetrahydrofuran and tetrahydropyran; (21) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl, oxo or C₂₋₆ alkylenedioxy; (22) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl; (23) phenyloxy optionally substituted by 1 to 3 substituents selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally substituted by a halogen atom, and C₁₋₆ alkoxy optionally substituted by a halogen atom; (24) pyridyloxy optionally substituted by a halogen atom, or C₁₋₆ alkyl optionally substituted by a halogen atom; (25) silyloxy substituted by C₁₋₆ alkyl; (26) tetrahydrofuranyloxy; (27) tetrahydropyranyloxy; and (28) dihydrobenzofuranyloxy, L is a bond, —O—, —O—CH₂—, —CH₂—O—, —CO—NH—, —CO—N(C₁₋₆ alkyl)—, —S—, —SO—, —SO₂—, C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene, excluding the following compounds; 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide, 9[4-(4-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide, and 9-[4-(cyclohexyloxy)phenyl]-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide, or a salt thereof.
 2. The compound according to claim 1, wherein the partial structural formula represented by the formula:

ring B is optionally substituted by substituent selected from a halogen atom, hydroxy, C₁₋₆ alkyl and C₁₋₆ alkoxy, ring D is C₃₋₇ cycloalkane, benzene, naphthalene, pyridine or thiophene optionally substituted by 1 to 3 substituents selected from (1) a halogen atom; (2) hydroxy; (3) C₁₋₆ alkyl optionally substituted by substituent selected from 1) a halogen atom, and 2) phenyl optionally substituted by substituent selected from a halogen atom and C₁₋₆ alkyl; (4) C₃₋₇ cycloalkyl; (5) phenyl-carbonyl; (6) C₂₋₆ alkenyl substituted by phenyl; (7) phenyl optionally substituted by a halogen atom or C₁₋₆ alkyl; (8) pyrrolidine; (9) dihydrobenzofuran; (10) C_(l-6) alkylsulfonyloxy substituted by a halogen atom; (11) C₁₋₆ alkoxy optionally substituted by substituent selected from a halogen atom, C₃₋₇ cycloalkyl, phenyl substituted by a halogen atom, tetrahydrofuran and tetrahydropyran; (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl; (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl; (14) phenyloxy optionally substituted by 1 to 3 substituents selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally substituted by a halogen atom, and C₁₋₆ alkoxy; (15) pyridyloxy substituted by a halogen atom, or C₁₋₆ alkyl substituted by a halogen atom; (16) tetrahydrofuranyloxy; (17) tetrahydropyranyloxy; and (18) dihydrobenzofuranyloxy, and L is a bond, —O—, —O—CH₂—, —CO—NH—, C₁₋₆ alkylene, or C₂₋₆ alkynylene, or a salt thereof.
 3. The compound according to claim 1, wherein the partial structural formula represented by the formula:

ring B is optionally substituted by C₁₋₆ alkyl, ring D is benzene optionally substituted by 1 to 3 substituents selected from (1) a halogen atom; (2) hydroxy; (3) C₁₋₆ alkyl optionally substituted by substituent selected from 1) a halogen atom, and 2) phenyl optionally substituted by substituent selected from a halogen atom and C₁₋₆ alkyl; (4) C₃₋₇ cycloalkyl optionally substituted by C₁₋₆ alkoxycarbonyl or phenyl; (5) phenyl-carbonyl; (6) C₂₋₆ alkenyl substituted by phenyl; (7) phenyl optionally substituted by a halogen atom or C₁₋₆ alkyl; (8) pyrrolidine; (9) dihydrobenzofuran; (10) C₁₋₆ alkylsulfonyloxy substituted by a halogen atom; (11) C₁₋₆ alkoxy optionally substituted by substituent selected from a halogen atom, C₃₋₇ cycloalkyl, phenyl substituted by a halogen atom, tetrahydrofuran and tetrahydropyran; (12) C₃₋₇ cycloalkyloxy optionally substituted by C₁₋₆ alkyl; (13) C₃₋₇ cycloalkenyloxy optionally substituted by C₁₋₆ alkyl; (14) phenyloxy optionally substituted by 1 to 3 substituents selected from a halogen atom, cyano, hydroxy, C₁₋₆ alkyl optionally substituted by a halogen atom, and C₁₋₆ alkoxy; (15) pyridyloxy substituted by a halogen atom, or C₁₋₆ alkyl substituted by a halogen atom; (16) tetrahydrofuranyloxy; (17) tetrahydropyranyloxy; and (18) dihydrobenzofuranyloxy, and L is a bond, or a salt thereof.
 4. A compound according to claim 1, which is 9-[4-(Cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 5. A pharmaceutical composition comprising a compound according to claim 1: or a salt thereof, and a pharmaceutically acceptable carrier.
 6. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder, comprising administering an effective amount of a compound according to claim 1 or a salt thereof to a mammal.
 7. A compound according to claim 1, which is 9-{4-[Difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 8. A compound according to claim 1, which is 9-[4-(3,4-Dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 9. A compound according to claim 1, which is 9-[4-(2,3-Dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 10. A compound according to claim 1, which is 9-[4-(3-Methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 11. A compound according to claim 1, which is 7-Chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 12. A compound according to claim 1, which is 7-Chloro-9-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 13. A compound according to claim 1, which is 9-{4-[Difluoro(4-methylpheny)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof.
 14. A pharmaceutical composition according to claim 5, comprising 9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 15. A pharmaceutical composition according to claim 5, comprising 9-{4-[difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 16. A pharmaceutical composition according to claim 5, comprising 9-[4-(3,4-dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 17. A pharmaceutical composition according to claim 5, comprising 9-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 18. A pharmaceutical composition according to claim 5, comprising 9-[4-(3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 19. A pharmaceutical composition according to claim 5, comprising 7-chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 20. A pharmaceutical composition according to claim 5, comprising 7-chloro-9-(4-{[2-(trifluoromethyl) pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide, and a pharmaceutically acceptable carrier.
 21. A pharmaceutical composition according to claim 5, comprising 9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof, and a pharmaceutically acceptable carrier.
 22. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-[4-(cyclohexyloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 23. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-{4-[difluoro(phenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 24. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-[4-(3,4-dimethylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 25. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-[4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 26. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-[4-(3-methylphenoxy)phenyl]-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 27. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 7-chloro-9-{4-[(5-chloropyridin-2-yl)oxy]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 28. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 7-chloro-9-(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)-3,4-dihydropyrido [2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
 29. A method for the treatment of depression, schizophrenia or attention deficit hyperactivity disorder according to claim 6, comprising administering an effective amount of 9-{4-[difluoro(4-methylphenyl)methyl]phenyl}-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal. 